Alteration	Alteration type	Assay type	Association	Biomarker	Curator	Drug	Drug family	Drug full name	Drug status	Evidence level	Gene	Metastatic Tumor Type	Primary Tumor acronym	Source	Targeting	gDNA	cDNA	individual_mutation	info	region	strand	transcript	Primary Tumor type
ABL1:T315I	MUT		Resistant	ABL1 (T315I)	CRubio-Perez	[Nilotinib,Dasatinib]	[BCR-ABL inhibitor 2nd gen]	BCR-ABL inhibitor 2nd gens (Nilotinib,Dasatinib,etc)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133748283C>T	c.944C>T	ABL1:T315I	CSQN=Missense;reference_codon=ACT;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748283_133748284delCTinsTC,chr9:g.133748283_133748284delCTinsTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:T315I	MUT		Responsive	ABL1 (T315I)	DTamborero	Axitinib	VEGFR inhibitor	Axitinib (VEGFR inhibitor)		Pre-clinical	ABL1		CANCER	PMID:25686603		chr9:g.133748283C>T	c.944C>T	ABL1:T315I	CSQN=Missense;reference_codon=ACT;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748283_133748284delCTinsTC,chr9:g.133748283_133748284delCTinsTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Any cancer type
ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)	RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		chr9:g.133748282A>G	c.943A>G	ABL1:T315A	CSQN=Missense;reference_codon=ACT;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr9:g.133748282_133748284delACTinsGCA,chr9:g.133748282_133748284delACTinsGCC,chr9:g.133748282_133748284delACTinsGCG;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)	RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		chr9:g.133748288T>C	c.949T>C	ABL1:F317L	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133748290C>A,chr9:g.133748290C>G;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsCTT,chr9:g.133748288_133748290delTTCinsCTG,chr9:g.133748288_133748290delTTCinsCTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)	RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		chr9:g.133748288T>G	c.949T>G	ABL1:F317V	CSQN=Missense;reference_codon=TTC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsGTA,chr9:g.133748288_133748290delTTCinsGTG,chr9:g.133748288_133748290delTTCinsGTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)	RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		chr9:g.133748288T>A	c.949T>A	ABL1:F317I	CSQN=Missense;reference_codon=TTC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsATA,chr9:g.133748288_133748290delTTCinsATT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)	RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		chr9:g.133748289T>G	c.950T>G	ABL1:F317C	CSQN=Missense;reference_codon=TTC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr9:g.133748289_133748290delTCinsGT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)	RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		chr9:g.133738357T>C	c.757T>C	ABL1:Y253H	CSQN=Missense;reference_codon=TAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr9:g.133738357_133738359delTACinsCAT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)	RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		chr9:g.133738363G>A	c.763G>A	ABL1:E255K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr9:g.133738363_133738365delGAGinsAAA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)	RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		chr9:g.133738364A>T	c.764A>T	ABL1:E255V	CSQN=Missense;reference_codon=GAG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133738364_133738365delAGinsTA,chr9:g.133738364_133738365delAGinsTC,chr9:g.133738364_133738365delAGinsTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)	RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		chr9:g.133748414T>G	c.1075T>G	ABL1:F359V	CSQN=Missense;reference_codon=TTC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133748414_133748416delTTCinsGTA,chr9:g.133748414_133748416delTTCinsGTG,chr9:g.133748414_133748416delTTCinsGTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)	RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		chr9:g.133748415T>G	c.1076T>G	ABL1:F359C	CSQN=Missense;reference_codon=TTC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr9:g.133748415_133748416delTCinsGT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)	RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		chr9:g.133748414T>A	c.1075T>A	ABL1:F359I	CSQN=Missense;reference_codon=TTC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748414_133748416delTTCinsATA,chr9:g.133748414_133748416delTTCinsATT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:T315I	MUT		Resistant	ABL1 (T315I)	CRubio-Perez	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133748283C>T	c.944C>T	ABL1:T315I	CSQN=Missense;reference_codon=ACT;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748283_133748284delCTinsTC,chr9:g.133748283_133748284delCTinsTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:V299L	MUT		Responsive	ABL1 (V299L)	DTamborero	Cabozantinib	Pan-kinase inhibitor	Cabozantinib (Pan-kinase inhibitor)		Pre-clinical	ABL1		CANCER	PMID:26924578		chr9:g.133747588G>C	c.895G>C	ABL1:V299L	CSQN=Missense;reference_codon=GTG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133747588G>T;candidate_mnv_variants=chr9:g.133747588_133747590delGTGinsCTT,chr9:g.133747588_133747590delGTGinsCTA,chr9:g.133747588_133747590delGTGinsCTC,chr9:g.133747588_133747590delGTGinsTTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Any cancer type
ABL1:V299L	MUT		Responsive	ABL1 (V299L)	DTamborero	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	ABL1		CANCER	PMID:26924578		chr9:g.133747588G>C	c.895G>C	ABL1:V299L	CSQN=Missense;reference_codon=GTG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133747588G>T;candidate_mnv_variants=chr9:g.133747588_133747590delGTGinsCTT,chr9:g.133747588_133747590delGTGinsCTA,chr9:g.133747588_133747590delGTGinsCTC,chr9:g.133747588_133747590delGTGinsTTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Any cancer type
ABL1:F359V,F359C,F359I,Y253H,E255K,E255V	MUT		Responsive	ABL1 (F359V,F359C,F359I,Y253H,E255K,E255V)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		chr9:g.133748414T>G	c.1075T>G	ABL1:F359V	CSQN=Missense;reference_codon=TTC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133748414_133748416delTTCinsGTA,chr9:g.133748414_133748416delTTCinsGTG,chr9:g.133748414_133748416delTTCinsGTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:F359V,F359C,F359I,Y253H,E255K,E255V	MUT		Responsive	ABL1 (F359V,F359C,F359I,Y253H,E255K,E255V)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		chr9:g.133748415T>G	c.1076T>G	ABL1:F359C	CSQN=Missense;reference_codon=TTC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr9:g.133748415_133748416delTCinsGT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:F359V,F359C,F359I,Y253H,E255K,E255V	MUT		Responsive	ABL1 (F359V,F359C,F359I,Y253H,E255K,E255V)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		chr9:g.133748414T>A	c.1075T>A	ABL1:F359I	CSQN=Missense;reference_codon=TTC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748414_133748416delTTCinsATA,chr9:g.133748414_133748416delTTCinsATT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:F359V,F359C,F359I,Y253H,E255K,E255V	MUT		Responsive	ABL1 (F359V,F359C,F359I,Y253H,E255K,E255V)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		chr9:g.133738357T>C	c.757T>C	ABL1:Y253H	CSQN=Missense;reference_codon=TAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr9:g.133738357_133738359delTACinsCAT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:F359V,F359C,F359I,Y253H,E255K,E255V	MUT		Responsive	ABL1 (F359V,F359C,F359I,Y253H,E255K,E255V)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		chr9:g.133738363G>A	c.763G>A	ABL1:E255K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr9:g.133738363_133738365delGAGinsAAA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:F359V,F359C,F359I,Y253H,E255K,E255V	MUT		Responsive	ABL1 (F359V,F359C,F359I,Y253H,E255K,E255V)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		chr9:g.133738364A>T	c.764A>T	ABL1:E255V	CSQN=Missense;reference_codon=GAG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133738364_133738365delAGinsTA,chr9:g.133738364_133738365delAGinsTC,chr9:g.133738364_133738365delAGinsTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:V299L,T315A,F317L,F317V,F317I,F317C	MUT		Resistant	ABL1 (V299L,T315A,F317L,F317V,F317I,F317C)	CRubio-Perez	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133747588G>C	c.895G>C	ABL1:V299L	CSQN=Missense;reference_codon=GTG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133747588G>T;candidate_mnv_variants=chr9:g.133747588_133747590delGTGinsCTT,chr9:g.133747588_133747590delGTGinsCTA,chr9:g.133747588_133747590delGTGinsCTC,chr9:g.133747588_133747590delGTGinsTTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:V299L,T315A,F317L,F317V,F317I,F317C	MUT		Resistant	ABL1 (V299L,T315A,F317L,F317V,F317I,F317C)	CRubio-Perez	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133748282A>G	c.943A>G	ABL1:T315A	CSQN=Missense;reference_codon=ACT;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr9:g.133748282_133748284delACTinsGCA,chr9:g.133748282_133748284delACTinsGCC,chr9:g.133748282_133748284delACTinsGCG;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:V299L,T315A,F317L,F317V,F317I,F317C	MUT		Resistant	ABL1 (V299L,T315A,F317L,F317V,F317I,F317C)	CRubio-Perez	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133748288T>C	c.949T>C	ABL1:F317L	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133748290C>A,chr9:g.133748290C>G;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsCTT,chr9:g.133748288_133748290delTTCinsCTG,chr9:g.133748288_133748290delTTCinsCTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:V299L,T315A,F317L,F317V,F317I,F317C	MUT		Resistant	ABL1 (V299L,T315A,F317L,F317V,F317I,F317C)	CRubio-Perez	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133748288T>G	c.949T>G	ABL1:F317V	CSQN=Missense;reference_codon=TTC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsGTA,chr9:g.133748288_133748290delTTCinsGTG,chr9:g.133748288_133748290delTTCinsGTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:V299L,T315A,F317L,F317V,F317I,F317C	MUT		Resistant	ABL1 (V299L,T315A,F317L,F317V,F317I,F317C)	CRubio-Perez	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133748288T>A	c.949T>A	ABL1:F317I	CSQN=Missense;reference_codon=TTC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsATA,chr9:g.133748288_133748290delTTCinsATT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:V299L,T315A,F317L,F317V,F317I,F317C	MUT		Resistant	ABL1 (V299L,T315A,F317L,F317V,F317I,F317C)	CRubio-Perez	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133748289T>G	c.950T>G	ABL1:F317C	CSQN=Missense;reference_codon=TTC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr9:g.133748289_133748290delTCinsGT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:V299L	MUT		Responsive	ABL1 (V299L)	DTamborero	Foretinib 	MET inhibitor	Foretinib  (MET inhibitor)		Pre-clinical	ABL1		CANCER	PMID:26924578		chr9:g.133747588G>C	c.895G>C	ABL1:V299L	CSQN=Missense;reference_codon=GTG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133747588G>T;candidate_mnv_variants=chr9:g.133747588_133747590delGTGinsCTT,chr9:g.133747588_133747590delGTGinsCTA,chr9:g.133747588_133747590delGTGinsCTC,chr9:g.133747588_133747590delGTGinsTTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Any cancer type
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133738325T>C	c.725T>C	ABL1:I242T	CSQN=Missense;reference_codon=ATC;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr9:g.133738325_133738326delTCinsCA,chr9:g.133738325_133738326delTCinsCG,chr9:g.133738325_133738326delTCinsCT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133738330A>G	c.730A>G	ABL1:M244V	CSQN=Missense;reference_codon=ATG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133738330_133738332delATGinsGTA,chr9:g.133738330_133738332delATGinsGTC,chr9:g.133738330_133738332delATGinsGTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133738340A>G	c.740A>G	ABL1:K247R	CSQN=Missense;reference_codon=AAG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr9:g.133738340_133738341delAGinsGA,chr9:g.133738339_133738340delAAinsCG,chr9:g.133738339_133738341delAAGinsCGA,chr9:g.133738339_133738341delAAGinsCGC,chr9:g.133738339_133738341delAAGinsCGT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133738342C>G	c.742C>G	ABL1:L248V	CSQN=Missense;reference_codon=CTG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133738342_133738344delCTGinsGTA,chr9:g.133738342_133738344delCTGinsGTC,chr9:g.133738342_133738344delCTGinsGTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133738349G>A	c.749G>A	ABL1:G250E	CSQN=Missense;reference_codon=GGG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr9:g.133738349_133738350delGGinsAA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133738348G>A	c.748G>A	ABL1:G250R	CSQN=Missense;reference_codon=GGG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr9:g.133738348G>C;candidate_mnv_variants=chr9:g.133738348_133738350delGGGinsAGA,chr9:g.133738348_133738350delGGGinsCGA,chr9:g.133738348_133738350delGGGinsCGC,chr9:g.133738348_133738350delGGGinsCGT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133738355A>G	c.755A>G	ABL1:Q252R	CSQN=Missense;reference_codon=CAG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr9:g.133738354_133738355delCAinsAG,chr9:g.133738355_133738356delAGinsGA,chr9:g.133738355_133738356delAGinsGC,chr9:g.133738355_133738356delAGinsGT,chr9:g.133738354_133738356delCAGinsAGA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133738356G>T	c.756G>T	ABL1:Q252H	CSQN=Missense;reference_codon=CAG;candidate_codons=CAT,CAC;candidate_snv_variants=chr9:g.133738356G>C;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133738358A>T	c.758A>T	ABL1:Y253F	CSQN=Missense;reference_codon=TAC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr9:g.133738358_133738359delACinsTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133738357T>C	c.757T>C	ABL1:Y253H	CSQN=Missense;reference_codon=TAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr9:g.133738357_133738359delTACinsCAT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133738363G>A	c.763G>A	ABL1:E255K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr9:g.133738363_133738365delGAGinsAAA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133738364A>T	c.764A>T	ABL1:E255V	CSQN=Missense;reference_codon=GAG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133738364_133738365delAGinsTA,chr9:g.133738364_133738365delAGinsTC,chr9:g.133738364_133738365delAGinsTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133738309A>G	c.709A>G	ABL1:M237V	CSQN=Missense;reference_codon=ATG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133738309_133738311delATGinsGTA,chr9:g.133738309_133738311delATGinsGTC,chr9:g.133738309_133738311delATGinsGTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133738374G>C	c.774G>C	ABL1:E258D	CSQN=Missense;reference_codon=GAG;candidate_codons=GAC,GAT;candidate_snv_variants=chr9:g.133738374G>T;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133738382G>T	c.782G>T	ABL1:W261L	CSQN=Missense;reference_codon=TGG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_mnv_variants=chr9:g.133738381_133738382delTGinsCT,chr9:g.133738382_133738383delGGinsTA,chr9:g.133738381_133738383delTGGinsCTT,chr9:g.133738381_133738383delTGGinsCTA,chr9:g.133738381_133738383delTGGinsCTC;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133738417T>A	c.817T>A	ABL1:L273M	CSQN=Missense;reference_codon=TTG;candidate_codons=ATG;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133747516G>A	c.823G>A	ABL1:E275K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr9:g.133747516_133747518delGAGinsAAA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133747516G>C	c.823G>C	ABL1:E275Q	CSQN=Missense;reference_codon=GAG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr9:g.133747516_133747518delGAGinsCAA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133747520A>G	c.827A>G	ABL1:D276G	CSQN=Missense;reference_codon=GAC;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr9:g.133747520_133747521delACinsGT,chr9:g.133747520_133747521delACinsGG,chr9:g.133747520_133747521delACinsGA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133747522A>G	c.829A>G	ABL1:T277A	CSQN=Missense;reference_codon=ACC;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr9:g.133747522_133747524delACCinsGCA,chr9:g.133747522_133747524delACCinsGCG,chr9:g.133747522_133747524delACCinsGCT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133747528G>A	c.835G>A	ABL1:E279K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr9:g.133747528_133747530delGAGinsAAA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133747532T>C	c.839T>C	ABL1:V280A	CSQN=Missense;reference_codon=GTG;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr9:g.133747532_133747533delTGinsCA,chr9:g.133747532_133747533delTGinsCC,chr9:g.133747532_133747533delTGinsCT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133747559T>C	c.866T>C	ABL1:V289A	CSQN=Missense;reference_codon=GTC;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr9:g.133747559_133747560delTCinsCA,chr9:g.133747559_133747560delTCinsCG,chr9:g.133747559_133747560delTCinsCT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133747558G>A	c.865G>A	ABL1:V289I	CSQN=Missense;reference_codon=GTC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133747558_133747560delGTCinsATA,chr9:g.133747558_133747560delGTCinsATT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133747568A>T	c.875A>T	ABL1:E292V	CSQN=Missense;reference_codon=GAG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133747568_133747569delAGinsTA,chr9:g.133747568_133747569delAGinsTC,chr9:g.133747568_133747569delAGinsTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133747567G>C	c.874G>C	ABL1:E292Q	CSQN=Missense;reference_codon=GAG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr9:g.133747567_133747569delGAGinsCAA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133747570A>G	c.877A>G	ABL1:I293V	CSQN=Missense;reference_codon=ATC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133747570_133747572delATCinsGTA,chr9:g.133747570_133747572delATCinsGTG,chr9:g.133747570_133747572delATCinsGTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133747585C>G	c.892C>G	ABL1:L298V	CSQN=Missense;reference_codon=CTG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133747585_133747587delCTGinsGTA,chr9:g.133747585_133747587delCTGinsGTC,chr9:g.133747585_133747587delCTGinsGTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133747588G>C	c.895G>C	ABL1:V299L	CSQN=Missense;reference_codon=GTG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133747588G>T;candidate_mnv_variants=chr9:g.133747588_133747590delGTGinsCTT,chr9:g.133747588_133747590delGTGinsCTA,chr9:g.133747588_133747590delGTGinsCTC,chr9:g.133747588_133747590delGTGinsTTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133748270T>C	c.931T>C	ABL1:F311L	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133748272C>A,chr9:g.133748272C>G;candidate_mnv_variants=chr9:g.133748270_133748272delTTCinsCTT,chr9:g.133748270_133748272delTTCinsCTG,chr9:g.133748270_133748272delTTCinsCTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133748270T>A	c.931T>A	ABL1:F311I	CSQN=Missense;reference_codon=TTC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748270_133748272delTTCinsATA,chr9:g.133748270_133748272delTTCinsATT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133748283C>T	c.944C>T	ABL1:T315I	CSQN=Missense;reference_codon=ACT;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748283_133748284delCTinsTC,chr9:g.133748283_133748284delCTinsTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133748288T>C	c.949T>C	ABL1:F317L	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133748290C>A,chr9:g.133748290C>G;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsCTT,chr9:g.133748288_133748290delTTCinsCTG,chr9:g.133748288_133748290delTTCinsCTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133748288T>G	c.949T>G	ABL1:F317V	CSQN=Missense;reference_codon=TTC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsGTA,chr9:g.133748288_133748290delTTCinsGTG,chr9:g.133748288_133748290delTTCinsGTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133748288T>A	c.949T>A	ABL1:F317I	CSQN=Missense;reference_codon=TTC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsATA,chr9:g.133748288_133748290delTTCinsATT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133748289T>G	c.950T>G	ABL1:F317C	CSQN=Missense;reference_codon=TTC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr9:g.133748289_133748290delTCinsGT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133748298A>G	c.959A>G	ABL1:Y320C	CSQN=Missense;reference_codon=TAC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr9:g.133748298_133748299delACinsGT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133748310T>A	c.971T>A	ABL1:L324Q	CSQN=Missense;reference_codon=CTG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr9:g.133748310_133748311delTGinsAA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133748363T>C	c.1024T>C	ABL1:Y342H	CSQN=Missense;reference_codon=TAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr9:g.133748363_133748365delTACinsCAT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133748367T>C	c.1028T>C	ABL1:M343T	CSQN=Missense;reference_codon=ATG;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr9:g.133748367_133748368delTGinsCA,chr9:g.133748367_133748368delTGinsCT,chr9:g.133748367_133748368delTGinsCC;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133748370C>T	c.1031C>T	ABL1:A344V	CSQN=Missense;reference_codon=GCC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133748370_133748371delCCinsTA,chr9:g.133748370_133748371delCCinsTG,chr9:g.133748370_133748371delCCinsTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133748388C>T	c.1049C>T	ABL1:A350V	CSQN=Missense;reference_codon=GCC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133748388_133748389delCCinsTA,chr9:g.133748388_133748389delCCinsTG,chr9:g.133748388_133748389delCCinsTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133748391T>C	c.1052T>C	ABL1:M351T	CSQN=Missense;reference_codon=ATG;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr9:g.133748391_133748392delTGinsCA,chr9:g.133748391_133748392delTGinsCT,chr9:g.133748391_133748392delTGinsCC;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133748404G>C	c.1065G>C	ABL1:E355D	CSQN=Missense;reference_codon=GAG;candidate_codons=GAC,GAT;candidate_snv_variants=chr9:g.133748404G>T;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133748403A>G	c.1064A>G	ABL1:E355G	CSQN=Missense;reference_codon=GAG;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr9:g.133748403_133748404delAGinsGT,chr9:g.133748403_133748404delAGinsGA,chr9:g.133748403_133748404delAGinsGC;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133748403A>C	c.1064A>C	ABL1:E355A	CSQN=Missense;reference_codon=GAG;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr9:g.133748403_133748404delAGinsCA,chr9:g.133748403_133748404delAGinsCC,chr9:g.133748403_133748404delAGinsCT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133748414T>G	c.1075T>G	ABL1:F359V	CSQN=Missense;reference_codon=TTC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133748414_133748416delTTCinsGTA,chr9:g.133748414_133748416delTTCinsGTG,chr9:g.133748414_133748416delTTCinsGTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133748414T>A	c.1075T>A	ABL1:F359I	CSQN=Missense;reference_codon=TTC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748414_133748416delTTCinsATA,chr9:g.133748414_133748416delTTCinsATT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133748415T>G	c.1076T>G	ABL1:F359C	CSQN=Missense;reference_codon=TTC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr9:g.133748415_133748416delTCinsGT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133748414T>C	c.1075T>C	ABL1:F359L	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133748416C>A,chr9:g.133748416C>G;candidate_mnv_variants=chr9:g.133748414_133748416delTTCinsCTT,chr9:g.133748414_133748416delTTCinsCTG,chr9:g.133748414_133748416delTTCinsCTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133750256G>T	c.1087G>T	ABL1:D363Y	CSQN=Missense;reference_codon=GAT;candidate_codons=TAT,TAC;candidate_mnv_variants=chr9:g.133750256_133750258delGATinsTAC;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133750259C>A	c.1090C>A	ABL1:L364I	CSQN=Missense;reference_codon=CTT;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133750259_133750261delCTTinsATC,chr9:g.133750259_133750261delCTTinsATA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133750263C>T	c.1094C>T	ABL1:A365V	CSQN=Missense;reference_codon=GCT;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133750263_133750264delCTinsTA,chr9:g.133750263_133750264delCTinsTC,chr9:g.133750263_133750264delCTinsTG;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133750266C>G	c.1097C>G	ABL1:A366G	CSQN=Missense;reference_codon=GCC;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr9:g.133750266_133750267delCCinsGT,chr9:g.133750266_133750267delCCinsGG,chr9:g.133750266_133750267delCCinsGA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133750278T>C	c.1109T>C	ABL1:L370P	CSQN=Missense;reference_codon=CTG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr9:g.133750278_133750279delTGinsCT,chr9:g.133750278_133750279delTGinsCA,chr9:g.133750278_133750279delTGinsCC;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133750281T>C	c.1112T>C	ABL1:V371A	CSQN=Missense;reference_codon=GTA;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr9:g.133750281_133750282delTAinsCC,chr9:g.133750281_133750282delTAinsCG,chr9:g.133750281_133750282delTAinsCT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133750286G>A	c.1117G>A	ABL1:E373K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr9:g.133750286_133750288delGAGinsAAA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133750304G>A	c.1135G>A	ABL1:V379I	CSQN=Missense;reference_codon=GTA;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133750304_133750306delGTAinsATC,chr9:g.133750304_133750306delGTAinsATT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133750307G>A	c.1138G>A	ABL1:A380T	CSQN=Missense;reference_codon=GCT;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr9:g.133750307_133750309delGCTinsACA,chr9:g.133750307_133750309delGCTinsACG,chr9:g.133750307_133750309delGCTinsACC;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133750313T>C	c.1144T>C	ABL1:F382L	CSQN=Missense;reference_codon=TTT;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133750315T>A,chr9:g.133750315T>G;candidate_mnv_variants=chr9:g.133750313_133750315delTTTinsCTG,chr9:g.133750313_133750315delTTTinsCTA,chr9:g.133750313_133750315delTTTinsCTC;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133750319C>A	c.1150C>A	ABL1:L384M	CSQN=Missense;reference_codon=CTG;candidate_codons=ATG;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133750328T>A	c.1159T>A	ABL1:L387M	CSQN=Missense;reference_codon=TTG;candidate_codons=ATG;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133750330G>T	c.1161G>T	ABL1:L387F	CSQN=Missense;reference_codon=TTG;candidate_codons=TTT,TTC;candidate_snv_variants=chr9:g.133750330G>C;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133750328T>G	c.1159T>G	ABL1:L387V	CSQN=Missense;reference_codon=TTG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133750328_133750330delTTGinsGTA,chr9:g.133750328_133750330delTTGinsGTC,chr9:g.133750328_133750330delTTGinsGTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133750331A>C	c.1162A>C	ABL1:M388L	CSQN=Missense;reference_codon=ATG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133750331A>T;candidate_mnv_variants=chr9:g.133750331_133750333delATGinsCTT,chr9:g.133750331_133750333delATGinsCTA,chr9:g.133750331_133750333delATGinsCTC,chr9:g.133750331_133750333delATGinsTTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133750347A>G	c.1178A>G	ABL1:Y393C	CSQN=Missense;reference_codon=TAC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr9:g.133750347_133750348delACinsGT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133750356A>C	c.1187A>C	ABL1:H396P	CSQN=Missense;reference_codon=CAT;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr9:g.133750356_133750357delATinsCG,chr9:g.133750356_133750357delATinsCA,chr9:g.133750356_133750357delATinsCC;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133750356A>G	c.1187A>G	ABL1:H396R	CSQN=Missense;reference_codon=CAT;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr9:g.133750356_133750357delATinsGA,chr9:g.133750356_133750357delATinsGC,chr9:g.133750356_133750357delATinsGG,chr9:g.133750355_133750357delCATinsAGG,chr9:g.133750355_133750357delCATinsAGA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133750355_133750356delCAinsGC	c.1186_1187delCAinsGC	ABL1:H396A	CSQN=Missense;reference_codon=CAT;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr9:g.133750355_133750357delCATinsGCA,chr9:g.133750355_133750357delCATinsGCC,chr9:g.133750355_133750357delCATinsGCG;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133750358G>C	c.1189G>C	ABL1:A397P	CSQN=Missense;reference_codon=GCT;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr9:g.133750358_133750360delGCTinsCCG,chr9:g.133750358_133750360delGCTinsCCA,chr9:g.133750358_133750360delGCTinsCCC;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133750419C>T	c.1250C>T	ABL1:S417F	CSQN=Missense;reference_codon=TCC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr9:g.133750419_133750420delCCinsTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133750419C>A	c.1250C>A	ABL1:S417Y	CSQN=Missense;reference_codon=TCC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr9:g.133750419_133750420delCCinsAT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133750422T>G	c.1253T>G	ABL1:I418S	CSQN=Missense;reference_codon=ATC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr9:g.133750422_133750423delTCinsGT,chr9:g.133750421_133750422delATinsTC,chr9:g.133750421_133750423delATCinsTCT,chr9:g.133750421_133750423delATCinsTCG,chr9:g.133750421_133750423delATCinsTCA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133750421A>G	c.1252A>G	ABL1:I418V	CSQN=Missense;reference_codon=ATC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133750421_133750423delATCinsGTA,chr9:g.133750421_133750423delATCinsGTG,chr9:g.133750421_133750423delATCinsGTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133753828G>A	c.1297G>A	ABL1:A433T	CSQN=Missense;reference_codon=GCT;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr9:g.133753828_133753830delGCTinsACA,chr9:g.133753828_133753830delGCTinsACG,chr9:g.133753828_133753830delGCTinsACC;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133753844C>G	c.1313C>G	ABL1:S438C	CSQN=Missense;reference_codon=TCC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr9:g.133753844_133753845delCCinsGT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133753879G>A	c.1348G>A	ABL1:E450K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr9:g.133753879_133753881delGAGinsAAA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133753880A>G	c.1349A>G	ABL1:E450G	CSQN=Missense;reference_codon=GAG;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr9:g.133753880_133753881delAGinsGT,chr9:g.133753880_133753881delAGinsGA,chr9:g.133753880_133753881delAGinsGC;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133753880A>C	c.1349A>C	ABL1:E450A	CSQN=Missense;reference_codon=GAG;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr9:g.133753880_133753881delAGinsCA,chr9:g.133753880_133753881delAGinsCC,chr9:g.133753880_133753881delAGinsCT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133753880A>T	c.1349A>T	ABL1:E450V	CSQN=Missense;reference_codon=GAG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133753880_133753881delAGinsTA,chr9:g.133753880_133753881delAGinsTC,chr9:g.133753880_133753881delAGinsTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133753888G>A	c.1357G>A	ABL1:E453K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr9:g.133753888_133753890delGAGinsAAA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133753889A>G	c.1358A>G	ABL1:E453G	CSQN=Missense;reference_codon=GAG;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr9:g.133753889_133753890delAGinsGT,chr9:g.133753889_133753890delAGinsGA,chr9:g.133753889_133753890delAGinsGC;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133753889A>C	c.1358A>C	ABL1:E453A	CSQN=Missense;reference_codon=GAG;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr9:g.133753889_133753890delAGinsCA,chr9:g.133753889_133753890delAGinsCC,chr9:g.133753889_133753890delAGinsCT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133753889A>T	c.1358A>T	ABL1:E453V	CSQN=Missense;reference_codon=GAG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133753889_133753890delAGinsTA,chr9:g.133753889_133753890delAGinsTC,chr9:g.133753889_133753890delAGinsTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133753906G>A	c.1375G>A	ABL1:E459K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr9:g.133753906_133753908delGAGinsAAA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133753907A>G	c.1376A>G	ABL1:E459G	CSQN=Missense;reference_codon=GAG;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr9:g.133753907_133753908delAGinsGT,chr9:g.133753907_133753908delAGinsGA,chr9:g.133753907_133753908delAGinsGC;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133753907A>C	c.1376A>C	ABL1:E459A	CSQN=Missense;reference_codon=GAG;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr9:g.133753907_133753908delAGinsCA,chr9:g.133753907_133753908delAGinsCC,chr9:g.133753907_133753908delAGinsCT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133753907A>T	c.1376A>T	ABL1:E459V	CSQN=Missense;reference_codon=GAG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133753907_133753908delAGinsTA,chr9:g.133753907_133753908delAGinsTC,chr9:g.133753907_133753908delAGinsTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133753947G>C	c.1416G>C	ABL1:M472I	CSQN=Missense;reference_codon=ATG;candidate_codons=ATC,ATA,ATT;candidate_snv_variants=chr9:g.133753947G>A,chr9:g.133753947G>T;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133755470C>T	c.1439C>T	ABL1:P480L	CSQN=Missense;reference_codon=CCC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_mnv_variants=chr9:g.133755470_133755471delCCinsTT,chr9:g.133755470_133755471delCCinsTG,chr9:g.133755470_133755471delCCinsTA,chr9:g.133755469_133755471delCCCinsTTA,chr9:g.133755469_133755471delCCCinsTTG;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_9]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133755488T>C	c.1457T>C	ABL1:F486S	CSQN=Missense;reference_codon=TTT;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr9:g.133755487_133755488delTTinsAG,chr9:g.133755488_133755489delTTinsCG,chr9:g.133755488_133755489delTTinsCC,chr9:g.133755488_133755489delTTinsCA,chr9:g.133755487_133755489delTTTinsAGC;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_9]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133755893A>G	c.1520A>G	ABL1:E507G	CSQN=Missense;reference_codon=GAA;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr9:g.133755893_133755894delAAinsGT,chr9:g.133755893_133755894delAAinsGG,chr9:g.133755893_133755894delAAinsGC;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_10]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:E255K,E255V,Y253H,F359V,F359C,F359I	MUT		Resistant	ABL1 (E255K,E255V,Y253H,F359V,F359C,F359I)	CRubio-Perez	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133738363G>A	c.763G>A	ABL1:E255K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr9:g.133738363_133738365delGAGinsAAA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:E255K,E255V,Y253H,F359V,F359C,F359I	MUT		Resistant	ABL1 (E255K,E255V,Y253H,F359V,F359C,F359I)	CRubio-Perez	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133738364A>T	c.764A>T	ABL1:E255V	CSQN=Missense;reference_codon=GAG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133738364_133738365delAGinsTA,chr9:g.133738364_133738365delAGinsTC,chr9:g.133738364_133738365delAGinsTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:E255K,E255V,Y253H,F359V,F359C,F359I	MUT		Resistant	ABL1 (E255K,E255V,Y253H,F359V,F359C,F359I)	CRubio-Perez	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133738357T>C	c.757T>C	ABL1:Y253H	CSQN=Missense;reference_codon=TAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr9:g.133738357_133738359delTACinsCAT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:E255K,E255V,Y253H,F359V,F359C,F359I	MUT		Resistant	ABL1 (E255K,E255V,Y253H,F359V,F359C,F359I)	CRubio-Perez	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133748414T>G	c.1075T>G	ABL1:F359V	CSQN=Missense;reference_codon=TTC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133748414_133748416delTTCinsGTA,chr9:g.133748414_133748416delTTCinsGTG,chr9:g.133748414_133748416delTTCinsGTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:E255K,E255V,Y253H,F359V,F359C,F359I	MUT		Resistant	ABL1 (E255K,E255V,Y253H,F359V,F359C,F359I)	CRubio-Perez	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133748415T>G	c.1076T>G	ABL1:F359C	CSQN=Missense;reference_codon=TTC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr9:g.133748415_133748416delTCinsGT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:E255K,E255V,Y253H,F359V,F359C,F359I	MUT		Resistant	ABL1 (E255K,E255V,Y253H,F359V,F359C,F359I)	CRubio-Perez	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		chr9:g.133748414T>A	c.1075T>A	ABL1:F359I	CSQN=Missense;reference_codon=TTC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748414_133748416delTTCinsATA,chr9:g.133748414_133748416delTTCinsATT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:T315A,F317L,F317V,F317I,F317C,V299L	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,V299L)	RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		chr9:g.133748282A>G	c.943A>G	ABL1:T315A	CSQN=Missense;reference_codon=ACT;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr9:g.133748282_133748284delACTinsGCA,chr9:g.133748282_133748284delACTinsGCC,chr9:g.133748282_133748284delACTinsGCG;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:T315A,F317L,F317V,F317I,F317C,V299L	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,V299L)	RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		chr9:g.133748288T>C	c.949T>C	ABL1:F317L	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133748290C>A,chr9:g.133748290C>G;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsCTT,chr9:g.133748288_133748290delTTCinsCTG,chr9:g.133748288_133748290delTTCinsCTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:T315A,F317L,F317V,F317I,F317C,V299L	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,V299L)	RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		chr9:g.133748288T>G	c.949T>G	ABL1:F317V	CSQN=Missense;reference_codon=TTC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsGTA,chr9:g.133748288_133748290delTTCinsGTG,chr9:g.133748288_133748290delTTCinsGTT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:T315A,F317L,F317V,F317I,F317C,V299L	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,V299L)	RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		chr9:g.133748288T>A	c.949T>A	ABL1:F317I	CSQN=Missense;reference_codon=TTC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsATA,chr9:g.133748288_133748290delTTCinsATT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:T315A,F317L,F317V,F317I,F317C,V299L	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,V299L)	RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		chr9:g.133748289T>G	c.950T>G	ABL1:F317C	CSQN=Missense;reference_codon=TTC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr9:g.133748289_133748290delTCinsGT;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:T315A,F317L,F317V,F317I,F317C,V299L	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,V299L)	RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		chr9:g.133747588G>C	c.895G>C	ABL1:V299L	CSQN=Missense;reference_codon=GTG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133747588G>T;candidate_mnv_variants=chr9:g.133747588_133747590delGTGinsCTT,chr9:g.133747588_133747590delGTGinsCTA,chr9:g.133747588_133747590delGTGinsCTC,chr9:g.133747588_133747590delGTGinsTTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:T315I	MUT		Responsive	ABL1 (T315I)	CRubio-Perez;DTamborero;RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Approved	FDA guidelines	ABL1		CML;ALL	FDA		chr9:g.133748283C>T	c.944C>T	ABL1:T315I	CSQN=Missense;reference_codon=ACT;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748283_133748284delCTinsTC,chr9:g.133748283_133748284delCTinsTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia;Acute lymphoblastic leukemia
ABL1:T315I	MUT		Responsive	ABL1 (T315I)	RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		chr9:g.133748283C>T	c.944C>T	ABL1:T315I	CSQN=Missense;reference_codon=ACT;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748283_133748284delCTinsTC,chr9:g.133748283_133748284delCTinsTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000318560	Chronic myeloid leukemia
ABL1:V299L	MUT		Responsive	ABL1 (V299L)	DTamborero	Vandetanib	Pan-TK inhibitor	Vandetanib (Pan-TK inhibitor)		Pre-clinical	ABL1		CANCER	PMID:26924578		chr9:g.133747588G>C	c.895G>C	ABL1:V299L	CSQN=Missense;reference_codon=GTG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133747588G>T;candidate_mnv_variants=chr9:g.133747588_133747590delGTGinsCTT,chr9:g.133747588_133747590delGTGinsCTA,chr9:g.133747588_133747590delGTGinsCTC,chr9:g.133747588_133747590delGTGinsTTA;aliases=ENSP00000323315;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000318560	Any cancer type
AKT1:E17K	MUT		Responsive	AKT1 (E17K)	RDientsmann	[]	[AKT inhibitor]	AKT inhibitors	Clinical Trials	Pre-clinical	AKT1		CANCER	PMID:21464312;PMID:17611497;PMID:23134728; ENA 2015 (abstr B109)		chr14:g.105246551C>T	c.49G>A	AKT1:E17K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr14:g.105246549_105246551delCTCinsTTT;aliases=ENSP00000451828;source=Ensembl	inside_[cds_in_exon_2]	-	ENST00000554581	Any cancer type
AKT1:E17K	MUT		Responsive	AKT1 (E17K)	RDientsmann	[]	[allosteric AKT inhibitor]	allosteric AKT inhibitors		Early trials	AKT1		CANCER	ENA 2015 (abstract B109);PMID:28489509		chr14:g.105246551C>T	c.49G>A	AKT1:E17K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr14:g.105246549_105246551delCTCinsTTT;aliases=ENSP00000451828;source=Ensembl	inside_[cds_in_exon_2]	-	ENST00000554581	Any cancer type
AKT1:Q79K,E17K	MUT		Resistant	AKT1 (Q79K,E17K)	RDientsmann;DTamborero	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	AKT1		CM	PMID:24265152		chr14:g.105243048G>T	c.235C>A	AKT1:Q79K	CSQN=Missense;reference_codon=CAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr14:g.105243046_105243048delCTGinsTTT;aliases=ENSP00000451828;source=Ensembl	inside_[cds_in_exon_3]	-	ENST00000554581	Cutaneous melanoma
AKT1:Q79K,E17K	MUT		Resistant	AKT1 (Q79K,E17K)	RDientsmann;DTamborero	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	AKT1		CM	PMID:24265152		chr14:g.105246551C>T	c.49G>A	AKT1:E17K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr14:g.105246549_105246551delCTCinsTTT;aliases=ENSP00000451828;source=Ensembl	inside_[cds_in_exon_2]	-	ENST00000554581	Cutaneous melanoma
AKT1:E17K	MUT		Responsive	AKT1 (E17K)	RDientsmann	[]	[non-allosteric AKT inhibitor]	non-allosteric AKT inhibitors	Clinical Trials	Early trials	AKT1		CANCER	ENA 2015 (abstract B109);PMID:28489509		chr14:g.105246551C>T	c.49G>A	AKT1:E17K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr14:g.105246549_105246551delCTCinsTTT;aliases=ENSP00000451828;source=Ensembl	inside_[cds_in_exon_2]	-	ENST00000554581	Any cancer type
AKT1:E17K	MUT		Responsive	AKT1 (E17K)	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Case report	AKT1		HNSC	PMID:26763254		chr14:g.105246551C>T	c.49G>A	AKT1:E17K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr14:g.105246549_105246551delCTCinsTTT;aliases=ENSP00000451828;source=Ensembl	inside_[cds_in_exon_2]	-	ENST00000554581	Head an neck squamous
AKT1:H238Y	MUT		Responsive	AKT1 (H238Y)	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	AKT1		FH	ASCO 2015 (abstr 11010)		chr14:g.105239908G>A	c.712C>T	AKT1:H238Y	CSQN=Missense;reference_codon=CAC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr14:g.105239906_105239908delGTGinsATA;aliases=ENSP00000451828;source=Ensembl	inside_[cds_in_exon_8]	-	ENST00000554581	Fibrous histiocytoma
AKT1:E17K	MUT		Responsive	AKT1 (E17K)	RDientsmann	Tensirolimus	MTOR inhibitor	Tensirolimus (MTOR inhibitor)		Early trials	AKT1		ED	PMID:27016228		chr14:g.105246551C>T	c.49G>A	AKT1:E17K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr14:g.105246549_105246551delCTCinsTTT;aliases=ENSP00000451828;source=Ensembl	inside_[cds_in_exon_2]	-	ENST00000554581	Endometrium
ALK:F1174L	MUT		Responsive	ALK (F1174L)	RDientsmann	[]	[novel ALK inhibitor]	novel ALK inhibitors		Pre-clinical	ALK		LUAD	PMID:24327273		chr2:g.29443697A>G	c.3520T>C	ALK:F1174L	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr2:g.29443695G>T,chr2:g.29443695G>C;candidate_mnv_variants=chr2:g.29443695_29443697delGAAinsAAG,chr2:g.29443695_29443697delGAAinsCAG,chr2:g.29443695_29443697delGAAinsTAG;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_23]	-	ENST00000389048	Lung adenocarcinoma
ALK:I1171T	MUT		Resistant	ALK (I1171T)	RDientsmann	Alectinib	ALK inhibitor	Alectinib (ALK inhibitor)		Case report	ALK		LUAD	PMID:25228534		chr2:g.29445213A>G	c.3512T>C	ALK:I1171T	CSQN=Missense;reference_codon=ATC;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr2:g.29445212_29445213delGAinsTG,chr2:g.29445212_29445213delGAinsCG,chr2:g.29445212_29445213delGAinsAG;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_22]	-	ENST00000389048	Lung adenocarcinoma
ALK:E1408V	MUT		Responsive	ALK (E1408V)	RDientsmann	Brigatinib	Pan-TK inhibitor	Brigatinib (Pan-TK inhibitor)		Case report	ALK		LUAD	ASCO 2017 (abstr 9065)		chr2:g.29416730T>A	c.4223A>T	ALK:E1408V	CSQN=Missense;reference_codon=GAA;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr2:g.29416729_29416730delTTinsGA,chr2:g.29416729_29416730delTTinsCA,chr2:g.29416729_29416730delTTinsAA;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_29]	-	ENST00000389048	Lung adenocarcinoma
ALK:L1196M	MUT		Responsive	ALK (L1196M)	RDientsmann	Brigatinib	Pan-TK inhibitor	Brigatinib (Pan-TK inhibitor)		Case report	ALK		LUAD	ASCO 2017 (abstr 9065)		chr2:g.29443631G>T	c.3586C>A	ALK:L1196M	CSQN=Missense;reference_codon=CTG;candidate_codons=ATG;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_23]	-	ENST00000389048	Lung adenocarcinoma
ALK::consequence::inframe_insertion:.1151T.	MUT		Responsive	ALK inframe insertion (1151T)	RDientsmann	Ceritinib	ALK inhibitor	Ceritinib (ALK inhibitor)		FDA guidelines	ALK		LUAD	PMID:24670165									Lung adenocarcinoma
ALK:G1123S	MUT		Resistant	ALK (G1123S)	EArriola	Ceritinib	ALK inhibitor	Ceritinib (ALK inhibitor)		Case report	ALK		LUAD	PMID:26134233		chr2:g.29445466C>T	c.3367G>A	ALK:G1123S	CSQN=Missense;reference_codon=GGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr2:g.29445464_29445466delGCCinsACT,chr2:g.29445465_29445466delCCinsGA,chr2:g.29445464_29445466delGCCinsAGA,chr2:g.29445464_29445466delGCCinsCGA,chr2:g.29445464_29445466delGCCinsTGA;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_21]	-	ENST00000389048	Lung adenocarcinoma
ALK:L1196M,S1206Y,G1269A,I1171T	MUT		Responsive	ALK (L1196M,S1206Y,G1269A,I1171T)	RDientsmann	Ceritinib	ALK inhibitor	Ceritinib (ALK inhibitor)		FDA guidelines	ALK		LUAD	PMID:24670165;PMID:24327273		chr2:g.29443631G>T	c.3586C>A	ALK:L1196M	CSQN=Missense;reference_codon=CTG;candidate_codons=ATG;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_23]	-	ENST00000389048	Lung adenocarcinoma
ALK:L1196M,S1206Y,G1269A,I1171T	MUT		Responsive	ALK (L1196M,S1206Y,G1269A,I1171T)	RDientsmann	Ceritinib	ALK inhibitor	Ceritinib (ALK inhibitor)		FDA guidelines	ALK		LUAD	PMID:24670165;PMID:24327273		chr2:g.29443600G>T	c.3617C>A	ALK:S1206Y	CSQN=Missense;reference_codon=TCC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr2:g.29443599_29443600delGGinsAT;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_23]	-	ENST00000389048	Lung adenocarcinoma
ALK:L1196M,S1206Y,G1269A,I1171T	MUT		Responsive	ALK (L1196M,S1206Y,G1269A,I1171T)	RDientsmann	Ceritinib	ALK inhibitor	Ceritinib (ALK inhibitor)		FDA guidelines	ALK		LUAD	PMID:24670165;PMID:24327273		chr2:g.29432682C>G	c.3806G>C	ALK:G1269A	CSQN=Missense;reference_codon=GGA;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr2:g.29432681_29432682delTCinsGG,chr2:g.29432681_29432682delTCinsCG,chr2:g.29432681_29432682delTCinsAG;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_25]	-	ENST00000389048	Lung adenocarcinoma
ALK:L1196M,S1206Y,G1269A,I1171T	MUT		Responsive	ALK (L1196M,S1206Y,G1269A,I1171T)	RDientsmann	Ceritinib	ALK inhibitor	Ceritinib (ALK inhibitor)		FDA guidelines	ALK		LUAD	PMID:24670165;PMID:24327273		chr2:g.29445213A>G	c.3512T>C	ALK:I1171T	CSQN=Missense;reference_codon=ATC;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr2:g.29445212_29445213delGAinsTG,chr2:g.29445212_29445213delGAinsCG,chr2:g.29445212_29445213delGAinsAG;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_22]	-	ENST00000389048	Lung adenocarcinoma
ALK::consequence::inframe_insertion:.1151T.	MUT		Resistant	ALK inframe insertion (1151T)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ALK		LUAD	PMID:22277784									Lung adenocarcinoma
ALK:.	MUT		Resistant	ALK oncogenic mutation	EArriola	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)	Approved	Clinical trials	ALK		NSCLC	PMID:22235099									Non-small cell lung
ALK:C1156Y,L1196M	MUT		Resistant	ALK (C1156Y,L1196M)	EArriola	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)	Approved	Case report	ALK		NSCLC	PMID:20979473		chr2:g.29445258C>T	c.3467G>A	ALK:C1156Y	CSQN=Missense;reference_codon=TGC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr2:g.29445257_29445258delGCinsAT;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_22]	-	ENST00000389048	Non-small cell lung
ALK:C1156Y,L1196M	MUT		Resistant	ALK (C1156Y,L1196M)	EArriola	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)	Approved	Case report	ALK		NSCLC	PMID:20979473		chr2:g.29443631G>T	c.3586C>A	ALK:L1196M	CSQN=Missense;reference_codon=CTG;candidate_codons=ATG;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_23]	-	ENST00000389048	Non-small cell lung
ALK:F1174L	MUT		Resistant	ALK (F1174L)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	ALK		G	PMID:22072639		chr2:g.29443697A>G	c.3520T>C	ALK:F1174L	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr2:g.29443695G>T,chr2:g.29443695G>C;candidate_mnv_variants=chr2:g.29443695_29443697delGAAinsAAG,chr2:g.29443695_29443697delGAAinsCAG,chr2:g.29443695_29443697delGAAinsTAG;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_23]	-	ENST00000389048	Glioma
ALK:F856S,A348D	MUT		Responsive	ALK (F856S,A348D)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	ALK		AML	PMID:26032424		chr2:g.29455235A>G	c.2567T>C	ALK:F856S	CSQN=Missense;reference_codon=TTC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr2:g.29455235_29455236delAAinsCT,chr2:g.29455234_29455235delGAinsAG,chr2:g.29455234_29455235delGAinsCG,chr2:g.29455234_29455235delGAinsTG,chr2:g.29455234_29455236delGAAinsACT;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000389048	Acute myeloid leukemia
ALK:F856S,A348D	MUT		Responsive	ALK (F856S,A348D)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	ALK		AML	PMID:26032424		chr2:g.29754892G>T	c.1043C>A	ALK:A348D	CSQN=Missense;reference_codon=GCC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr2:g.29754891_29754892delGGinsAT;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_4]	-	ENST00000389048	Acute myeloid leukemia
ALK:L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T	MUT		Resistant	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ALK		LUAD	PMID:22277784;PMID:25228534		chr2:g.29443631G>T	c.3586C>A	ALK:L1196M	CSQN=Missense;reference_codon=CTG;candidate_codons=ATG;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_23]	-	ENST00000389048	Lung adenocarcinoma
ALK:L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T	MUT		Resistant	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ALK		LUAD	PMID:22277784;PMID:25228534		chr2:g.29445270A>C	c.3455T>G	ALK:L1152R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr2:g.29445270_29445271delAGinsCT,chr2:g.29445269_29445270delCAinsTC,chr2:g.29445269_29445270delCAinsGC,chr2:g.29445269_29445270delCAinsAC,chr2:g.29445269_29445271delCAGinsTCT;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_22]	-	ENST00000389048	Lung adenocarcinoma
ALK:L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T	MUT		Resistant	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ALK		LUAD	PMID:22277784;PMID:25228534		chr2:g.29445258C>T	c.3467G>A	ALK:C1156Y	CSQN=Missense;reference_codon=TGC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr2:g.29445257_29445258delGCinsAT;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_22]	-	ENST00000389048	Lung adenocarcinoma
ALK:L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T	MUT		Resistant	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ALK		LUAD	PMID:22277784;PMID:25228534		chr2:g.29443697A>G	c.3520T>C	ALK:F1174L	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr2:g.29443695G>T,chr2:g.29443695G>C;candidate_mnv_variants=chr2:g.29443695_29443697delGAAinsAAG,chr2:g.29443695_29443697delGAAinsCAG,chr2:g.29443695_29443697delGAAinsTAG;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_23]	-	ENST00000389048	Lung adenocarcinoma
ALK:L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T	MUT		Resistant	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ALK		LUAD	PMID:22277784;PMID:25228534		chr2:g.29443613C>T	c.3604G>A	ALK:G1202R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr2:g.29443613C>G;candidate_mnv_variants=chr2:g.29443611_29443613delTCCinsCCT,chr2:g.29443611_29443613delTCCinsGCG,chr2:g.29443611_29443613delTCCinsCCG,chr2:g.29443611_29443613delTCCinsACG;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_23]	-	ENST00000389048	Lung adenocarcinoma
ALK:L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T	MUT		Resistant	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ALK		LUAD	PMID:22277784;PMID:25228534		chr2:g.29443600G>T	c.3617C>A	ALK:S1206Y	CSQN=Missense;reference_codon=TCC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr2:g.29443599_29443600delGGinsAT;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_23]	-	ENST00000389048	Lung adenocarcinoma
ALK:L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T	MUT		Resistant	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ALK		LUAD	PMID:22277784;PMID:25228534		chr2:g.29432682C>G	c.3806G>C	ALK:G1269A	CSQN=Missense;reference_codon=GGA;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr2:g.29432681_29432682delTCinsGG,chr2:g.29432681_29432682delTCinsCG,chr2:g.29432681_29432682delTCinsAG;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_25]	-	ENST00000389048	Lung adenocarcinoma
ALK:L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T	MUT		Resistant	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ALK		LUAD	PMID:22277784;PMID:25228534		chr2:g.29445213A>G	c.3512T>C	ALK:I1171T	CSQN=Missense;reference_codon=ATC;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr2:g.29445212_29445213delGAinsTG,chr2:g.29445212_29445213delGAinsCG,chr2:g.29445212_29445213delGAinsAG;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_22]	-	ENST00000389048	Lung adenocarcinoma
ALK:L1198F	MUT		Responsive	ALK (L1198F)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ALK		LUAD	PMID:26698910		chr2:g.29443625G>A	c.3592C>T	ALK:L1198F	CSQN=Missense;reference_codon=CTC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr2:g.29443623_29443625delGAGinsAAA;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_23]	-	ENST00000389048	Lung adenocarcinoma
ALK:R1275Q,G1128A,I1171N,R1192P,F1245C	MUT		Responsive	ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	ALK		G	PMID:22072639		chr2:g.29432664C>T	c.3824G>A	ALK:R1275Q	CSQN=Missense;reference_codon=CGA;candidate_codons=CAA,CAG;candidate_mnv_variants=chr2:g.29432663_29432664delTCinsCT;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_25]	-	ENST00000389048	Glioma
ALK:R1275Q,G1128A,I1171N,R1192P,F1245C	MUT		Responsive	ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	ALK		G	PMID:22072639		chr2:g.29445450C>G	c.3383G>C	ALK:G1128A	CSQN=Missense;reference_codon=GGG;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr2:g.29445449_29445450delCCinsTG,chr2:g.29445449_29445450delCCinsGG,chr2:g.29445449_29445450delCCinsAG;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_21]	-	ENST00000389048	Glioma
ALK:R1275Q,G1128A,I1171N,R1192P,F1245C	MUT		Responsive	ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	ALK		G	PMID:22072639		chr2:g.29445213A>T	c.3512T>A	ALK:I1171N	CSQN=Missense;reference_codon=ATC;candidate_codons=AAC,AAT;candidate_mnv_variants=chr2:g.29445212_29445213delGAinsAT;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_22]	-	ENST00000389048	Glioma
ALK:R1275Q,G1128A,I1171N,R1192P,F1245C	MUT		Responsive	ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	ALK		G	PMID:22072639		chr2:g.29443642C>G	c.3575G>C	ALK:R1192P	CSQN=Missense;reference_codon=CGG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr2:g.29443641_29443642delCCinsAG,chr2:g.29443641_29443642delCCinsTG,chr2:g.29443641_29443642delCCinsGG;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_23]	-	ENST00000389048	Glioma
ALK:R1275Q,G1128A,I1171N,R1192P,F1245C	MUT		Responsive	ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	ALK		G	PMID:22072639		chr2:g.29436859A>C	c.3734T>G	ALK:F1245C	CSQN=Missense;reference_codon=TTC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr2:g.29436858_29436859delGAinsAC;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_24]	-	ENST00000389048	Glioma
ALK:C1156Y	MUT		Responsive	ALK (C1156Y)	RDientsmann	Lorlatinib	ALK&ROS1 inhibitor	Lorlatinib (ALK&ROS1 inhibitor)		Pre-clinical	ALK		LUAD	PMID:27401242		chr2:g.29445258C>T	c.3467G>A	ALK:C1156Y	CSQN=Missense;reference_codon=TGC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr2:g.29445257_29445258delGCinsAT;aliases=ENSP00000373700;source=Ensembl	inside_[cds_in_exon_22]	-	ENST00000389048	Lung adenocarcinoma
APC:.	MUT		Responsive	APC oncogenic mutation	RDientsmann	[]	[Tankyrase inhibitor]	Tankyrase inhibitors		Pre-clinical	APC		COREAD	PMID:22440753;PMID:23539443									Colorectal adenocarcinoma
AR:L702H,T878A	MUT		Resistant	AR (L702H,T878A)	RDientsmann	Abiraterone	AR inhibitor	Abiraterone (AR inhibitor)	Approved	Early trials	AR		PRAD	PMID:26537258		chrX:g.66931463T>A	c.2105T>A	AR:L702H	CSQN=Missense;reference_codon=CTC;candidate_codons=CAT,CAC;candidate_mnv_variants=chrX:g.66931463_66931464delTCinsAT;aliases=ENSP00000363822;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000374690	Prostate adenocarcinoma
AR:L702H,T878A	MUT		Resistant	AR (L702H,T878A)	RDientsmann	Abiraterone	AR inhibitor	Abiraterone (AR inhibitor)	Approved	Early trials	AR		PRAD	PMID:26537258		chrX:g.66943552A>G	c.2632A>G	AR:T878A	CSQN=Missense;reference_codon=ACT;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chrX:g.66943552_66943554delACTinsGCA,chrX:g.66943552_66943554delACTinsGCC,chrX:g.66943552_66943554delACTinsGCG;aliases=ENSP00000363822;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000374690	Prostate adenocarcinoma
AR:F877L	MUT		Resistant	AR (F877L)	RDientsmann;ARodriguez-Vida	Arn-509	AR inhibitor	Arn-509 (AR inhibitor)		Case report	AR	PRAD	PRAD	PMID:23779130		chrX:g.66943549T>C	c.2629T>C	AR:F877L	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chrX:g.66943551C>A,chrX:g.66943551C>G;candidate_mnv_variants=chrX:g.66943549_66943551delTTCinsCTT,chrX:g.66943549_66943551delTTCinsCTG,chrX:g.66943549_66943551delTTCinsCTA;aliases=ENSP00000363822;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000374690	Prostate adenocarcinoma
AR:F877L	MUT		Resistant	AR (F877L)	RDientsmann;ARodriguez-Vida	Enzalutamide	AR inhibitor	Enzalutamide (AR inhibitor)		Case report	AR	PRAD	PRAD	PMID:23779130		chrX:g.66943549T>C	c.2629T>C	AR:F877L	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chrX:g.66943551C>A,chrX:g.66943551C>G;candidate_mnv_variants=chrX:g.66943549_66943551delTTCinsCTT,chrX:g.66943549_66943551delTTCinsCTG,chrX:g.66943549_66943551delTTCinsCTA;aliases=ENSP00000363822;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000374690	Prostate adenocarcinoma
AR:T878A	MUT		Resistant	AR (T878A)	RDientsmann;ARodriguez-Vida	Flutamide	AR inhibitor	Flutamide (AR inhibitor)		Case report	AR	PRAD	PRAD	PMID:2260966		chrX:g.66943552A>G	c.2632A>G	AR:T878A	CSQN=Missense;reference_codon=ACT;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chrX:g.66943552_66943554delACTinsGCA,chrX:g.66943552_66943554delACTinsGCC,chrX:g.66943552_66943554delACTinsGCG;aliases=ENSP00000363822;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000374690	Prostate adenocarcinoma
ARAF:.	MUT		Resistant	ARAF oncogenic mutation	RDientsmann	[]	[BRAF inhibitor;EGFR mAb inhibitor]	BRAF inhibitor + EGFR mAb inhibitors		Case report	ARAF		COREAD	ENA 2014 (abstr 428)									Colorectal adenocarcinoma
ARAF:.	MUT		Resistant	ARAF oncogenic mutation	RDientsmann	[]	[BRAF inhibitor;MEK inhibitor]	BRAF inhibitor + MEK inhibitors		Case report	ARAF		COREAD	ENA 2014 (abstr 428)									Colorectal adenocarcinoma
ARAF:S214C	MUT		Responsive	ARAF (S214C)	JAlbanell;ARovira;RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)	FDA approved	Case report	ARAF		LUAD	http://www.jci.org/articles/view/72763;PMID:24569458	Direct:primary target	chrX:g.47426121C>G	c.641C>G	ARAF:S214C	CSQN=Missense;reference_codon=TCC;candidate_codons=TGT,TGC;candidate_mnv_variants=chrX:g.47426121_47426122delCCinsGT;aliases=ENSP00000366244;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000377045	Lung adenocarcinoma
ARID1A:.	MUT		Responsive	ARID1A oncogenic mutation	RDientsmann	[]	[ATR inhibitors]	ATR inhibitors		Pre-clinical	ARID1A		CANCER	PMID:27958275									Any cancer type
ARID1A:.	MUT		Responsive	ARID1A oncogenic mutation	RDientsmann	[]	[EZH2 inhibitor]	EZH2 inhibitors		Pre-clinical	ARID1A		OV	PMID:25686104									Ovary
ARID1A:.	MUT		Responsive	ARID1A oncogenic mutation	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Pre-clinical	ARID1A		CANCER	PMID:26069190									Any cancer type
ATM:.	MUT		Responsive	ATM oncogenic mutation	RDientsmann	[]	[ATR inhibitor]	ATR inhibitors		Case report	ATM		COREAD	ENA 2015 (abstr A48)									Colorectal adenocarcinoma
ATM:.	MUT		Responsive	ATM oncogenic mutation	RDientsmann	[]	[DNA-PKc inhibitor]	DNA-PKc inhibitors		Pre-clinical	ATM		LY	PMID:23761041									Lymphoma
ATM:.	MUT		Responsive	ATM oncogenic mutation	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Early trials	ATM		ST	ENA 2014 (abstr 8LBA)									Stomach
ATM:.	MUT		Responsive	ATM oncogenic mutation	ARodriguez-Vida	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	Early trials	ATM	BLCA	BLCA	PMID:26238431	Indirect								Bladder
ATM:.	MUT		Responsive	ATM oncogenic mutation	RDientsmann	Olaparib	PARP inhibitor	Olaparib (PARP inhibitor)		Early trials	ATM		ST;PRAD	ENA 2014 (abstr 8LBA);PMID:26510020									Stomach;Prostate adenocarcinoma
ATM:.	MUT		Responsive	ATM oncogenic mutation	RDientsmann	Temozolomide	Chemotherapy	Temozolomide (Chemotherapy)		Pre-clinical	ATM		G	PMID:23960094									Glioma
ATR:.	MUT	Cell line	Responsive	ATR oncogenic mutation	CRubio-Perez;ECampo;RDientsmann	Olaparib	PARP inhibitor	Olaparib (PARP inhibitor)	Approved	Pre-clinical	ATR		OV;CANCER	PMID:23548269	Indirect								Ovary;Any cancer type
ATR:.	MUT		Responsive	ATR oncogenic mutation	RDientsmann	Temozolomide	Chemotherapy	Temozolomide (Chemotherapy)		Pre-clinical	ATR		G	PMID:23960094									Glioma
B2M:.	MUT		Resistant	B2M oncogenic mutation	RDientsmann	[]	[PD1 Ab inhibitor]	PD1 Ab inhibitors		Case report	B2M		CM	PMID:27433843									Cutaneous melanoma
BAP1:.	MUT		Responsive	BAP1 oncogenic mutation	RDientsmann	[]	[EZH2 inhibitor]	EZH2 inhibitors		Pre-clinical	BAP1		MESO	PMID:26437366									Mesothelioma
BAP1:.	MUT		Responsive	BAP1 oncogenic mutation	RDientsmann	[]	[HDAC inhibitor]	HDAC inhibitors		Pre-clinical	BAP1		CM	PMID:22038994									Cutaneous melanoma
BAP1:.	MUT		Responsive	BAP1 oncogenic mutation	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Pre-clinical	BAP1		R;CANCER	PMID:22683710									Renal;Any cancer type
BCOR:.	MUT		Responsive	BCOR oncogenic mutation	RDientsmann	Enzastaurin	PKCb inhibitor	Enzastaurin (PKCb inhibitor)		Pre-clinical	BCOR		ST	PMID:27397505									Stomach
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	[]	[BRAF inhibitor;CDK2/4 inhibitor]	BRAF inhibitor + CDK2/4 inhibitors		Pre-clinical	BRAF		CM	PMID:22997239		chr7:g.140453136A>T	c.1799T>A	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:V600.	MUT		Responsive	BRAF (V600)	RDientsmann	[]	[BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor]	BRAF inhibitor + EGFR mAb inhibitor +/- PI3K inhibitors		Early trials	BRAF		COREAD	PMID:28363909									Colorectal adenocarcinoma
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	[]	[BRAF inhibitor;HSP90 inhibitor]	BRAF inhibitor + HSP90 inhibitors		Pre-clinical	BRAF		CM	PMID:22351686		chr7:g.140453136A>T	c.1799T>A	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	[]	[BRAF inhibitor;MEK inhibitor]	BRAF inhibitor + MEK inhibitors		Early trials	BRAF		TH	ASCO 2013 (abstr 9029)		chr7:g.140453136A>T	c.1799T>A	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Thyroid
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	[]	[BRAF inhibitor;PI3K pathway inhibitor]	BRAF inhibitor + PI3K pathway inhibitors		Pre-clinical	BRAF		CM	PMID:22389471;PMID:21156289		chr7:g.140453136A>T	c.1799T>A	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:L597R	MUT		Responsive	BRAF (L597R)	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	BRAF		CM	PMID:23715574		chr7:g.140453145A>C	c.1790T>G	BRAF:L597R	CSQN=Missense;reference_codon=CTA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.140453145_140453146delAGinsCT,chr7:g.140453144_140453145delTAinsGC,chr7:g.140453144_140453145delTAinsCC,chr7:g.140453144_140453145delTAinsAC,chr7:g.140453144_140453146delTAGinsCCT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Pre-clinical	BRAF		G	PMID:22038996;PMID:22586120		chr7:g.140453136A>T	c.1799T>A	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Glioma
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	BRAF		OV	PMID:22608338		chr7:g.140453136A>T	c.1799T>A	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Ovary
BRAF:V600E,G469A	MUT		Resistant	BRAF (V600E,G469A)	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Case report	BRAF		LUAD	PMID:22773810		chr7:g.140453136A>T	c.1799T>A	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Lung adenocarcinoma
BRAF:V600E,G469A	MUT		Resistant	BRAF (V600E,G469A)	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Case report	BRAF		LUAD	PMID:22773810		chr7:g.140481402C>G	c.1406G>C	BRAF:G469A	CSQN=Missense;reference_codon=GGA;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr7:g.140481401_140481402delTCinsGG,chr7:g.140481401_140481402delTCinsCG,chr7:g.140481401_140481402delTCinsAG;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_11]	-	ENST00000288602	Lung adenocarcinoma
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	[]	[ERK inhibitor]	ERK inhibitors		Pre-clinical	BRAF		CM	PMID:23614898;PMID:22997239		chr7:g.140453136A>T	c.1799T>A	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:G469A	MUT		Responsive	BRAF (G469A)	RDientsmann	[]	[ERK inhibitor]	ERK inhibitors		Case report	BRAF		HNSC	ASCO 2017 (abstr 2508)		chr7:g.140481402C>G	c.1406G>C	BRAF:G469A	CSQN=Missense;reference_codon=GGA;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr7:g.140481401_140481402delTCinsGG,chr7:g.140481401_140481402delTCinsCG,chr7:g.140481401_140481402delTCinsAG;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_11]	-	ENST00000288602	Head an neck squamous
BRAF:L485W	MUT		Responsive	BRAF (L485W)	RDientsmann	[]	[ERK inhibitor]	ERK inhibitors		Case report	BRAF		BT	ASCO 2017 (abstr 2508)		chr7:g.140477854A>C	c.1454T>G	BRAF:L485W	CSQN=Missense;reference_codon=TTG;candidate_codons=TGG;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_12]	-	ENST00000288602	Billiary tract
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	[]	[ERK inhibitor]	ERK inhibitors		Early trials	BRAF		LUAD	ASCO 2017 (abstr 2508)		chr7:g.140453136A>T	c.1799T>A	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Lung adenocarcinoma
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Early trials	BRAF		TH	PMID:22241789		chr7:g.140453136A>T	c.1799T>A	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Thyroid
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	BRAF		OV	PMID:19018267		chr7:g.140453136A>T	c.1799T>A	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Ovary
BRAF::consequence::inframe_deletion:L485.,::inframe_deletion:P490.	MUT		Responsive	BRAF inframe deletion (L485),inframe deletion (P490)	RDientsmann	[]	[Pan-RAF inhibitor]	Pan-RAF inhibitors		Pre-clinical	BRAF		CANCER	PMID:26732095									Any cancer type
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	[]	[Pan-RAF inhibitor]	Pan-RAF inhibitors		Early trials	BRAF		CM	ESMO 2015 (abstract 300);AACR 2016 (abstr CT005);AACR 2017 (abstr  CT002)		chr7:g.140453136A>T	c.1799T>A	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:K601R,L597R,V600R	MUT		Responsive	BRAF (K601R,L597R,V600R)	RDientsmann	[Trametinib]	[MEK inhibitor]	MEK inhibitors (Trametinib,etc)		Case report	BRAF		CM	PMID:23248257;PMID:22805292;PMID:23248257		chr7:g.140453133T>C	c.1802A>G	BRAF:K601R	CSQN=Missense;reference_codon=AAA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.140453132_140453133delTTinsCC,chr7:g.140453133_140453134delTTinsCG,chr7:g.140453132_140453134delTTTinsGCG,chr7:g.140453132_140453134delTTTinsCCG,chr7:g.140453132_140453134delTTTinsACG;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:K601R,L597R,V600R	MUT		Responsive	BRAF (K601R,L597R,V600R)	RDientsmann	[Trametinib]	[MEK inhibitor]	MEK inhibitors (Trametinib,etc)		Case report	BRAF		CM	PMID:23248257;PMID:22805292;PMID:23248257		chr7:g.140453145A>C	c.1790T>G	BRAF:L597R	CSQN=Missense;reference_codon=CTA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.140453145_140453146delAGinsCT,chr7:g.140453144_140453145delTAinsGC,chr7:g.140453144_140453145delTAinsCC,chr7:g.140453144_140453145delTAinsAC,chr7:g.140453144_140453146delTAGinsCCT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:K601R,L597R,V600R	MUT		Responsive	BRAF (K601R,L597R,V600R)	RDientsmann	[Trametinib]	[MEK inhibitor]	MEK inhibitors (Trametinib,etc)		Case report	BRAF		CM	PMID:23248257;PMID:22805292;PMID:23248257		chr7:g.140453136_140453137delACinsCT	c.1798_1799delGTinsAG	BRAF:V600R	CSQN=Missense;reference_codon=GTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.140453136_140453137delACinsCG,chr7:g.140453135_140453137delCACinsTCT,chr7:g.140453135_140453137delCACinsTCG,chr7:g.140453135_140453137delCACinsGCG,chr7:g.140453135_140453137delCACinsACG;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:V600E	MUT		Resistant	BRAF (V600E)	RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)		Late trials	BRAF		COREAD	PMID:20619739;PMID:21163703;PMID:23325582		chr7:g.140453136A>T	c.1799T>A	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Colorectal adenocarcinoma
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	Dabrafenib	BRAF inhibitor	Dabrafenib (BRAF inhibitor)		Early trials	BRAF		LUAD;TH	PMID:23524406;PMID:22608338;ASCO 2013 (abstr 8009);ESMO 2014 (abstr LBA38_PR);PMID:20818844;PMID:23489023;PMID:27080216		chr7:g.140453136A>T	c.1799T>A	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Lung adenocarcinoma;Thyroid
BRAF:V600E	MUT		Responsive	BRAF (V600E)	CRubio-Perez	Dabrafenib	BRAF inhibitor	Dabrafenib (BRAF inhibitor)		NCCN guidelines	BRAF		NSCLC	NCCN		chr7:g.140453136A>T	c.1799T>A	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Non-small cell lung
BRAF:V600E	MUT		Responsive	BRAF (V600E)	CRubio-Perez;DTamborero;RDientsmann	Dabrafenib	BRAF inhibitor	Dabrafenib (BRAF inhibitor)	Approved	FDA guidelines	BRAF		CM	FDA		chr7:g.140453136A>T	c.1799T>A	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	Dabrafenib	BRAF inhibitor	Dabrafenib (BRAF inhibitor)		Case report	BRAF		GIST	PMID:23470635;PMID:22608338		chr7:g.140453136A>T	c.1799T>A	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Gastrointestinal stromal
BRAF:V600R	MUT		Responsive	BRAF (V600R)	RDientsmann	Dabrafenib	BRAF inhibitor	Dabrafenib (BRAF inhibitor)		Early trials	BRAF		CM	PMID:23237741		chr7:g.140453136_140453137delACinsCT	c.1798_1799delGTinsAG	BRAF:V600R	CSQN=Missense;reference_codon=GTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.140453136_140453137delACinsCG,chr7:g.140453135_140453137delCACinsTCT,chr7:g.140453135_140453137delCACinsTCG,chr7:g.140453135_140453137delCACinsGCG,chr7:g.140453135_140453137delCACinsACG;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	Dabrafenib;Trametinib	BRAF inhibitor;MEK inhibitor	Dabrafenib + Trametinib (BRAF inhibitor + MEK inhibitor)		Early trials	BRAF		COREAD	PMID:26392102;ASCO 2015 (abstr 8006)		chr7:g.140453136A>T	c.1799T>A	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Colorectal adenocarcinoma
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	Dabrafenib;Trametinib	BRAF inhibitor;MEK inhibitor	Dabrafenib + Trametinib (BRAF inhibitor + MEK inhibitor)		Case report	BRAF		NEU	PMID:27048246		chr7:g.140453136A>T	c.1799T>A	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Neuroendocrine
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	Dabrafenib;Trametinib	BRAF inhibitor;MEK inhibitor	Dabrafenib + Trametinib (BRAF inhibitor + MEK inhibitor)		FDA guidelines	BRAF		LUAD	PMID:27283860		chr7:g.140453136A>T	c.1799T>A	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Lung adenocarcinoma
BRAF:V600E,V600K	MUT		Responsive	BRAF (V600E,V600K)	RDientsmann	Dabrafenib;Trametinib	BRAF inhibitor;MEK inhibitor	Dabrafenib + Trametinib (BRAF inhibitor + MEK inhibitor)	Approved	FDA guidelines	BRAF		CM	FDA		chr7:g.140453136A>T	c.1799T>A	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:V600E,V600K	MUT		Responsive	BRAF (V600E,V600K)	RDientsmann	Dabrafenib;Trametinib	BRAF inhibitor;MEK inhibitor	Dabrafenib + Trametinib (BRAF inhibitor + MEK inhibitor)	Approved	FDA guidelines	BRAF		CM	FDA		chr7:g.140453136_140453137delACinsTT	c.1798_1799delGTinsAA	BRAF:V600K	CSQN=Missense;reference_codon=GTG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr7:g.140453135_140453137delCACinsTTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:G466V	MUT		Responsive	BRAF (G466V)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	BRAF		LUAD	PMID:22649091		chr7:g.140481411C>A	c.1397G>T	BRAF:G466V	CSQN=Missense;reference_codon=GGA;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr7:g.140481410_140481411delTCinsGA,chr7:g.140481410_140481411delTCinsCA,chr7:g.140481410_140481411delTCinsAA;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_11]	-	ENST00000288602	Lung adenocarcinoma
BRAF:Y472C	MUT		Responsive	BRAF (Y472C)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Case report	BRAF		LUAD	PMID:22649091		chr7:g.140481393T>C	c.1415A>G	BRAF:Y472C	CSQN=Missense;reference_codon=TAC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr7:g.140481392_140481393delGTinsAC;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_11]	-	ENST00000288602	Lung adenocarcinoma
BRAF:V600.	MUT		Responsive	BRAF (V600)	RDientsmann	Irinotecan;Vemurafenib;Cetuximab	TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor	Irinotecan + Vemurafenib + Cetuximab (TOPO1 inhibitor + BRAF inhibitor + EGFR mAb inhibitor)		Early trials	BRAF		COREAD	PMID:27729313									Colorectal adenocarcinoma
BRAF:V600E	MUT		Resistant	BRAF (V600E)	RDientsmann	Panitumumab	EGFR mAb inhibitor	Panitumumab (EGFR mAb inhibitor)		Late trials	BRAF		COREAD	PMID:20619739;PMID:21163703;PMID:23325582		chr7:g.140453136A>T	c.1799T>A	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Colorectal adenocarcinoma
BRAF:V600.	MUT		Responsive	BRAF (V600)	RDientsmann	Panitumumab;Dabrafenib;BYL719	EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor	Panitumumab + Dabrafenib + BYL719 (EGFR mAb inhibitor + BRAF inhibitor + PI3K inhibitor)	Approved; Approved;Clinical Trials	Early trials	BRAF		COREAD	ENA 2014 (abstr 11LBA)	Indirect								Colorectal adenocarcinoma
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	Panitumumab;Dabrafenib;Trametinib	EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor	Panitumumab + Dabrafenib + Trametinib (EGFR mAb inhibitor + BRAF inhibitor + MEK inhibitor)	Approved; Approved;Clinical Trials	Early trials	BRAF		COREAD	ASCO 2014 (abstr 3515);ASCO 2015 (abstr 103)	Indirect	chr7:g.140453136A>T	c.1799T>A	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Colorectal adenocarcinoma
BRAF:V600E	MUT	Cell line	Responsive	BRAF (V600E)	MMartínez	PLX4720	BRAF inhibitor	PLX4720 (BRAF inhibitor)		Pre-clinical	BRAF		MA	PMC3638050		chr7:g.140453136A>T	c.1799T>A	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Malignant astrocytoma
BRAF:V600E	MUT		Responsive	BRAF (V600E)	MMartínez	Selumetinib	MEK inhibitor	Selumetinib (MEK inhibitor)	Clinical Trials	Early trials	BRAF		PG	NCT01089101		chr7:g.140453136A>T	c.1799T>A	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Pediatric glioma
BRAF:D594G,G469E	MUT		Responsive	BRAF (D594G,G469E)	RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Pre-clinical	BRAF		CM	PMID:18794803		chr7:g.140453154T>C	c.1781A>G	BRAF:D594G	CSQN=Missense;reference_codon=GAT;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr7:g.140453153_140453154delATinsCC,chr7:g.140453153_140453154delATinsTC,chr7:g.140453153_140453154delATinsGC;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:D594G,G469E	MUT		Responsive	BRAF (D594G,G469E)	RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Pre-clinical	BRAF		CM	PMID:18794803		chr7:g.140481402C>T	c.1406G>A	BRAF:G469E	CSQN=Missense;reference_codon=GGA;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140481401_140481402delTCinsCT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_11]	-	ENST00000288602	Cutaneous melanoma
BRAF:V600E,V600K	MUT		Responsive	BRAF (V600E,V600K)	CRubio-Perez;DTamborero;RDientsmann	Trametinib	MEK inhibitor	Trametinib (MEK inhibitor)	Approved	FDA guidelines	BRAF		CM	FDA		chr7:g.140453136A>T	c.1799T>A	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:V600E,V600K	MUT		Responsive	BRAF (V600E,V600K)	CRubio-Perez;DTamborero;RDientsmann	Trametinib	MEK inhibitor	Trametinib (MEK inhibitor)	Approved	FDA guidelines	BRAF		CM	FDA		chr7:g.140453136_140453137delACinsTT	c.1798_1799delGTinsAA	BRAF:V600K	CSQN=Missense;reference_codon=GTG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr7:g.140453135_140453137delCACinsTTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF::consequence::inframe_deletion:L485.,::inframe_deletion:P490.	MUT		Resistant	BRAF inframe deletion (L485),inframe deletion (P490)	RDientsmann	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	Pre-clinical	BRAF		CANCER	PMID:26732095									Any cancer type
BRAF:V600.	MUT		No Responsive	BRAF (V600)	DTamborero	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	Early trials	BRAF		COREAD	PMID:26287849									Colorectal adenocarcinoma
BRAF:V600D,V600K,V600M,V600G,V600R	MUT		Responsive	BRAF (V600D,V600K,V600M,V600G,V600R)	CRubio-Perez	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	NCCN guidelines	BRAF		CM	NCCN		chr7:g.140453135_140453136delCAinsGT	c.1799_1800delTGinsAC	BRAF:V600D	CSQN=Missense;reference_codon=GTG;candidate_codons=GAC,GAT;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsAT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:V600D,V600K,V600M,V600G,V600R	MUT		Responsive	BRAF (V600D,V600K,V600M,V600G,V600R)	CRubio-Perez	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	NCCN guidelines	BRAF		CM	NCCN		chr7:g.140453136_140453137delACinsTT	c.1798_1799delGTinsAA	BRAF:V600K	CSQN=Missense;reference_codon=GTG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr7:g.140453135_140453137delCACinsTTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:V600D,V600K,V600M,V600G,V600R	MUT		Responsive	BRAF (V600D,V600K,V600M,V600G,V600R)	CRubio-Perez	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	NCCN guidelines	BRAF		CM	NCCN		chr7:g.140453137C>T	c.1798G>A	BRAF:V600M	CSQN=Missense;reference_codon=GTG;candidate_codons=ATG;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:V600D,V600K,V600M,V600G,V600R	MUT		Responsive	BRAF (V600D,V600K,V600M,V600G,V600R)	CRubio-Perez	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	NCCN guidelines	BRAF		CM	NCCN		chr7:g.140453136A>C	c.1799T>G	BRAF:V600G	CSQN=Missense;reference_codon=GTG;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsAC,chr7:g.140453135_140453136delCAinsTC,chr7:g.140453135_140453136delCAinsGC;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:V600D,V600K,V600M,V600G,V600R	MUT		Responsive	BRAF (V600D,V600K,V600M,V600G,V600R)	CRubio-Perez	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	NCCN guidelines	BRAF		CM	NCCN		chr7:g.140453136_140453137delACinsCT	c.1798_1799delGTinsAG	BRAF:V600R	CSQN=Missense;reference_codon=GTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.140453136_140453137delACinsCG,chr7:g.140453135_140453137delCACinsTCT,chr7:g.140453135_140453137delCACinsTCG,chr7:g.140453135_140453137delCACinsGCG,chr7:g.140453135_140453137delCACinsACG;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	Case report	BRAF		LUAD;HCL;MYMA	PMID:22743296;PMID:22621641;PMID:23612012		chr7:g.140453136A>T	c.1799T>A	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Lung adenocarcinoma;Hairy-Cell leukemia;Myeloma
BRAF:V600E	MUT		Responsive	BRAF (V600E)	MMartínez	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	Early trials	BRAF		MA	PMID:22586120		chr7:g.140453136A>T	c.1799T>A	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Malignant astrocytoma
BRAF:V600E	MUT		Responsive	BRAF (V600E)	CRubio-Perez;DTamborero;RDientsmann	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	FDA guidelines	BRAF		CM	FDA		chr7:g.140453136A>T	c.1799T>A	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	Early trials	BRAF		THCA	PMID:22608338;PMID:20818844;PMID:23489023		chr7:g.140453136A>T	c.1799T>A	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Thyroid carcinoma
BRAF:V600E,V600D,V600K,V600M,V600G,V600R	MUT		Responsive	BRAF (V600E,V600D,V600K,V600M,V600G,V600R)	DTamborero	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	NCCN guidelines	BRAF		NSCLC;HISLC;HISEC	PMID:26287849	Indirect	chr7:g.140453136A>T	c.1799T>A	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Non-small cell lung;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis
BRAF:V600E,V600D,V600K,V600M,V600G,V600R	MUT		Responsive	BRAF (V600E,V600D,V600K,V600M,V600G,V600R)	DTamborero	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	NCCN guidelines	BRAF		NSCLC;HISLC;HISEC	PMID:26287849	Indirect	chr7:g.140453135_140453136delCAinsGT	c.1799_1800delTGinsAC	BRAF:V600D	CSQN=Missense;reference_codon=GTG;candidate_codons=GAC,GAT;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsAT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Non-small cell lung;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis
BRAF:V600E,V600D,V600K,V600M,V600G,V600R	MUT		Responsive	BRAF (V600E,V600D,V600K,V600M,V600G,V600R)	DTamborero	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	NCCN guidelines	BRAF		NSCLC;HISLC;HISEC	PMID:26287849	Indirect	chr7:g.140453136_140453137delACinsTT	c.1798_1799delGTinsAA	BRAF:V600K	CSQN=Missense;reference_codon=GTG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr7:g.140453135_140453137delCACinsTTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Non-small cell lung;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis
BRAF:V600E,V600D,V600K,V600M,V600G,V600R	MUT		Responsive	BRAF (V600E,V600D,V600K,V600M,V600G,V600R)	DTamborero	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	NCCN guidelines	BRAF		NSCLC;HISLC;HISEC	PMID:26287849	Indirect	chr7:g.140453137C>T	c.1798G>A	BRAF:V600M	CSQN=Missense;reference_codon=GTG;candidate_codons=ATG;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Non-small cell lung;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis
BRAF:V600E,V600D,V600K,V600M,V600G,V600R	MUT		Responsive	BRAF (V600E,V600D,V600K,V600M,V600G,V600R)	DTamborero	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	NCCN guidelines	BRAF		NSCLC;HISLC;HISEC	PMID:26287849	Indirect	chr7:g.140453136A>C	c.1799T>G	BRAF:V600G	CSQN=Missense;reference_codon=GTG;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsAC,chr7:g.140453135_140453136delCAinsTC,chr7:g.140453135_140453136delCAinsGC;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Non-small cell lung;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis
BRAF:V600E,V600D,V600K,V600M,V600G,V600R	MUT		Responsive	BRAF (V600E,V600D,V600K,V600M,V600G,V600R)	DTamborero	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	NCCN guidelines	BRAF		NSCLC;HISLC;HISEC	PMID:26287849	Indirect	chr7:g.140453136_140453137delACinsCT	c.1798_1799delGTinsAG	BRAF:V600R	CSQN=Missense;reference_codon=GTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.140453136_140453137delACinsCG,chr7:g.140453135_140453137delCACinsTCT,chr7:g.140453135_140453137delCACinsTCG,chr7:g.140453135_140453137delCACinsGCG,chr7:g.140453135_140453137delCACinsACG;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Non-small cell lung;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis
BRAF:V600E,V600K	MUT		Responsive	BRAF (V600E,V600K)	RDientsmann	Vemurafenib;Cobimetinib	BRAF inhibitor;MEK inhibitor	Vemurafenib + Cobimetinib (BRAF inhibitor + MEK inhibitor)	Approved	FDA guidelines	BRAF		CM	FDA		chr7:g.140453136A>T	c.1799T>A	BRAF:V600E	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRAF:V600E,V600K	MUT		Responsive	BRAF (V600E,V600K)	RDientsmann	Vemurafenib;Cobimetinib	BRAF inhibitor;MEK inhibitor	Vemurafenib + Cobimetinib (BRAF inhibitor + MEK inhibitor)	Approved	FDA guidelines	BRAF		CM	FDA		chr7:g.140453136_140453137delACinsTT	c.1798_1799delGTinsAA	BRAF:V600K	CSQN=Missense;reference_codon=GTG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr7:g.140453135_140453137delCACinsTTT;aliases=ENSP00000288602;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000288602	Cutaneous melanoma
BRCA1:.	MUT		Responsive	BRCA1 oncogenic mutation	RDientsmann	[]	[PARP inhibitor;Chemotherapy]	PARP inhibitor + Chemotherapys		Early trials	BRCA1		OV	PMID:22307137;ASCO 2012 (abstr 1009)									Ovary
BRCA1:.	MUT		Responsive	BRCA1 oncogenic mutation	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Case report	BRCA1		PA	PMID:25366685;PMID:25719666;PMID:19553641;PMID:25366685									Pancreas
BRCA1:.	MUT		Responsive	BRCA1 oncogenic mutation	RDientsmann	[]	[WEE1 inhibitor]	WEE1 inhibitors		Case report	BRCA1		CANCER	PMID:25964244									Any cancer type
BRCA1:.	MUT		Responsive	BRCA1 oncogenic mutation	RDientsmann;JAlbanell	[Olaparib]	[PARP inhibitor]	PARP inhibitors (Olaparib,etc)		Early trials	BRCA1		BRCA	PMID:20609467;PMID:25366685									Breast adenocarcinoma
BRCA1:.	MUT		Responsive	BRCA1 oncogenic mutation	RDientsmann	Olaparib	PARP inhibitor	Olaparib (PARP inhibitor)		Early trials	BRCA1		PRAD	PMID:26510020									Prostate adenocarcinoma
BRCA1:.	MUT		Responsive	BRCA1 oncogenic mutation	RDientsmann	Olaparib	PARP inhibitor	Olaparib (PARP inhibitor)	Approved	FDA guidelines	BRCA1		OV	FDA									Ovary
BRCA1:.	MUT		Responsive	BRCA1 oncogenic mutation	RDientsmann	Platinum Agent	Chemotherapy	Platinum Agent (Chemotherapy)		Early trials	BRCA1		BRCA	PMID:25847936									Breast adenocarcinoma
BRCA1:.	MUT		Responsive	BRCA1 oncogenic mutation	RDientsmann	Platinum Agent	Chemotherapy	Platinum Agent (Chemotherapy)		Late trials	BRCA1		OV	PMID:22406760;PMID:22711857									Ovary
BRCA1:.	MUT		Responsive	BRCA1 oncogenic mutation	RDientsmann	Rucaparib	PARP inhibitor	Rucaparib (PARP inhibitor)		FDA guidelines	BRCA1		OV	FDA									Ovary
BRCA1:.	MUT		Responsive	BRCA1 oncogenic mutation	RDientsmann	Veliparib;Cisplatin	PARP inhibitor;Chemotherapy	Veliparib + Cisplatin (PARP inhibitor + Chemotherapy)		Early trials	BRCA1		BRCA	PMID:26801247									Breast adenocarcinoma
BRCA2:.	MUT		Responsive	BRCA2 oncogenic mutation	RDientsmann	[]	[PARP inhibitor;Chemotherapy]	PARP inhibitor + Chemotherapys		Early trials	BRCA2		OV	PMID:22307137;ASCO 2012 (abstr 1009)									Ovary
BRCA2:.	MUT		Responsive	BRCA2 oncogenic mutation	RDientsmann	[]	[PD1 Ab inhibitor]	PD1 Ab inhibitors		Case report	BRCA2		CM	PMID:26997480									Cutaneous melanoma
BRCA2:.	MUT		Responsive	BRCA2 oncogenic mutation	JAlbanell;ARovira;RDientsmann	[Olaparib]	[PARP inhibitor]	PARP inhibitors (Olaparib,etc)	Approved	Early trials	BRCA2		BRCA	PMID:20609467	Indirect								Breast adenocarcinoma
BRCA2:.	MUT		Responsive	BRCA2 oncogenic mutation	RDientsmann;ARodriguez-Vida	Olaparib	PARP inhibitor	Olaparib (PARP inhibitor)	Approved	Early trials	BRCA2		PRAD	PMID:26510020;NCT01682772;http://cancerres.aacrjournals.org/content/75/15_Supplement/CT322	Indirect								Prostate adenocarcinoma
BRCA2:.	MUT		Responsive	BRCA2 oncogenic mutation	RDientsmann	Olaparib	PARP inhibitor	Olaparib (PARP inhibitor)	Approved	FDA guidelines	BRCA2		OV	FDA									Ovary
BRCA2:.	MUT		Responsive	BRCA2 oncogenic mutation	RDientsmann	Platinum Agent	Chemotherapy	Platinum Agent (Chemotherapy)		Early trials	BRCA2		BRCA	PMID:25847936									Breast adenocarcinoma
BRCA2:.	MUT		Responsive	BRCA2 oncogenic mutation	RDientsmann	Platinum Agent	Chemotherapy	Platinum Agent (Chemotherapy)		Late trials	BRCA2		OV	PMID:22406760;PMID:22711857									Ovary
BRCA2:.	MUT		Responsive	BRCA2 oncogenic mutation	RDientsmann	Platinum Agent	Chemotherapy	Platinum Agent (Chemotherapy)		Case report	BRCA2		PA	PMID:25719666									Pancreas
BRCA2:.	MUT		Responsive	BRCA2 oncogenic mutation	RDientsmann	Rucaparib	PARP inhibitor	Rucaparib (PARP inhibitor)		FDA guidelines	BRCA2		OV	FDA									Ovary
BRCA2:.	MUT		Responsive	BRCA2 oncogenic mutation	RDientsmann	Veliparib;Cisplatin	PARP inhibitor;Chemotherapy	Veliparib + Cisplatin (PARP inhibitor + Chemotherapy)		Early trials	BRCA2		BRCA	PMID:26801247									Breast adenocarcinoma
BTK:C481.	MUT		Resistant	BTK (C481)	RDientsmann	Ibrutinib	BTK inhibitor	Ibrutinib (BTK inhibitor)		Case report	BTK		MCL	PMID:25082755									Mantle cell lymphoma
BTK:C481S	MUT		Resistant	BTK (C481S)	RDientsmann	Ibrutinib	BTK inhibitor	Ibrutinib (BTK inhibitor)		Early trials	BTK		CLL	PMID:24869598;PMID:27199251		chrX:g.100611165A>T	c.1441T>A	BTK:C481S	CSQN=Missense;reference_codon=TGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_snv_variants=chrX:g.100611164C>G;candidate_mnv_variants=chrX:g.100611163_100611165delGCAinsACT,chrX:g.100611163_100611164delGCinsAG,chrX:g.100611163_100611164delGCinsCG,chrX:g.100611163_100611164delGCinsTG;aliases=ENSP00000308176;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000308731	Chronic lymphocytic leukemia
CBL:Y371H,C384R	MUT		Responsive	CBL (Y371H,C384R)	RDientsmann	[]	[JAK inhibitor]	JAK inhibitors		Pre-clinical	CBL		MDPS	PMID:23696637		chr11:g.119148891T>C	c.1111T>C	CBL:Y371H	CSQN=Missense;reference_codon=TAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr11:g.119148891_119148893delTACinsCAT;aliases=ENSP00000264033;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000264033	Myelodisplasic proliferative syndrome
CBL:Y371H,C384R	MUT		Responsive	CBL (Y371H,C384R)	RDientsmann	[]	[JAK inhibitor]	JAK inhibitors		Pre-clinical	CBL		MDPS	PMID:23696637		chr11:g.119148930T>C	c.1150T>C	CBL:C384R	CSQN=Missense;reference_codon=TGT;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr11:g.119148930_119148932delTGTinsAGG,chr11:g.119148930_119148932delTGTinsAGA,chr11:g.119148930_119148932delTGTinsCGA,chr11:g.119148930_119148932delTGTinsCGC,chr11:g.119148930_119148932delTGTinsCGG;aliases=ENSP00000264033;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000264033	Myelodisplasic proliferative syndrome
CBL:Y371H,C384R	MUT		Responsive	CBL (Y371H,C384R)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	CBL		MDPS	PMID:23696637		chr11:g.119148891T>C	c.1111T>C	CBL:Y371H	CSQN=Missense;reference_codon=TAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr11:g.119148891_119148893delTACinsCAT;aliases=ENSP00000264033;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000264033	Myelodisplasic proliferative syndrome
CBL:Y371H,C384R	MUT		Responsive	CBL (Y371H,C384R)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	CBL		MDPS	PMID:23696637		chr11:g.119148930T>C	c.1150T>C	CBL:C384R	CSQN=Missense;reference_codon=TGT;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr11:g.119148930_119148932delTGTinsAGG,chr11:g.119148930_119148932delTGTinsAGA,chr11:g.119148930_119148932delTGTinsCGA,chr11:g.119148930_119148932delTGTinsCGC,chr11:g.119148930_119148932delTGTinsCGG;aliases=ENSP00000264033;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000264033	Myelodisplasic proliferative syndrome
CDH1:.	MUT		Responsive	CDH1 oncogenic mutation	RDientsmann	Bicalutamide	AR inhibitor	Bicalutamide (AR inhibitor)		Pre-clinical	CDH1		BRCA	PMID:27397505									Breast adenocarcinoma
CDK12:.	MUT		Responsive	CDK12 oncogenic mutation	RDientsmann	[]	[PARP inhibitors]	PARP inhibitors		Pre-clinical	CDK12		OV	PMID:24240700;PMID:24554720									Ovary
CDK4:.	MUT		Responsive	CDK4 oncogenic mutation	CRubio-Perez;DTamborero	LEE011	CDK4/6 inhibitor	LEE011 (CDK4/6 inhibitor)	Clinical Trials	Early trials	CDK4		LIP;LY;CANCER	NCT02187783;NCT01237236; http://meetinglibrary.asco.org/content/83791-102	Direct								Liposarcoma;Lymphoma;Any cancer type
CDK6:.	MUT		Responsive	CDK6 oncogenic mutation	CRubio-Perez;DTamborero	LEE011	CDK4/6 inhibitor	LEE011 (CDK4/6 inhibitor)	Clinical Trials	Early trials	CDK6		LIP;LY;CANCER	NCT02187783;NCT01237236	Direct								Liposarcoma;Lymphoma;Any cancer type
CDKN1A:.	MUT		Responsive	CDKN1A oncogenic mutation	RDientsmann	[]	[CDK2/4 inhibitor]	CDK2/4 inhibitors		Pre-clinical	CDKN1A		CANCER	PMID:22471707;PMID:22997239									Any cancer type
CDKN1B:.	MUT		Responsive	CDKN1B oncogenic mutation	RDientsmann	[]	[CDK2/4 inhibitor]	CDK2/4 inhibitors		Pre-clinical	CDKN1B		CANCER	PMID:22471707									Any cancer type
CDKN2A:.	MUT		Responsive	CDKN2A oncogenic mutation	RDientsmann	[]	[CDK4/6 inhibitor]	CDK4/6 inhibitors		Case report	CDKN2A		CM	ASCO 2013 (abstr 2500)									Cutaneous melanoma
CDKN2A:.	MUT		Responsive	CDKN2A oncogenic mutation	RDientsmann	[]	[CDK4/6 inhibitor]	CDK4/6 inhibitors		Pre-clinical	CDKN2A		G;CANCER	PMID:22471707;PMID:22586120;PMID:22711607									Glioma;Any cancer type
CDKN2A:.	MUT		Responsive	CDKN2A oncogenic mutation	CRubio-Perez;DTamborero	Ilorasertib	AURKA-VEGF inhibitor	Ilorasertib (AURKA-VEGF inhibitor)	Clinical Trials	Early trials	CDKN2A		CANCER	NCT02478320	Indirect								Any cancer type
CDKN2B:.	MUT		Responsive	CDKN2B oncogenic mutation	RDientsmann	[]	[CDK4/6 inhibitor]	CDK4/6 inhibitors		Pre-clinical	CDKN2B		G;CANCER	PMID:22471707;PMID:22711607									Glioma;Any cancer type
CDKN2C:.	MUT		Responsive	CDKN2C oncogenic mutation	RDientsmann	[]	[CDK2 inhibitor]	CDK2 inhibitors		Pre-clinical	CDKN2C		G;CANCER	PMID:22471707;PMID:22997239;PMID:22711607									Glioma;Any cancer type
CHEK2:.	MUT		Responsive	CHEK2 oncogenic mutation	RDientsmann	Olaparib	PARP inhibitor	Olaparib (PARP inhibitor)		Early trials	CHEK2		PRAD	PMID:26510020;AACR 2015 (abstr CT322)									Prostate adenocarcinoma
CRBN:.	MUT		Resistant	CRBN oncogenic mutation	DTamborero	Lenalidomide	Immunomodulator	Lenalidomide (Immunomodulator)		Case report	CRBN		MYMA	PMID:25108355									Myeloma
CRBN:Q100*,R283K	MUT		Resistant	CRBN (Q100*,R283K)	DTamborero	Lenalidomide	Immunomodulator	Lenalidomide (Immunomodulator)		Case report	CRBN		MYMA	PMID:23480694		chr3:g.3215822G>A	c.298C>T	CRBN:Q100*	CSQN=Nonsense;reference_codon=CAG;candidate_codons=TAA,TAG,TGA;candidate_mnv_variants=chr3:g.3215820_3215822delCTGinsTTA,chr3:g.3215820_3215822delCTGinsTCA;aliases=ENSP00000231948;source=Ensembl	inside_[cds_in_exon_3]	-	ENST00000231948	Myeloma
CRBN:Q100*,R283K	MUT		Resistant	CRBN (Q100*,R283K)	DTamborero	Lenalidomide	Immunomodulator	Lenalidomide (Immunomodulator)		Case report	CRBN		MYMA	PMID:23480694		chr3:g.3195747C>T	c.848G>A	CRBN:R283K	CSQN=Missense;reference_codon=AGA;candidate_codons=AAG,AAA;candidate_mnv_variants=chr3:g.3195746_3195747delTCinsCT;aliases=ENSP00000231948;source=Ensembl	inside_[cds_in_exon_8]	-	ENST00000231948	Myeloma
CRBN:.	MUT		Resistant	CRBN oncogenic mutation	DTamborero	Pomalidomide	Immunomodulator	Pomalidomide (Immunomodulator)		Case report	CRBN		MYMA	PMID:25108355									Myeloma
CRBN:Q100*,R283K	MUT		Resistant	CRBN (Q100*,R283K)	DTamborero	Pomalidomide	Immunomodulator	Pomalidomide (Immunomodulator)		Case report	CRBN		MYMA	PMID:23480694		chr3:g.3215822G>A	c.298C>T	CRBN:Q100*	CSQN=Nonsense;reference_codon=CAG;candidate_codons=TAA,TAG,TGA;candidate_mnv_variants=chr3:g.3215820_3215822delCTGinsTTA,chr3:g.3215820_3215822delCTGinsTCA;aliases=ENSP00000231948;source=Ensembl	inside_[cds_in_exon_3]	-	ENST00000231948	Myeloma
CRBN:Q100*,R283K	MUT		Resistant	CRBN (Q100*,R283K)	DTamborero	Pomalidomide	Immunomodulator	Pomalidomide (Immunomodulator)		Case report	CRBN		MYMA	PMID:23480694		chr3:g.3195747C>T	c.848G>A	CRBN:R283K	CSQN=Missense;reference_codon=AGA;candidate_codons=AAG,AAA;candidate_mnv_variants=chr3:g.3195746_3195747delTCinsCT;aliases=ENSP00000231948;source=Ensembl	inside_[cds_in_exon_8]	-	ENST00000231948	Myeloma
CSF1R:Y571D	MUT		Responsive	CSF1R (Y571D)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	CSF1R		MDPS	PMID:18971950		chr5:g.149441328A>C	c.1711T>G	CSF1R:Y571D	CSQN=Missense;reference_codon=TAC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr5:g.149441326_149441328delGTAinsATC;aliases=ENSP00000286301;source=Ensembl	inside_[cds_in_exon_12]	-	ENST00000286301	Myelodisplasic proliferative syndrome
CSF3R::consequence::frameshift_variant:D771.,::frameshift_variant:S783.	MUT		Responsive	CSF3R frameshift variant (D771),frameshift variant (S783)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	CSF3R		ACML	PMID:23656643									Atypical chronic myeloid leukemia
CTNNB1:.	MUT		Resistant	CTNNB1 oncogenic mutation	RDientsmann	[]	[Tankyrase inhibitor]	Tankyrase inhibitors		Pre-clinical	CTNNB1		COREAD	PMID:23539443									Colorectal adenocarcinoma
CTNNB1:H36Y,S37C,S37Y,D32V	MUT		Responsive	CTNNB1 (H36Y,S37C,S37Y,D32V)	RDientsmann	Everolimus;Letrozole	MTOR inhibitor;Hormonal therapy	Everolimus + Letrozole (MTOR inhibitor + Hormonal therapy)		Early trials	CTNNB1		ED	PMID:25624430		chr3:g.41266109C>T	c.106C>T	CTNNB1:H36Y	CSQN=Missense;reference_codon=CAT;candidate_codons=TAT,TAC;candidate_mnv_variants=chr3:g.41266109_41266111delCATinsTAC;aliases=ENSP00000344456;source=Ensembl	inside_[cds_in_exon_3]	+	ENST00000349496	Endometrium
CTNNB1:H36Y,S37C,S37Y,D32V	MUT		Responsive	CTNNB1 (H36Y,S37C,S37Y,D32V)	RDientsmann	Everolimus;Letrozole	MTOR inhibitor;Hormonal therapy	Everolimus + Letrozole (MTOR inhibitor + Hormonal therapy)		Early trials	CTNNB1		ED	PMID:25624430		chr3:g.41266113C>G	c.110C>G	CTNNB1:S37C	CSQN=Missense;reference_codon=TCT;candidate_codons=TGT,TGC;candidate_mnv_variants=chr3:g.41266113_41266114delCTinsGC;aliases=ENSP00000344456;source=Ensembl	inside_[cds_in_exon_3]	+	ENST00000349496	Endometrium
CTNNB1:H36Y,S37C,S37Y,D32V	MUT		Responsive	CTNNB1 (H36Y,S37C,S37Y,D32V)	RDientsmann	Everolimus;Letrozole	MTOR inhibitor;Hormonal therapy	Everolimus + Letrozole (MTOR inhibitor + Hormonal therapy)		Early trials	CTNNB1		ED	PMID:25624430		chr3:g.41266113C>A	c.110C>A	CTNNB1:S37Y	CSQN=Missense;reference_codon=TCT;candidate_codons=TAT,TAC;candidate_mnv_variants=chr3:g.41266113_41266114delCTinsAC;aliases=ENSP00000344456;source=Ensembl	inside_[cds_in_exon_3]	+	ENST00000349496	Endometrium
CTNNB1:H36Y,S37C,S37Y,D32V	MUT		Responsive	CTNNB1 (H36Y,S37C,S37Y,D32V)	RDientsmann	Everolimus;Letrozole	MTOR inhibitor;Hormonal therapy	Everolimus + Letrozole (MTOR inhibitor + Hormonal therapy)		Early trials	CTNNB1		ED	PMID:25624430		chr3:g.41266098A>T	c.95A>T	CTNNB1:D32V	CSQN=Missense;reference_codon=GAC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr3:g.41266098_41266099delACinsTA,chr3:g.41266098_41266099delACinsTG,chr3:g.41266098_41266099delACinsTT;aliases=ENSP00000344456;source=Ensembl	inside_[cds_in_exon_3]	+	ENST00000349496	Endometrium
DDR2:I638F,L239R,G253C,G774V,L63V,G505S	MUT		Responsive	DDR2 (I638F,L239R,G253C,G774V,L63V,G505S)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	DDR2		LUSC	PMID:22328973		chr1:g.162745497A>T	c.1912A>T	DDR2:I638F	CSQN=Missense;reference_codon=ATC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr1:g.162745497_162745499delATCinsTTT;aliases=ENSP00000356899;source=Ensembl	inside_[cds_in_exon_16]	+	ENST00000367922	Lung squamous cell
DDR2:I638F,L239R,G253C,G774V,L63V,G505S	MUT		Responsive	DDR2 (I638F,L239R,G253C,G774V,L63V,G505S)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	DDR2		LUSC	PMID:22328973		chr1:g.162729630T>G	c.716T>G	DDR2:L239R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr1:g.162729629_162729630delCTinsAG,chr1:g.162729630_162729631delTGinsGA,chr1:g.162729630_162729631delTGinsGC,chr1:g.162729630_162729631delTGinsGT,chr1:g.162729629_162729631delCTGinsAGA;aliases=ENSP00000356899;source=Ensembl	inside_[cds_in_exon_9]	+	ENST00000367922	Lung squamous cell
DDR2:I638F,L239R,G253C,G774V,L63V,G505S	MUT		Responsive	DDR2 (I638F,L239R,G253C,G774V,L63V,G505S)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	DDR2		LUSC	PMID:22328973		chr1:g.162729671G>T	c.757G>T	DDR2:G253C	CSQN=Missense;reference_codon=GGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr1:g.162729671_162729673delGGCinsTGT;aliases=ENSP00000356899;source=Ensembl	inside_[cds_in_exon_9]	+	ENST00000367922	Lung squamous cell
DDR2:I638F,L239R,G253C,G774V,L63V,G505S	MUT		Responsive	DDR2 (I638F,L239R,G253C,G774V,L63V,G505S)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	DDR2		LUSC	PMID:22328973		chr1:g.162748407G>T	c.2321G>T	DDR2:G774V	CSQN=Missense;reference_codon=GGG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr1:g.162748407_162748408delGGinsTA,chr1:g.162748407_162748408delGGinsTC,chr1:g.162748407_162748408delGGinsTT;aliases=ENSP00000356899;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000367922	Lung squamous cell
DDR2:I638F,L239R,G253C,G774V,L63V,G505S	MUT		Responsive	DDR2 (I638F,L239R,G253C,G774V,L63V,G505S)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	DDR2		LUSC	PMID:22328973		chr1:g.162724415C>G	c.187C>G	DDR2:L63V	CSQN=Missense;reference_codon=CTG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr1:g.162724415_162724417delCTGinsGTA,chr1:g.162724415_162724417delCTGinsGTC,chr1:g.162724415_162724417delCTGinsGTT;aliases=ENSP00000356899;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000367922	Lung squamous cell
DDR2:I638F,L239R,G253C,G774V,L63V,G505S	MUT		Responsive	DDR2 (I638F,L239R,G253C,G774V,L63V,G505S)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	DDR2		LUSC	PMID:22328973		chr1:g.162741822G>A	c.1513G>A	DDR2:G505S	CSQN=Missense;reference_codon=GGT;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr1:g.162741822_162741824delGGTinsAGC,chr1:g.162741822_162741823delGGinsTC,chr1:g.162741822_162741824delGGTinsTCG,chr1:g.162741822_162741824delGGTinsTCC,chr1:g.162741822_162741824delGGTinsTCA;aliases=ENSP00000356899;source=Ensembl	inside_[cds_in_exon_14]	+	ENST00000367922	Lung squamous cell
DDR2:S768R	MUT		Responsive	DDR2 (S768R)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Case report	DDR2		LUSC	PMID:22328973		chr1:g.162748390T>G	c.2304T>G	DDR2:S768R	CSQN=Missense;reference_codon=AGT;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr1:g.162748390T>A,chr1:g.162748388A>C;candidate_mnv_variants=chr1:g.162748388_162748390delAGTinsCGA,chr1:g.162748388_162748390delAGTinsCGC,chr1:g.162748388_162748390delAGTinsCGG;aliases=ENSP00000356899;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000367922	Lung squamous cell
DDR2:S768R	MUT		Responsive	DDR2 (S768R)	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)		Case report	DDR2		LUSC	PMID:22328973		chr1:g.162748390T>G	c.2304T>G	DDR2:S768R	CSQN=Missense;reference_codon=AGT;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr1:g.162748390T>A,chr1:g.162748388A>C;candidate_mnv_variants=chr1:g.162748388_162748390delAGTinsCGA,chr1:g.162748388_162748390delAGTinsCGC,chr1:g.162748388_162748390delAGTinsCGG;aliases=ENSP00000356899;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000367922	Lung squamous cell
DNMT3A:.	MUT		Responsive	DNMT3A oncogenic mutation	RDientsmann	Daunorubicin	Chemotherapy	Daunorubicin (Chemotherapy)	Approved	FDA guidelines	DNMT3A		AML	PMID:22417203									Acute myeloid leukemia
DPYD::consequence::splice_donor_variant:.	MUT		Increased Toxicity	DPYD splice donor variant	DTamborero;CRubio-Perez	Capecitabine	Fluoropyrimidine	Capecitabine (Fluoropyrimidine)	Approved	FDA guidelines	DPYD		CANCER	FDA									Any cancer type
DPYD:I560S,D949V	MUT		Increased Toxicity	DPYD (I560S,D949V)	DTamborero;CRubio-Perez	Capecitabine	Fluoropyrimidine	Capecitabine (Fluoropyrimidine)	Approved	FDA guidelines	DPYD		CANCER	FDA		chr1:g.97981343A>C	c.1679T>G	DPYD:I560S	CSQN=Missense;reference_codon=ATT;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr1:g.97981342_97981343delAAinsGC,chr1:g.97981343_97981344delATinsGA,chr1:g.97981342_97981344delAATinsCGA,chr1:g.97981342_97981344delAATinsGGA,chr1:g.97981342_97981344delAATinsTGA;aliases=ENSP00000359211;source=Ensembl	inside_[cds_in_exon_13]	-	ENST00000370192	Any cancer type
DPYD:I560S,D949V	MUT		Increased Toxicity	DPYD (I560S,D949V)	DTamborero;CRubio-Perez	Capecitabine	Fluoropyrimidine	Capecitabine (Fluoropyrimidine)	Approved	FDA guidelines	DPYD		CANCER	FDA		chr1:g.97547947T>A	c.2846A>T	DPYD:D949V	CSQN=Missense;reference_codon=GAT;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr1:g.97547946_97547947delATinsTA,chr1:g.97547946_97547947delATinsGA,chr1:g.97547946_97547947delATinsCA;aliases=ENSP00000359211;source=Ensembl	inside_[cds_in_exon_22]	-	ENST00000370192	Any cancer type
DPYD::consequence::splice_donor_variant:.	MUT		Increased Toxicity	DPYD splice donor variant	DTamborero;CRubio-Perez	Flourouracil	Fluoropyrimidine	Flourouracil (Fluoropyrimidine)	Approved	FDA guidelines	DPYD		CANCER	FDA									Any cancer type
DPYD:I560S,D949V	MUT		Increased Toxicity	DPYD (I560S,D949V)	DTamborero;CRubio-Perez	Flourouracil	Fluoropyrimidine	Flourouracil (Fluoropyrimidine)	Approved	FDA guidelines	DPYD		CANCER	FDA		chr1:g.97981343A>C	c.1679T>G	DPYD:I560S	CSQN=Missense;reference_codon=ATT;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr1:g.97981342_97981343delAAinsGC,chr1:g.97981343_97981344delATinsGA,chr1:g.97981342_97981344delAATinsCGA,chr1:g.97981342_97981344delAATinsGGA,chr1:g.97981342_97981344delAATinsTGA;aliases=ENSP00000359211;source=Ensembl	inside_[cds_in_exon_13]	-	ENST00000370192	Any cancer type
DPYD:I560S,D949V	MUT		Increased Toxicity	DPYD (I560S,D949V)	DTamborero;CRubio-Perez	Flourouracil	Fluoropyrimidine	Flourouracil (Fluoropyrimidine)	Approved	FDA guidelines	DPYD		CANCER	FDA		chr1:g.97547947T>A	c.2846A>T	DPYD:D949V	CSQN=Missense;reference_codon=GAT;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr1:g.97547946_97547947delATinsTA,chr1:g.97547946_97547947delATinsGA,chr1:g.97547946_97547947delATinsCA;aliases=ENSP00000359211;source=Ensembl	inside_[cds_in_exon_22]	-	ENST00000370192	Any cancer type
DPYD::consequence::splice_donor_variant:.	MUT		Increased Toxicity	DPYD splice donor variant	DTamborero;CRubio-Perez	Tegafur	Fluoropyrimidine	Tegafur (Fluoropyrimidine)	Approved	CPIC guidelines	DPYD		CANCER	PMID:23988873									Any cancer type
DPYD:I560S,D949V	MUT		Increased Toxicity	DPYD (I560S,D949V)	DTamborero;CRubio-Perez	Tegafur	Fluoropyrimidine	Tegafur (Fluoropyrimidine)	Approved	CPIC guidelines	DPYD		CANCER	PMID:23988873		chr1:g.97981343A>C	c.1679T>G	DPYD:I560S	CSQN=Missense;reference_codon=ATT;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr1:g.97981342_97981343delAAinsGC,chr1:g.97981343_97981344delATinsGA,chr1:g.97981342_97981344delAATinsCGA,chr1:g.97981342_97981344delAATinsGGA,chr1:g.97981342_97981344delAATinsTGA;aliases=ENSP00000359211;source=Ensembl	inside_[cds_in_exon_13]	-	ENST00000370192	Any cancer type
DPYD:I560S,D949V	MUT		Increased Toxicity	DPYD (I560S,D949V)	DTamborero;CRubio-Perez	Tegafur	Fluoropyrimidine	Tegafur (Fluoropyrimidine)	Approved	CPIC guidelines	DPYD		CANCER	PMID:23988873		chr1:g.97547947T>A	c.2846A>T	DPYD:D949V	CSQN=Missense;reference_codon=GAT;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr1:g.97547946_97547947delATinsTA,chr1:g.97547946_97547947delATinsGA,chr1:g.97547946_97547947delATinsCA;aliases=ENSP00000359211;source=Ensembl	inside_[cds_in_exon_22]	-	ENST00000370192	Any cancer type
EGFR::consequence::inframe_deletion:30-336	MUT		No Responsive	EGFR inframe deletion (30-336)	RDientsmann	[]	[EGFR inhibitor 1st gen]	EGFR inhibitor 1st gens		Early trials	EGFR		G	PMID:19204207									Glioma
EGFR::consequence::inframe_insertion:762-823	MUT		Resistant	EGFR exon 20 insertions	RDientsmann	[]	[EGFR inhibitor 1st gen]	EGFR inhibitor 1st gens		Late trials	EGFR		L	PMID:21764376;PMID:26773740;PMID:26051236									Lung
EGFR:D761Y	MUT		Resistant	EGFR (D761Y)	DTamborero	[]	[EGFR inhibitor 1st gen]	EGFR inhibitor 1st gens		Case report	EGFR		NSCLC	PMID:19680293		chr7:g.55242511G>T	c.2281G>T	EGFR:D761Y	CSQN=Missense;reference_codon=GAT;candidate_codons=TAT,TAC;candidate_mnv_variants=chr7:g.55242511_55242513delGATinsTAC;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000275493	Non-small cell lung
EGFR:T790M	MUT		Resistant	EGFR (T790M)	DTamborero	[]	[EGFR inhibitor 1st gen]	EGFR inhibitor 1st gens		Late trials	EGFR		NSCLC	PMID:19680293		chr7:g.55249071C>T	c.2369C>T	EGFR:T790M	CSQN=Missense;reference_codon=ACG;candidate_codons=ATG;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Non-small cell lung
EGFR::consequence::inframe_deletion:30-336	MUT		No Responsive	EGFR inframe deletion (30-336)	RDientsmann	[]	[EGFR inhibitor 2nd gen]	EGFR inhibitor 2nd gens		Early trials	EGFR		G	PMID:19204207									Glioma
EGFR:T790M	MUT		Resistant	EGFR (T790M)	DTamborero	[]	[EGFR inhibitor 2nd gen]	EGFR inhibitor 2nd gens		Late trials	EGFR		NSCLC	PMID:22452896		chr7:g.55249071C>T	c.2369C>T	EGFR:T790M	CSQN=Missense;reference_codon=ACG;candidate_codons=ATG;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Non-small cell lung
EGFR::consequence::inframe_deletion:30-336	MUT		No Responsive	EGFR inframe deletion (30-336)	RDientsmann	[]	[EGFR inhibitor 3rd gen]	EGFR inhibitor 3rd gens		Early trials	EGFR		G	PMID:19204207									Glioma
EGFR:T790M	MUT		Responsive	EGFR (T790M)	RDientsmann	[]	[EGFR inhibitor 3rd gen]	EGFR inhibitor 3rd gens		Early trials	EGFR		L	ASCO 2014 (abstr 8009);ENA 2014 (abstr 10LBA);ENA 2014 (abstr 9LBA);ASCO 2015 (abstr 8001)		chr7:g.55249071C>T	c.2369C>T	EGFR:T790M	CSQN=Missense;reference_codon=ACG;candidate_codons=ATG;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Lung
EGFR::consequence::inframe_insertion:729-761	MUT		Responsive	EGFR exon 19 insertions	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Late trials	EGFR		L	PMID:22753918									Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Late trials	EGFR		L	PMID:22753918		chr7:g.55259515T>G	c.2573T>G	EGFR:L858R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259514_55259515delCTinsAG,chr7:g.55259515_55259516delTGinsGA,chr7:g.55259515_55259516delTGinsGC,chr7:g.55259515_55259516delTGinsGT,chr7:g.55259514_55259516delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Late trials	EGFR		L	PMID:22753918		chr7:g.55259524T>A	c.2582T>A	EGFR:L861Q	CSQN=Missense;reference_codon=CTG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsAA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Late trials	EGFR		L	PMID:22753918		chr7:g.55241708G>C	c.2156G>C	EGFR:G719A	CSQN=Missense;reference_codon=GGC;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsCA,chr7:g.55241708_55241709delGCinsCG,chr7:g.55241708_55241709delGCinsCT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Late trials	EGFR		L	PMID:22753918		chr7:g.55241707G>A	c.2155G>A	EGFR:G719S	CSQN=Missense;reference_codon=GGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsAGT,chr7:g.55241707_55241708delGGinsTC,chr7:g.55241707_55241709delGGCinsTCT,chr7:g.55241707_55241709delGGCinsTCG,chr7:g.55241707_55241709delGGCinsTCA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Late trials	EGFR		L	PMID:22753918		chr7:g.55241707G>T	c.2155G>T	EGFR:G719C	CSQN=Missense;reference_codon=GGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsTGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Late trials	EGFR		L	PMID:22753918		chr7:g.55241708G>A	c.2156G>A	EGFR:G719D	CSQN=Missense;reference_codon=GGC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsAT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Late trials	EGFR		L	PMID:22753918		chr7:g.55242470T>C	c.2240T>C	EGFR:L747S	CSQN=Missense;reference_codon=TTA;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55242470_55242471delTAinsCT,chr7:g.55242470_55242471delTAinsCG,chr7:g.55242470_55242471delTAinsCC,chr7:g.55242469_55242471delTTAinsAGC,chr7:g.55242469_55242471delTTAinsAGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Late trials	EGFR		L	PMID:22753918		chr7:g.55249005G>T	c.2303G>T	EGFR:S768I	CSQN=Missense;reference_codon=AGC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.55249005_55249006delGCinsTA,chr7:g.55249005_55249006delGCinsTT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Late trials	EGFR		L	PMID:22753918		chr7:g.55259524T>C	c.2582T>C	EGFR:L861P	CSQN=Missense;reference_codon=CTG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsCT,chr7:g.55259524_55259525delTGinsCA,chr7:g.55259524_55259525delTGinsCC;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Late trials	EGFR		L	PMID:22753918		chr7:g.55259524T>G	c.2582T>G	EGFR:L861R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259523_55259524delCTinsAG,chr7:g.55259524_55259525delTGinsGA,chr7:g.55259524_55259525delTGinsGC,chr7:g.55259524_55259525delTGinsGT,chr7:g.55259523_55259525delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Lung
EGFR::consequence::inframe_insertion:729-761	MUT		Responsive	EGFR exon 19 insertions	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	EGFR		L	ESMO 2012 (abstr 4380)									Lung
EGFR::consequence::inframe_insertion:762-823	MUT		Responsive	EGFR exon 20 insertions	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Case report	EGFR		L	ASCO 2014 (abstr 8015)									Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	EGFR		L	ESMO 2012 (abstr 4380)		chr7:g.55259515T>G	c.2573T>G	EGFR:L858R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259514_55259515delCTinsAG,chr7:g.55259515_55259516delTGinsGA,chr7:g.55259515_55259516delTGinsGC,chr7:g.55259515_55259516delTGinsGT,chr7:g.55259514_55259516delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	EGFR		L	ESMO 2012 (abstr 4380)		chr7:g.55259524T>A	c.2582T>A	EGFR:L861Q	CSQN=Missense;reference_codon=CTG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsAA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	EGFR		L	ESMO 2012 (abstr 4380)		chr7:g.55241708G>C	c.2156G>C	EGFR:G719A	CSQN=Missense;reference_codon=GGC;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsCA,chr7:g.55241708_55241709delGCinsCG,chr7:g.55241708_55241709delGCinsCT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	EGFR		L	ESMO 2012 (abstr 4380)		chr7:g.55241707G>A	c.2155G>A	EGFR:G719S	CSQN=Missense;reference_codon=GGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsAGT,chr7:g.55241707_55241708delGGinsTC,chr7:g.55241707_55241709delGGCinsTCT,chr7:g.55241707_55241709delGGCinsTCG,chr7:g.55241707_55241709delGGCinsTCA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	EGFR		L	ESMO 2012 (abstr 4380)		chr7:g.55241707G>T	c.2155G>T	EGFR:G719C	CSQN=Missense;reference_codon=GGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsTGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	EGFR		L	ESMO 2012 (abstr 4380)		chr7:g.55241708G>A	c.2156G>A	EGFR:G719D	CSQN=Missense;reference_codon=GGC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsAT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	EGFR		L	ESMO 2012 (abstr 4380)		chr7:g.55242470T>C	c.2240T>C	EGFR:L747S	CSQN=Missense;reference_codon=TTA;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55242470_55242471delTAinsCT,chr7:g.55242470_55242471delTAinsCG,chr7:g.55242470_55242471delTAinsCC,chr7:g.55242469_55242471delTTAinsAGC,chr7:g.55242469_55242471delTTAinsAGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	EGFR		L	ESMO 2012 (abstr 4380)		chr7:g.55249005G>T	c.2303G>T	EGFR:S768I	CSQN=Missense;reference_codon=AGC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.55249005_55249006delGCinsTA,chr7:g.55249005_55249006delGCinsTT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	EGFR		L	ESMO 2012 (abstr 4380)		chr7:g.55259524T>C	c.2582T>C	EGFR:L861P	CSQN=Missense;reference_codon=CTG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsCT,chr7:g.55259524_55259525delTGinsCA,chr7:g.55259524_55259525delTGinsCC;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	EGFR		L	ESMO 2012 (abstr 4380)		chr7:g.55259524T>G	c.2582T>G	EGFR:L861R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259523_55259524delCTinsAG,chr7:g.55259524_55259525delTGinsGA,chr7:g.55259524_55259525delTGinsGC,chr7:g.55259524_55259525delTGinsGT,chr7:g.55259523_55259525delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Lung
EGFR:T790M	MUT		Responsive	EGFR (T790M)	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	EGFR		L	ESMO 2012 (abstr 4380)		chr7:g.55249071C>T	c.2369C>T	EGFR:T790M	CSQN=Missense;reference_codon=ACG;candidate_codons=ATG;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Lung
EGFR::consequence::inframe_insertion:729-761	MUT		Responsive	EGFR exon 19 insertions	RDientsmann	[]	[MEK inhibitor (alone or in combination)]	MEK inhibitor (alone or in combination)s		Pre-clinical	EGFR		L	PMID:23102728									Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)	RDientsmann	[]	[MEK inhibitor (alone or in combination)]	MEK inhibitor (alone or in combination)s		Pre-clinical	EGFR		L	PMID:23102728		chr7:g.55259515T>G	c.2573T>G	EGFR:L858R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259514_55259515delCTinsAG,chr7:g.55259515_55259516delTGinsGA,chr7:g.55259515_55259516delTGinsGC,chr7:g.55259515_55259516delTGinsGT,chr7:g.55259514_55259516delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)	RDientsmann	[]	[MEK inhibitor (alone or in combination)]	MEK inhibitor (alone or in combination)s		Pre-clinical	EGFR		L	PMID:23102728		chr7:g.55259524T>A	c.2582T>A	EGFR:L861Q	CSQN=Missense;reference_codon=CTG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsAA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)	RDientsmann	[]	[MEK inhibitor (alone or in combination)]	MEK inhibitor (alone or in combination)s		Pre-clinical	EGFR		L	PMID:23102728		chr7:g.55241708G>C	c.2156G>C	EGFR:G719A	CSQN=Missense;reference_codon=GGC;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsCA,chr7:g.55241708_55241709delGCinsCG,chr7:g.55241708_55241709delGCinsCT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)	RDientsmann	[]	[MEK inhibitor (alone or in combination)]	MEK inhibitor (alone or in combination)s		Pre-clinical	EGFR		L	PMID:23102728		chr7:g.55241707G>A	c.2155G>A	EGFR:G719S	CSQN=Missense;reference_codon=GGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsAGT,chr7:g.55241707_55241708delGGinsTC,chr7:g.55241707_55241709delGGCinsTCT,chr7:g.55241707_55241709delGGCinsTCG,chr7:g.55241707_55241709delGGCinsTCA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)	RDientsmann	[]	[MEK inhibitor (alone or in combination)]	MEK inhibitor (alone or in combination)s		Pre-clinical	EGFR		L	PMID:23102728		chr7:g.55241707G>T	c.2155G>T	EGFR:G719C	CSQN=Missense;reference_codon=GGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsTGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)	RDientsmann	[]	[MEK inhibitor (alone or in combination)]	MEK inhibitor (alone or in combination)s		Pre-clinical	EGFR		L	PMID:23102728		chr7:g.55241708G>A	c.2156G>A	EGFR:G719D	CSQN=Missense;reference_codon=GGC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsAT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)	RDientsmann	[]	[MEK inhibitor (alone or in combination)]	MEK inhibitor (alone or in combination)s		Pre-clinical	EGFR		L	PMID:23102728		chr7:g.55242470T>C	c.2240T>C	EGFR:L747S	CSQN=Missense;reference_codon=TTA;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55242470_55242471delTAinsCT,chr7:g.55242470_55242471delTAinsCG,chr7:g.55242470_55242471delTAinsCC,chr7:g.55242469_55242471delTTAinsAGC,chr7:g.55242469_55242471delTTAinsAGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)	RDientsmann	[]	[MEK inhibitor (alone or in combination)]	MEK inhibitor (alone or in combination)s		Pre-clinical	EGFR		L	PMID:23102728		chr7:g.55249005G>T	c.2303G>T	EGFR:S768I	CSQN=Missense;reference_codon=AGC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.55249005_55249006delGCinsTA,chr7:g.55249005_55249006delGCinsTT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)	RDientsmann	[]	[MEK inhibitor (alone or in combination)]	MEK inhibitor (alone or in combination)s		Pre-clinical	EGFR		L	PMID:23102728		chr7:g.55259524T>C	c.2582T>C	EGFR:L861P	CSQN=Missense;reference_codon=CTG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsCT,chr7:g.55259524_55259525delTGinsCA,chr7:g.55259524_55259525delTGinsCC;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)	RDientsmann	[]	[MEK inhibitor (alone or in combination)]	MEK inhibitor (alone or in combination)s		Pre-clinical	EGFR		L	PMID:23102728		chr7:g.55259524T>G	c.2582T>G	EGFR:L861R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259523_55259524delCTinsAG,chr7:g.55259524_55259525delTGinsGA,chr7:g.55259524_55259525delTGinsGC,chr7:g.55259524_55259525delTGinsGT,chr7:g.55259523_55259525delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)	RDientsmann	[]	[MEK inhibitor (alone or in combination)]	MEK inhibitor (alone or in combination)s		Pre-clinical	EGFR		L	PMID:23102728		chr7:g.55249071C>T	c.2369C>T	EGFR:T790M	CSQN=Missense;reference_codon=ACG;candidate_codons=ATG;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Lung
EGFR:S492R	MUT		Responsive	EGFR (S492R)	RDientsmann	[]	[novel EGFR mAb inhibitor]	novel EGFR mAb inhibitors		Early trials	EGFR		COREAD	PMID:25962717		chr7:g.55228009C>G	c.1476C>G	EGFR:S492R	CSQN=Missense;reference_codon=AGC;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr7:g.55228009C>A,chr7:g.55228007A>C;candidate_mnv_variants=chr7:g.55228007_55228009delAGCinsCGA,chr7:g.55228007_55228009delAGCinsCGG,chr7:g.55228007_55228009delAGCinsCGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_12]	+	ENST00000275493	Colorectal adenocarcinoma
EGFR:T790M	MUT		Responsive	EGFR (T790M)	CRubio-Perez;RDientsmann	[Rociletinib,HM61713]	[EGFR inhibitor 3rd gen]	EGFR inhibitor 3rd gens (Rociletinib,HM61713,etc)		Late trials	EGFR		NSCLC	NCT02322281		chr7:g.55249071C>T	c.2369C>T	EGFR:T790M	CSQN=Missense;reference_codon=ACG;candidate_codons=ATG;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Non-small cell lung
EGFR::consequence::inframe_deletion:729-761	MUT		Responsive	EGFR exon 19 deletions	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA									Non-small cell lung
EGFR::consequence::inframe_insertion:729-761	MUT		Responsive	EGFR exon 19 insertions	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)		Late trials	EGFR		L	PMID:22753918;PMID:25589191									Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		chr7:g.55259515T>G	c.2573T>G	EGFR:L858R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259514_55259515delCTinsAG,chr7:g.55259515_55259516delTGinsGA,chr7:g.55259515_55259516delTGinsGC,chr7:g.55259515_55259516delTGinsGT,chr7:g.55259514_55259516delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Non-small cell lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		chr7:g.55259524T>A	c.2582T>A	EGFR:L861Q	CSQN=Missense;reference_codon=CTG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsAA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Non-small cell lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		chr7:g.55241708G>C	c.2156G>C	EGFR:G719A	CSQN=Missense;reference_codon=GGC;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsCA,chr7:g.55241708_55241709delGCinsCG,chr7:g.55241708_55241709delGCinsCT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Non-small cell lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		chr7:g.55241707G>A	c.2155G>A	EGFR:G719S	CSQN=Missense;reference_codon=GGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsAGT,chr7:g.55241707_55241708delGGinsTC,chr7:g.55241707_55241709delGGCinsTCT,chr7:g.55241707_55241709delGGCinsTCG,chr7:g.55241707_55241709delGGCinsTCA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Non-small cell lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		chr7:g.55241707G>T	c.2155G>T	EGFR:G719C	CSQN=Missense;reference_codon=GGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsTGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Non-small cell lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		chr7:g.55241708G>A	c.2156G>A	EGFR:G719D	CSQN=Missense;reference_codon=GGC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsAT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Non-small cell lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		chr7:g.55242470T>C	c.2240T>C	EGFR:L747S	CSQN=Missense;reference_codon=TTA;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55242470_55242471delTAinsCT,chr7:g.55242470_55242471delTAinsCG,chr7:g.55242470_55242471delTAinsCC,chr7:g.55242469_55242471delTTAinsAGC,chr7:g.55242469_55242471delTTAinsAGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000275493	Non-small cell lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		chr7:g.55249005G>T	c.2303G>T	EGFR:S768I	CSQN=Missense;reference_codon=AGC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.55249005_55249006delGCinsTA,chr7:g.55249005_55249006delGCinsTT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Non-small cell lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		chr7:g.55259524T>C	c.2582T>C	EGFR:L861P	CSQN=Missense;reference_codon=CTG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsCT,chr7:g.55259524_55259525delTGinsCA,chr7:g.55259524_55259525delTGinsCC;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Non-small cell lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		chr7:g.55259524T>G	c.2582T>G	EGFR:L861R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259523_55259524delCTinsAG,chr7:g.55259524_55259525delTGinsGA,chr7:g.55259524_55259525delTGinsGC,chr7:g.55259524_55259525delTGinsGT,chr7:g.55259523_55259525delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Non-small cell lung
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		chr7:g.55259524T>A	c.2582T>A	EGFR:L861Q	CSQN=Missense;reference_codon=CTG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsAA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Non-small cell lung
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		chr7:g.55241708G>C	c.2156G>C	EGFR:G719A	CSQN=Missense;reference_codon=GGC;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsCA,chr7:g.55241708_55241709delGCinsCG,chr7:g.55241708_55241709delGCinsCT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Non-small cell lung
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		chr7:g.55241707G>A	c.2155G>A	EGFR:G719S	CSQN=Missense;reference_codon=GGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsAGT,chr7:g.55241707_55241708delGGinsTC,chr7:g.55241707_55241709delGGCinsTCT,chr7:g.55241707_55241709delGGCinsTCG,chr7:g.55241707_55241709delGGCinsTCA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Non-small cell lung
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		chr7:g.55241707G>T	c.2155G>T	EGFR:G719C	CSQN=Missense;reference_codon=GGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsTGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Non-small cell lung
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		chr7:g.55241708G>A	c.2156G>A	EGFR:G719D	CSQN=Missense;reference_codon=GGC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsAT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Non-small cell lung
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		chr7:g.55242470T>C	c.2240T>C	EGFR:L747S	CSQN=Missense;reference_codon=TTA;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55242470_55242471delTAinsCT,chr7:g.55242470_55242471delTAinsCG,chr7:g.55242470_55242471delTAinsCC,chr7:g.55242469_55242471delTTAinsAGC,chr7:g.55242469_55242471delTTAinsAGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000275493	Non-small cell lung
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		chr7:g.55249005G>T	c.2303G>T	EGFR:S768I	CSQN=Missense;reference_codon=AGC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.55249005_55249006delGCinsTA,chr7:g.55249005_55249006delGCinsTT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Non-small cell lung
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		chr7:g.55259524T>C	c.2582T>C	EGFR:L861P	CSQN=Missense;reference_codon=CTG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsCT,chr7:g.55259524_55259525delTGinsCA,chr7:g.55259524_55259525delTGinsCC;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Non-small cell lung
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		chr7:g.55259524T>G	c.2582T>G	EGFR:L861R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259523_55259524delCTinsAG,chr7:g.55259524_55259525delTGinsGA,chr7:g.55259524_55259525delTGinsGC,chr7:g.55259524_55259525delTGinsGT,chr7:g.55259523_55259525delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Non-small cell lung
EGFR:T790M	MUT		Resistant	EGFR (T790M)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)		NCCN/CAP guidelines	EGFR		L	NCCN		chr7:g.55249071C>T	c.2369C>T	EGFR:T790M	CSQN=Missense;reference_codon=ACG;candidate_codons=ATG;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Lung
EGFR::consequence::inframe_insertion:729-761	MUT		Responsive	EGFR exon 19 insertions	RDientsmann	Afatinib;Cetuximab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	ESMO 2012 (abstr 1289)									Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	Afatinib;Cetuximab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	ESMO 2012 (abstr 1289)		chr7:g.55259515T>G	c.2573T>G	EGFR:L858R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259514_55259515delCTinsAG,chr7:g.55259515_55259516delTGinsGA,chr7:g.55259515_55259516delTGinsGC,chr7:g.55259515_55259516delTGinsGT,chr7:g.55259514_55259516delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	Afatinib;Cetuximab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	ESMO 2012 (abstr 1289)		chr7:g.55259524T>A	c.2582T>A	EGFR:L861Q	CSQN=Missense;reference_codon=CTG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsAA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	Afatinib;Cetuximab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	ESMO 2012 (abstr 1289)		chr7:g.55241708G>C	c.2156G>C	EGFR:G719A	CSQN=Missense;reference_codon=GGC;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsCA,chr7:g.55241708_55241709delGCinsCG,chr7:g.55241708_55241709delGCinsCT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	Afatinib;Cetuximab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	ESMO 2012 (abstr 1289)		chr7:g.55241707G>A	c.2155G>A	EGFR:G719S	CSQN=Missense;reference_codon=GGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsAGT,chr7:g.55241707_55241708delGGinsTC,chr7:g.55241707_55241709delGGCinsTCT,chr7:g.55241707_55241709delGGCinsTCG,chr7:g.55241707_55241709delGGCinsTCA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	Afatinib;Cetuximab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	ESMO 2012 (abstr 1289)		chr7:g.55241707G>T	c.2155G>T	EGFR:G719C	CSQN=Missense;reference_codon=GGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsTGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	Afatinib;Cetuximab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	ESMO 2012 (abstr 1289)		chr7:g.55241708G>A	c.2156G>A	EGFR:G719D	CSQN=Missense;reference_codon=GGC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsAT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	Afatinib;Cetuximab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	ESMO 2012 (abstr 1289)		chr7:g.55242470T>C	c.2240T>C	EGFR:L747S	CSQN=Missense;reference_codon=TTA;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55242470_55242471delTAinsCT,chr7:g.55242470_55242471delTAinsCG,chr7:g.55242470_55242471delTAinsCC,chr7:g.55242469_55242471delTTAinsAGC,chr7:g.55242469_55242471delTTAinsAGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	Afatinib;Cetuximab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	ESMO 2012 (abstr 1289)		chr7:g.55249005G>T	c.2303G>T	EGFR:S768I	CSQN=Missense;reference_codon=AGC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.55249005_55249006delGCinsTA,chr7:g.55249005_55249006delGCinsTT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	Afatinib;Cetuximab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	ESMO 2012 (abstr 1289)		chr7:g.55259524T>C	c.2582T>C	EGFR:L861P	CSQN=Missense;reference_codon=CTG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsCT,chr7:g.55259524_55259525delTGinsCA,chr7:g.55259524_55259525delTGinsCC;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	Afatinib;Cetuximab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	ESMO 2012 (abstr 1289)		chr7:g.55259524T>G	c.2582T>G	EGFR:L861R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259523_55259524delCTinsAG,chr7:g.55259524_55259525delTGinsGA,chr7:g.55259524_55259525delTGinsGC,chr7:g.55259524_55259525delTGinsGT,chr7:g.55259523_55259525delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Lung
EGFR:T790M	MUT		Responsive	EGFR (T790M)	RDientsmann	Afatinib;Cetuximab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	PMID:25074459		chr7:g.55249071C>T	c.2369C>T	EGFR:T790M	CSQN=Missense;reference_codon=ACG;candidate_codons=ATG;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Lung
EGFR:T790M	MUT		Responsive	EGFR (T790M)	RDientsmann	Afatinib;Nimotuzumab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Nimotuzumab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	PMID:26667485		chr7:g.55249071C>T	c.2369C>T	EGFR:T790M	CSQN=Missense;reference_codon=ACG;candidate_codons=ATG;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Lung
EGFR:P546S	MUT		Responsive	EGFR (P546S)	RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)		Case report	EGFR		HNC	PMID:23578570		chr7:g.55231430C>T	c.1636C>T	EGFR:P546S	CSQN=Missense;reference_codon=CCA;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55231430_55231432delCCAinsTCT,chr7:g.55231430_55231432delCCAinsTCG,chr7:g.55231430_55231432delCCAinsTCC,chr7:g.55231430_55231432delCCAinsAGC,chr7:g.55231430_55231432delCCAinsAGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_14]	+	ENST00000275493	Head an neck
EGFR:S464L,G465R,I491M	MUT		Resistant	EGFR (S464L,G465R,I491M)	RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)	Approved	Pre-clinical	EGFR		COREAD	PMID:25623215		chr7:g.55227924C>T	c.1391C>T	EGFR:S464L	CSQN=Missense;reference_codon=TCA;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_mnv_variants=chr7:g.55227923_55227924delTCinsCT,chr7:g.55227924_55227925delCAinsTG,chr7:g.55227923_55227925delTCAinsCTT,chr7:g.55227923_55227925delTCAinsCTG,chr7:g.55227923_55227925delTCAinsCTC;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_12]	+	ENST00000275493	Colorectal adenocarcinoma
EGFR:S464L,G465R,I491M	MUT		Resistant	EGFR (S464L,G465R,I491M)	RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)	Approved	Pre-clinical	EGFR		COREAD	PMID:25623215		chr7:g.55227926G>A	c.1393G>A	EGFR:G465R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr7:g.55227926G>C;candidate_mnv_variants=chr7:g.55227926_55227928delGGAinsAGG,chr7:g.55227926_55227928delGGAinsCGC,chr7:g.55227926_55227928delGGAinsCGG,chr7:g.55227926_55227928delGGAinsCGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_12]	+	ENST00000275493	Colorectal adenocarcinoma
EGFR:S464L,G465R,I491M	MUT		Resistant	EGFR (S464L,G465R,I491M)	RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)	Approved	Pre-clinical	EGFR		COREAD	PMID:25623215		chr7:g.55228006A>G	c.1473A>G	EGFR:I491M	CSQN=Missense;reference_codon=ATA;candidate_codons=ATG;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_12]	+	ENST00000275493	Colorectal adenocarcinoma
EGFR:S492R,G465R,R451C,K467T	MUT		Resistant	EGFR (S492R,G465R,R451C,K467T)	RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)		Case report	EGFR		COREAD	PMID:22270724;PMID:26059438;PMID:25623215;PMID:22270724;PMID:26888827		chr7:g.55228009C>G	c.1476C>G	EGFR:S492R	CSQN=Missense;reference_codon=AGC;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr7:g.55228009C>A,chr7:g.55228007A>C;candidate_mnv_variants=chr7:g.55228007_55228009delAGCinsCGA,chr7:g.55228007_55228009delAGCinsCGG,chr7:g.55228007_55228009delAGCinsCGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_12]	+	ENST00000275493	Colorectal adenocarcinoma
EGFR:S492R,G465R,R451C,K467T	MUT		Resistant	EGFR (S492R,G465R,R451C,K467T)	RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)		Case report	EGFR		COREAD	PMID:22270724;PMID:26059438;PMID:25623215;PMID:22270724;PMID:26888827		chr7:g.55227926G>A	c.1393G>A	EGFR:G465R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr7:g.55227926G>C;candidate_mnv_variants=chr7:g.55227926_55227928delGGAinsAGG,chr7:g.55227926_55227928delGGAinsCGC,chr7:g.55227926_55227928delGGAinsCGG,chr7:g.55227926_55227928delGGAinsCGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_12]	+	ENST00000275493	Colorectal adenocarcinoma
EGFR:S492R,G465R,R451C,K467T	MUT		Resistant	EGFR (S492R,G465R,R451C,K467T)	RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)		Case report	EGFR		COREAD	PMID:22270724;PMID:26059438;PMID:25623215;PMID:22270724;PMID:26888827		chr7:g.55227884C>T	c.1351C>T	EGFR:R451C	CSQN=Missense;reference_codon=CGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr7:g.55227884_55227886delCGCinsTGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_12]	+	ENST00000275493	Colorectal adenocarcinoma
EGFR:S492R,G465R,R451C,K467T	MUT		Resistant	EGFR (S492R,G465R,R451C,K467T)	RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)		Case report	EGFR		COREAD	PMID:22270724;PMID:26059438;PMID:25623215;PMID:22270724;PMID:26888827		chr7:g.55227933A>C	c.1400A>C	EGFR:K467T	CSQN=Missense;reference_codon=AAA;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr7:g.55227933_55227934delAAinsCG,chr7:g.55227933_55227934delAAinsCT,chr7:g.55227933_55227934delAAinsCC;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_12]	+	ENST00000275493	Colorectal adenocarcinoma
EGFR:P753S	MUT		Responsive	EGFR (P753S)	RDientsmann	Cetuximab;Sirolimus	EGFR mAb inhibitor;MTOR inhibitor	Cetuximab + Sirolimus (EGFR mAb inhibitor + MTOR inhibitor)		Case report	EGFR		HNC	PMID:24934779		chr7:g.55242487C>T	c.2257C>T	EGFR:P753S	CSQN=Missense;reference_codon=CCG;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55242487_55242489delCCGinsTCT,chr7:g.55242487_55242489delCCGinsTCC,chr7:g.55242487_55242489delCCGinsTCA,chr7:g.55242487_55242489delCCGinsAGC,chr7:g.55242487_55242489delCCGinsAGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000275493	Head an neck
EGFR::consequence::inframe_deletion:729-761	MUT		Responsive	EGFR exon 19 deletions	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA									Non-small cell lung
EGFR::consequence::inframe_insertion:729-761	MUT		Responsive	EGFR exon 19 insertions	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)	Approved	Early trials	EGFR		L	PMID:22190593									Lung
EGFR::consequence::inframe_insertion:769-770	MUT		Responsive	EGFR inframe insertion (769-770)	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)		Case report	EGFR		L	PMID:26773740;PMID:23328547									Lung
EGFR:A289V,R108K,G598V,T263P	MUT		Responsive	EGFR (A289V,R108K,G598V,T263P)	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)	Approved	Pre-clinical	EGFR		G	PMID:17177598		chr7:g.55221822C>T	c.866C>T	EGFR:A289V	CSQN=Missense;reference_codon=GCC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr7:g.55221822_55221823delCCinsTA,chr7:g.55221822_55221823delCCinsTG,chr7:g.55221822_55221823delCCinsTT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000275493	Glioma
EGFR:A289V,R108K,G598V,T263P	MUT		Responsive	EGFR (A289V,R108K,G598V,T263P)	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)	Approved	Pre-clinical	EGFR		G	PMID:17177598		chr7:g.55211080G>A	c.323G>A	EGFR:R108K	CSQN=Missense;reference_codon=AGA;candidate_codons=AAG,AAA;candidate_mnv_variants=chr7:g.55211080_55211081delGAinsAG;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_3]	+	ENST00000275493	Glioma
EGFR:A289V,R108K,G598V,T263P	MUT		Responsive	EGFR (A289V,R108K,G598V,T263P)	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)	Approved	Pre-clinical	EGFR		G	PMID:17177598		chr7:g.55233043G>T	c.1793G>T	EGFR:G598V	CSQN=Missense;reference_codon=GGA;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr7:g.55233043_55233044delGAinsTC,chr7:g.55233043_55233044delGAinsTG,chr7:g.55233043_55233044delGAinsTT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_15]	+	ENST00000275493	Glioma
EGFR:A289V,R108K,G598V,T263P	MUT		Responsive	EGFR (A289V,R108K,G598V,T263P)	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)	Approved	Pre-clinical	EGFR		G	PMID:17177598		chr7:g.55221743A>C	c.787A>C	EGFR:T263P	CSQN=Missense;reference_codon=ACC;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr7:g.55221743_55221745delACCinsCCT,chr7:g.55221743_55221745delACCinsCCG,chr7:g.55221743_55221745delACCinsCCA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000275493	Glioma
EGFR:K757R,E746G	MUT		Responsive	EGFR (K757R,E746G)	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)		Case report	EGFR		L	PMID:26773740		chr7:g.55242500A>G	c.2270A>G	EGFR:K757R	CSQN=Missense;reference_codon=AAG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55242500_55242501delAGinsGA,chr7:g.55242499_55242500delAAinsCG,chr7:g.55242499_55242501delAAGinsCGA,chr7:g.55242499_55242501delAAGinsCGC,chr7:g.55242499_55242501delAAGinsCGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000275493	Lung
EGFR:K757R,E746G	MUT		Responsive	EGFR (K757R,E746G)	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)		Case report	EGFR		L	PMID:26773740		chr7:g.55242467A>G	c.2237A>G	EGFR:E746G	CSQN=Missense;reference_codon=GAA;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr7:g.55242467_55242468delAAinsGT,chr7:g.55242467_55242468delAAinsGG,chr7:g.55242467_55242468delAAinsGC;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000275493	Lung
EGFR:L858R	MUT		Responsive	EGFR (L858R)	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		chr7:g.55259515T>G	c.2573T>G	EGFR:L858R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259514_55259515delCTinsAG,chr7:g.55259515_55259516delTGinsGA,chr7:g.55259515_55259516delTGinsGC,chr7:g.55259515_55259516delTGinsGT,chr7:g.55259514_55259516delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Non-small cell lung
EGFR:L858R,L861.,G719.,S768I	MUT		Responsive	EGFR (L858R,L861,G719,S768I)	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)	Approved	NCCN guidelines	EGFR		NSCLC	NCCN									Non-small cell lung
EGFR:S720.	MUT		No Responsive	EGFR (S720)	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)		Case report	EGFR		L	PMID:26773740									Lung
EGFR:T790M	MUT		Resistant	EGFR (T790M)	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)		NCCN/CAP guidelines	EGFR		L	NCCN		chr7:g.55249071C>T	c.2369C>T	EGFR:T790M	CSQN=Missense;reference_codon=ACG;candidate_codons=ATG;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Lung
EGFR::consequence::inframe_deletion:729-761	MUT		Responsive	EGFR exon 19 deletions	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA									Non-small cell lung
EGFR::consequence::inframe_deletion:L747.,::inframe_insertion:P753PS	MUT		No Responsive	EGFR inframe deletion (L747),inframe insertion (P753PS)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	Case report	EGFR		HNC	PMID:21274259									Head an neck
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		chr7:g.55259515T>G	c.2573T>G	EGFR:L858R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259514_55259515delCTinsAG,chr7:g.55259515_55259516delTGinsGA,chr7:g.55259515_55259516delTGinsGC,chr7:g.55259515_55259516delTGinsGT,chr7:g.55259514_55259516delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Non-small cell lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		chr7:g.55259524T>A	c.2582T>A	EGFR:L861Q	CSQN=Missense;reference_codon=CTG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsAA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Non-small cell lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		chr7:g.55241708G>C	c.2156G>C	EGFR:G719A	CSQN=Missense;reference_codon=GGC;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsCA,chr7:g.55241708_55241709delGCinsCG,chr7:g.55241708_55241709delGCinsCT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Non-small cell lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		chr7:g.55241707G>A	c.2155G>A	EGFR:G719S	CSQN=Missense;reference_codon=GGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsAGT,chr7:g.55241707_55241708delGGinsTC,chr7:g.55241707_55241709delGGCinsTCT,chr7:g.55241707_55241709delGGCinsTCG,chr7:g.55241707_55241709delGGCinsTCA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Non-small cell lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		chr7:g.55241707G>T	c.2155G>T	EGFR:G719C	CSQN=Missense;reference_codon=GGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsTGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Non-small cell lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		chr7:g.55241708G>A	c.2156G>A	EGFR:G719D	CSQN=Missense;reference_codon=GGC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsAT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Non-small cell lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		chr7:g.55242470T>C	c.2240T>C	EGFR:L747S	CSQN=Missense;reference_codon=TTA;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55242470_55242471delTAinsCT,chr7:g.55242470_55242471delTAinsCG,chr7:g.55242470_55242471delTAinsCC,chr7:g.55242469_55242471delTTAinsAGC,chr7:g.55242469_55242471delTTAinsAGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000275493	Non-small cell lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		chr7:g.55249005G>T	c.2303G>T	EGFR:S768I	CSQN=Missense;reference_codon=AGC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.55249005_55249006delGCinsTA,chr7:g.55249005_55249006delGCinsTT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Non-small cell lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		chr7:g.55259524T>C	c.2582T>C	EGFR:L861P	CSQN=Missense;reference_codon=CTG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsCT,chr7:g.55259524_55259525delTGinsCA,chr7:g.55259524_55259525delTGinsCC;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Non-small cell lung
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		chr7:g.55259524T>G	c.2582T>G	EGFR:L861R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259523_55259524delCTinsAG,chr7:g.55259524_55259525delTGinsGA,chr7:g.55259524_55259525delTGinsGC,chr7:g.55259524_55259525delTGinsGT,chr7:g.55259523_55259525delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Non-small cell lung
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		chr7:g.55259524T>A	c.2582T>A	EGFR:L861Q	CSQN=Missense;reference_codon=CTG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsAA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Non-small cell lung
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		chr7:g.55241708G>C	c.2156G>C	EGFR:G719A	CSQN=Missense;reference_codon=GGC;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsCA,chr7:g.55241708_55241709delGCinsCG,chr7:g.55241708_55241709delGCinsCT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Non-small cell lung
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		chr7:g.55241707G>A	c.2155G>A	EGFR:G719S	CSQN=Missense;reference_codon=GGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsAGT,chr7:g.55241707_55241708delGGinsTC,chr7:g.55241707_55241709delGGCinsTCT,chr7:g.55241707_55241709delGGCinsTCG,chr7:g.55241707_55241709delGGCinsTCA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Non-small cell lung
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		chr7:g.55241707G>T	c.2155G>T	EGFR:G719C	CSQN=Missense;reference_codon=GGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsTGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Non-small cell lung
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		chr7:g.55241708G>A	c.2156G>A	EGFR:G719D	CSQN=Missense;reference_codon=GGC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsAT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Non-small cell lung
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		chr7:g.55242470T>C	c.2240T>C	EGFR:L747S	CSQN=Missense;reference_codon=TTA;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55242470_55242471delTAinsCT,chr7:g.55242470_55242471delTAinsCG,chr7:g.55242470_55242471delTAinsCC,chr7:g.55242469_55242471delTTAinsAGC,chr7:g.55242469_55242471delTTAinsAGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000275493	Non-small cell lung
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		chr7:g.55249005G>T	c.2303G>T	EGFR:S768I	CSQN=Missense;reference_codon=AGC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.55249005_55249006delGCinsTA,chr7:g.55249005_55249006delGCinsTT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Non-small cell lung
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		chr7:g.55259524T>C	c.2582T>C	EGFR:L861P	CSQN=Missense;reference_codon=CTG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsCT,chr7:g.55259524_55259525delTGinsCA,chr7:g.55259524_55259525delTGinsCC;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Non-small cell lung
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		chr7:g.55259524T>G	c.2582T>G	EGFR:L861R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259523_55259524delCTinsAG,chr7:g.55259524_55259525delTGinsGA,chr7:g.55259524_55259525delTGinsGC,chr7:g.55259524_55259525delTGinsGT,chr7:g.55259523_55259525delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Non-small cell lung
EGFR:V843I	MUT		No Responsive	EGFR (V843I)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	Case report	EGFR		HNC	PMID:21274259		chr7:g.55259469G>A	c.2527G>A	EGFR:V843I	CSQN=Missense;reference_codon=GTA;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.55259469_55259471delGTAinsATC,chr7:g.55259469_55259471delGTAinsATT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Head an neck
EGFR:E690K	MUT		Responsive	EGFR (E690K)	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)	Approved	Case report	EGFR		ED	PMID:22885469		chr7:g.55241620G>A	c.2068G>A	EGFR:E690K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr7:g.55241620_55241622delGAGinsAAA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000275493	Endometrium
EGFR::consequence::inframe_deletion:729-761	MUT		Responsive	EGFR exon 19 deletions	CRubio-Perez	Osimertinib	EGFR inhibitor 3rd gen	Osimertinib (EGFR inhibitor 3rd gen)	Approved	Early trials	EGFR		L	NCT02465060									Lung
EGFR::consequence::inframe_insertion:762-823	MUT		Responsive	EGFR exon 20 insertions	RDientsmann	Osimertinib	EGFR inhibitor 3rd gen	Osimertinib (EGFR inhibitor 3rd gen)		Pre-clinical	EGFR		L	PMID:26515464									Lung
EGFR:C797S	MUT		Resistant	EGFR (C797S)	RDientsmann	Osimertinib	EGFR inhibitor 3rd gen	Osimertinib (EGFR inhibitor 3rd gen)		Early trials	EGFR		L	PMID:25939061		chr7:g.55249091T>A	c.2389T>A	EGFR:C797S	CSQN=Missense;reference_codon=TGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_snv_variants=chr7:g.55249092G>C;candidate_mnv_variants=chr7:g.55249091_55249093delTGCinsAGT,chr7:g.55249092_55249093delGCinsCT,chr7:g.55249092_55249093delGCinsCG,chr7:g.55249092_55249093delGCinsCA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Lung
EGFR:L718.	MUT		Resistant	EGFR (L718)	RDientsmann	Osimertinib	EGFR inhibitor 3rd gen	Osimertinib (EGFR inhibitor 3rd gen)		Early trials	EGFR		L	ASCO 2017 (abstr 2572)									Lung
EGFR:L792.	MUT		Resistant	EGFR (L792)	RDientsmann	Osimertinib	EGFR inhibitor 3rd gen	Osimertinib (EGFR inhibitor 3rd gen)		Early trials	EGFR		L	ASCO 2017 (abstr 2572)									Lung
EGFR:L858R	MUT		Responsive	EGFR (L858R)	CRubio-Perez	Osimertinib	EGFR inhibitor 3rd gen	Osimertinib (EGFR inhibitor 3rd gen)	Approved	Early trials	EGFR		L	NCT02465060		chr7:g.55259515T>G	c.2573T>G	EGFR:L858R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259514_55259515delCTinsAG,chr7:g.55259515_55259516delTGinsGA,chr7:g.55259515_55259516delTGinsGC,chr7:g.55259515_55259516delTGinsGT,chr7:g.55259514_55259516delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000275493	Lung
EGFR:T790M	MUT		Responsive	EGFR (T790M)	RDientsmann	Osimertinib	EGFR inhibitor 3rd gen	Osimertinib (EGFR inhibitor 3rd gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		chr7:g.55249071C>T	c.2369C>T	EGFR:T790M	CSQN=Missense;reference_codon=ACG;candidate_codons=ATG;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Non-small cell lung
EGFR:G465R	MUT		Resistant	EGFR (G465R)	RDientsmann	Panitumumab	EGFR mAb inhibitor	Panitumumab (EGFR mAb inhibitor)		Case report	EGFR		COREAD	PMID:26059438		chr7:g.55227926G>A	c.1393G>A	EGFR:G465R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr7:g.55227926G>C;candidate_mnv_variants=chr7:g.55227926_55227928delGGAinsAGG,chr7:g.55227926_55227928delGGAinsCGC,chr7:g.55227926_55227928delGGAinsCGG,chr7:g.55227926_55227928delGGAinsCGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_12]	+	ENST00000275493	Colorectal adenocarcinoma
EGFR:S492R	MUT		Responsive	EGFR (S492R)	RDientsmann	Panitumumab	EGFR mAb inhibitor	Panitumumab (EGFR mAb inhibitor)		Case report	EGFR		COREAD	PMID:22270724		chr7:g.55228009C>G	c.1476C>G	EGFR:S492R	CSQN=Missense;reference_codon=AGC;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr7:g.55228009C>A,chr7:g.55228007A>C;candidate_mnv_variants=chr7:g.55228007_55228009delAGCinsCGA,chr7:g.55228007_55228009delAGCinsCGG,chr7:g.55228007_55228009delAGCinsCGT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_12]	+	ENST00000275493	Colorectal adenocarcinoma
EGFR::consequence::inframe_deletion:6-273	MUT		Responsive	EGFR inframe deletion (6-273)	MMartínez	Rindopepimut	Vaccine	Rindopepimut (Vaccine)	Clinical Trials	Late trials	EGFR		GB	NCT01480479	Indirect								Glioblastoma
EGFR:L798I	MUT		Resistant	EGFR (L798I)	RDientsmann	Rociletinib	EGFR inhibitor	Rociletinib (EGFR inhibitor)		Case report	EGFR		LUAD	PMID:27283993		chr7:g.55249094C>A	c.2392C>A	EGFR:L798I	CSQN=Missense;reference_codon=CTC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.55249094_55249096delCTCinsATA,chr7:g.55249094_55249096delCTCinsATT;aliases=ENSP00000275493;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000275493	Lung adenocarcinoma
EPHA2:G391R	MUT		Responsive	EPHA2 (G391R)	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	EPHA2		LUSC	PMID:20360610		chr1:g.16464489C>T	c.1171G>A	EPHA2:G391R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr1:g.16464489C>G;candidate_mnv_variants=chr1:g.16464487_16464489delTCCinsCCT,chr1:g.16464487_16464489delTCCinsGCG,chr1:g.16464487_16464489delTCCinsCCG,chr1:g.16464487_16464489delTCCinsACG;aliases=ENSP00000351209;source=Ensembl	inside_[cds_in_exon_5]	-	ENST00000358432	Lung squamous cell
EPHA2:G391R	MUT		Responsive	EPHA2 (G391R)	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	EPHA2		LUSC	PMID:20360610		chr1:g.16464489C>T	c.1171G>A	EPHA2:G391R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr1:g.16464489C>G;candidate_mnv_variants=chr1:g.16464487_16464489delTCCinsCCT,chr1:g.16464487_16464489delTCCinsGCG,chr1:g.16464487_16464489delTCCinsCCG,chr1:g.16464487_16464489delTCCinsACG;aliases=ENSP00000351209;source=Ensembl	inside_[cds_in_exon_5]	-	ENST00000358432	Lung squamous cell
EPHA2:G391R	MUT		Responsive	EPHA2 (G391R)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	EPHA2		LUSC	PMID:20360610		chr1:g.16464489C>T	c.1171G>A	EPHA2:G391R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr1:g.16464489C>G;candidate_mnv_variants=chr1:g.16464487_16464489delTCCinsCCT,chr1:g.16464487_16464489delTCCinsGCG,chr1:g.16464487_16464489delTCCinsCCG,chr1:g.16464487_16464489delTCCinsACG;aliases=ENSP00000351209;source=Ensembl	inside_[cds_in_exon_5]	-	ENST00000358432	Lung squamous cell
EPHA2:G391R	MUT		Responsive	EPHA2 (G391R)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	EPHA2		LUSC	PMID:20360610		chr1:g.16464489C>T	c.1171G>A	EPHA2:G391R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr1:g.16464489C>G;candidate_mnv_variants=chr1:g.16464487_16464489delTCCinsCCT,chr1:g.16464487_16464489delTCCinsGCG,chr1:g.16464487_16464489delTCCinsCCG,chr1:g.16464487_16464489delTCCinsACG;aliases=ENSP00000351209;source=Ensembl	inside_[cds_in_exon_5]	-	ENST00000358432	Lung squamous cell
ERBB2::consequence::inframe_insertion:775-881	MUT		Responsive	ERBB2 proximal exon 20	RDientsmann	[Afatinib,Lapatinib,Neratinib]	[ERBB2 inhibitor]	ERBB2 inhibitors (Afatinib,Lapatinib,Neratinib,etc)		Early trials	ERBB2		LUAD	PMID:26598547									Lung adenocarcinoma
ERBB2::consequence::inframe_insertion:775-881	MUT		Responsive	ERBB2 proximal exon 20	RDientsmann	[Trastuzumab]	[ERBB2 mAb inhibitor]	ERBB2 mAb inhibitors (Trastuzumab,etc)		Early trials	ERBB2		LUAD	PMID:26598547									Lung adenocarcinoma
ERBB2::consequence::inframe_insertion:A775YVMA,::inframe_insertion:G776VC	MUT		Responsive	ERBB2 inframe insertion (A775YVMA),inframe insertion (G776VC)	RDientsmann	Ado-Trastuzumab Emtansine	ERBB2 mAb inhibitor	Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)		Early trials	ERBB2		L	ASCO 2017 (abstr 8510)									Lung
ERBB2:V659E,S310F	MUT		Responsive	ERBB2 (V659E,S310F)	RDientsmann	Ado-Trastuzumab Emtansine	ERBB2 mAb inhibitor	Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)		Early trials	ERBB2		L	ASCO 2017 (abstr 8510)		chr17:g.37879601_37879602delTTinsAG	c.1976_1977delTTinsAG	ERBB2:V659E	CSQN=Missense;reference_codon=GTT;candidate_codons=GAG,GAA;candidate_mnv_variants=chr17:g.37879601_37879602delTTinsAA;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_17]	+	ENST00000269571	Lung
ERBB2:V659E,S310F	MUT		Responsive	ERBB2 (V659E,S310F)	RDientsmann	Ado-Trastuzumab Emtansine	ERBB2 mAb inhibitor	Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)		Early trials	ERBB2		L	ASCO 2017 (abstr 8510)		chr17:g.37868208C>T	c.929C>T	ERBB2:S310F	CSQN=Missense;reference_codon=TCC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr17:g.37868208_37868209delCCinsTT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000269571	Lung
ERBB2::consequence::inframe_insertion:775-881	MUT		Responsive	ERBB2 proximal exon 20	RDientsmann	Afatinib	ERBB2&EGFR inhibitor 2nd gen	Afatinib (ERBB2&EGFR inhibitor 2nd gen)		Early trials	ERBB2		LUAD	PMID:26598547;ASCO 2017 (abstr 9071)									Lung adenocarcinoma
ERBB2:T798I	MUT		Responsive	ERBB2 (T798I)	RDientsmann	Afatinib	ERBB2&EGFR inhibitor 2nd gen	Afatinib (ERBB2&EGFR inhibitor 2nd gen)		Pre-clinical	ERBB2		BRCA	PMID:28274957		chr17:g.37881064C>T	c.2393C>T	ERBB2:T798I	CSQN=Missense;reference_codon=ACA;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr17:g.37881064_37881065delCAinsTC,chr17:g.37881064_37881065delCAinsTT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000269571	Breast adenocarcinoma
ERBB2:.	MUT		Responsive	ERBB2 oncogenic mutation	EArriola	Dacomitinib	Pan ERBB inhibitor	Dacomitinib (Pan ERBB inhibitor)		Early trials	ERBB2		NSCLC	PMID:25899785									Non-small cell lung
ERBB2:D769Y,D769H,R896C,V777L,V842I,G309A	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,V777L,V842I,G309A)	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	PMID:23220880		chr17:g.37880261G>T	c.2305G>T	ERBB2:D769Y	CSQN=Missense;reference_codon=GAC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr17:g.37880261_37880263delGACinsTAT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000269571	Breast adenocarcinoma
ERBB2:D769Y,D769H,R896C,V777L,V842I,G309A	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,V777L,V842I,G309A)	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	PMID:23220880		chr17:g.37880261G>C	c.2305G>C	ERBB2:D769H	CSQN=Missense;reference_codon=GAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr17:g.37880261_37880263delGACinsCAT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000269571	Breast adenocarcinoma
ERBB2:D769Y,D769H,R896C,V777L,V842I,G309A	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,V777L,V842I,G309A)	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	PMID:23220880		chr17:g.37881616C>T	c.2686C>T	ERBB2:R896C	CSQN=Missense;reference_codon=CGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr17:g.37881616_37881618delCGCinsTGT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_22]	+	ENST00000269571	Breast adenocarcinoma
ERBB2:D769Y,D769H,R896C,V777L,V842I,G309A	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,V777L,V842I,G309A)	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	PMID:23220880		chr17:g.37881000G>C	c.2329G>C	ERBB2:V777L	CSQN=Missense;reference_codon=GTG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr17:g.37881000G>T;candidate_mnv_variants=chr17:g.37881000_37881002delGTGinsCTT,chr17:g.37881000_37881002delGTGinsCTA,chr17:g.37881000_37881002delGTGinsCTC,chr17:g.37881000_37881002delGTGinsTTA;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000269571	Breast adenocarcinoma
ERBB2:D769Y,D769H,R896C,V777L,V842I,G309A	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,V777L,V842I,G309A)	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	PMID:23220880		chr17:g.37881332G>A	c.2524G>A	ERBB2:V842I	CSQN=Missense;reference_codon=GTA;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr17:g.37881332_37881334delGTAinsATC,chr17:g.37881332_37881334delGTAinsATT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000269571	Breast adenocarcinoma
ERBB2:D769Y,D769H,R896C,V777L,V842I,G309A	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,V777L,V842I,G309A)	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	PMID:23220880		chr17:g.37868205G>C	c.926G>C	ERBB2:G309A	CSQN=Missense;reference_codon=GGA;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr17:g.37868205_37868206delGAinsCC,chr17:g.37868205_37868206delGAinsCG,chr17:g.37868205_37868206delGAinsCT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000269571	Breast adenocarcinoma
ERBB2:K753E	MUT		Resistant	ERBB2 (K753E)	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	PMID:27697991		chr17:g.37880213A>G	c.2257A>G	ERBB2:K753E	CSQN=Missense;reference_codon=AAA;candidate_codons=GAG,GAA;candidate_mnv_variants=chr17:g.37880213_37880215delAAAinsGAG;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000269571	Breast adenocarcinoma
ERBB2:V659E	MUT		Responsive	ERBB2 (V659E)	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Case report	ERBB2		BRCA;LUAD	PMID:23950206		chr17:g.37879601_37879602delTTinsAG	c.1976_1977delTTinsAG	ERBB2:V659E	CSQN=Missense;reference_codon=GTT;candidate_codons=GAG,GAA;candidate_mnv_variants=chr17:g.37879601_37879602delTTinsAA;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_17]	+	ENST00000269571	Breast adenocarcinoma;Lung adenocarcinoma
ERBB2::consequence::inframe_insertion:775-881	MUT		Responsive	ERBB2 proximal exon 20	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Early trials	ERBB2		LUAD	PMID:26598547;ASCO 2017 (abstr 9071)									Lung adenocarcinoma
ERBB2::consequence::inframe_deletion:755-759,::inframe_insertion:.780GSP,::inframe_insertion:.781GSP	MUT		Responsive	ERBB2 inframe deletion (755-759),inframe insertion (780GSP),inframe insertion (781GSP)	RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	PMID:23220880									Breast adenocarcinoma
ERBB2:.	MUT		Responsive	ERBB2 oncogenic mutation	RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Early trials	ERBB2		LUAD	ESMO 2014 (abstr LBA39_PR)									Lung adenocarcinoma
ERBB2:K753E	MUT		Responsive	ERBB2 (K753E)	RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	PMID:27697991		chr17:g.37880213A>G	c.2257A>G	ERBB2:K753E	CSQN=Missense;reference_codon=AAA;candidate_codons=GAG,GAA;candidate_mnv_variants=chr17:g.37880213_37880215delAAAinsGAG;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000269571	Breast adenocarcinoma
ERBB2:L755S,G309A,D769Y,D769H,R896C,V777L,V842I	MUT		Responsive	ERBB2 (L755S,G309A,D769Y,D769H,R896C,V777L,V842I)	RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	PMID:23220880		chr17:g.37880220T>C	c.2264T>C	ERBB2:L755S	CSQN=Missense;reference_codon=TTG;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr17:g.37880220_37880221delTGinsCT,chr17:g.37880220_37880221delTGinsCC,chr17:g.37880220_37880221delTGinsCA,chr17:g.37880219_37880221delTTGinsAGC,chr17:g.37880219_37880221delTTGinsAGT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000269571	Breast adenocarcinoma
ERBB2:L755S,G309A,D769Y,D769H,R896C,V777L,V842I	MUT		Responsive	ERBB2 (L755S,G309A,D769Y,D769H,R896C,V777L,V842I)	RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	PMID:23220880		chr17:g.37868205G>C	c.926G>C	ERBB2:G309A	CSQN=Missense;reference_codon=GGA;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr17:g.37868205_37868206delGAinsCC,chr17:g.37868205_37868206delGAinsCG,chr17:g.37868205_37868206delGAinsCT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000269571	Breast adenocarcinoma
ERBB2:L755S,G309A,D769Y,D769H,R896C,V777L,V842I	MUT		Responsive	ERBB2 (L755S,G309A,D769Y,D769H,R896C,V777L,V842I)	RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	PMID:23220880		chr17:g.37880261G>T	c.2305G>T	ERBB2:D769Y	CSQN=Missense;reference_codon=GAC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr17:g.37880261_37880263delGACinsTAT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000269571	Breast adenocarcinoma
ERBB2:L755S,G309A,D769Y,D769H,R896C,V777L,V842I	MUT		Responsive	ERBB2 (L755S,G309A,D769Y,D769H,R896C,V777L,V842I)	RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	PMID:23220880		chr17:g.37880261G>C	c.2305G>C	ERBB2:D769H	CSQN=Missense;reference_codon=GAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr17:g.37880261_37880263delGACinsCAT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000269571	Breast adenocarcinoma
ERBB2:L755S,G309A,D769Y,D769H,R896C,V777L,V842I	MUT		Responsive	ERBB2 (L755S,G309A,D769Y,D769H,R896C,V777L,V842I)	RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	PMID:23220880		chr17:g.37881616C>T	c.2686C>T	ERBB2:R896C	CSQN=Missense;reference_codon=CGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr17:g.37881616_37881618delCGCinsTGT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_22]	+	ENST00000269571	Breast adenocarcinoma
ERBB2:L755S,G309A,D769Y,D769H,R896C,V777L,V842I	MUT		Responsive	ERBB2 (L755S,G309A,D769Y,D769H,R896C,V777L,V842I)	RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	PMID:23220880		chr17:g.37881000G>C	c.2329G>C	ERBB2:V777L	CSQN=Missense;reference_codon=GTG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr17:g.37881000G>T;candidate_mnv_variants=chr17:g.37881000_37881002delGTGinsCTT,chr17:g.37881000_37881002delGTGinsCTA,chr17:g.37881000_37881002delGTGinsCTC,chr17:g.37881000_37881002delGTGinsTTA;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000269571	Breast adenocarcinoma
ERBB2:L755S,G309A,D769Y,D769H,R896C,V777L,V842I	MUT		Responsive	ERBB2 (L755S,G309A,D769Y,D769H,R896C,V777L,V842I)	RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	PMID:23220880		chr17:g.37881332G>A	c.2524G>A	ERBB2:V842I	CSQN=Missense;reference_codon=GTA;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr17:g.37881332_37881334delGTAinsATC,chr17:g.37881332_37881334delGTAinsATT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000269571	Breast adenocarcinoma
ERBB2::consequence::inframe_insertion:775-881	MUT		Responsive	ERBB2 proximal exon 20	RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Early trials	ERBB2		LUAD	PMID:26598547;ASCO 2017 (abstr 9071)									Lung adenocarcinoma
ERBB2:L869R	MUT		Responsive	ERBB2 (L869R)	RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Case report	ERBB2		BRCA	PMID:28274957		chr17:g.37881414T>G	c.2606T>G	ERBB2:L869R	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr17:g.37881413_37881414delCTinsAG,chr17:g.37881414_37881415delTGinsGA,chr17:g.37881414_37881415delTGinsGC,chr17:g.37881414_37881415delTGinsGT,chr17:g.37881413_37881415delCTGinsAGA;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_21]	+	ENST00000269571	Breast adenocarcinoma
ERBB2:S310.,L755.,V777.	MUT		Responsive	ERBB2 (S310,L755,V777)	RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Early trials	ERBB2		CANCER	AACR 2017 (abstr CT001)									Any cancer type
ERBB2::consequence::inframe_insertion:P780GSP,::inframe_insertion:.781GSP,::inframe_insertion:A775YVMA,::inframe_insertion:G776YVMA	MUT		Responsive	ERBB2 inframe insertion (P780GSP),inframe insertion (781GSP),inframe insertion (A775YVMA),inframe insertion (G776YVMA)	RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Early trials	ERBB2		CANCER	AACR 2017 (abstr CT001)									Any cancer type
ERBB2:T798I	MUT		Resistant	ERBB2 (T798I)	RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Case report	ERBB2		BRCA	PMID:28274957		chr17:g.37881064C>T	c.2393C>T	ERBB2:T798I	CSQN=Missense;reference_codon=ACA;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr17:g.37881064_37881065delCAinsTC,chr17:g.37881064_37881065delCAinsTT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000269571	Breast adenocarcinoma
ERBB2:.	MUT		Responsive	ERBB2 oncogenic mutation	RDientsmann	Tensirolimus	MTOR inhibitor	Tensirolimus (MTOR inhibitor)		Early trials	ERBB2		LUAD	ESMO 2014 (abstr LBA39_PR)									Lung adenocarcinoma
ERBB2:D769Y,D769H,R896C,G309E,S310F,S310Y,C311R	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,G309E,S310F,S310Y,C311R)	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		BRCA;CANCER	PMID:23220880;PMID:22908275		chr17:g.37880261G>T	c.2305G>T	ERBB2:D769Y	CSQN=Missense;reference_codon=GAC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr17:g.37880261_37880263delGACinsTAT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000269571	Breast adenocarcinoma;Any cancer type
ERBB2:D769Y,D769H,R896C,G309E,S310F,S310Y,C311R	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,G309E,S310F,S310Y,C311R)	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		BRCA;CANCER	PMID:23220880;PMID:22908275		chr17:g.37880261G>C	c.2305G>C	ERBB2:D769H	CSQN=Missense;reference_codon=GAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr17:g.37880261_37880263delGACinsCAT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000269571	Breast adenocarcinoma;Any cancer type
ERBB2:D769Y,D769H,R896C,G309E,S310F,S310Y,C311R	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,G309E,S310F,S310Y,C311R)	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		BRCA;CANCER	PMID:23220880;PMID:22908275		chr17:g.37881616C>T	c.2686C>T	ERBB2:R896C	CSQN=Missense;reference_codon=CGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr17:g.37881616_37881618delCGCinsTGT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_22]	+	ENST00000269571	Breast adenocarcinoma;Any cancer type
ERBB2:D769Y,D769H,R896C,G309E,S310F,S310Y,C311R	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,G309E,S310F,S310Y,C311R)	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		BRCA;CANCER	PMID:23220880;PMID:22908275		chr17:g.37868205G>A	c.926G>A	ERBB2:G309E	CSQN=Missense;reference_codon=GGA;candidate_codons=GAG,GAA;candidate_mnv_variants=chr17:g.37868205_37868206delGAinsAG;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000269571	Breast adenocarcinoma;Any cancer type
ERBB2:D769Y,D769H,R896C,G309E,S310F,S310Y,C311R	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,G309E,S310F,S310Y,C311R)	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		BRCA;CANCER	PMID:23220880;PMID:22908275		chr17:g.37868208C>T	c.929C>T	ERBB2:S310F	CSQN=Missense;reference_codon=TCC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr17:g.37868208_37868209delCCinsTT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000269571	Breast adenocarcinoma;Any cancer type
ERBB2:D769Y,D769H,R896C,G309E,S310F,S310Y,C311R	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,G309E,S310F,S310Y,C311R)	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		BRCA;CANCER	PMID:23220880;PMID:22908275		chr17:g.37868208C>A	c.929C>A	ERBB2:S310Y	CSQN=Missense;reference_codon=TCC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr17:g.37868208_37868209delCCinsAT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000269571	Breast adenocarcinoma;Any cancer type
ERBB2:D769Y,D769H,R896C,G309E,S310F,S310Y,C311R	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,G309E,S310F,S310Y,C311R)	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		BRCA;CANCER	PMID:23220880;PMID:22908275		chr17:g.37868210T>C	c.931T>C	ERBB2:C311R	CSQN=Missense;reference_codon=TGC;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr17:g.37868210_37868212delTGCinsAGG,chr17:g.37868210_37868212delTGCinsAGA,chr17:g.37868210_37868212delTGCinsCGA,chr17:g.37868210_37868212delTGCinsCGG,chr17:g.37868210_37868212delTGCinsCGT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000269571	Breast adenocarcinoma;Any cancer type
ERBB2:G309E,S310F,S310Y,C311R,E321G,C334S	MUT		Responsive	ERBB2 (G309E,S310F,S310Y,C311R,E321G,C334S)	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		CANCER	PMID:22908275		chr17:g.37868205G>A	c.926G>A	ERBB2:G309E	CSQN=Missense;reference_codon=GGA;candidate_codons=GAG,GAA;candidate_mnv_variants=chr17:g.37868205_37868206delGAinsAG;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000269571	Any cancer type
ERBB2:G309E,S310F,S310Y,C311R,E321G,C334S	MUT		Responsive	ERBB2 (G309E,S310F,S310Y,C311R,E321G,C334S)	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		CANCER	PMID:22908275		chr17:g.37868208C>T	c.929C>T	ERBB2:S310F	CSQN=Missense;reference_codon=TCC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr17:g.37868208_37868209delCCinsTT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000269571	Any cancer type
ERBB2:G309E,S310F,S310Y,C311R,E321G,C334S	MUT		Responsive	ERBB2 (G309E,S310F,S310Y,C311R,E321G,C334S)	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		CANCER	PMID:22908275		chr17:g.37868208C>A	c.929C>A	ERBB2:S310Y	CSQN=Missense;reference_codon=TCC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr17:g.37868208_37868209delCCinsAT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000269571	Any cancer type
ERBB2:G309E,S310F,S310Y,C311R,E321G,C334S	MUT		Responsive	ERBB2 (G309E,S310F,S310Y,C311R,E321G,C334S)	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		CANCER	PMID:22908275		chr17:g.37868210T>C	c.931T>C	ERBB2:C311R	CSQN=Missense;reference_codon=TGC;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr17:g.37868210_37868212delTGCinsAGG,chr17:g.37868210_37868212delTGCinsAGA,chr17:g.37868210_37868212delTGCinsCGA,chr17:g.37868210_37868212delTGCinsCGG,chr17:g.37868210_37868212delTGCinsCGT;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000269571	Any cancer type
ERBB2:G309E,S310F,S310Y,C311R,E321G,C334S	MUT		Responsive	ERBB2 (G309E,S310F,S310Y,C311R,E321G,C334S)	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		CANCER	PMID:22908275		chr17:g.37868241A>G	c.962A>G	ERBB2:E321G	CSQN=Missense;reference_codon=GAG;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr17:g.37868241_37868242delAGinsGT,chr17:g.37868241_37868242delAGinsGA,chr17:g.37868241_37868242delAGinsGC;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000269571	Any cancer type
ERBB2:G309E,S310F,S310Y,C311R,E321G,C334S	MUT		Responsive	ERBB2 (G309E,S310F,S310Y,C311R,E321G,C334S)	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		CANCER	PMID:22908275		chr17:g.37868279T>A	c.1000T>A	ERBB2:C334S	CSQN=Missense;reference_codon=TGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_snv_variants=chr17:g.37868280G>C;candidate_mnv_variants=chr17:g.37868279_37868281delTGCinsAGT,chr17:g.37868280_37868281delGCinsCT,chr17:g.37868280_37868281delGCinsCG,chr17:g.37868280_37868281delGCinsCA;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000269571	Any cancer type
ERBB2:G776L	MUT		Responsive	ERBB2 (G776L)	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Case report	ERBB2		LUAD	PMID:16775247		chr17:g.37880997_37880998delGGinsCT	c.2326_2327delGGinsCT	ERBB2:G776L	CSQN=Missense;reference_codon=GGT;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_mnv_variants=chr17:g.37880997_37880999delGGTinsCTG,chr17:g.37880997_37880999delGGTinsCTA,chr17:g.37880997_37880999delGGTinsCTC,chr17:g.37880997_37880999delGGTinsTTA,chr17:g.37880997_37880999delGGTinsTTG;aliases=ENSP00000269571;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000269571	Lung adenocarcinoma
ERBB2::consequence::inframe_insertion:775-881	MUT		Responsive	ERBB2 proximal exon 20	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Early trials	ERBB2		LUAD	PMID:26598547;ASCO 2017 (abstr 9071)									Lung adenocarcinoma
ERBB3:P262H,G284R	MUT		Responsive	ERBB3 (P262H,G284R)	RDientsmann	[]	[ERBB3 mAb inhibitor]	ERBB3 mAb inhibitors		Pre-clinical	ERBB3		CANCER	PMID:23680147		chr12:g.56481857C>A	c.785C>A	ERBB3:P262H	CSQN=Missense;reference_codon=CCT;candidate_codons=CAT,CAC;candidate_mnv_variants=chr12:g.56481857_56481858delCTinsAC;aliases=ENSP00000267101;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000267101	Any cancer type
ERBB3:P262H,G284R	MUT		Responsive	ERBB3 (P262H,G284R)	RDientsmann	[]	[ERBB3 mAb inhibitor]	ERBB3 mAb inhibitors		Pre-clinical	ERBB3		CANCER	PMID:23680147		chr12:g.56481922G>A	c.850G>A	ERBB3:G284R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr12:g.56481922G>C;candidate_mnv_variants=chr12:g.56481922_56481924delGGAinsAGG,chr12:g.56481922_56481924delGGAinsCGC,chr12:g.56481922_56481924delGGAinsCGG,chr12:g.56481922_56481924delGGAinsCGT;aliases=ENSP00000267101;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000267101	Any cancer type
ERBB3:P262H,G284R,Q809R	MUT		Responsive	ERBB3 (P262H,G284R,Q809R)	RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Pre-clinical	ERBB3		CANCER	PMID:23680147		chr12:g.56481857C>A	c.785C>A	ERBB3:P262H	CSQN=Missense;reference_codon=CCT;candidate_codons=CAT,CAC;candidate_mnv_variants=chr12:g.56481857_56481858delCTinsAC;aliases=ENSP00000267101;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000267101	Any cancer type
ERBB3:P262H,G284R,Q809R	MUT		Responsive	ERBB3 (P262H,G284R,Q809R)	RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Pre-clinical	ERBB3		CANCER	PMID:23680147		chr12:g.56481922G>A	c.850G>A	ERBB3:G284R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr12:g.56481922G>C;candidate_mnv_variants=chr12:g.56481922_56481924delGGAinsAGG,chr12:g.56481922_56481924delGGAinsCGC,chr12:g.56481922_56481924delGGAinsCGG,chr12:g.56481922_56481924delGGAinsCGT;aliases=ENSP00000267101;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000267101	Any cancer type
ERBB3:P262H,G284R,Q809R	MUT		Responsive	ERBB3 (P262H,G284R,Q809R)	RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Pre-clinical	ERBB3		CANCER	PMID:23680147		chr12:g.56490980A>G	c.2426A>G	ERBB3:Q809R	CSQN=Missense;reference_codon=CAG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr12:g.56490979_56490980delCAinsAG,chr12:g.56490980_56490981delAGinsGA,chr12:g.56490980_56490981delAGinsGC,chr12:g.56490980_56490981delAGinsGT,chr12:g.56490979_56490981delCAGinsAGA;aliases=ENSP00000267101;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000267101	Any cancer type
ERBB3:G284R,R103G	MUT		Responsive	ERBB3 (G284R,R103G)	RDientsmann	Afatinib	ERBB2&EGFR inhibitor 2nd gen	Afatinib (ERBB2&EGFR inhibitor 2nd gen)		Case report	ERBB3		BLCA	ASCO 2015 (abstr e15516)		chr12:g.56481922G>A	c.850G>A	ERBB3:G284R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr12:g.56481922G>C;candidate_mnv_variants=chr12:g.56481922_56481924delGGAinsAGG,chr12:g.56481922_56481924delGGAinsCGC,chr12:g.56481922_56481924delGGAinsCGG,chr12:g.56481922_56481924delGGAinsCGT;aliases=ENSP00000267101;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000267101	Bladder
ERBB3:G284R,R103G	MUT		Responsive	ERBB3 (G284R,R103G)	RDientsmann	Afatinib	ERBB2&EGFR inhibitor 2nd gen	Afatinib (ERBB2&EGFR inhibitor 2nd gen)		Case report	ERBB3		BLCA	ASCO 2015 (abstr e15516)		chr12:g.56478851C>G	c.307C>G	ERBB3:R103G	CSQN=Missense;reference_codon=CGC;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr12:g.56478851_56478853delCGCinsGGT,chr12:g.56478851_56478853delCGCinsGGG,chr12:g.56478851_56478853delCGCinsGGA;aliases=ENSP00000267101;source=Ensembl	inside_[cds_in_exon_3]	+	ENST00000267101	Bladder
ERBB3:G284R,V104M,R103G	MUT		Responsive	ERBB3 (G284R,V104M,R103G)	RDientsmann	Afatinib	ERBB2&EGFR inhibitor 2nd gen	Afatinib (ERBB2&EGFR inhibitor 2nd gen)		Case report	ERBB3		BLCA	PMID:27044931		chr12:g.56481922G>A	c.850G>A	ERBB3:G284R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr12:g.56481922G>C;candidate_mnv_variants=chr12:g.56481922_56481924delGGAinsAGG,chr12:g.56481922_56481924delGGAinsCGC,chr12:g.56481922_56481924delGGAinsCGG,chr12:g.56481922_56481924delGGAinsCGT;aliases=ENSP00000267101;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000267101	Bladder
ERBB3:G284R,V104M,R103G	MUT		Responsive	ERBB3 (G284R,V104M,R103G)	RDientsmann	Afatinib	ERBB2&EGFR inhibitor 2nd gen	Afatinib (ERBB2&EGFR inhibitor 2nd gen)		Case report	ERBB3		BLCA	PMID:27044931		chr12:g.56478854G>A	c.310G>A	ERBB3:V104M	CSQN=Missense;reference_codon=GTG;candidate_codons=ATG;aliases=ENSP00000267101;source=Ensembl	inside_[cds_in_exon_3]	+	ENST00000267101	Bladder
ERBB3:G284R,V104M,R103G	MUT		Responsive	ERBB3 (G284R,V104M,R103G)	RDientsmann	Afatinib	ERBB2&EGFR inhibitor 2nd gen	Afatinib (ERBB2&EGFR inhibitor 2nd gen)		Case report	ERBB3		BLCA	PMID:27044931		chr12:g.56478851C>G	c.307C>G	ERBB3:R103G	CSQN=Missense;reference_codon=CGC;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr12:g.56478851_56478853delCGCinsGGT,chr12:g.56478851_56478853delCGCinsGGG,chr12:g.56478851_56478853delCGCinsGGA;aliases=ENSP00000267101;source=Ensembl	inside_[cds_in_exon_3]	+	ENST00000267101	Bladder
ERBB3:P262H,G284R,Q809R	MUT		Responsive	ERBB3 (P262H,G284R,Q809R)	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB3		CANCER	PMID:23680147		chr12:g.56481857C>A	c.785C>A	ERBB3:P262H	CSQN=Missense;reference_codon=CCT;candidate_codons=CAT,CAC;candidate_mnv_variants=chr12:g.56481857_56481858delCTinsAC;aliases=ENSP00000267101;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000267101	Any cancer type
ERBB3:P262H,G284R,Q809R	MUT		Responsive	ERBB3 (P262H,G284R,Q809R)	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB3		CANCER	PMID:23680147		chr12:g.56481922G>A	c.850G>A	ERBB3:G284R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr12:g.56481922G>C;candidate_mnv_variants=chr12:g.56481922_56481924delGGAinsAGG,chr12:g.56481922_56481924delGGAinsCGC,chr12:g.56481922_56481924delGGAinsCGG,chr12:g.56481922_56481924delGGAinsCGT;aliases=ENSP00000267101;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000267101	Any cancer type
ERBB3:P262H,G284R,Q809R	MUT		Responsive	ERBB3 (P262H,G284R,Q809R)	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB3		CANCER	PMID:23680147		chr12:g.56490980A>G	c.2426A>G	ERBB3:Q809R	CSQN=Missense;reference_codon=CAG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr12:g.56490979_56490980delCAinsAG,chr12:g.56490980_56490981delAGinsGA,chr12:g.56490980_56490981delAGinsGC,chr12:g.56490980_56490981delAGinsGT,chr12:g.56490979_56490981delCAGinsAGA;aliases=ENSP00000267101;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000267101	Any cancer type
ERBB3:P262H,G284R	MUT		Responsive	ERBB3 (P262H,G284R)	RDientsmann	Pertuzumab	ERBB2 mAb inhibitor	Pertuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB3		CANCER	PMID:23680147		chr12:g.56481857C>A	c.785C>A	ERBB3:P262H	CSQN=Missense;reference_codon=CCT;candidate_codons=CAT,CAC;candidate_mnv_variants=chr12:g.56481857_56481858delCTinsAC;aliases=ENSP00000267101;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000267101	Any cancer type
ERBB3:P262H,G284R	MUT		Responsive	ERBB3 (P262H,G284R)	RDientsmann	Pertuzumab	ERBB2 mAb inhibitor	Pertuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB3		CANCER	PMID:23680147		chr12:g.56481922G>A	c.850G>A	ERBB3:G284R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr12:g.56481922G>C;candidate_mnv_variants=chr12:g.56481922_56481924delGGAinsAGG,chr12:g.56481922_56481924delGGAinsCGC,chr12:g.56481922_56481924delGGAinsCGG,chr12:g.56481922_56481924delGGAinsCGT;aliases=ENSP00000267101;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000267101	Any cancer type
ERBB3:P262H,G284R,Q809R	MUT		Responsive	ERBB3 (P262H,G284R,Q809R)	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB3		CANCER	PMID:23680147		chr12:g.56481857C>A	c.785C>A	ERBB3:P262H	CSQN=Missense;reference_codon=CCT;candidate_codons=CAT,CAC;candidate_mnv_variants=chr12:g.56481857_56481858delCTinsAC;aliases=ENSP00000267101;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000267101	Any cancer type
ERBB3:P262H,G284R,Q809R	MUT		Responsive	ERBB3 (P262H,G284R,Q809R)	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB3		CANCER	PMID:23680147		chr12:g.56481922G>A	c.850G>A	ERBB3:G284R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr12:g.56481922G>C;candidate_mnv_variants=chr12:g.56481922_56481924delGGAinsAGG,chr12:g.56481922_56481924delGGAinsCGC,chr12:g.56481922_56481924delGGAinsCGG,chr12:g.56481922_56481924delGGAinsCGT;aliases=ENSP00000267101;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000267101	Any cancer type
ERBB3:P262H,G284R,Q809R	MUT		Responsive	ERBB3 (P262H,G284R,Q809R)	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB3		CANCER	PMID:23680147		chr12:g.56490980A>G	c.2426A>G	ERBB3:Q809R	CSQN=Missense;reference_codon=CAG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr12:g.56490979_56490980delCAinsAG,chr12:g.56490980_56490981delAGinsGA,chr12:g.56490980_56490981delAGinsGC,chr12:g.56490980_56490981delAGinsGT,chr12:g.56490979_56490981delCAGinsAGA;aliases=ENSP00000267101;source=Ensembl	inside_[cds_in_exon_20]	+	ENST00000267101	Any cancer type
ERBB4:H809G	MUT		Resistant	ERBB4 (H809G)	RDientsmann	[Lapatinib]	[ERBB2 inhibitor]	ERBB2 inhibitors (Lapatinib,etc)		Case report	ERBB4		BRCA	PMID:26530965		chr2:g.212426689_212426690delTGinsCC	c.2425_2426delCAinsGG	ERBB4:H809G	CSQN=Missense;reference_codon=CAC;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr2:g.212426688_212426690delGTGinsACC,chr2:g.212426688_212426690delGTGinsCCC,chr2:g.212426688_212426690delGTGinsTCC;aliases=ENSP00000342235;source=Ensembl	inside_[cds_in_exon_20]	-	ENST00000342788	Breast adenocarcinoma
ERBB4:E317K,E452K,R544W,R393W,E872K	MUT		Responsive	ERBB4 (E317K,E452K,R544W,R393W,E872K)	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB4		CM	PMID:19718025		chr2:g.212578308C>T	c.949G>A	ERBB4:E317K	CSQN=Missense;reference_codon=GAA;candidate_codons=AAG,AAA;candidate_mnv_variants=chr2:g.212578306_212578308delTTCinsCTT;aliases=ENSP00000342235;source=Ensembl	inside_[cds_in_exon_8]	-	ENST00000342788	Cutaneous melanoma
ERBB4:E317K,E452K,R544W,R393W,E872K	MUT		Responsive	ERBB4 (E317K,E452K,R544W,R393W,E872K)	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB4		CM	PMID:19718025		chr2:g.212566827C>T	c.1354G>A	ERBB4:E452K	CSQN=Missense;reference_codon=GAA;candidate_codons=AAG,AAA;candidate_mnv_variants=chr2:g.212566825_212566827delTTCinsCTT;aliases=ENSP00000342235;source=Ensembl	inside_[cds_in_exon_12]	-	ENST00000342788	Cutaneous melanoma
ERBB4:E317K,E452K,R544W,R393W,E872K	MUT		Responsive	ERBB4 (E317K,E452K,R544W,R393W,E872K)	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB4		CM	PMID:19718025		chr2:g.212537975G>A	c.1630C>T	ERBB4:R544W	CSQN=Missense;reference_codon=CGG;candidate_codons=TGG;aliases=ENSP00000342235;source=Ensembl	inside_[cds_in_exon_14]	-	ENST00000342788	Cutaneous melanoma
ERBB4:E317K,E452K,R544W,R393W,E872K	MUT		Responsive	ERBB4 (E317K,E452K,R544W,R393W,E872K)	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB4		CM	PMID:19718025		chr2:g.212570064G>A	c.1177C>T	ERBB4:R393W	CSQN=Missense;reference_codon=CGG;candidate_codons=TGG;aliases=ENSP00000342235;source=Ensembl	inside_[cds_in_exon_10]	-	ENST00000342788	Cutaneous melanoma
ERBB4:E317K,E452K,R544W,R393W,E872K	MUT		Responsive	ERBB4 (E317K,E452K,R544W,R393W,E872K)	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB4		CM	PMID:19718025		chr2:g.212295699C>T	c.2614G>A	ERBB4:E872K	CSQN=Missense;reference_codon=GAA;candidate_codons=AAG,AAA;candidate_mnv_variants=chr2:g.212295697_212295699delTTCinsCTT;aliases=ENSP00000342235;source=Ensembl	inside_[cds_in_exon_21]	-	ENST00000342788	Cutaneous melanoma
ERCC1:.	MUT		Responsive	ERCC1 oncogenic mutation	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Pre-clinical	ERCC1		L	PMID:23934192									Lung
ERCC1:.	MUT		Responsive	ERCC1 oncogenic mutation	RDientsmann	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)		Pre-clinical	ERCC1		L	PMID:23275151;PMID:23934192									Lung
ERCC2:.	MUT		Responsive	ERCC2 oncogenic mutation	RDientsmann	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)		Early trials	ERCC2		BLCA	PMID:25096233									Bladder
ERCC4:.	MUT		Responsive	ERCC4 oncogenic mutation	RDientsmann	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)		Pre-clinical	ERCC4		OV	PMID:25634215									Ovary
ERCC6:.	MUT		Responsive	ERCC6 oncogenic mutation	RDientsmann	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)		Pre-clinical	ERCC6		OV	PMID:25634215									Ovary
ESR1:E380Q,.537.,.538.,L536.,P535H	MUT		Responsive	ESR1 (E380Q,537,538,L536,P535H)	RDientsmann	[GDC-0810]	[novel ER degrader]	novel ER degraders (GDC-0810,etc)		Case report	ESR1		BRCA	AACR 2015 (abstr CT231)									Breast adenocarcinoma
ESR1:.	MUT		Resistant	ESR1 oncogenic mutation	RDientsmann	Exemestane	Hormonal therapy	Exemestane (Hormonal therapy)		Late trials	ESR1		BRCA	PMID:27269946									Breast adenocarcinoma
ESR1:.	MUT		Responsive	ESR1 oncogenic mutation	RDientsmann	Fluvestrant	Hormonal therapy	Fluvestrant (Hormonal therapy)		Late trials	ESR1		BRCA	PMID:27269946									Breast adenocarcinoma
ESR1:Y537S	MUT		Resistant	ESR1 (Y537S)	RDientsmann	Fulvestrant	Hormonal therapy	Fulvestrant (Hormonal therapy)		Pre-clinical	ESR1		BRCA	PMID:27986707		chr6:g.152419923A>C	c.1610A>C	ESR1:Y537S	CSQN=Missense;reference_codon=TAT;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr6:g.152419922_152419923delTAinsAG,chr6:g.152419923_152419924delATinsCG,chr6:g.152419923_152419924delATinsCC,chr6:g.152419923_152419924delATinsCA,chr6:g.152419922_152419924delTATinsAGC;aliases=ENSP00000405330;source=Ensembl	inside_[cds_in_exon_10]	+	ENST00000440973	Breast adenocarcinoma
ESR1:E380Q,.537.,.538.,L536.,P535H	MUT		Resistant	ESR1 (E380Q,537,538,L536,P535H)	RDientsmann	Tamoxifen	Hormonal therapy	Tamoxifen (Hormonal therapy)		Early trials	ESR1		BRCA	PMID:24185512;PMID:24185510;PMID:24398047									Breast adenocarcinoma
EZH2:Y641.,A677.	MUT	Cell line	Responsive	EZH2 (Y641,A677)	RDientsmann;ECampo	[EPZ-005687,EPZ-6438]	[EZH2 inhibitor]	EZH2 inhibitors (EPZ-005687,EPZ-6438,etc)	Pre-clinical	Pre-clinical	EZH2		LY	PMID:23023262;PMID:24563539	Direct								Lymphoma
FANCA:.	MUT		Responsive	FANCA oncogenic mutation	RDientsmann	Olaparib	PARP inhibitor	Olaparib (PARP inhibitor)		Case report	FANCA		PRAD	PMID:26510020									Prostate adenocarcinoma
FANCC:.	MUT		Responsive	FANCC oncogenic mutation	ARodriguez-Vida	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	Early trials	FANCC	BLCA	BLCA	PMID:26238431	Indirect								Bladder
FAT1:.	MUT		Responsive	FAT1 oncogenic mutation	RDientsmann	[]	[BET inhibitor]	BET inhibitors		Pre-clinical	FAT1		HNSC	PMID:27397505									Head an neck squamous
FBXW7:.	MUT		Responsive	FBXW7 oncogenic mutation	RDientsmann	[]	[Steroid]	Steroids		Late trials	FBXW7		ALL	PMID:20861909									Acute lymphoblastic leukemia
FBXW7:.	MUT		Resistant	FBXW7 oncogenic mutation	RDientsmann	[]	[Tubulin inhibitor]	Tubulin inhibitors		Pre-clinical	FBXW7		CANCER	PMID:21368834									Any cancer type
FGFR2::consequence::inframe_insertion:A266.,::inframe_insertion:S267.	MUT		Responsive	FGFR2 inframe insertion (A266),inframe insertion (S267)	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR2		L	PMID:26048680									Lung
FGFR2:S252W,N550K	MUT		Responsive	FGFR2 (S252W,N550K)	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR2		ED	PMID:18552176;PMID:22238366;PMID:23002168		chr10:g.123279677G>C	c.755C>G	FGFR2:S252W	CSQN=Missense;reference_codon=TCG;candidate_codons=TGG;aliases=ENSP00000410294;source=Ensembl	inside_[cds_in_exon_7]	-	ENST00000457416	Endometrium
FGFR2:S252W,N550K	MUT		Responsive	FGFR2 (S252W,N550K)	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR2		ED	PMID:18552176;PMID:22238366;PMID:23002168		chr10:g.123258034A>C	c.1650T>G	FGFR2:N550K	CSQN=Missense;reference_codon=AAT;candidate_codons=AAG,AAA;candidate_snv_variants=chr10:g.123258034A>T;aliases=ENSP00000410294;source=Ensembl	inside_[cds_in_exon_12]	-	ENST00000457416	Endometrium
FGFR2:V565I	MUT		Responsive	FGFR2 (V565I)	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR2		ED	ENA 2014 (abstr 381)		chr10:g.123256219C>T	c.1693G>A	FGFR2:V565I	CSQN=Missense;reference_codon=GTT;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr10:g.123256217_123256219delAACinsGAT,chr10:g.123256217_123256219delAACinsTAT;aliases=ENSP00000410294;source=Ensembl	inside_[cds_in_exon_13]	-	ENST00000457416	Endometrium
FGFR2:W290C,S320C,K660N	MUT		Responsive	FGFR2 (W290C,S320C,K660N)	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR2		LUSC	PMID:23786770;PMID:25035393		chr10:g.123279562C>A	c.870G>T	FGFR2:W290C	CSQN=Missense;reference_codon=TGG;candidate_codons=TGT,TGC;candidate_snv_variants=chr10:g.123279562C>G;aliases=ENSP00000410294;source=Ensembl	inside_[cds_in_exon_7]	-	ENST00000457416	Lung squamous cell
FGFR2:W290C,S320C,K660N	MUT		Responsive	FGFR2 (W290C,S320C,K660N)	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR2		LUSC	PMID:23786770;PMID:25035393		chr10:g.123278324G>C	c.959C>G	FGFR2:S320C	CSQN=Missense;reference_codon=TCC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr10:g.123278323_123278324delGGinsAC;aliases=ENSP00000410294;source=Ensembl	inside_[cds_in_exon_8]	-	ENST00000457416	Lung squamous cell
FGFR2:W290C,S320C,K660N	MUT		Responsive	FGFR2 (W290C,S320C,K660N)	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR2		LUSC	PMID:23786770;PMID:25035393		chr10:g.123247514C>G	c.1980G>C	FGFR2:K660N	CSQN=Missense;reference_codon=AAG;candidate_codons=AAC,AAT;candidate_snv_variants=chr10:g.123247514C>A;aliases=ENSP00000410294;source=Ensembl	inside_[cds_in_exon_14]	-	ENST00000457416	Lung squamous cell
FGFR2:V565I,M536I,M538I,I548V,N550.,E566G,L618M,K660E	MUT		Resistant	FGFR2 (V565I,M536I,M538I,I548V,N550,E566G,L618M,K660E)	RDientsmann	Dovitinib	FGFR inhibitor	Dovitinib (FGFR inhibitor)		Pre-clinical	FGFR2		ED	PMID:23908597									Endometrium
FGFR2:M536I,M538I,I548V,N550.,E566G,L618M,K660E	MUT		Responsive	FGFR2 (M536I,M538I,I548V,N550,E566G,L618M,K660E)	RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)		Pre-clinical	FGFR2		ED	PMID:23908597									Endometrium
FGFR3:.	MUT		Responsive	FGFR3 oncogenic mutation	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Early trials	FGFR3		BLCA	PMID:27870574									Bladder
FGFR3:K650.,Y373C	MUT		Responsive	FGFR3 (K650,Y373C)	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR3		MYMA	PMID:16091734;PMID:20439987;PMID:22869148									Myeloma
FGFR3:S249C,G691R	MUT		Responsive	FGFR3 (S249C,G691R)	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR3		LUAD	PMID:27998968		chr4:g.1803568C>G	c.746C>G	FGFR3:S249C	CSQN=Missense;reference_codon=TCC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr4:g.1803568_1803569delCCinsGT;aliases=ENSP00000414914;source=Ensembl	inside_[cds_in_exon_7]	+	ENST00000440486	Lung adenocarcinoma
FGFR3:S249C,G691R	MUT		Responsive	FGFR3 (S249C,G691R)	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR3		LUAD	PMID:27998968		chr4:g.1808313G>A	c.2071G>A	FGFR3:G691R	CSQN=Missense;reference_codon=GGG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr4:g.1808313G>C;candidate_mnv_variants=chr4:g.1808313_1808315delGGGinsAGA,chr4:g.1808313_1808315delGGGinsCGA,chr4:g.1808313_1808315delGGGinsCGC,chr4:g.1808313_1808315delGGGinsCGT;aliases=ENSP00000414914;source=Ensembl	inside_[cds_in_exon_16]	+	ENST00000440486	Lung adenocarcinoma
FGFR3:V555M	MUT		Resistant	FGFR3 (V555M)	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR3		MYMA	PMID:22869148		chr4:g.1807494G>A	c.1663G>A	FGFR3:V555M	CSQN=Missense;reference_codon=GTG;candidate_codons=ATG;aliases=ENSP00000414914;source=Ensembl	inside_[cds_in_exon_13]	+	ENST00000440486	Myeloma
FGFR3:K650.	MUT		Responsive	FGFR3 (K650)	RDientsmann	Bortezomib	Proteasome inhibitor	Bortezomib (Proteasome inhibitor)		Pre-clinical	FGFR3		MYMA	PMID:19331127;PMID:21273588									Myeloma
FGFR3:Y373C	MUT		Resistant	FGFR3 (Y373C)	RDientsmann	Bortezomib	Proteasome inhibitor	Bortezomib (Proteasome inhibitor)		Pre-clinical	FGFR3		MYMA	PMID:19331127;PMID:21273588		chr4:g.1806099A>G	c.1118A>G	FGFR3:Y373C	CSQN=Missense;reference_codon=TAT;candidate_codons=TGT,TGC;candidate_mnv_variants=chr4:g.1806099_1806100delATinsGC;aliases=ENSP00000414914;source=Ensembl	inside_[cds_in_exon_9]	+	ENST00000440486	Myeloma
FGFR4:N535.,V550.	MUT		Responsive	FGFR4 (N535,V550)	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR4		RHBDS	PMID:19809159;PMID:24124571									Rhabdomyosarcoma
FLCN:.	MUT		Responsive	FLCN oncogenic mutation	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	FLCN		R	PMID:23995526									Renal
FLT3::consequence::inframe_variant:572-603	MUT		Responsive	FLT3-ITD	RDientsmann	[]	[FLT3 inhibitor]	FLT3 inhibitors		Early trials	FLT3		AML	PMID:16857985									Acute myeloid leukemia
FLT3:F691.	MUT		Responsive	FLT3 (F691)	RDientsmann	[]	[novel FLT3 inhibitor]	novel FLT3 inhibitors		Pre-clinical	FLT3		AML	PMID:25847190									Acute myeloid leukemia
FLT3:N676.	MUT		Responsive	FLT3 (N676)	RDientsmann	Crenolanib	FLT3 inhibitor	Crenolanib (FLT3 inhibitor)		Pre-clinical	FLT3		AML	PMID:24619500									Acute myeloid leukemia
FLT3:D835.	MUT		Responsive	FLT3 (D835)	RDientsmann	Lestaurtinib	Pan-TK inhibitor	Lestaurtinib (Pan-TK inhibitor)		Case report	FLT3		AML	PMID:16857985									Acute myeloid leukemia
FLT3:D835.	MUT		Responsive	FLT3 (D835)	RDientsmann	Midostaurin	Pan-TK inhibitor	Midostaurin (Pan-TK inhibitor)		Case report	FLT3		AML	PMID:20733134									Acute myeloid leukemia
FLT3:N676.	MUT		Responsive	FLT3 (N676)	RDientsmann	Midostaurin	Pan-TK inhibitor	Midostaurin (Pan-TK inhibitor)		Pre-clinical	FLT3		AML	PMID:24619500									Acute myeloid leukemia
FLT3:D835.,Y842.	MUT		Resistant	FLT3 (D835,Y842)	RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)		Pre-clinical	FLT3		AML	PMID:23430109									Acute myeloid leukemia
FLT3::consequence::inframe_variant:572-603	MUT		Responsive	FLT3-ITD	RDientsmann	Quizartinib	Pan-TK inhibitor	Quizartinib (Pan-TK inhibitor)		Early trials	FLT3		AML	ASH 2012 (abstr 673);ASH 2012 (abstr 48)									Acute myeloid leukemia
FLT3:F691.,D835.,N676.,Y842.	MUT		Resistant	FLT3 (F691,D835,N676,Y842)	RDientsmann	Quizartinib	Pan-TK inhibitor	Quizartinib (Pan-TK inhibitor)		Pre-clinical	FLT3		AML	PMID:22504184;PMID:23878140									Acute myeloid leukemia
FLT3::consequence::inframe_variant:572-603	MUT		Responsive	FLT3-ITD	RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Early trials	FLT3		AML	PMID:19389879;PMID:22368270									Acute myeloid leukemia
FLT3::consequence::inframe_variant:572-603	MUT		Responsive	FLT3-ITD	RDientsmann	Sorafenib;Azacytidine	Pan-TK inhibitor;Chemotherapy	Sorafenib + Azacytidine (Pan-TK inhibitor + Chemotherapy)		Early trials	FLT3		AML	PMID:23613521									Acute myeloid leukemia
FLT3::consequence::inframe_variant:572-603	MUT		Resistant	FLT3-ITD	DTamborero;CRubio-Perez	Venetoclax	BCL2 inhibitor	Venetoclax (BCL2 inhibitor)		Early trials	FLT3		AML	PMID:27520294									Acute myeloid leukemia
G6PD:S218F	MUT		Increased Toxicity (Haemolytic Anemia)	G6PD (S218F)	DTamborero;CRubio-Perez	Dabrafenib	BRAF inhibitor	Dabrafenib (BRAF inhibitor)	Approved	FDA guidelines	G6PD		CANCER	FDA		chrX:g.153762634G>A	c.653C>T	G6PD:S218F	CSQN=Missense;reference_codon=TCC;candidate_codons=TTT,TTC;candidate_mnv_variants=chrX:g.153762633_153762634delGGinsAA;aliases=ENSP00000377192;source=Ensembl	inside_[cds_in_exon_6]	-	ENST00000393562	Any cancer type
GATA3:.	MUT		Responsive	GATA3 oncogenic mutation	RDientsmann	[]	[Aromatase ihibitor]	Aromatase ihibitors		Pre-clinical	GATA3		BRCA	PMID:24758297									Breast adenocarcinoma
GNA11:Q209L,Q209P	MUT		Responsive	GNA11 (Q209L,Q209P)	RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Pre-clinical	GNA11		CM	PMID:22733540;PMID:22808163		chr19:g.3118942A>T	c.626A>T	GNA11:Q209L	CSQN=Missense;reference_codon=CAG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_mnv_variants=chr19:g.3118942_3118943delAGinsTT,chr19:g.3118942_3118943delAGinsTA,chr19:g.3118942_3118943delAGinsTC,chr19:g.3118941_3118942delCAinsTT,chr19:g.3118941_3118943delCAGinsTTA;aliases=ENSP00000078429;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000078429	Cutaneous melanoma
GNA11:Q209L,Q209P	MUT		Responsive	GNA11 (Q209L,Q209P)	RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Pre-clinical	GNA11		CM	PMID:22733540;PMID:22808163		chr19:g.3118942A>C	c.626A>C	GNA11:Q209P	CSQN=Missense;reference_codon=CAG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr19:g.3118942_3118943delAGinsCT,chr19:g.3118942_3118943delAGinsCA,chr19:g.3118942_3118943delAGinsCC;aliases=ENSP00000078429;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000078429	Cutaneous melanoma
GNA11:Q209L,Q209P	MUT		Responsive	GNA11 (Q209L,Q209P)	RDientsmann	Selumetinib	MEK inhibitor	Selumetinib (MEK inhibitor)		Early trials	GNA11		CM	ASCO 2013 (abstr CRA9003)		chr19:g.3118942A>T	c.626A>T	GNA11:Q209L	CSQN=Missense;reference_codon=CAG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_mnv_variants=chr19:g.3118942_3118943delAGinsTT,chr19:g.3118942_3118943delAGinsTA,chr19:g.3118942_3118943delAGinsTC,chr19:g.3118941_3118942delCAinsTT,chr19:g.3118941_3118943delCAGinsTTA;aliases=ENSP00000078429;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000078429	Cutaneous melanoma
GNA11:Q209L,Q209P	MUT		Responsive	GNA11 (Q209L,Q209P)	RDientsmann	Selumetinib	MEK inhibitor	Selumetinib (MEK inhibitor)		Early trials	GNA11		CM	ASCO 2013 (abstr CRA9003)		chr19:g.3118942A>C	c.626A>C	GNA11:Q209P	CSQN=Missense;reference_codon=CAG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr19:g.3118942_3118943delAGinsCT,chr19:g.3118942_3118943delAGinsCA,chr19:g.3118942_3118943delAGinsCC;aliases=ENSP00000078429;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000078429	Cutaneous melanoma
GNA11:Q209L,Q209P	MUT		Responsive	GNA11 (Q209L,Q209P)	RDientsmann	Vorinostat	HDAC inhibitor	Vorinostat (HDAC inhibitor)		Pre-clinical	GNA11		CM	NCT01587352		chr19:g.3118942A>T	c.626A>T	GNA11:Q209L	CSQN=Missense;reference_codon=CAG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_mnv_variants=chr19:g.3118942_3118943delAGinsTT,chr19:g.3118942_3118943delAGinsTA,chr19:g.3118942_3118943delAGinsTC,chr19:g.3118941_3118942delCAinsTT,chr19:g.3118941_3118943delCAGinsTTA;aliases=ENSP00000078429;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000078429	Cutaneous melanoma
GNA11:Q209L,Q209P	MUT		Responsive	GNA11 (Q209L,Q209P)	RDientsmann	Vorinostat	HDAC inhibitor	Vorinostat (HDAC inhibitor)		Pre-clinical	GNA11		CM	NCT01587352		chr19:g.3118942A>C	c.626A>C	GNA11:Q209P	CSQN=Missense;reference_codon=CAG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr19:g.3118942_3118943delAGinsCT,chr19:g.3118942_3118943delAGinsCA,chr19:g.3118942_3118943delAGinsCC;aliases=ENSP00000078429;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000078429	Cutaneous melanoma
GNAQ:Q209.	MUT		Responsive	GNAQ (Q209)	RDientsmann	[]	[HDAC inhibitor]	HDAC inhibitors		Pre-clinical	GNAQ		CM	NCT01587352									Cutaneous melanoma
GNAQ:Q209.	MUT		Responsive	GNAQ (Q209)	RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Pre-clinical	GNAQ		CM	PMID:22733540;PMID:22808163									Cutaneous melanoma
GNAQ:Q209.	MUT		Responsive	GNAQ (Q209)	RDientsmann	[]	[PKC inhibitor]	PKC inhibitors		Pre-clinical	GNAQ		CM	PMID:22653968;PMID:22253748									Cutaneous melanoma
GNAQ:Q209.	MUT		Responsive	GNAQ (Q209)	RDientsmann	Selumetinib	MEK inhibitor	Selumetinib (MEK inhibitor)		Early trials	GNAQ		CM	ASCO 2013 (abstr CRA9003)									Cutaneous melanoma
GNAS:R201.	MUT		Responsive	GNAS (R201)	RDientsmann	[]	[JAK inhibitor]	JAK inhibitors		Pre-clinical	GNAS		CANCER	PMID:21835143									Any cancer type
HRAS:.	MUT		Responsive	HRAS oncogenic mutation	RDientsmann	[]	[MEK inhibitor +/- MTOR inhibitor]	MEK inhibitor +/- MTOR inhibitors		Pre-clinical	HRAS		AML	PMID:22399013;PMID:22507781									Acute myeloid leukemia
HRAS:.	MUT		Responsive	HRAS oncogenic mutation	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	HRAS		CESC	PMID:22345164									Cervix squamous cell
HRAS:.	MUT		Responsive	HRAS oncogenic mutation	RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Pre-clinical	HRAS		CER	PMID:15950068									Cervix
HRAS:.	MUT		Responsive	HRAS oncogenic mutation	RDientsmann	Tipifarnib	Farnesyltransferase inhibitor	Tipifarnib (Farnesyltransferase inhibitor)		Early trials	HRAS		CANCER	NCT02383927									Any cancer type
HRAS:.	MUT		Responsive	HRAS oncogenic mutation	RDientsmann	Tipifarnib	Farnesyltransferase inhibitor	Tipifarnib (Farnesyltransferase inhibitor)	Clinical Trials	Early trials	HRAS		CANCER	NCT02383927									Any cancer type
IDH1:.	MUT		Responsive	IDH1 oncogenic mutation	RDientsmann	[]	[BCL2 inhibitor]	BCL2 inhibitors		Pre-clinical	IDH1		AML	PMID:25599133									Acute myeloid leukemia
IDH1:.	MUT		Responsive	IDH1 oncogenic mutation	RDientsmann	[]	[IDH1 inhibitor]	IDH1 inhibitors		Early trials	IDH1		AML	ENA 2014 (abstr 1LBA)									Acute myeloid leukemia
IDH1:R132.	MUT		Responsive	IDH1 (R132)	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Pre-clinical	IDH1		CANCER	PMID:28148839									Any cancer type
IDH1:.	MUT		Responsive	IDH1 oncogenic mutation	MMartínez;RDientsmann;CRubio-Perez	AG-120	IDH1 inhibitor	AG-120 (IDH1 inhibitor)	Clinical Trials	Early trials	IDH1		G	NCT02073994;PMID:23558169	Direct								Glioma
IDH1:.	MUT		Responsive	IDH1 oncogenic mutation	CRubio-Perez	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Clinical Trials	Early trials	IDH1		CH	NCT02428855	Indirect								Cholangiocarcinoma
IDH1:R132.	MUT		Responsive	IDH1 (R132)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	IDH1		BT	PMID:27231123									Billiary tract
IDH1:.	MUT		Responsive	IDH1 oncogenic mutation	DTamborero;CRubio-Perez	Venetoclax	BCL2 inhibitor	Venetoclax (BCL2 inhibitor)		Early trials	IDH1		AML	PMID:27520294									Acute myeloid leukemia
IDH2:R140K,R172K	MUT		Responsive	IDH2 (R140K,R172K)	RDientsmann	AG-221	IDH2 inhibitor	AG-221 (IDH2 inhibitor)	Clinical Trials	Early trials	IDH2		HEMATO	AACR 2014 (abstr CT103)	Direct	chr15:g.90631934_90631935delCGinsTT	c.418_419delCGinsAA	IDH2:R140K	CSQN=Missense;reference_codon=CGG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr15:g.90631933_90631935delCCGinsTTT;aliases=ENSP00000331897;source=Ensembl	inside_[cds_in_exon_4]	-	ENST00000330062	Hematologic malignancies
IDH2:R140K,R172K	MUT		Responsive	IDH2 (R140K,R172K)	RDientsmann	AG-221	IDH2 inhibitor	AG-221 (IDH2 inhibitor)	Clinical Trials	Early trials	IDH2		HEMATO	AACR 2014 (abstr CT103)	Direct	chr15:g.90631838C>T	c.515G>A	IDH2:R172K	CSQN=Missense;reference_codon=AGG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr15:g.90631837_90631838delCCinsTT;aliases=ENSP00000331897;source=Ensembl	inside_[cds_in_exon_4]	-	ENST00000330062	Hematologic malignancies
IDH2:.	MUT		Responsive	IDH2 oncogenic mutation	CRubio-Perez	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Clinical Trials	Early trials	IDH2		CH	NCT02428855	Indirect								Cholangiocarcinoma
IDH2:R172.	MUT		Responsive	IDH2 (R172)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	IDH2		BT	PMID:27231123									Billiary tract
IDH2:.	MUT		Responsive	IDH2 oncogenic mutation	DTamborero;CRubio-Perez	Venetoclax	BCL2 inhibitor	Venetoclax (BCL2 inhibitor)		Early trials	IDH2		AML	PMID:27520294									Acute myeloid leukemia
INPP4B:.	MUT		Responsive	INPP4B oncogenic mutation	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Pre-clinical	INPP4B		BRCA	PMID:23551093									Breast adenocarcinoma
JAK1:.	MUT		Resistant	JAK1 oncogenic mutation	RDientsmann	[]	[PD1 inhibitor]	PD1 inhibitors		Case report	JAK1		COREAD	PMID:27903500									Colorectal adenocarcinoma
JAK1:.	MUT		Resistant	JAK1 oncogenic mutation	RDientsmann	[]	[PD1 inhibitor]	PD1 inhibitors		Case report	JAK1		CM	PMID:27433843									Cutaneous melanoma
JAK1:S646F;R683.	MUT		Responsive	JAK1 (S646F;R683)	RDientsmann	Ruxolitinib	JAK inhibitor	Ruxolitinib (JAK inhibitor)		Pre-clinical	JAK1		ALL	PMID:22955920;PMID:18805579									Acute lymphoblastic leukemia
JAK2:V617F	MUT		Responsive	JAK2 (V617F)	RDientsmann	[]	[JAK inhibitor (alone or in combination)]	JAK inhibitor (alone or in combination)s		Pre-clinical	JAK2		AML	PMID:22829971		chr9:g.5073770G>T	c.1849G>T	JAK2:V617F	CSQN=Missense;reference_codon=GTC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr9:g.5073770_5073772delGTCinsTTT;aliases=ENSP00000371067;source=Ensembl	inside_[cds_in_exon_14]	+	ENST00000381652	Acute myeloid leukemia
JAK2:.	MUT		Resistant	JAK2 oncogenic mutation	RDientsmann	[]	[PD1 inhibitor]	PD1 inhibitors		Case report	JAK2		CM	PMID:27433843									Cutaneous melanoma
JAK2:V617F	MUT		Responsive	JAK2 (V617F)	RDientsmann	Ruxolitinib	JAK inhibitor	Ruxolitinib (JAK inhibitor)		Early trials	JAK2		AML	PMID:22422826		chr9:g.5073770G>T	c.1849G>T	JAK2:V617F	CSQN=Missense;reference_codon=GTC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr9:g.5073770_5073772delGTCinsTTT;aliases=ENSP00000371067;source=Ensembl	inside_[cds_in_exon_14]	+	ENST00000381652	Acute myeloid leukemia
JAK2:V617F	MUT		Responsive	JAK2 (V617F)	RDientsmann	Ruxolitinib	JAK inhibitor	Ruxolitinib (JAK inhibitor)	Approved	FDA guidelines	JAK2		MY	FDA		chr9:g.5073770G>T	c.1849G>T	JAK2:V617F	CSQN=Missense;reference_codon=GTC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr9:g.5073770_5073772delGTCinsTTT;aliases=ENSP00000371067;source=Ensembl	inside_[cds_in_exon_14]	+	ENST00000381652	Myelofibrosis
JAK3:A572V,A573V	MUT		Responsive	JAK3 (A572V,A573V)	RDientsmann	[]	[JAK inhibitor]	JAK inhibitors		Pre-clinical	JAK3		LY	PMID:22705984		chr19:g.17948009G>A	c.1715C>T	JAK3:A572V	CSQN=Missense;reference_codon=GCA;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr19:g.17948008_17948009delTGinsGA,chr19:g.17948008_17948009delTGinsCA,chr19:g.17948008_17948009delTGinsAA;aliases=ENSP00000391676;source=Ensembl	inside_[cds_in_exon_13]	-	ENST00000458235	Lymphoma
JAK3:A572V,A573V	MUT		Responsive	JAK3 (A572V,A573V)	RDientsmann	[]	[JAK inhibitor]	JAK inhibitors		Pre-clinical	JAK3		LY	PMID:22705984		chr19:g.17948006G>A	c.1718C>T	JAK3:A573V	CSQN=Missense;reference_codon=GCG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr19:g.17948005_17948006delCGinsTA,chr19:g.17948005_17948006delCGinsGA,chr19:g.17948005_17948006delCGinsAA;aliases=ENSP00000391676;source=Ensembl	inside_[cds_in_exon_13]	-	ENST00000458235	Lymphoma
JAK3:R657Q,I87T,Q501H	MUT		Responsive	JAK3 (R657Q,I87T,Q501H)	RDientsmann	[]	[JAK inhibitor]	JAK inhibitors		Pre-clinical	JAK3		MKB	PMID:18397343		chr19:g.17945969C>T	c.1970G>A	JAK3:R657Q	CSQN=Missense;reference_codon=CGG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr19:g.17945968_17945969delCCinsTT;aliases=ENSP00000391676;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000458235	Megakaryoblastic leukemia
JAK3:R657Q,I87T,Q501H	MUT		Responsive	JAK3 (R657Q,I87T,Q501H)	RDientsmann	[]	[JAK inhibitor]	JAK inhibitors		Pre-clinical	JAK3		MKB	PMID:18397343		chr19:g.17954634A>G	c.260T>C	JAK3:I87T	CSQN=Missense;reference_codon=ATC;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr19:g.17954633_17954634delGAinsTG,chr19:g.17954633_17954634delGAinsCG,chr19:g.17954633_17954634delGAinsAG;aliases=ENSP00000391676;source=Ensembl	inside_[cds_in_exon_3]	-	ENST00000458235	Megakaryoblastic leukemia
JAK3:R657Q,I87T,Q501H	MUT		Responsive	JAK3 (R657Q,I87T,Q501H)	RDientsmann	[]	[JAK inhibitor]	JAK inhibitors		Pre-clinical	JAK3		MKB	PMID:18397343		chr19:g.17949138C>A	c.1503G>T	JAK3:Q501H	CSQN=Missense;reference_codon=CAG;candidate_codons=CAT,CAC;candidate_snv_variants=chr19:g.17949138C>G;aliases=ENSP00000391676;source=Ensembl	inside_[cds_in_exon_11]	-	ENST00000458235	Megakaryoblastic leukemia
KCNJ5:L168R	MUT	Cell line	Responsive	KCNJ5 (L168R)	ECampo	Amiloride	Na-Ca chanel blocker	Amiloride (Na-Ca chanel blocker)	Approved	Pre-clinical	KCNJ5		AA	PMID:24506072	Indirect	chr11:g.128781671T>G	c.503T>G	KCNJ5:L168R	CSQN=Missense;reference_codon=CTC;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr11:g.128781671_128781672delTCinsGA,chr11:g.128781671_128781672delTCinsGG,chr11:g.128781671_128781672delTCinsGT,chr11:g.128781670_128781672delCTCinsAGG,chr11:g.128781670_128781672delCTCinsAGA;aliases=ENSP00000433295;source=Ensembl	inside_[cds_in_exon_2]	+	ENST00000529694	Adrenal adenoma
KCNJ5:L168R	MUT	Cell line	Responsive	KCNJ5 (L168R)	ECampo	Verapamil	Na-Ca chanel blocker	Verapamil (Na-Ca chanel blocker)	Approved	Pre-clinical	KCNJ5		AA	PMID:24506072	Indirect	chr11:g.128781671T>G	c.503T>G	KCNJ5:L168R	CSQN=Missense;reference_codon=CTC;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr11:g.128781671_128781672delTCinsGA,chr11:g.128781671_128781672delTCinsGG,chr11:g.128781671_128781672delTCinsGT,chr11:g.128781670_128781672delCTCinsAGG,chr11:g.128781670_128781672delCTCinsAGA;aliases=ENSP00000433295;source=Ensembl	inside_[cds_in_exon_2]	+	ENST00000529694	Adrenal adenoma
KDR:A1065T	MUT		Responsive	KDR (A1065T)	RDientsmann	[]	[VEGFR inhibitor]	VEGFR inhibitors		Pre-clinical	KDR		CANCER	PMID:24569783		chr4:g.55955969C>T	c.3193G>A	KDR:A1065T	CSQN=Missense;reference_codon=GCT;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr4:g.55955967_55955969delAGCinsTGT,chr4:g.55955967_55955969delAGCinsCGT,chr4:g.55955967_55955969delAGCinsGGT;aliases=ENSP00000263923;source=Ensembl	inside_[cds_in_exon_24]	-	ENST00000263923	Any cancer type
KIT:550-592	MUT		Responsive	KIT mutation in exon 11	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	KIT		GIST	PMID:22898035									Gastrointestinal stromal
KIT:788-828,449-514	MUT		Responsive	KIT mutation in exon 9 or 17	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Pre-clinical	KIT		GIST	PMID:21737509									Gastrointestinal stromal
KIT::wildtype:.	MUT		Responsive	KIT wildtype	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	KIT		GIST	PMID:16397263									Gastrointestinal stromal
KIT:550-592,627-664	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Case report	KIT		CM	PMID:19671763									Cutaneous melanoma
KIT:D816V	MUT		Responsive	KIT (D816V)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Early trials	KIT		SM	PMID:18559612		chr4:g.55599321A>T	c.2447A>T	KIT:D816V	CSQN=Missense;reference_codon=GAC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr4:g.55599321_55599322delACinsTA,chr4:g.55599321_55599322delACinsTG,chr4:g.55599321_55599322delACinsTT;aliases=ENSP00000288135;source=Ensembl	inside_[cds_in_exon_17]	+	ENST00000288135	Systemic mastocytosis
KIT:D816V	MUT		Responsive	KIT (D816V)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Case report	KIT		AML	PMID:18986703		chr4:g.55599321A>T	c.2447A>T	KIT:D816V	CSQN=Missense;reference_codon=GAC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr4:g.55599321_55599322delACinsTA,chr4:g.55599321_55599322delACinsTG,chr4:g.55599321_55599322delACinsTT;aliases=ENSP00000288135;source=Ensembl	inside_[cds_in_exon_17]	+	ENST00000288135	Acute myeloid leukemia
KIT:D816Y,D816F,D816V	MUT		Responsive	KIT (D816Y,D816F,D816V)	CRubio-Perez;RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	KIT		CANCER	PMID:16397263		chr4:g.55599320G>T	c.2446G>T	KIT:D816Y	CSQN=Missense;reference_codon=GAC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr4:g.55599320_55599322delGACinsTAT;aliases=ENSP00000288135;source=Ensembl	inside_[cds_in_exon_17]	+	ENST00000288135	Any cancer type
KIT:D816Y,D816F,D816V	MUT		Responsive	KIT (D816Y,D816F,D816V)	CRubio-Perez;RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	KIT		CANCER	PMID:16397263		chr4:g.55599320_55599321delGAinsTT	c.2446_2447delGAinsTT	KIT:D816F	CSQN=Missense;reference_codon=GAC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr4:g.55599320_55599322delGACinsTTT;aliases=ENSP00000288135;source=Ensembl	inside_[cds_in_exon_17]	+	ENST00000288135	Any cancer type
KIT:D816Y,D816F,D816V	MUT		Responsive	KIT (D816Y,D816F,D816V)	CRubio-Perez;RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	KIT		CANCER	PMID:16397263		chr4:g.55599321A>T	c.2447A>T	KIT:D816V	CSQN=Missense;reference_codon=GAC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr4:g.55599321_55599322delACinsTA,chr4:g.55599321_55599322delACinsTG,chr4:g.55599321_55599322delACinsTT;aliases=ENSP00000288135;source=Ensembl	inside_[cds_in_exon_17]	+	ENST00000288135	Any cancer type
KIT:N822K	MUT		Responsive	KIT (N822K)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	KIT		AML	PMID:23149070		chr4:g.55599340T>G	c.2466T>G	KIT:N822K	CSQN=Missense;reference_codon=AAT;candidate_codons=AAG,AAA;candidate_snv_variants=chr4:g.55599340T>A;aliases=ENSP00000288135;source=Ensembl	inside_[cds_in_exon_17]	+	ENST00000288135	Acute myeloid leukemia
KIT::consequence::inframe_deletion:416-422,::inframe_insertion:416-422	MUT		Responsive	KIT inframe deletion (416-422),inframe insertion (416-422)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	KIT		AML	PMID:15618474									Acute myeloid leukemia
KIT::consequence::inframe_deletion:V560.	MUT		Responsive	KIT inframe deletion (V560)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Case report	KIT		THYM	PMID:15201427									Thymic
KIT::wildtype:.	MUT		Resistant	KIT wildtype	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Late trials	KIT		GIST	PMID:18955458									Gastrointestinal stromal
KIT:449-514,550-592,627-664,664-714,788-828	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17	CRubio-Perez;DTamborero;RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	FDA guidelines	KIT		GIST	FDA									Gastrointestinal stromal
KIT:550-592,627-664	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Late trials	KIT		CM	PMID:18421059;PMID:21642685;PMID:21690468;PMID:22261812									Cutaneous melanoma
KIT:550-592,627-664	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	NCCN guidelines	KIT		CM	NCCN									Cutaneous melanoma
KIT:627-664,664-714,449-514	MUT		Resistant	KIT (627-664,664-714,449-514)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Late trials	KIT		GIST	PMID:18955458;PMID:18955451;PMID:16624552									Gastrointestinal stromal
KIT:788-828	MUT		Resistant	KIT mutation in exon 17	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	KIT		GIST	PMID:23840364									Gastrointestinal stromal
KIT:788-828,829-860	MUT		Resistant	KIT mutation in exon 17 or 18	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Early trials	KIT		CM	PMID:21690468;PMID:21642685									Cutaneous melanoma
KIT:D816.	MUT		Resistant	KIT (D816)	CRubio-Perez;DTamborero;RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	FDA guidelines	KIT		GIST;MDS;MDPS;HES;ECL;CML;ALL;SM	FDA									Gastrointestinal stromal;Myelodisplasic syndrome;Myelodisplasic proliferative syndrome;Hyper eosinophilic advanced snydrome;Eosinophilic chronic leukemia;Chronic myeloid leukemia;Acute lymphoblastic leukemia;Systemic mastocytosis
KIT:D820Y	MUT		Responsive	KIT (D820Y)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Case report	KIT		CM	PMID:23775962		chr4:g.55599332G>T	c.2458G>T	KIT:D820Y	CSQN=Missense;reference_codon=GAT;candidate_codons=TAT,TAC;candidate_mnv_variants=chr4:g.55599332_55599334delGATinsTAC;aliases=ENSP00000288135;source=Ensembl	inside_[cds_in_exon_17]	+	ENST00000288135	Cutaneous melanoma
KIT:T670I	MUT		Resistant	KIT (T670I)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Case report	KIT		GIST	PMID:24687822		chr4:g.55595519C>T	c.2009C>T	KIT:T670I	CSQN=Missense;reference_codon=ACA;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr4:g.55595519_55595520delCAinsTC,chr4:g.55595519_55595520delCAinsTT;aliases=ENSP00000288135;source=Ensembl	inside_[cds_in_exon_14]	+	ENST00000288135	Gastrointestinal stromal
KIT:V559I,H697Y,T670.,V654A,A829P,D816.,N822.,Y823D	MUT		Resistant	KIT (V559I,H697Y,T670,V654A,A829P,D816,N822,Y823D)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	KIT		GIST	PMID:23582185;PMID:21689725;PMID:17259998									Gastrointestinal stromal
KIT:Y553N	MUT		Responsive	KIT (Y553N)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Case report	KIT		THYM	PMID:21969494		chr4:g.55593591T>A	c.1657T>A	KIT:Y553N	CSQN=Missense;reference_codon=TAT;candidate_codons=AAC,AAT;candidate_mnv_variants=chr4:g.55593591_55593593delTATinsAAC;aliases=ENSP00000288135;source=Ensembl	inside_[cds_in_exon_11]	+	ENST00000288135	Thymic
KIT:550-592,627-664	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17	RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)		Early trials	KIT		CM	PMID:22068222;PMID:25695690									Cutaneous melanoma
KIT:788-828	MUT		Responsive	KIT mutation in exon 17	RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)		Early trials	KIT		GIST	PMID:22119758;PMID:21456006									Gastrointestinal stromal
KIT:D820Y	MUT		Responsive	KIT (D820Y)	RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)		Case report	KIT		CM	PMID:25695690		chr4:g.55599332G>T	c.2458G>T	KIT:D820Y	CSQN=Missense;reference_codon=GAT;candidate_codons=TAT,TAC;candidate_mnv_variants=chr4:g.55599332_55599334delGATinsTAC;aliases=ENSP00000288135;source=Ensembl	inside_[cds_in_exon_17]	+	ENST00000288135	Cutaneous melanoma
KIT:788-828,829-860,550-592	MUT		Responsive	KIT (788-828,829-860,550-592)	RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)		Early trials	KIT		GIST	ASCO 2015 (abstr 10517);PMID:25239608;ASCO 2015 (abstr 10535)									Gastrointestinal stromal
KIT:A829P,V654A,T670I	MUT		Responsive	KIT (A829P,V654A,T670I)	RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)		Pre-clinical	KIT		GIST	PMID:25239608		chr4:g.55602664G>C	c.2485G>C	KIT:A829P	CSQN=Missense;reference_codon=GCT;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr4:g.55602664_55602666delGCTinsCCG,chr4:g.55602664_55602666delGCTinsCCA,chr4:g.55602664_55602666delGCTinsCCC;aliases=ENSP00000288135;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000288135	Gastrointestinal stromal
KIT:A829P,V654A,T670I	MUT		Responsive	KIT (A829P,V654A,T670I)	RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)		Pre-clinical	KIT		GIST	PMID:25239608		chr4:g.55594258T>C	c.1961T>C	KIT:V654A	CSQN=Missense;reference_codon=GTG;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr4:g.55594258_55594259delTGinsCA,chr4:g.55594258_55594259delTGinsCC,chr4:g.55594258_55594259delTGinsCT;aliases=ENSP00000288135;source=Ensembl	inside_[cds_in_exon_13]	+	ENST00000288135	Gastrointestinal stromal
KIT:A829P,V654A,T670I	MUT		Responsive	KIT (A829P,V654A,T670I)	RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)		Pre-clinical	KIT		GIST	PMID:25239608		chr4:g.55595519C>T	c.2009C>T	KIT:T670I	CSQN=Missense;reference_codon=ACA;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr4:g.55595519_55595520delCAinsTC,chr4:g.55595519_55595520delCAinsTT;aliases=ENSP00000288135;source=Ensembl	inside_[cds_in_exon_14]	+	ENST00000288135	Gastrointestinal stromal
KIT:449-514,550-592,627-664,664-714,788-828	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17	RDientsmann	Regorafenib	Pan-kinase inhibitor	Regorafenib (Pan-kinase inhibitor)	Approved	FDA guidelines	KIT		GIST	FDA									Gastrointestinal stromal
KIT::consequence::inframe_deletion:577-579	MUT		Responsive	KIT inframe deletion (577-579)	RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Case report	KIT		THYM	PMID:20970876									Thymic
KIT::wildtype:.	MUT		Responsive	KIT wildtype	RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Early trials	KIT		GIST	ASCO 2011 (abstr 10009)									Gastrointestinal stromal
KIT:550-592,449-514	MUT		Responsive	KIT mutation in exon 9 or 11	RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Early trials	KIT		GIST	PMID:22270258									Gastrointestinal stromal
KIT:550-592,627-664,788-828,829-860	MUT		Responsive	KIT (550-592,627-664,788-828,829-860)	RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Case report	KIT		CM	PMID:18936790;PMID:20372153									Cutaneous melanoma
KIT:788-828	MUT		Responsive	KIT mutation in exon 17	RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Pre-clinical	KIT		GIST	PMID:23840364									Gastrointestinal stromal
KIT:D820E	MUT		Responsive	KIT (D820E)	RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Case report	KIT		THYM	PMID:19461405		chr4:g.55599334T>G	c.2460T>G	KIT:D820E	CSQN=Missense;reference_codon=GAT;candidate_codons=GAG,GAA;candidate_snv_variants=chr4:g.55599334T>A;aliases=ENSP00000288135;source=Ensembl	inside_[cds_in_exon_17]	+	ENST00000288135	Thymic
KIT::wildtype:.	MUT		Responsive	KIT wildtype	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Late trials	KIT		GIST	PMID:18955458									Gastrointestinal stromal
KIT:449-514,550-592,627-664,664-714,788-828	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)	Approved	FDA guidelines	KIT		GIST	FDA									Gastrointestinal stromal
KIT:550-592	MUT		Resistant	KIT mutation in exon 11	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Late trials	KIT		GIST	PMID:18955458									Gastrointestinal stromal
KIT:550-592,627-664	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Late trials	KIT		CM	PMID:18421059;PMID:21642685;PMID:21690468;PMID:22261812									Cutaneous melanoma
KIT:788-828	MUT		Resistant	KIT mutation in exon 17	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Pre-clinical	KIT		GIST	PMID:23840364									Gastrointestinal stromal
KIT:H697Y	MUT		Responsive	KIT (H697Y)	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Pre-clinical	KIT		THYM	PMID:19861435		chr4:g.55595599C>T	c.2089C>T	KIT:H697Y	CSQN=Missense;reference_codon=CAT;candidate_codons=TAT,TAC;candidate_mnv_variants=chr4:g.55595599_55595601delCATinsTAC;aliases=ENSP00000288135;source=Ensembl	inside_[cds_in_exon_14]	+	ENST00000288135	Thymic
KIT:H697Y	MUT		Responsive	KIT (H697Y)	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Pre-clinical	KIT		THYM	PMID:19861435		chr4:g.55595599C>T	c.2089C>T	KIT:H697Y	CSQN=Missense;reference_codon=CAT;candidate_codons=TAT,TAC;candidate_mnv_variants=chr4:g.55595599_55595601delCATinsTAC;aliases=ENSP00000288135;source=Ensembl	inside_[cds_in_exon_14]	+	ENST00000288135	Thymic
KIT:Y553N	MUT		Responsive	KIT (Y553N)	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Case report	KIT		THYM	PMID:23375402		chr4:g.55593591T>A	c.1657T>A	KIT:Y553N	CSQN=Missense;reference_codon=TAT;candidate_codons=AAC,AAT;candidate_mnv_variants=chr4:g.55593591_55593593delTATinsAAC;aliases=ENSP00000288135;source=Ensembl	inside_[cds_in_exon_11]	+	ENST00000288135	Thymic
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[BET inhibitor]	BET inhibitors		Pre-clinical	KRAS		L	PMID:23129625;PMID:24045185									Lung
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[CDK4 inhibitor]	CDK4 inhibitors		Pre-clinical	KRAS		L	PMID:20609353									Lung
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[CDK4/6 inhibitor;MEK inhibitor]	CDK4/6 inhibitor + MEK inhibitors		Early trials	KRAS		L	AACR 2017 (CT046)									Lung
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[CDK4/6 inhibitor;MEK inhibitor]	CDK4/6 inhibitor + MEK inhibitors		Pre-clinical	KRAS		CESC	PMID:27167191									Cervix squamous cell
KRAS:.	MUT		Resistant	KRAS oncogenic mutation	RDientsmann	[]	[EGFR inhibitor 1st gen]	EGFR inhibitor 1st gens		NCCN guidelines	KRAS		L	PMID:20921461									Lung
KRAS:.	MUT		Resistant	KRAS oncogenic mutation	RDientsmann	[]	[EGFR inhibitor 2nd gen]	EGFR inhibitor 2nd gens		NCCN guidelines	KRAS		L	PMID:20921461									Lung
KRAS:.	MUT		Resistant	KRAS oncogenic mutation	DTamborero	[]	[EGFR inhibitor]	EGFR inhibitors		Pre-clinical	KRAS		NSCLC	PMID:19238210									Non-small cell lung
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[EGFR mAb inhibitor;MEK inhibitor]	EGFR mAb inhibitor + MEK inhibitors		Pre-clinical	KRAS		COREAD	PMID:24553387									Colorectal adenocarcinoma
KRAS:.	MUT		Resistant	KRAS oncogenic mutation	RDientsmann	[]	[EGFR mAb inhibitor]	EGFR mAb inhibitors		Pre-clinical	KRAS		ST	PMID:22614881;PMID:22290393									Stomach
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[ERK inhibitor]	ERK inhibitors		Pre-clinical	KRAS		COREAD	PMID:23614898									Colorectal adenocarcinoma
KRAS:.	MUT		Resistant	KRAS oncogenic mutation	RDientsmann	[]	[EZH2 inhibitor]	EZH2 inhibitors		Pre-clinical	KRAS		CANCER	PMID:26552009									Any cancer type
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[FAK inhibitor]	FAK inhibitors		Pre-clinical	KRAS		L	PMID:23358651									Lung
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[FAS inhibitor]	FAS inhibitors		Case report	KRAS		L	AACR 2016;abstr									Lung
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[FAS inhibitor]	FAS inhibitors		Case report	KRAS		L	AACR 2016, abstr LB214									Lung
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[HSP90 inhibitor (in combination)]	HSP90 inhibitor (in combination)s		Pre-clinical	KRAS		L	PMID:23012248;PMID:21907929									Lung
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[JAK/TBK1/IKKε inhibitor]	JAK/TBK1/IKKε inhibitors		Pre-clinical	KRAS		L	PMID:24444711									Lung
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[MEK inhibitor;BCL-XL inhibitor]	MEK inhibitor + BCL-XL inhibitors		Pre-clinical	KRAS		COREAD	PMID:23245996									Colorectal adenocarcinoma
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[MEK inhibitor;IGF1R inhibitor]	MEK inhibitor + IGF1R inhibitors		Pre-clinical	KRAS		COREAD	PMID:24045180									Colorectal adenocarcinoma
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[MEK inhibitor;PI3K pathway inhibitor]	MEK inhibitor + PI3K pathway inhibitors		Pre-clinical	KRAS		COREAD	PMID:22392911									Colorectal adenocarcinoma
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Early trials	KRAS		L;BT	PMID:23200175;PMID:24947927;PMID:25667274;PMID:25722381;PMID:23391555									Lung;Billiary tract
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	KRAS		AML;CER;OV	PMID:22507781;PMID:22169769;PMID:19018267									Acute myeloid leukemia;Cervix;Ovary
KRAS:G12.	MUT		Responsive	KRAS (G12)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	KRAS		ALL	PMID:18701506									Acute lymphoblastic leukemia
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[MTOR inhibitor;BH3 mimetics]	MTOR inhibitor + BH3 mimeticss		Pre-clinical	KRAS		COREAD	PMID:24163374									Colorectal adenocarcinoma
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[pan-RAF inhibitor]	pan-RAF inhibitors		Early trials	KRAS		L	AACR 2017 (abstr  CT002)									Lung
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[pan-RAF inhibitor]	pan-RAF inhibitors		Case report	KRAS		ED	AACR 2016 (abstr CT005);AACR 2017 (abstr CT002)									Endometrium
KRAS:.	MUT		No Responsive	KRAS oncogenic mutation	RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Early trials	KRAS		PA	ASCO 2015 (abstr 4119)									Pancreas
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Pre-clinical	KRAS		ED	PMID:21984976;PMID:22662154									Endometrium
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Early trials	KRAS		L	PMID:25516890									Lung
KRAS:.	MUT		Resistant	KRAS oncogenic mutation	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Pre-clinical	KRAS		ED	PMID:22662154									Endometrium
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann;DTamborero;CRubio-Perez	Abemaciclib	CDK4/6 inhibitor	Abemaciclib (CDK4/6 inhibitor)		Early trials	KRAS		L	PMID:27217383									Lung
KRAS:.	MUT		Resistant	KRAS oncogenic mutation	CRubio-Perez;RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)	Approved	FDA guidelines	KRAS		COREAD	FDA guidelines									Colorectal adenocarcinoma
KRAS:G13D	MUT		No Responsive	KRAS (G13D)	RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)		Late trials	KRAS		COREAD	PMID:27114605		chr12:g.25398281C>T	c.38G>A	KRAS:G13D	CSQN=Missense;reference_codon=GGC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr12:g.25398280_25398281delGCinsAT;aliases=ENSP00000256078;source=Ensembl	inside_[cds_in_exon_2]	-	ENST00000256078	Colorectal adenocarcinoma
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	Decitabine;BCL2 inhibitor	Chemotherapy;BCL2 inhibitor	Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)		Pre-clinical	KRAS		OV	PMID:25968887									Ovary
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	Gemcitabine;MEK inhibitor	Chemotherapy;MEK inhibitor	Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)		Early trials	KRAS		PA	PMID:23583440									Pancreas
KRAS:G12.	MUT		Resistant	KRAS (G12)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Case report	KRAS		GIST	PMID:24687822									Gastrointestinal stromal
KRAS:.	MUT		Resistant	KRAS oncogenic mutation	CRubio-Perez;RDientsmann	Panitumumab	EGFR mAb inhibitor	Panitumumab (EGFR mAb inhibitor)	Approved	FDA guidelines	KRAS		COREAD	FDA guidelines									Colorectal adenocarcinoma
KRAS:.	MUT		Resistant	KRAS oncogenic mutation	CRubio-Perez;RDientsmann	Regorafenib	Pan-kinase inhibitor	Regorafenib (Pan-kinase inhibitor)		FDA guidelines	KRAS	COREAD	COREAD	FDA guidelines									Colorectal adenocarcinoma
KRAS:.	MUT		No Responsive	KRAS oncogenic mutation	RDientsmann	Selumetinib	MEK inhibitor	Selumetinib (MEK inhibitor)		Early trials	KRAS		L	PMID:26802155									Lung
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	EArriola	Selumetinib	MEK inhibitor	Selumetinib (MEK inhibitor)	Clinical Trials	Early trials	KRAS		NSCLC	NCT00890825									Non-small cell lung
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	Sorafenib;MEK inhibitor	Pan-TK inhibitor;MEK inhibitor	Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)		Early Trials,Case Report	KRAS		HC	PMID:25294897									Hepatic carcinoma
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	Trametinib;Ponatinib	MEK inhibitor;BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)		Pre-clinical	KRAS		LUAD	PMID:27338794									Lung adenocarcinoma
KRAS:.	MUT		Resistant	KRAS oncogenic mutation	RDientsmann	Trastuzumab;Lapatinib	ERBB2 mAb inhibitor;ERBB2 inhibitor	Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)		Late trials	KRAS		COREAD	ASCO 2015 (abstr 3508);NCT01104571;EBCC10									Colorectal adenocarcinoma
LRP1B:.	MUT		Resistant	LRP1B oncogenic mutation	RDientsmann	Liposomal Doxorubicin	Chemotherapy	Liposomal Doxorubicin (Chemotherapy)		Early trials	LRP1B		OV	PMID:22896685									Ovary
MAP2K1:P124.	MUT		Resistant	MAP2K1 (P124)	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Early trials	MAP2K1		CM	PMID:25370473									Cutaneous melanoma
MAP2K1:Q56P,P124S,P124L;C121S	MUT		Resistant	MAP2K1 (Q56P,P124S,P124L;C121S)	RDientsmann;DTamborero	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	MAP2K1		CM	PMID:19915144;PMID:21383288									Cutaneous melanoma
MAP2K1:.	MUT		Resistant	MAP2K1 oncogenic mutation	RDientsmann	[]	[EGFR mAb inhibitor]	EGFR mAb inhibitors		Case report	MAP2K1		COREAD	PMID:26030179									Colorectal adenocarcinoma
MAP2K1:F129L,L215P,I103N,P124.	MUT		Responsive	MAP2K1 (F129L,L215P,I103N,P124)	RDientsmann	[]	[ERK inhibitor]	ERK inhibitors		Pre-clinical	MAP2K1		CANCER	PMID:23614898									Any cancer type
MAP2K1:P124.	MUT		Responsive	MAP2K1 (P124)	RDientsmann	[]	[ERK inhibitor]	ERK inhibitors		Pre-clinical	MAP2K1		CM	PMID:25370473									Cutaneous melanoma
MAP2K1:I99T,L115.,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124.,D67N	MUT		Resistant	MAP2K1 (I99T,L115,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124,D67N)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	MAP2K1		CANCER	PMID:19915144									Any cancer type
MAP2K1:P124L,K57N,C121S	MUT		Resistant	MAP2K1 (P124L,K57N,C121S)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Case report	MAP2K1		CM	PMID:19915144;PMID:23444215;PMID:21383288		chr15:g.66729163C>T	c.371C>T	MAP2K1:P124L	CSQN=Missense;reference_codon=CCG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_mnv_variants=chr15:g.66729163_66729164delCGinsTT,chr15:g.66729163_66729164delCGinsTA,chr15:g.66729163_66729164delCGinsTC,chr15:g.66729162_66729163delCCinsTT,chr15:g.66729162_66729164delCCGinsTTA;aliases=ENSP00000302486;source=Ensembl	inside_[cds_in_exon_3]	+	ENST00000307102	Cutaneous melanoma
MAP2K1:P124L,K57N,C121S	MUT		Resistant	MAP2K1 (P124L,K57N,C121S)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Case report	MAP2K1		CM	PMID:19915144;PMID:23444215;PMID:21383288		chr15:g.66727455G>C	c.171G>C	MAP2K1:K57N	CSQN=Missense;reference_codon=AAG;candidate_codons=AAC,AAT;candidate_snv_variants=chr15:g.66727455G>T;aliases=ENSP00000302486;source=Ensembl	inside_[cds_in_exon_2]	+	ENST00000307102	Cutaneous melanoma
MAP2K1:P124L,K57N,C121S	MUT		Resistant	MAP2K1 (P124L,K57N,C121S)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Case report	MAP2K1		CM	PMID:19915144;PMID:23444215;PMID:21383288		chr15:g.66729153T>A	c.361T>A	MAP2K1:C121S	CSQN=Missense;reference_codon=TGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_snv_variants=chr15:g.66729154G>C;candidate_mnv_variants=chr15:g.66729153_66729155delTGCinsAGT,chr15:g.66729154_66729155delGCinsCT,chr15:g.66729154_66729155delGCinsCG,chr15:g.66729154_66729155delGCinsCA;aliases=ENSP00000302486;source=Ensembl	inside_[cds_in_exon_3]	+	ENST00000307102	Cutaneous melanoma
MAP2K1:Q56P,P124S,P124L	MUT		Resistant	MAP2K1 (Q56P,P124S,P124L)	DTamborero	[]	[MEK inhibitor]	MEK inhibitors		Case report	MAP2K1		CM	PMID:19915144		chr15:g.66727451A>C	c.167A>C	MAP2K1:Q56P	CSQN=Missense;reference_codon=CAG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr15:g.66727451_66727452delAGinsCT,chr15:g.66727451_66727452delAGinsCA,chr15:g.66727451_66727452delAGinsCC;aliases=ENSP00000302486;source=Ensembl	inside_[cds_in_exon_2]	+	ENST00000307102	Cutaneous melanoma
MAP2K1:Q56P,P124S,P124L	MUT		Resistant	MAP2K1 (Q56P,P124S,P124L)	DTamborero	[]	[MEK inhibitor]	MEK inhibitors		Case report	MAP2K1		CM	PMID:19915144		chr15:g.66729162C>T	c.370C>T	MAP2K1:P124S	CSQN=Missense;reference_codon=CCG;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr15:g.66729162_66729164delCCGinsTCT,chr15:g.66729162_66729164delCCGinsTCC,chr15:g.66729162_66729164delCCGinsTCA,chr15:g.66729162_66729164delCCGinsAGC,chr15:g.66729162_66729164delCCGinsAGT;aliases=ENSP00000302486;source=Ensembl	inside_[cds_in_exon_3]	+	ENST00000307102	Cutaneous melanoma
MAP2K1:Q56P,P124S,P124L	MUT		Resistant	MAP2K1 (Q56P,P124S,P124L)	DTamborero	[]	[MEK inhibitor]	MEK inhibitors		Case report	MAP2K1		CM	PMID:19915144		chr15:g.66729163C>T	c.371C>T	MAP2K1:P124L	CSQN=Missense;reference_codon=CCG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_mnv_variants=chr15:g.66729163_66729164delCGinsTT,chr15:g.66729163_66729164delCGinsTA,chr15:g.66729163_66729164delCGinsTC,chr15:g.66729162_66729163delCCinsTT,chr15:g.66729162_66729164delCCGinsTTA;aliases=ENSP00000302486;source=Ensembl	inside_[cds_in_exon_3]	+	ENST00000307102	Cutaneous melanoma
MAP2K1:C121S	MUT		Responsive	MAP2K1 (C121S)	RDientsmann	[]	[novel MEK inhibitor]	novel MEK inhibitors		Pre-clinical	MAP2K1		CM	PMID:24448821		chr15:g.66729153T>A	c.361T>A	MAP2K1:C121S	CSQN=Missense;reference_codon=TGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_snv_variants=chr15:g.66729154G>C;candidate_mnv_variants=chr15:g.66729153_66729155delTGCinsAGT,chr15:g.66729154_66729155delGCinsCT,chr15:g.66729154_66729155delGCinsCG,chr15:g.66729154_66729155delGCinsCA;aliases=ENSP00000302486;source=Ensembl	inside_[cds_in_exon_3]	+	ENST00000307102	Cutaneous melanoma
MAP2K1:K57T	MUT		Responsive	MAP2K1 (K57T)	RDientsmann	Panitumumab;Trametinib	EGFR mAb inhibitor;MEK inhibitor	Panitumumab + Trametinib (EGFR mAb inhibitor + MEK inhibitor)		Case report	MAP2K1		COREAD	PMID:26644315		chr15:g.66727454A>C	c.170A>C	MAP2K1:K57T	CSQN=Missense;reference_codon=AAG;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr15:g.66727454_66727455delAGinsCA,chr15:g.66727454_66727455delAGinsCT,chr15:g.66727454_66727455delAGinsCC;aliases=ENSP00000302486;source=Ensembl	inside_[cds_in_exon_2]	+	ENST00000307102	Colorectal adenocarcinoma
MAP2K1::consequence::inframe_deletion:56-60	MUT		Responsive	MAP2K1 inframe deletion (56-60)	RDientsmann	Selumetinib	MEK inhibitor	Selumetinib (MEK inhibitor)		Case report	MAP2K1		OV	PMID:26324360									Ovary
MAP2K1:Q56P	MUT		Responsive	MAP2K1 (Q56P)	RDientsmann	Trametinib	MEK inhibitor	Trametinib (MEK inhibitor)		Pre-clinical	MAP2K1		CANCER	PMID:26582713		chr15:g.66727451A>C	c.167A>C	MAP2K1:Q56P	CSQN=Missense;reference_codon=CAG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr15:g.66727451_66727452delAGinsCT,chr15:g.66727451_66727452delAGinsCA,chr15:g.66727451_66727452delAGinsCC;aliases=ENSP00000302486;source=Ensembl	inside_[cds_in_exon_2]	+	ENST00000307102	Any cancer type
MAP2K1:E203K,Q56P,K57E	MUT		Resistant	MAP2K1 (E203K,Q56P,K57E)	RDientsmann	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)		Case report	MAP2K1		CM	PMID:23569304		chr15:g.66774131G>A	c.607G>A	MAP2K1:E203K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr15:g.66774131_66774133delGAGinsAAA;aliases=ENSP00000302486;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000307102	Cutaneous melanoma
MAP2K1:E203K,Q56P,K57E	MUT		Resistant	MAP2K1 (E203K,Q56P,K57E)	RDientsmann	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)		Case report	MAP2K1		CM	PMID:23569304		chr15:g.66727451A>C	c.167A>C	MAP2K1:Q56P	CSQN=Missense;reference_codon=CAG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr15:g.66727451_66727452delAGinsCT,chr15:g.66727451_66727452delAGinsCA,chr15:g.66727451_66727452delAGinsCC;aliases=ENSP00000302486;source=Ensembl	inside_[cds_in_exon_2]	+	ENST00000307102	Cutaneous melanoma
MAP2K1:E203K,Q56P,K57E	MUT		Resistant	MAP2K1 (E203K,Q56P,K57E)	RDientsmann	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)		Case report	MAP2K1		CM	PMID:23569304		chr15:g.66727453A>G	c.169A>G	MAP2K1:K57E	CSQN=Missense;reference_codon=AAG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr15:g.66727453_66727455delAAGinsGAA;aliases=ENSP00000302486;source=Ensembl	inside_[cds_in_exon_2]	+	ENST00000307102	Cutaneous melanoma
MAP2K2:Q60P	MUT		Resistant	MAP2K2 (Q60P)	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	MAP2K2		CM	PMID:24265154		chr19:g.4117541T>G	c.179A>C	MAP2K2:Q60P	CSQN=Missense;reference_codon=CAG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr19:g.4117540_4117541delCTinsAG,chr19:g.4117540_4117541delCTinsTG,chr19:g.4117540_4117541delCTinsGG;aliases=ENSP00000262948;source=Ensembl	inside_[cds_in_exon_2]	-	ENST00000262948	Cutaneous melanoma
MAP2K2:V35M,L46F,N126D,C125S	MUT		Resistant	MAP2K2 (V35M,L46F,N126D,C125S)	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Pre-clinical	MAP2K2		CM	PMID:24265153		chr19:g.4117617C>T	c.103G>A	MAP2K2:V35M	CSQN=Missense;reference_codon=GTG;candidate_codons=ATG;aliases=ENSP00000262948;source=Ensembl	inside_[cds_in_exon_2]	-	ENST00000262948	Cutaneous melanoma
MAP2K2:V35M,L46F,N126D,C125S	MUT		Resistant	MAP2K2 (V35M,L46F,N126D,C125S)	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Pre-clinical	MAP2K2		CM	PMID:24265153		chr19:g.4117584G>A	c.136C>T	MAP2K2:L46F	CSQN=Missense;reference_codon=CTT;candidate_codons=TTT,TTC;candidate_mnv_variants=chr19:g.4117582_4117584delAAGinsGAA;aliases=ENSP00000262948;source=Ensembl	inside_[cds_in_exon_2]	-	ENST00000262948	Cutaneous melanoma
MAP2K2:V35M,L46F,N126D,C125S	MUT		Resistant	MAP2K2 (V35M,L46F,N126D,C125S)	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Pre-clinical	MAP2K2		CM	PMID:24265153		chr19:g.4110581T>C	c.376A>G	MAP2K2:N126D	CSQN=Missense;reference_codon=AAC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr19:g.4110579_4110581delGTTinsATC;aliases=ENSP00000262948;source=Ensembl	inside_[cds_in_exon_3]	-	ENST00000262948	Cutaneous melanoma
MAP2K2:V35M,L46F,N126D,C125S	MUT		Resistant	MAP2K2 (V35M,L46F,N126D,C125S)	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Pre-clinical	MAP2K2		CM	PMID:24265153		chr19:g.4110584A>T	c.373T>A	MAP2K2:C125S	CSQN=Missense;reference_codon=TGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_snv_variants=chr19:g.4110583C>G;candidate_mnv_variants=chr19:g.4110582_4110584delGCAinsACT,chr19:g.4110582_4110583delGCinsAG,chr19:g.4110582_4110583delGCinsCG,chr19:g.4110582_4110583delGCinsTG;aliases=ENSP00000262948;source=Ensembl	inside_[cds_in_exon_3]	-	ENST00000262948	Cutaneous melanoma
MAP2K2:Q60P	MUT		Resistant	MAP2K2 (Q60P)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Case report	MAP2K2		CM	PMID:24265154		chr19:g.4117541T>G	c.179A>C	MAP2K2:Q60P	CSQN=Missense;reference_codon=CAG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr19:g.4117540_4117541delCTinsAG,chr19:g.4117540_4117541delCTinsTG,chr19:g.4117540_4117541delCTinsGG;aliases=ENSP00000262948;source=Ensembl	inside_[cds_in_exon_2]	-	ENST00000262948	Cutaneous melanoma
MAP2K2:V35M,L46F,N126D,C125S	MUT		Resistant	MAP2K2 (V35M,L46F,N126D,C125S)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	MAP2K2		CM	PMID:24265153		chr19:g.4117617C>T	c.103G>A	MAP2K2:V35M	CSQN=Missense;reference_codon=GTG;candidate_codons=ATG;aliases=ENSP00000262948;source=Ensembl	inside_[cds_in_exon_2]	-	ENST00000262948	Cutaneous melanoma
MAP2K2:V35M,L46F,N126D,C125S	MUT		Resistant	MAP2K2 (V35M,L46F,N126D,C125S)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	MAP2K2		CM	PMID:24265153		chr19:g.4117584G>A	c.136C>T	MAP2K2:L46F	CSQN=Missense;reference_codon=CTT;candidate_codons=TTT,TTC;candidate_mnv_variants=chr19:g.4117582_4117584delAAGinsGAA;aliases=ENSP00000262948;source=Ensembl	inside_[cds_in_exon_2]	-	ENST00000262948	Cutaneous melanoma
MAP2K2:V35M,L46F,N126D,C125S	MUT		Resistant	MAP2K2 (V35M,L46F,N126D,C125S)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	MAP2K2		CM	PMID:24265153		chr19:g.4110581T>C	c.376A>G	MAP2K2:N126D	CSQN=Missense;reference_codon=AAC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr19:g.4110579_4110581delGTTinsATC;aliases=ENSP00000262948;source=Ensembl	inside_[cds_in_exon_3]	-	ENST00000262948	Cutaneous melanoma
MAP2K2:V35M,L46F,N126D,C125S	MUT		Resistant	MAP2K2 (V35M,L46F,N126D,C125S)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	MAP2K2		CM	PMID:24265153		chr19:g.4110584A>T	c.373T>A	MAP2K2:C125S	CSQN=Missense;reference_codon=TGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_snv_variants=chr19:g.4110583C>G;candidate_mnv_variants=chr19:g.4110582_4110584delGCAinsACT,chr19:g.4110582_4110583delGCinsAG,chr19:g.4110582_4110583delGCinsCG,chr19:g.4110582_4110583delGCinsTG;aliases=ENSP00000262948;source=Ensembl	inside_[cds_in_exon_3]	-	ENST00000262948	Cutaneous melanoma
MET:1078-1345	MUT		Responsive	MET kinase domain mutation	RDientsmann	Savolitinib	MET inhibitor	Savolitinib (MET inhibitor)		Early trials	MET		R	PMID:28644771									Renal
MET:D1246V	MUT		Resistant	MET (D1246V)	RDientsmann	[]	[MET inhibitor]	MET inhibitors		Case report	MET		LUAD	PMID:27694386		chr7:g.116423408A>T	c.3737A>T	MET:D1246V	CSQN=Missense;reference_codon=GAC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr7:g.116423408_116423409delACinsTA,chr7:g.116423408_116423409delACinsTG,chr7:g.116423408_116423409delACinsTT;aliases=ENSP00000317272;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000318493	Lung adenocarcinoma
MET:H1112R	MUT		Responsive	MET (H1112R)	RDientsmann	[]	[MET inhibitor]	MET inhibitors		Early trials	MET		R	PMID:23213094		chr7:g.116417464A>G	c.3335A>G	MET:H1112R	CSQN=Missense;reference_codon=CAT;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.116417464_116417465delATinsGA,chr7:g.116417464_116417465delATinsGC,chr7:g.116417464_116417465delATinsGG,chr7:g.116417463_116417465delCATinsAGG,chr7:g.116417463_116417465delCATinsAGA;aliases=ENSP00000317272;source=Ensembl	inside_[cds_in_exon_16]	+	ENST00000318493	Renal
MET:M1268T	MUT		Responsive	MET (M1268T)	RDientsmann	[]	[MET inhibitor]	MET inhibitors		Case report	MET		R	PMID:23610116		chr7:g.116423474T>C	c.3803T>C	MET:M1268T	CSQN=Missense;reference_codon=ATG;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr7:g.116423474_116423475delTGinsCA,chr7:g.116423474_116423475delTGinsCT,chr7:g.116423474_116423475delTGinsCC;aliases=ENSP00000317272;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000318493	Renal
MET:H1112L	MUT		Responsive	MET (H1112L)	RDientsmann	[Crizotinib]	[MET inhibitor]	MET inhibitors (Crizotinib,etc)		Pre-clinical	MET		CANCER	AACR 2012 (abstr 1786)		chr7:g.116417464A>T	c.3335A>T	MET:H1112L	CSQN=Missense;reference_codon=CAT;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_mnv_variants=chr7:g.116417464_116417465delATinsTG,chr7:g.116417464_116417465delATinsTA,chr7:g.116417464_116417465delATinsTC,chr7:g.116417463_116417465delCATinsTTA,chr7:g.116417463_116417465delCATinsTTG;aliases=ENSP00000317272;source=Ensembl	inside_[cds_in_exon_16]	+	ENST00000318493	Any cancer type
MET:1132-1330	MUT		Responsive	MET mutation in exon 16-19	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Early trials	MET		R	AACR 2016 (abstr CT2006)									Renal
MET:V1110I,H1112R,M1268T,R988C,T1010I	MUT		Responsive	MET (V1110I,H1112R,M1268T,R988C,T1010I)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	MET		CANCER	PMID:17483355		chr7:g.116417457G>A	c.3328G>A	MET:V1110I	CSQN=Missense;reference_codon=GTA;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.116417457_116417459delGTAinsATC,chr7:g.116417457_116417459delGTAinsATT;aliases=ENSP00000317272;source=Ensembl	inside_[cds_in_exon_16]	+	ENST00000318493	Any cancer type
MET:V1110I,H1112R,M1268T,R988C,T1010I	MUT		Responsive	MET (V1110I,H1112R,M1268T,R988C,T1010I)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	MET		CANCER	PMID:17483355		chr7:g.116417464A>G	c.3335A>G	MET:H1112R	CSQN=Missense;reference_codon=CAT;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.116417464_116417465delATinsGA,chr7:g.116417464_116417465delATinsGC,chr7:g.116417464_116417465delATinsGG,chr7:g.116417463_116417465delCATinsAGG,chr7:g.116417463_116417465delCATinsAGA;aliases=ENSP00000317272;source=Ensembl	inside_[cds_in_exon_16]	+	ENST00000318493	Any cancer type
MET:V1110I,H1112R,M1268T,R988C,T1010I	MUT		Responsive	MET (V1110I,H1112R,M1268T,R988C,T1010I)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	MET		CANCER	PMID:17483355		chr7:g.116423474T>C	c.3803T>C	MET:M1268T	CSQN=Missense;reference_codon=ATG;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr7:g.116423474_116423475delTGinsCA,chr7:g.116423474_116423475delTGinsCT,chr7:g.116423474_116423475delTGinsCC;aliases=ENSP00000317272;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000318493	Any cancer type
MET:V1110I,H1112R,M1268T,R988C,T1010I	MUT		Responsive	MET (V1110I,H1112R,M1268T,R988C,T1010I)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	MET		CANCER	PMID:17483355		chr7:g.116411923C>T	c.2962C>T	MET:R988C	CSQN=Missense;reference_codon=CGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr7:g.116411923_116411925delCGCinsTGT;aliases=ENSP00000317272;source=Ensembl	inside_[cds_in_exon_14]	+	ENST00000318493	Any cancer type
MET:V1110I,H1112R,M1268T,R988C,T1010I	MUT		Responsive	MET (V1110I,H1112R,M1268T,R988C,T1010I)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	MET		CANCER	PMID:17483355		chr7:g.116411990C>T	c.3029C>T	MET:T1010I	CSQN=Missense;reference_codon=ACT;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.116411990_116411991delCTinsTC,chr7:g.116411990_116411991delCTinsTA;aliases=ENSP00000317272;source=Ensembl	inside_[cds_in_exon_14]	+	ENST00000318493	Any cancer type
MET:Y1230C;Y1235D	MUT		Resistant	MET (Y1230C;Y1235D)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	MET		CANCER	PMID:17483355									Any cancer type
MLL2:.	MUT		Responsive	MLL2 oncogenic mutation	RDientsmann	Bicalutamide	AR inhibitor	Bicalutamide (AR inhibitor)		Pre-clinical	MLL2		LUSC	PMID:27397505									Lung squamous cell
MPL:W515F	MUT		Responsive	MPL (W515F)	RDientsmann	[]	[JAK inhibitor]	JAK inhibitors		Pre-clinical	MPL		MDPS	PMID:16834459		chr1:g.43815009_43815010delGGinsTT	c.1544_1545delGGinsTT	MPL:W515F	CSQN=Missense;reference_codon=TGG;candidate_codons=TTT,TTC;candidate_mnv_variants=chr1:g.43815009_43815010delGGinsTC;aliases=ENSP00000361548;source=Ensembl	inside_[cds_in_exon_10]	+	ENST00000372470	Myelodisplasic proliferative syndrome
MSH3:.	MUT		Responsive	MSH3 oncogenic mutation	RDientsmann	[]	[DNA-PKc inhibitor]	DNA-PKc inhibitors		Pre-clinical	MSH3		CANCER	PMID:24556366									Any cancer type
MTOR:F2108L	MUT		Responsive	MTOR (F2108L)	RDientsmann	[]	[MTOR kinase inhibitor]	MTOR kinase inhibitors		Pre-clinical	MTOR		CANCER	PMID:25295501		chr1:g.11187096A>G	c.6322T>C	MTOR:F2108L	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr1:g.11187094G>T,chr1:g.11187094G>C;candidate_mnv_variants=chr1:g.11187094_11187096delGAAinsAAG,chr1:g.11187094_11187096delGAAinsCAG,chr1:g.11187094_11187096delGAAinsTAG;aliases=ENSP00000354558;source=Ensembl	inside_[cds_in_exon_45]	-	ENST00000361445	Any cancer type
MTOR:E2014K,E2419K,N1421D	MUT		Responsive	MTOR (E2014K,E2419K,N1421D)	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	MTOR		BLCA	PMID:24625776		chr1:g.11187857C>T	c.6040G>A	MTOR:E2014K	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr1:g.11187855_11187857delCTCinsTTT;aliases=ENSP00000354558;source=Ensembl	inside_[cds_in_exon_44]	-	ENST00000361445	Bladder
MTOR:E2014K,E2419K,N1421D	MUT		Responsive	MTOR (E2014K,E2419K,N1421D)	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	MTOR		BLCA	PMID:24625776		chr1:g.11174420C>T	c.7255G>A	MTOR:E2419K	CSQN=Missense;reference_codon=GAA;candidate_codons=AAG,AAA;candidate_mnv_variants=chr1:g.11174418_11174420delTTCinsCTT;aliases=ENSP00000354558;source=Ensembl	inside_[cds_in_exon_53]	-	ENST00000361445	Bladder
MTOR:E2014K,E2419K,N1421D	MUT		Responsive	MTOR (E2014K,E2419K,N1421D)	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	MTOR		BLCA	PMID:24625776		chr1:g.11227567T>C	c.4261A>G	MTOR:N1421D	CSQN=Missense;reference_codon=AAT;candidate_codons=GAC,GAT;candidate_mnv_variants=chr1:g.11227565_11227567delATTinsGTC;aliases=ENSP00000354558;source=Ensembl	inside_[cds_in_exon_29]	-	ENST00000361445	Bladder
MTOR:F2108L	MUT		Resistant	MTOR (F2108L)	DTamborero;RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	MTOR		THCA	PMID:25295501		chr1:g.11187096A>G	c.6322T>C	MTOR:F2108L	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr1:g.11187094G>T,chr1:g.11187094G>C;candidate_mnv_variants=chr1:g.11187094_11187096delGAAinsAAG,chr1:g.11187094_11187096delGAAinsCAG,chr1:g.11187094_11187096delGAAinsTAG;aliases=ENSP00000354558;source=Ensembl	inside_[cds_in_exon_45]	-	ENST00000361445	Thyroid carcinoma
MTOR:I1973F	MUT		Responsive	MTOR (I1973F)	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	MTOR		AS;R	ASCO 2015 (abstr 11010);PMID:26859683		chr1:g.11188177T>A	c.5917A>T	MTOR:I1973F	CSQN=Missense;reference_codon=ATC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr1:g.11188175_11188177delGATinsAAA;aliases=ENSP00000354558;source=Ensembl	inside_[cds_in_exon_43]	-	ENST00000361445	Angiosarcoma;Renal
MTOR:K1771R	MUT		Responsive	MTOR (K1771R)	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	MTOR		ST;AG	ASCO 2015 (abstr 11010);PMID:26859683		chr1:g.11193189T>C	c.5312A>G	MTOR:K1771R	CSQN=Missense;reference_codon=AAA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr1:g.11193188_11193189delTTinsCC,chr1:g.11193189_11193190delTTinsCG,chr1:g.11193188_11193190delTTTinsGCG,chr1:g.11193188_11193190delTTTinsCCG,chr1:g.11193188_11193190delTTTinsACG;aliases=ENSP00000354558;source=Ensembl	inside_[cds_in_exon_38]	-	ENST00000361445	Stomach;Anaplastic oligodendroglioma
MTOR:N1421D	MUT		Responsive	MTOR (N1421D)	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	MTOR		ST	PMID:26859683		chr1:g.11227567T>C	c.4261A>G	MTOR:N1421D	CSQN=Missense;reference_codon=AAT;candidate_codons=GAC,GAT;candidate_mnv_variants=chr1:g.11227565_11227567delATTinsGTC;aliases=ENSP00000354558;source=Ensembl	inside_[cds_in_exon_29]	-	ENST00000361445	Stomach
MTOR:Q2223K	MUT		Responsive	MTOR (Q2223K)	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	MTOR		R	PMID:24622468		chr1:g.11182179G>T	c.6667C>A	MTOR:Q2223K	CSQN=Missense;reference_codon=CAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr1:g.11182177_11182179delCTGinsTTT;aliases=ENSP00000354558;source=Ensembl	inside_[cds_in_exon_48]	-	ENST00000361445	Renal
MTOR:L1460P,S2215Y,R2505P	MUT		Responsive	MTOR (L1460P,S2215Y,R2505P)	RDientsmann	Sirolimus	MTOR inhibitor	Sirolimus (MTOR inhibitor)		Pre-clinical	MTOR		CANCER	PMID:24631838		chr1:g.11217299A>G	c.4379T>C	MTOR:L1460P	CSQN=Missense;reference_codon=CTT;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr1:g.11217298_11217299delAAinsCG,chr1:g.11217298_11217299delAAinsTG,chr1:g.11217298_11217299delAAinsGG;aliases=ENSP00000354558;source=Ensembl	inside_[cds_in_exon_30]	-	ENST00000361445	Any cancer type
MTOR:L1460P,S2215Y,R2505P	MUT		Responsive	MTOR (L1460P,S2215Y,R2505P)	RDientsmann	Sirolimus	MTOR inhibitor	Sirolimus (MTOR inhibitor)		Pre-clinical	MTOR		CANCER	PMID:24631838		chr1:g.11184573G>T	c.6644C>A	MTOR:S2215Y	CSQN=Missense;reference_codon=TCT;candidate_codons=TAT,TAC;candidate_mnv_variants=chr1:g.11184572_11184573delAGinsGT;aliases=ENSP00000354558;source=Ensembl	inside_[cds_in_exon_47]	-	ENST00000361445	Any cancer type
MTOR:L1460P,S2215Y,R2505P	MUT		Responsive	MTOR (L1460P,S2215Y,R2505P)	RDientsmann	Sirolimus	MTOR inhibitor	Sirolimus (MTOR inhibitor)		Pre-clinical	MTOR		CANCER	PMID:24631838		chr1:g.11169361C>G	c.7514G>C	MTOR:R2505P	CSQN=Missense;reference_codon=CGA;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr1:g.11169360_11169361delTCinsAG,chr1:g.11169360_11169361delTCinsCG,chr1:g.11169360_11169361delTCinsGG;aliases=ENSP00000354558;source=Ensembl	inside_[cds_in_exon_56]	-	ENST00000361445	Any cancer type
MYD88:L265P	MUT		Responsive	MYD88 (L265P)	RDientsmann	Ibrutinib	BTK inhibitor	Ibrutinib (BTK inhibitor)		FDA guidelines	MYD88		WM	PMID:25853747				MYD88:L265P					Waldenström macroglobulinemia
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	[]	[AURK inhibitor]	AURK inhibitors		Pre-clinical	NF1		MPN	PMID:24373973									Malignant peripheral nerve sheat tumor
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	[]	[BRD4 inhibitor]	BRD4 inhibitors		Pre-clinical	NF1		MPN	PMID:24373973									Malignant peripheral nerve sheat tumor
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	[]	[KIT inhibitor;MTOR inhibitor]	KIT inhibitor + MTOR inhibitors		Pre-clinical	NF1		MPN	PMID:24718867									Malignant peripheral nerve sheat tumor
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	NF1		MPN	PMID:23221341									Malignant peripheral nerve sheat tumor
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	NF1		G;LK	PMID:22573716;PMID:19727076									Glioma;Leukemia
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	[]	[MTOR inhibitor;HSP90 inhibitor]	MTOR inhibitor + HSP90 inhibitors		Pre-clinical	NF1		MPN	PMID:21907929									Malignant peripheral nerve sheat tumor
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	NF1		G;MPN;LK	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877									Glioma;Malignant peripheral nerve sheat tumor;Leukemia
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	[]	[Pan-RAF inhibitor;MEK inhibitor]	Pan-RAF inhibitor + MEK inhibitors		Pre-clinical	NF1		CM	PMID:26351322									Cutaneous melanoma
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	[]	[PD1 Ab inhibitor]	PD1 Ab inhibitors		Early trials	NF1		CM	ASCO 2016 (abstr 105)									Cutaneous melanoma
NF1:.	MUT		Resistant	NF1 oncogenic mutation	RDientsmann	[]	[Retinoic Acid]	Retinoic Acids		Pre-clinical	NF1		NB	PMID:20655465									Neuroblastoma
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	Bevacizumab	VEGFR mAb inhibitor	Bevacizumab (VEGFR mAb inhibitor)		Case report	NF1		G	PMID:24232489;PMID:2485933									Glioma
NF1:.	MUT		No Responsive	NF1 oncogenic mutation	RDientsmann	Cediranib	ALK inhibitor	Cediranib (ALK inhibitor)		Early trials	NF1		PLEN	NCT00326872									Plexiform neurofibroma
NF1:.	MUT		Resistant	NF1 oncogenic mutation	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	NF1		L	PMID:24296828									Lung
NF1:.	MUT		Resistant	NF1 oncogenic mutation	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)		Pre-clinical	NF1		L	PMID:24535670									Lung
NF1:.	MUT		No Responsive	NF1 oncogenic mutation	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Early trials	NF1		MPN	NCT01365468									Malignant peripheral nerve sheat tumor
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	NF1		HNC;SG	PMID:26859683;ASCO 2016 (abstr e17557)									Head an neck;Salivary glands
NF1:.	MUT		Responsive	NF1 oncogenic mutation	MMartínez	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)	Approved	Late trials	NF1		NF	NCT01365468	Indirect								Neurofibroma
NF1:D1644A	MUT		Responsive	NF1 (D1644A)	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	NF1		HNC	ASCO 2015 (abstr 11010);PMID:26859683		chr17:g.29652933A>C	c.4931A>C	NF1:D1644A	CSQN=Missense;reference_codon=GAC;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr17:g.29652933_29652934delACinsCA,chr17:g.29652933_29652934delACinsCG,chr17:g.29652933_29652934delACinsCT;aliases=ENSP00000351015;source=Ensembl	inside_[cds_in_exon_37]	+	ENST00000358273	Head an neck
NF1:.	MUT		No Responsive	NF1 oncogenic mutation	RDientsmann	Everolimus;Bevacizumab	MTOR inhibitor;VEGFR mAb inhibitor	Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)		Early trials	NF1		MPN	ASCO 2016 (abstr 11053)									Malignant peripheral nerve sheat tumor
NF1:.	MUT		No Responsive	NF1 oncogenic mutation	RDientsmann	Everolimus;Erlotinib	MTOR inhibitor;EGFR inhibitor 1st gen	Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)		Case report	NF1		G	PMID:24634382									Glioma
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	Everolimus;Pazopanib	MTOR inhibitor;VEGFR inhibitor	Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)		Case report	NF1		HC	PMID:24931142									Hepatic carcinoma
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Early trials	NF1		PLEN	PMID:23099009									Plexiform neurofibroma
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	NF1		PLEN;MPN	PMID:24173684									Plexiform neurofibroma;Malignant peripheral nerve sheat tumor
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	PLX3397	Pan-TK inhibitor	PLX3397 (Pan-TK inhibitor)		Pre-clinical	NF1		PLEN	PMID:23099891									Plexiform neurofibroma
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	Selumetinib	MEK inhibitor	Selumetinib (MEK inhibitor)		Early trials	NF1		PLEN	ASCO 2014 (abstr 10018)									Plexiform neurofibroma
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	Sirolimus	MTOR inhibitor	Sirolimus (MTOR inhibitor)		Early trials	NF1		PLEN	PMID:25314964									Plexiform neurofibroma
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	Sirolimus;Erlotinib	MTOR inhibitor;EGFR inhibitor 1st gen	Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)		Case report	NF1		G	PMID:22434731									Glioma
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	Sorafenib;Sirolimus	Pan-TK inhibitor;MTOR inhibitor	Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)		Pre-clinical	NF1		MPN	PMID:25810463									Malignant peripheral nerve sheat tumor
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	Tamoxifen	Hormonal therapy	Tamoxifen (Hormonal therapy)		Pre-clinical	NF1		MPN	PMID:21075781									Malignant peripheral nerve sheat tumor
NF1:.	MUT		No Responsive	NF1 oncogenic mutation	RDientsmann	Tipifarnib	Farnesyltransferase inhibitor	Tipifarnib (Farnesyltransferase inhibitor)		Early trials	NF1		PLEN	PMID:24500418									Plexiform neurofibroma
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	Trametinib	MEK inhibitor	Trametinib (MEK inhibitor)		Case report	NF1		G	PMID:26936308									Glioma
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	Trametinib	MEK inhibitor	Trametinib (MEK inhibitor)		Pre-clinical	NF1		CM	PMID:24576830;PMID:2524381									Cutaneous melanoma
NF1:.	MUT		No Responsive	NF1 oncogenic mutation	RDientsmann	Trametinib	MEK inhibitor	Trametinib (MEK inhibitor)		Case report	NF1		OS	PMID:26325560									Osteosarcoma
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	Vinblastine	Chemotherapy	Vinblastine (Chemotherapy)		Early trials	NF1		G	ASCO 2016 (abstr 2019)									Glioma
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	Vinblastine;Nilotinib	Chemotherapy;BCR-ABL inhibitor 2nd gen	Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)		Case report	NF1		G	ASCO 2016 (abstr 10555)									Glioma
NF2:.	MUT		Responsive	NF2 oncogenic mutation	RDientsmann	[]	[FAK inhibitor]	FAK inhibitors		Early trials	NF2		MESO	ENA 2012 (abstr 610)									Mesothelioma
NF2:.	MUT		Responsive	NF2 oncogenic mutation	RDientsmann	[]	[FAK inhibitor]	FAK inhibitors		Pre-clinical	NF2		MESO;OV	PMID:24848258;PMID:24786638									Mesothelioma;Ovary
NF2:.	MUT		Responsive	NF2 oncogenic mutation	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Pre-clinical	NF2		MEN	PMID:23714726									Meningioma
NF2:.	MUT		Responsive	NF2 oncogenic mutation	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	NF2		TH	PMID:26359368									Thyroid
NF2:.	MUT		Responsive	NF2 oncogenic mutation	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	NF2		MEN	PMID:19451225;PMID:2242646									Meningioma
NF2:.	MUT		Responsive	NF2 oncogenic mutation	RDientsmann	[]	[PAK inhibitor]	PAK inhibitors		Pre-clinical	NF2		SCHW;MEN	PMID:23960073;PMID:25596744									Schwannoma;Meningioma
NF2:.	MUT		Responsive	NF2 oncogenic mutation	RDientsmann	[]	[PDK1 inhibitor]	PDK1 inhibitors		Pre-clinical	NF2		SCHW	PMID:19359162									Schwannoma
NF2:.	MUT		Responsive	NF2 oncogenic mutation	RDientsmann	AR42	HDAC inhibitor	AR42 (HDAC inhibitor)		Pre-clinical	NF2		SCHW	PMID:21778190									Schwannoma
NF2:.	MUT		Responsive	NF2 oncogenic mutation	RDientsmann	AR42	HDAC inhibitor	AR42 (HDAC inhibitor)		Early trials	NF2		MEN	ASCO 2016 (abstr 2558)									Meningioma
NF2:.	MUT		Responsive	NF2 oncogenic mutation	RDientsmann	Bevacizumab	VEGFR mAb inhibitor	Bevacizumab (VEGFR mAb inhibitor)		Early trials	NF2		SCHW	PMID:19587327;PMID:22805104;PMID:26022982									Schwannoma
NF2:.	MUT		No Responsive	NF2 oncogenic mutation	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)		Early trials	NF2		SCHW	PMID:20736812									Schwannoma
NF2:.	MUT		Responsive	NF2 oncogenic mutation	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Early trials	NF2		SCHW	PMID:24311643;2556735									Schwannoma
NF2:.	MUT		Responsive	NF2 oncogenic mutation	RDientsmann	Everolimus;Octreotide	MTOR inhibitor;Somatostatin analog	Everolimus + Octreotide (MTOR inhibitor + Somatostatin analog)		Pre-clinical	NF2		MEN	PMID:26015296									Meningioma
NF2:.	MUT		Responsive	NF2 oncogenic mutation	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	NF2		SCHW	PMID:19509233;PMID:2290085									Schwannoma
NF2:.	MUT		Responsive	NF2 oncogenic mutation	RDientsmann;MMartínez	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Early trials	NF2		SCHW;NF	PMID:22844108;NCT00973739									Schwannoma;Neurofibroma
NF2:.	MUT		Responsive	NF2 oncogenic mutation	RDientsmann	Tensirolimus;Chemotherapy	MTOR inhibitor;Chemotherapy	Tensirolimus + Chemotherapy (MTOR inhibitor + Chemotherapy)		Case report	NF2		BRCA	PMID:25878190									Breast adenocarcinoma
NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2245-2536,::splice_acceptor_variant:2245-2536,::stop_gained:2245-2536,::stop_lost:2245-2536,::frameshift_variant:2245-2536	MUT		Responsive	NOTCH1 activating mutation in Cterm-PEST domain	RDientsmann	[]	[Gamma secretase inhibitor;CDK4 inhibitor]	Gamma secretase inhibitor + CDK4 inhibitors		Pre-clinical	NOTCH1		ALL	PMID:19318552									Acute lymphoblastic leukemia
NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2245-2536,::splice_acceptor_variant:2245-2536,::stop_gained:2245-2536,::stop_lost:2245-2536,::frameshift_variant:2245-2536	MUT		Responsive	NOTCH1 activating mutation in Cterm-PEST domain	RDientsmann	[]	[Gamma secretase inhibitor;MTOR inhibitor]	Gamma secretase inhibitor + MTOR inhibitors		Pre-clinical	NOTCH1		ALL	PMID:19246562									Acute lymphoblastic leukemia
NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2245-2536,::splice_acceptor_variant:2245-2536,::stop_gained:2245-2536,::stop_lost:2245-2536,::frameshift_variant:2245-2536	MUT		Responsive	NOTCH1 activating mutation in Cterm-PEST domain	RDientsmann	[]	[Gamma secretase inhibitor]	Gamma secretase inhibitors		Early trials	NOTCH1		ALL	ASCO 2006 (abstr 6585)									Acute lymphoblastic leukemia
NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2245-2536,::splice_acceptor_variant:2245-2536,::stop_gained:2245-2536,::stop_lost:2245-2536,::frameshift_variant:2245-2536	MUT		Responsive	NOTCH1 activating mutation in Cterm-PEST domain	RDientsmann	[]	[Gamma secretase inhibitor]	Gamma secretase inhibitors		Pre-clinical	NOTCH1		ALL	PMID:15472075;PMID:19778842;PMID:22510873;PMID:23001755									Acute lymphoblastic leukemia
NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2245-2536,::splice_acceptor_variant:2245-2536,::stop_gained:2245-2536,::stop_lost:2245-2536,::frameshift_variant:2245-2536	MUT		Responsive	NOTCH1 activating mutation in Cterm-PEST domain	RDientsmann	[]	[Gamma secretase inhibitor]	Gamma secretase inhibitors		Pre-clinical	NOTCH1		BRCA	PMID:25564152									Breast adenocarcinoma
NOTCH1:.	MUT		Responsive	NOTCH1 oncogenic mutation	RDientsmann	[]	[Gamma secretase inhibitor]	Gamma secretase inhibitors		Pre-clinical	NOTCH1		MCL	PMID:22210878									Mantle cell lymphoma
NOTCH1::consequence::splice_donor_variant:2245-2536,::splice_acceptor_variant:2245-2536,::stop_gained:2245-2536,::stop_lost:2245-2536,::frameshift_variant:2245-2536	MUT		Responsive	NOTCH1 splice donor variant (2245-2536),splice acceptor variant (2245-2536),stop gained (2245-2536),stop lost (2245-2536),frameshift variant (2245-2536)	RDientsmann	[]	[NOTCH1 inhibitor]	NOTCH1 inhibitors		Case report	NOTCH1		ADCC	PMID:27870570									Adenoid cystic carcinoma
NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2245-2536,::splice_acceptor_variant:2245-2536,::stop_gained:2245-2536,::stop_lost:2245-2536,::frameshift_variant:2245-2536	MUT		Responsive	NOTCH1 activating mutation in Cterm-PEST domain	ECampo	[Ro4929097,Pf-03084014,Mk-0752]	[Gamma secretase inhibitor]	Gamma secretase inhibitors (Ro4929097,Pf-03084014,Mk-0752,etc)	Clinical Trials	Early trials	NOTCH1		CANCER	NCT01703572;NCT01778439; NCT01098344; NCT01981551	Indirect								Any cancer type
NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2245-2536,::splice_acceptor_variant:2245-2536,::stop_gained:2245-2536,::stop_lost:2245-2536,::frameshift_variant:2245-2536	MUT		Responsive	NOTCH1 activating mutation in Cterm-PEST domain	ECampo	OMP-52M51	NOTCH1 inhibitor	OMP-52M51 (NOTCH1 inhibitor)	Clinical Trials	Early trials	NOTCH1		CANCER	NCT01703572;NCT01778439	Direct								Any cancer type
NOTCH2::consequence::splice_donor_variant:2381-2420,::splice_acceptor_variant:2381-2420,::stop_gained:2381-2420,::stop_lost:2381-2420,::frameshift_variant:2381-2420	MUT		Responsive	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	KKarube;RDientsmann	Mk-0752	Gamma secretase inhibitor	Mk-0752 (Gamma secretase inhibitor)	Clinical Trials	Early trials	NOTCH2		BRCA;AML;ALL	PMID:25564152	Direct								Breast adenocarcinoma;Acute myeloid leukemia;Acute lymphoblastic leukemia
NOTCH2::consequence::splice_donor_variant:2381-2420,::splice_acceptor_variant:2381-2420,::stop_gained:2381-2420,::stop_lost:2381-2420,::frameshift_variant:2381-2420	MUT		Responsive	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	ECampo	OMP-59R5	NOTCH2 inhibitor	OMP-59R5 (NOTCH2 inhibitor)	Clinical Trials	Early trials	NOTCH2		SOLID	NCT01859741;NCT01277146	Direct								Solid tumors
NPM1:.	MUT		Responsive	NPM1 oncogenic mutation	RDientsmann	[]	[DOT1L inhibitors;MLL1 inhibitors]	DOT1L inhibitors + MLL1 inhibitors		Pre-clinical	NPM1		AML	PMID:27535106									Acute myeloid leukemia
NPM1:.	MUT		Responsive	NPM1 oncogenic mutation	RDientsmann	Daunorubicin	Chemotherapy	Daunorubicin (Chemotherapy)	Approved	FDA guidelines	NPM1		AML	PMID:22417203									Acute myeloid leukemia
NRAS:Q61.	MUT		Resistant	NRAS (Q61)	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Early trials	NRAS		CM	PMID:23569304;PMID:24265153									Cutaneous melanoma
NRAS:.	MUT		Responsive	NRAS oncogenic mutation	DTamborero;CRubio-Perez;RDientsmann	[]	[CDK4/6 inhibitor;MEK inhibitor]	CDK4/6 inhibitor + MEK inhibitors	Approved	Early trials	NRAS		CM	PMID:26658964;NCT01781572;NCT02065063;NCT02022982;ASCO 2014 (abstr 9009)	Indirect								Cutaneous melanoma
NRAS:G12C	MUT		Responsive	NRAS (G12C)	RDientsmann	[]	[ERK inhibitor]	ERK inhibitors		Pre-clinical	NRAS		CANCER	PMID:23614898		chr1:g.115258748C>A	c.34G>T	NRAS:G12C	CSQN=Missense;reference_codon=GGT;candidate_codons=TGT,TGC;candidate_mnv_variants=chr1:g.115258746_115258748delACCinsGCA;aliases=ENSP00000358548;source=Ensembl	inside_[cds_in_exon_2]	-	ENST00000369535	Any cancer type
NRAS:.	MUT		Responsive	NRAS oncogenic mutation	RDientsmann	[]	[ERK inhibitor]	ERK inhibitors		Case report	NRAS		CM	ASCO 2017 (abstr 2508)									Cutaneous melanoma
NRAS:.	MUT		Responsive	NRAS oncogenic mutation	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Pre-clinical	NRAS		CM	PMID:23538902									Cutaneous melanoma
NRAS:.	MUT		Responsive	NRAS oncogenic mutation	RDientsmann	[]	[MEK inhibitor +/- PI3K pathway inhibitor]	MEK inhibitor +/- PI3K pathway inhibitors		Pre-clinical	NRAS		COREAD	PMID:23274911;PMID:22392911									Colorectal adenocarcinoma
NRAS:.	MUT		Responsive	NRAS oncogenic mutation	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	NRAS		AML;LUAD;ALL	PMID:22507781;PMID:23515407;PMID:18701506									Acute myeloid leukemia;Lung adenocarcinoma;Acute lymphoblastic leukemia
NRAS:Q61.	MUT		Responsive	NRAS (Q61)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Late trials	NRAS		CM	PMID:23414587,ASCO 2016 (abstr 9500)									Cutaneous melanoma
NRAS:.	MUT		Responsive	NRAS oncogenic mutation	RDientsmann	[]	[Pan-RAF inhibitor]	Pan-RAF inhibitors		Case report	NRAS		CM	ESMO 2015 (abstract 300);AACR 2017 (abstr CT002)									Cutaneous melanoma
NRAS:.	MUT		Responsive	NRAS oncogenic mutation	RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Pre-clinical	NRAS		MYMA	PMID:22985491									Myeloma
NRAS:.	MUT		Resistant	NRAS oncogenic mutation	RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)	Approved	NCCN guidelines	NRAS		COREAD	PMID:24024839;PMID:20619739;PMID:23325582									Colorectal adenocarcinoma
NRAS:.	MUT		Resistant	NRAS oncogenic mutation	RDientsmann	Panitumumab	EGFR mAb inhibitor	Panitumumab (EGFR mAb inhibitor)	Approved	NCCN guidelines	NRAS		COREAD	PMID:24024839;PMID:20619739;PMID:23325582									Colorectal adenocarcinoma
NRAS:.	MUT		Responsive	NRAS oncogenic mutation	RDientsmann	Sorafenib;MEK inhibitor	Pan-TK inhibitor;MEK inhibitor	Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)		Early Trials,Case Report	NRAS		HC	PMID:25294897									Hepatic carcinoma
NRAS:.	MUT		Resistant	NRAS oncogenic mutation	DTamborero	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)		Pre-clinical	NRAS		CM	PMID:20179705									Cutaneous melanoma
NTRK1:G595R,G667C	MUT		Resistant	NTRK1 (G595R,G667C)	RDientsmann	[Entrectinib]	[Pan-TK inhibitor]	Pan-TK inhibitors (Entrectinib,etc)		Case report	NTRK1		COREAD	PMID:26546295		chr1:g.156846342G>A	c.1783G>A	NTRK1:G595R	CSQN=Missense;reference_codon=GGG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr1:g.156846342G>C;candidate_mnv_variants=chr1:g.156846342_156846344delGGGinsAGA,chr1:g.156846342_156846344delGGGinsCGA,chr1:g.156846342_156846344delGGGinsCGC,chr1:g.156846342_156846344delGGGinsCGT;aliases=ENSP00000431418;source=Ensembl	inside_[cds_in_exon_14]	+	ENST00000524377	Colorectal adenocarcinoma
NTRK1:G595R,G667C	MUT		Resistant	NTRK1 (G595R,G667C)	RDientsmann	[Entrectinib]	[Pan-TK inhibitor]	Pan-TK inhibitors (Entrectinib,etc)		Case report	NTRK1		COREAD	PMID:26546295		chr1:g.156849107G>T	c.1999G>T	NTRK1:G667C	CSQN=Missense;reference_codon=GGT;candidate_codons=TGT,TGC;candidate_mnv_variants=chr1:g.156849107_156849109delGGTinsTGC;aliases=ENSP00000431418;source=Ensembl	inside_[cds_in_exon_15]	+	ENST00000524377	Colorectal adenocarcinoma
PALB2:.	MUT		Responsive	PALB2 oncogenic mutation	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Early trials	PALB2		PRAD	AACR 2015 (abstr CT322);PMID:26510020									Prostate adenocarcinoma
PALB2:.	MUT		Responsive	PALB2 oncogenic mutation	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Pre-clinical	PALB2		PA	PMID:25263539;NCT01585805									Pancreas
PALB2:.	MUT		Responsive	PALB2 oncogenic mutation	RDientsmann	Mytomycin C	Chemotherapy	Mytomycin C (Chemotherapy)		Case report	PALB2		PA	PMID:21135251									Pancreas
PALB2:.	MUT		Responsive	PALB2 oncogenic mutation	RDientsmann	Platinum Agent	Chemotherapy	Platinum Agent (Chemotherapy)		Case report	PALB2		PA	PMID:25719666									Pancreas
PBRM1:.	MUT		Responsive	PBRM1 oncogenic mutation	RDientsmann	[]	[EZH2 inhibitor]	EZH2 inhibitors		Pre-clinical	PBRM1		CANCER	PMID:26552009									Any cancer type
PDGFRA:D842V	MUT		Responsive	PDGFRA (D842V)	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Pre-clinical	PDGFRA		GIST	PMID:18794084		chr4:g.55152093A>T	c.2525A>T	PDGFRA:D842V	CSQN=Missense;reference_codon=GAC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr4:g.55152093_55152094delACinsTA,chr4:g.55152093_55152094delACinsTG,chr4:g.55152093_55152094delACinsTT;aliases=ENSP00000257290;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000257290	Gastrointestinal stromal
PDGFRA:D842V	MUT		Responsive	PDGFRA (D842V)	RDientsmann	Crenolanib	FLT3 inhibitor	Crenolanib (FLT3 inhibitor)		Early trials	PDGFRA		GIST	ASCO 2016 (abstr 11010)		chr4:g.55152093A>T	c.2525A>T	PDGFRA:D842V	CSQN=Missense;reference_codon=GAC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr4:g.55152093_55152094delACinsTA,chr4:g.55152093_55152094delACinsTG,chr4:g.55152093_55152094delACinsTT;aliases=ENSP00000257290;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000257290	Gastrointestinal stromal
PDGFRA:V658A,P577S,R841K,H845Y,G853D	MUT		Responsive	PDGFRA (V658A,P577S,R841K,H845Y,G853D)	RDientsmann	Crenolanib	FLT3 inhibitor	Crenolanib (FLT3 inhibitor)		Pre-clinical	PDGFRA		CM	PMID:24132921		chr4:g.55144144T>C	c.1973T>C	PDGFRA:V658A	CSQN=Missense;reference_codon=GTA;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr4:g.55144144_55144145delTAinsCC,chr4:g.55144144_55144145delTAinsCG,chr4:g.55144144_55144145delTAinsCT;aliases=ENSP00000257290;source=Ensembl	inside_[cds_in_exon_14]	+	ENST00000257290	Cutaneous melanoma
PDGFRA:V658A,P577S,R841K,H845Y,G853D	MUT		Responsive	PDGFRA (V658A,P577S,R841K,H845Y,G853D)	RDientsmann	Crenolanib	FLT3 inhibitor	Crenolanib (FLT3 inhibitor)		Pre-clinical	PDGFRA		CM	PMID:24132921		chr4:g.55141083C>T	c.1729C>T	PDGFRA:P577S	CSQN=Missense;reference_codon=CCG;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr4:g.55141083_55141085delCCGinsTCT,chr4:g.55141083_55141085delCCGinsTCC,chr4:g.55141083_55141085delCCGinsTCA,chr4:g.55141083_55141085delCCGinsAGC,chr4:g.55141083_55141085delCCGinsAGT;aliases=ENSP00000257290;source=Ensembl	inside_[cds_in_exon_12]	+	ENST00000257290	Cutaneous melanoma
PDGFRA:V658A,P577S,R841K,H845Y,G853D	MUT		Responsive	PDGFRA (V658A,P577S,R841K,H845Y,G853D)	RDientsmann	Crenolanib	FLT3 inhibitor	Crenolanib (FLT3 inhibitor)		Pre-clinical	PDGFRA		CM	PMID:24132921		chr4:g.55152090G>A	c.2522G>A	PDGFRA:R841K	CSQN=Missense;reference_codon=AGA;candidate_codons=AAG,AAA;candidate_mnv_variants=chr4:g.55152090_55152091delGAinsAG;aliases=ENSP00000257290;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000257290	Cutaneous melanoma
PDGFRA:V658A,P577S,R841K,H845Y,G853D	MUT		Responsive	PDGFRA (V658A,P577S,R841K,H845Y,G853D)	RDientsmann	Crenolanib	FLT3 inhibitor	Crenolanib (FLT3 inhibitor)		Pre-clinical	PDGFRA		CM	PMID:24132921		chr4:g.55152101C>T	c.2533C>T	PDGFRA:H845Y	CSQN=Missense;reference_codon=CAT;candidate_codons=TAT,TAC;candidate_mnv_variants=chr4:g.55152101_55152103delCATinsTAC;aliases=ENSP00000257290;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000257290	Cutaneous melanoma
PDGFRA:V658A,P577S,R841K,H845Y,G853D	MUT		Responsive	PDGFRA (V658A,P577S,R841K,H845Y,G853D)	RDientsmann	Crenolanib	FLT3 inhibitor	Crenolanib (FLT3 inhibitor)		Pre-clinical	PDGFRA		CM	PMID:24132921		chr4:g.55152126G>A	c.2558G>A	PDGFRA:G853D	CSQN=Missense;reference_codon=GGC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr4:g.55152126_55152127delGCinsAT;aliases=ENSP00000257290;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000257290	Cutaneous melanoma
PDGFRA::wildtype:.	MUT		Responsive	PDGFRA wildtype	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	PDGFRA		GIST	PMID:16397263									Gastrointestinal stromal
PDGFRA:D842V	MUT		Responsive	PDGFRA (D842V)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	PDGFRA		GIST	PMID:18794084		chr4:g.55152093A>T	c.2525A>T	PDGFRA:D842V	CSQN=Missense;reference_codon=GAC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr4:g.55152093_55152094delACinsTA,chr4:g.55152093_55152094delACinsTG,chr4:g.55152093_55152094delACinsTT;aliases=ENSP00000257290;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000257290	Gastrointestinal stromal
PDGFRA::consequence::inframe_deletion:I843.	MUT		Responsive	PDGFRA inframe deletion (I843)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	NCCN guidelines	PDGFRA		GIST	NCCN guidelines									Gastrointestinal stromal
PDGFRA::wildtype:.	MUT		Resistant	PDGFRA wildtype	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Late trials	PDGFRA		GIST	PMID:14645423;PMID:18955458									Gastrointestinal stromal
PDGFRA:552-596,631-668,814-854	MUT		Responsive	PDGFRA (552-596,631-668,814-854)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	NCCN guidelines	PDGFRA		GIST	NCCN guidelines									Gastrointestinal stromal
PDGFRA:D842V	MUT		Resistant	PDGFRA (D842V)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Late trials,Pre-clinical	PDGFRA		GIST	PMID:22718859;PMID:16638875		chr4:g.55152093A>T	c.2525A>T	PDGFRA:D842V	CSQN=Missense;reference_codon=GAC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr4:g.55152093_55152094delACinsTA,chr4:g.55152093_55152094delACinsTG,chr4:g.55152093_55152094delACinsTT;aliases=ENSP00000257290;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000257290	Gastrointestinal stromal
PDGFRA:P577S,R841K,H845Y,G853D	MUT		Responsive	PDGFRA (P577S,R841K,H845Y,G853D)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	PDGFRA		CM	PMID:24132921		chr4:g.55141083C>T	c.1729C>T	PDGFRA:P577S	CSQN=Missense;reference_codon=CCG;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr4:g.55141083_55141085delCCGinsTCT,chr4:g.55141083_55141085delCCGinsTCC,chr4:g.55141083_55141085delCCGinsTCA,chr4:g.55141083_55141085delCCGinsAGC,chr4:g.55141083_55141085delCCGinsAGT;aliases=ENSP00000257290;source=Ensembl	inside_[cds_in_exon_12]	+	ENST00000257290	Cutaneous melanoma
PDGFRA:P577S,R841K,H845Y,G853D	MUT		Responsive	PDGFRA (P577S,R841K,H845Y,G853D)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	PDGFRA		CM	PMID:24132921		chr4:g.55152090G>A	c.2522G>A	PDGFRA:R841K	CSQN=Missense;reference_codon=AGA;candidate_codons=AAG,AAA;candidate_mnv_variants=chr4:g.55152090_55152091delGAinsAG;aliases=ENSP00000257290;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000257290	Cutaneous melanoma
PDGFRA:P577S,R841K,H845Y,G853D	MUT		Responsive	PDGFRA (P577S,R841K,H845Y,G853D)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	PDGFRA		CM	PMID:24132921		chr4:g.55152101C>T	c.2533C>T	PDGFRA:H845Y	CSQN=Missense;reference_codon=CAT;candidate_codons=TAT,TAC;candidate_mnv_variants=chr4:g.55152101_55152103delCATinsTAC;aliases=ENSP00000257290;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000257290	Cutaneous melanoma
PDGFRA:P577S,R841K,H845Y,G853D	MUT		Responsive	PDGFRA (P577S,R841K,H845Y,G853D)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	PDGFRA		CM	PMID:24132921		chr4:g.55152126G>A	c.2558G>A	PDGFRA:G853D	CSQN=Missense;reference_codon=GGC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr4:g.55152126_55152127delGCinsAT;aliases=ENSP00000257290;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000257290	Cutaneous melanoma
PDGFRA:T674I	MUT		Resistant	PDGFRA (T674I)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Case report	PDGFRA		HES	PMID:12660384		chr4:g.55144547C>T	c.2021C>T	PDGFRA:T674I	CSQN=Missense;reference_codon=ACA;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr4:g.55144547_55144548delCAinsTC,chr4:g.55144547_55144548delCAinsTT;aliases=ENSP00000257290;source=Ensembl	inside_[cds_in_exon_15]	+	ENST00000257290	Hyper eosinophilic advanced snydrome
PDGFRA:552-596,631-668,814-854	MUT		Responsive	PDGFRA (552-596,631-668,814-854)	RDientsmann	Regorafenib	Pan-kinase inhibitor	Regorafenib (Pan-kinase inhibitor)	Approved	NCCN guidelines	PDGFRA		GIST	NCCN guidelines									Gastrointestinal stromal
PDGFRA::wildtype:.	MUT		Responsive	PDGFRA wildtype	RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Early trials	PDGFRA		GIST	ASCO 2011 (abstr 10009)									Gastrointestinal stromal
PDGFRA::wildtype:.	MUT		Responsive	PDGFRA wildtype	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Late trials	PDGFRA		GIST	PMID:18955458									Gastrointestinal stromal
PDGFRA:552-596,631-668,814-854	MUT		Responsive	PDGFRA (552-596,631-668,814-854)	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)	Approved	NCCN guidelines	PDGFRA		GIST	NCCN guidelines									Gastrointestinal stromal
PDGFRA:D842V	MUT		Resistant	PDGFRA (D842V)	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Late trials,Pre-clinical	PDGFRA		GIST	PMID:22718859;PMID:16638875		chr4:g.55152093A>T	c.2525A>T	PDGFRA:D842V	CSQN=Missense;reference_codon=GAC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr4:g.55152093_55152094delACinsTA,chr4:g.55152093_55152094delACinsTG,chr4:g.55152093_55152094delACinsTT;aliases=ENSP00000257290;source=Ensembl	inside_[cds_in_exon_18]	+	ENST00000257290	Gastrointestinal stromal
PIK3CA:.	MUT		Responsive	PIK3CA oncogenic mutation	RDientsmann	[]	[AKT inhibitor]	AKT inhibitors		Early trials	PIK3CA		BRCA	ASCO 2015 (abstr 2500)									Breast adenocarcinoma
PIK3CA:E545*	MUT		Resistant	PIK3CA (E545*)	DTamborero	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	PIK3CA		CM	PMC3936420		chr3:g.178936091G>T	c.1633G>T	PIK3CA:E545*	CSQN=Nonsense;reference_codon=GAG;candidate_codons=TAA,TAG,TGA;candidate_mnv_variants=chr3:g.178936091_178936093delGAGinsTAA,chr3:g.178936091_178936093delGAGinsTGA;aliases=ENSP00000263967;source=Ensembl	inside_[cds_in_exon_10]	+	ENST00000263967	Cutaneous melanoma
PIK3CA:.	MUT		Responsive	PIK3CA oncogenic mutation	RDientsmann	[]	[PI3K pathway inhibitor (alone or in combination)]	PI3K pathway inhibitor (alone or in combination)s		Pre-clinical	PIK3CA		L;COREAD	PMID:23136191;PMID:23475782;PMID:22392911									Lung;Colorectal adenocarcinoma
PIK3CA:.	MUT		Responsive	PIK3CA oncogenic mutation	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Case report	PIK3CA		BLCA;HNC;L	ASCO 2015 (abstr 2516);ASCO 2015 (abstr 6049);ESMO 2013 (abstr P017)									Bladder;Head an neck;Lung
PIK3CA:.	MUT		Responsive	PIK3CA oncogenic mutation	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Early trials	PIK3CA		BRCA;OV;CESC;ED	PMID:22271473;PMID:27672108;AACR 2013 (abstr LB-66);PMID:25231405;ASCO 2013 (abstr 2531);ASCO 2014 (abstr 5513)									Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium
PIK3CA:.	MUT		Responsive	PIK3CA oncogenic mutation	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Case report	PIK3CA		HNSC	PMID:26787751;PMID:26763254									Head an neck squamous
PIK3CA:.	MUT		Responsive	PIK3CA oncogenic mutation	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Pre-clinical	PIK3CA		G;THCA	PMID:19671762;PMID:21289267									Glioma;Thyroid carcinoma
PIK3CA:.	MUT		No Responsive	PIK3CA oncogenic mutation	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Early trials	PIK3CA		L	ASCO 2017 (abstr 9054)									Lung
PIK3CA:.	MUT		Responsive	PIK3CA oncogenic mutation	RDientsmann	[]	[PIK3CA inhibitor]	PIK3CA inhibitors		Early trials	PIK3CA		BRCA	PMID:28331003									Breast adenocarcinoma
PIK3CA:.	MUT		Responsive	PIK3CA oncogenic mutation	RDientsmann	[]	[PIK3CA inhibitor]	PIK3CA inhibitors		Case report	PIK3CA		ST	ASCO 2015 (abstr 2501)									Stomach
PIK3CA:.	MUT		Resistant	PIK3CA oncogenic mutation	RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)		Late trials	PIK3CA		COREAD	PMID:19223544;PMID:20619739									Colorectal adenocarcinoma
PIK3CB:.	MUT		Responsive	PIK3CB oncogenic mutation	RDientsmann	[]	[AKT inhibitor]	AKT inhibitors		Pre-clinical	PIK3CB		HNSC	PMID:23619167									Head an neck squamous
PIK3CB:D1067Y	MUT		Responsive	PIK3CB (D1067Y)	RDientsmann	[]	[AKT inhibitor]	AKT inhibitors		Pre-clinical	PIK3CB		BRCA	PMID:26759240		chr3:g.138374245C>A	c.3199G>T	PIK3CB:D1067Y	CSQN=Missense;reference_codon=GAC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr3:g.138374243_138374245delGTCinsATA;aliases=ENSP00000418143;source=Ensembl	inside_[cds_in_exon_23]	-	ENST00000477593	Breast adenocarcinoma
PIK3CB:.	MUT		Responsive	PIK3CB oncogenic mutation	RDientsmann	[]	[MTORC1/2 inhibitor]	MTORC1/2 inhibitors		Pre-clinical	PIK3CB		HNSC	PMID:23619167									Head an neck squamous
PIK3CB:D1067Y	MUT		Responsive	PIK3CB (D1067Y)	RDientsmann	[]	[MTORC1/2 inhibitor]	MTORC1/2 inhibitors		Pre-clinical	PIK3CB		BRCA	PMID:26759240		chr3:g.138374245C>A	c.3199G>T	PIK3CB:D1067Y	CSQN=Missense;reference_codon=GAC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr3:g.138374243_138374245delGTCinsATA;aliases=ENSP00000418143;source=Ensembl	inside_[cds_in_exon_23]	-	ENST00000477593	Breast adenocarcinoma
PIK3CB:.	MUT		Responsive	PIK3CB oncogenic mutation	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Pre-clinical	PIK3CB		HNSC	PMID:23619167									Head an neck squamous
PIK3CB:D1067Y	MUT		Resistant	PIK3CB (D1067Y)	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Case report	PIK3CB		BRCA	PMID:26759240		chr3:g.138374245C>A	c.3199G>T	PIK3CB:D1067Y	CSQN=Missense;reference_codon=GAC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr3:g.138374243_138374245delGTCinsATA;aliases=ENSP00000418143;source=Ensembl	inside_[cds_in_exon_23]	-	ENST00000477593	Breast adenocarcinoma
PIK3R1:.	MUT		Responsive	PIK3R1 oncogenic mutation	RDientsmann	[]	[AKT inhibitor]	AKT inhibitors		Pre-clinical	PIK3R1		G	PMID:23166678									Glioma
PIK3R1:.	MUT		Responsive	PIK3R1 oncogenic mutation	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Case report	PIK3R1		ED	ASCO 2015 (abstr 11075)									Endometrium
PIK3R2:A171V,N561D	MUT		Responsive	PIK3R2 (A171V,N561D)	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	PIK3R2		ED	PMID:21984976;PMID:19962665		chr19:g.18271909C>T	c.512C>T	PIK3R2:A171V	CSQN=Missense;reference_codon=GCT;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr19:g.18271909_18271910delCTinsTA,chr19:g.18271909_18271910delCTinsTC,chr19:g.18271909_18271910delCTinsTG;aliases=ENSP00000222254;source=Ensembl	inside_[cds_in_exon_5]	+	ENST00000222254	Endometrium
PIK3R2:A171V,N561D	MUT		Responsive	PIK3R2 (A171V,N561D)	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	PIK3R2		ED	PMID:21984976;PMID:19962665		chr19:g.18278061A>G	c.1681A>G	PIK3R2:N561D	CSQN=Missense;reference_codon=AAC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr19:g.18278061_18278063delAACinsGAT;aliases=ENSP00000222254;source=Ensembl	inside_[cds_in_exon_13]	+	ENST00000222254	Endometrium
PLCG2:R665W,L845F	MUT		Resistant	PLCG2 (R665W,L845F)	RDientsmann	Ibrutinib	BTK inhibitor	Ibrutinib (BTK inhibitor)	Approved	Early trials	PLCG2		CLL	PMID:24869598		chr16:g.81946260C>T	c.1993C>T	PLCG2:R665W	CSQN=Missense;reference_codon=CGG;candidate_codons=TGG;aliases=ENSP00000352336;source=Ensembl	inside_[cds_in_exon_19]	+	ENST00000359376	Chronic lymphocytic leukemia
PLCG2:R665W,L845F	MUT		Resistant	PLCG2 (R665W,L845F)	RDientsmann	Ibrutinib	BTK inhibitor	Ibrutinib (BTK inhibitor)	Approved	Early trials	PLCG2		CLL	PMID:24869598		chr16:g.81962183A>T	c.2535A>T	PLCG2:L845F	CSQN=Missense;reference_codon=TTA;candidate_codons=TTT,TTC;candidate_snv_variants=chr16:g.81962183A>C;aliases=ENSP00000352336;source=Ensembl	inside_[cds_in_exon_24]	+	ENST00000359376	Chronic lymphocytic leukemia
POLE:268-471	MUT		Responsive	POLE (268-471)	RDientsmann	[]	[PD1 Ab inhibitor]	PD1 Ab inhibitors		Case report	POLE		G;ED	PMID:27001570;PMID:27683556;PMID:27159395									Glioma;Endometrium
POLE:.	MUT		Responsive	POLE oncogenic mutation	RDientsmann	[]	[PD1 Ab inhibitor]	PD1 Ab inhibitors		Case report	POLE		COREAD	PMID:28188185									Colorectal adenocarcinoma
PTCH1:.	MUT		Responsive	PTCH1 oncogenic mutation	DTamborero;RDientsmann	[]	[SMO inhibitor]	SMO inhibitors	Approved	Pre-clinical	PTCH1		MB	PMID:24651015 									Medulloblastoma
PTCH1:.	MUT		Responsive	PTCH1 oncogenic mutation	RDientsmann	Foretinib	MET inhibitor	Foretinib (MET inhibitor)		Pre-clinical	PTCH1		MB	PMID:25391241									Medulloblastoma
PTCH1:.	MUT		Responsive	PTCH1 oncogenic mutation	RDientsmann	Vismodegib	SHH inhibitor	Vismodegib (SHH inhibitor)	Approved	FDA guidelines	PTCH1		BCC;MB	PMID:19726763;PMID:19726761									Basal cell carcinoma;Medulloblastoma
PTEN:.	MUT		Responsive	PTEN oncogenic mutation	RDientsmann	[]	[AKT inhibitor]	AKT inhibitors		Case report	PTEN		PA	PMID:22025163									Pancreas
PTEN:.	MUT		Responsive	PTEN oncogenic mutation	RDientsmann	[]	[ATM inhibitor]	ATM inhibitors		Pre-clinical	PTEN		BRCA	PMID:27397505									Breast adenocarcinoma
PTEN:.	MUT		Resistant	PTEN oncogenic mutation	RDientsmann	[]	[EGFR mAb inhibitor]	EGFR mAb inhibitors		Late trials	PTEN		COREAD	PMID:21163703;PMID:19398573									Colorectal adenocarcinoma
PTEN:.	MUT		No Responsive	PTEN oncogenic mutation	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Early trials	PTEN		ED	PMID:21788564;PMID:23238879									Endometrium
PTEN:.	MUT		Responsive	PTEN oncogenic mutation	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Case report	PTEN		ED	PMID:21468130;PMID:20944090									Endometrium
PTEN:.	MUT		Responsive	PTEN oncogenic mutation	RDientsmann	[]	[PD1 Ab inhibitor]	PD1 Ab inhibitors		Early trials	PTEN		CM	PMID:26645196									Cutaneous melanoma
PTEN:.	MUT		Responsive	PTEN oncogenic mutation	RDientsmann	[]	[PI3K pathway inhibitor;AR antagonist]	PI3K pathway inhibitor + AR antagonists		Pre-clinical	PTEN		PRAD	PMID:21575859									Prostate adenocarcinoma
PTEN:.	MUT		Responsive	PTEN oncogenic mutation	RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Pre-clinical	PTEN		OV	PMID:21632463									Ovary
PTEN:.	MUT		Responsive	PTEN oncogenic mutation	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Pre-clinical	PTEN		TH;G;L;OV;BRCA;CANCER;ED	PMID:21289267;PMID:21325073;PMID:21191045;PMID:17804702;PMID:23136191;PMID:21632463;PMID:21673091;PMID:23287563;PMID:21998291;PMID:22662154;PMID:23085766;PMID:22932669									Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium
PTEN:.	MUT		Responsive	PTEN oncogenic mutation	RDientsmann	[]	[PIK3CB inhibitor]	PIK3CB inhibitors		Case report	PTEN		PRAD	ASCO 2014 (abstr 2514)									Prostate adenocarcinoma
PTEN:.	MUT		Responsive	PTEN oncogenic mutation	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Early trials	PTEN		PRAD	PMID:23582881									Prostate adenocarcinoma
PTEN:.	MUT		Responsive	PTEN oncogenic mutation	RDientsmann	Sirolimus	MTOR inhibitor	Sirolimus (MTOR inhibitor)		Early trials	PTEN		CANCER	ASCO 2013 (abstr 2532)									Any cancer type
PTPRD:.	MUT		Responsive	PTPRD oncogenic mutation	RDientsmann	[]	[IGF1R inhibitor]	IGF1R inhibitors		Case report	PTPRD		S	PMID:23800680									Sarcoma
RAD51C:.	MUT		Responsive	RAD51C oncogenic mutation	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Early trials	RAD51C		OV	ASCO 2015 (abstr 5508)									Ovary
RAD51C:.	MUT		Responsive	RAD51C oncogenic mutation	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Early trials	RAD51C		OV	ASCO 2015 (abstr 5508)									Ovary
RB1:.	MUT		Responsive	RB1 oncogenic mutation	RDientsmann	[]	[HDAC inhibitor]	HDAC inhibitors		Pre-clinical	RB1		RB	PMID:18483379									Retinoblastoma
RB1:.	MUT		Responsive	RB1 oncogenic mutation	RDientsmann	[]	[MDM2/MDMX inhibitor]	MDM2/MDMX inhibitors		Pre-clinical	RB1		RB	PMID:17080083;PMID:21515735									Retinoblastoma
RB1:.	MUT		Responsive	RB1 oncogenic mutation	ARodriguez-Vida;RDientsmann	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	Early trials	RB1	BLCA	BLCA	PMID:26238431	Indirect								Bladder
RET:C634W,M918T	MUT		Responsive	RET (C634W,M918T)	RDientsmann	[]	[RET inhibitor]	RET inhibitors		Pre-clinical	RET		TH	PMID:23056499		chr10:g.43609950C>G	c.1902C>G	RET:C634W	CSQN=Missense;reference_codon=TGC;candidate_codons=TGG;aliases=ENSP00000347942;source=Ensembl	inside_[cds_in_exon_11]	+	ENST00000355710	Thyroid
RET:C634W,M918T	MUT		Responsive	RET (C634W,M918T)	RDientsmann	[]	[RET inhibitor]	RET inhibitors		Pre-clinical	RET		TH	PMID:23056499		chr10:g.43617416T>C	c.2753T>C	RET:M918T	CSQN=Missense;reference_codon=ATG;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr10:g.43617416_43617417delTGinsCA,chr10:g.43617416_43617417delTGinsCT,chr10:g.43617416_43617417delTGinsCC;aliases=ENSP00000347942;source=Ensembl	inside_[cds_in_exon_16]	+	ENST00000355710	Thyroid
RET:C634W,M918T	MUT		Responsive	RET (C634W,M918T)	RDientsmann	Cabozantinib	Pan-kinase inhibitor	Cabozantinib (Pan-kinase inhibitor)		Pre-clinical	RET		TH	PMID:21470995		chr10:g.43609950C>G	c.1902C>G	RET:C634W	CSQN=Missense;reference_codon=TGC;candidate_codons=TGG;aliases=ENSP00000347942;source=Ensembl	inside_[cds_in_exon_11]	+	ENST00000355710	Thyroid
RET:C634W,M918T	MUT		Responsive	RET (C634W,M918T)	RDientsmann	Cabozantinib	Pan-kinase inhibitor	Cabozantinib (Pan-kinase inhibitor)		Pre-clinical	RET		TH	PMID:21470995		chr10:g.43617416T>C	c.2753T>C	RET:M918T	CSQN=Missense;reference_codon=ATG;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr10:g.43617416_43617417delTGinsCA,chr10:g.43617416_43617417delTGinsCT,chr10:g.43617416_43617417delTGinsCC;aliases=ENSP00000347942;source=Ensembl	inside_[cds_in_exon_16]	+	ENST00000355710	Thyroid
RET:I788N	MUT		Resistant	RET (I788N)	RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)		Pre-clinical	RET		LUAD	PMID:28615362		chr10:g.43613899T>A	c.2363T>A	RET:I788N	CSQN=Missense;reference_codon=ATC;candidate_codons=AAC,AAT;candidate_mnv_variants=chr10:g.43613899_43613900delTCinsAT;aliases=ENSP00000347942;source=Ensembl	inside_[cds_in_exon_13]	+	ENST00000355710	Lung adenocarcinoma
RET:C634W,M918T	MUT		Responsive	RET (C634W,M918T)	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Pre-clinical	RET		TH	PMID:21470995		chr10:g.43609950C>G	c.1902C>G	RET:C634W	CSQN=Missense;reference_codon=TGC;candidate_codons=TGG;aliases=ENSP00000347942;source=Ensembl	inside_[cds_in_exon_11]	+	ENST00000355710	Thyroid
RET:C634W,M918T	MUT		Responsive	RET (C634W,M918T)	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Pre-clinical	RET		TH	PMID:21470995		chr10:g.43617416T>C	c.2753T>C	RET:M918T	CSQN=Missense;reference_codon=ATG;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr10:g.43617416_43617417delTGinsCA,chr10:g.43617416_43617417delTGinsCT,chr10:g.43617416_43617417delTGinsCC;aliases=ENSP00000347942;source=Ensembl	inside_[cds_in_exon_16]	+	ENST00000355710	Thyroid
RET:.618.,.620.,.634.,.768.,.791.,.891.,.918.,C634W,M918T	MUT		Responsive	RET (618,620,634,768,791,891,918,C634W,M918T)	RDientsmann	Vandetanib	Pan-TK inhibitor	Vandetanib (Pan-TK inhibitor)	Approved	FDA guidelines	RET		THCA	PMID:20065189;PMID:22025146									Thyroid carcinoma
RNF43:.	MUT		Responsive	RNF43 oncogenic mutation	RDientsmann	[]	[Porcupine inhibitor]	Porcupine inhibitors		Case report	RNF43		COREAD	ENA 2015 (abstr C45)									Colorectal adenocarcinoma
ROS1:G2032R	MUT		Responsive	ROS1 (G2032R)	RDientsmann	Cabozantinib	Pan-kinase inhibitor	Cabozantinib (Pan-kinase inhibitor)		Pre-clinical	ROS1		LUAD	PMID:25351743		chr6:g.117638347C>T	c.6094G>A	ROS1:G2032R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr6:g.117638347C>G;candidate_mnv_variants=chr6:g.117638345_117638347delTCCinsCCT,chr6:g.117638345_117638347delTCCinsGCG,chr6:g.117638345_117638347delTCCinsCCG,chr6:g.117638345_117638347delTCCinsACG;aliases=ENSP00000357494;source=Ensembl	inside_[cds_in_exon_38]	-	ENST00000368508	Lung adenocarcinoma
ROS1:S1986Y,S1986F	MUT		Resistant	ROS1 (S1986Y,S1986F)	RDientsmann	Ceritinib	ALK inhibitor	Ceritinib (ALK inhibitor)		Case report	ROS1		LUAD	PMID:27401242		chr6:g.117639399G>T	c.5957C>A	ROS1:S1986Y	CSQN=Missense;reference_codon=TCC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr6:g.117639398_117639399delGGinsAT;aliases=ENSP00000357494;source=Ensembl	inside_[cds_in_exon_37]	-	ENST00000368508	Lung adenocarcinoma
ROS1:S1986Y,S1986F	MUT		Resistant	ROS1 (S1986Y,S1986F)	RDientsmann	Ceritinib	ALK inhibitor	Ceritinib (ALK inhibitor)		Case report	ROS1		LUAD	PMID:27401242		chr6:g.117639399G>A	c.5957C>T	ROS1:S1986F	CSQN=Missense;reference_codon=TCC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr6:g.117639398_117639399delGGinsAA;aliases=ENSP00000357494;source=Ensembl	inside_[cds_in_exon_37]	-	ENST00000368508	Lung adenocarcinoma
ROS1:G2032R	MUT		Resistant	ROS1 (G2032R)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)	Approved	Case report	ROS1		LUAD	PMID:23724914;PMID:25688157		chr6:g.117638347C>T	c.6094G>A	ROS1:G2032R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr6:g.117638347C>G;candidate_mnv_variants=chr6:g.117638345_117638347delTCCinsCCT,chr6:g.117638345_117638347delTCCinsGCG,chr6:g.117638345_117638347delTCCinsCCG,chr6:g.117638345_117638347delTCCinsACG;aliases=ENSP00000357494;source=Ensembl	inside_[cds_in_exon_38]	-	ENST00000368508	Lung adenocarcinoma
ROS1:S1986Y,S1986F	MUT		Resistant	ROS1 (S1986Y,S1986F)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ROS1		LUAD	PMID:27401242		chr6:g.117639399G>T	c.5957C>A	ROS1:S1986Y	CSQN=Missense;reference_codon=TCC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr6:g.117639398_117639399delGGinsAT;aliases=ENSP00000357494;source=Ensembl	inside_[cds_in_exon_37]	-	ENST00000368508	Lung adenocarcinoma
ROS1:S1986Y,S1986F	MUT		Resistant	ROS1 (S1986Y,S1986F)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ROS1		LUAD	PMID:27401242		chr6:g.117639399G>A	c.5957C>T	ROS1:S1986F	CSQN=Missense;reference_codon=TCC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr6:g.117639398_117639399delGGinsAA;aliases=ENSP00000357494;source=Ensembl	inside_[cds_in_exon_37]	-	ENST00000368508	Lung adenocarcinoma
ROS1:S1986Y,S1986F	MUT		Responsive	ROS1 (S1986Y,S1986F)	RDientsmann	Lorlatinib	ALK&ROS1 inhibitor	Lorlatinib (ALK&ROS1 inhibitor)		Case report	ROS1		LUAD	PMID:27401242		chr6:g.117639399G>T	c.5957C>A	ROS1:S1986Y	CSQN=Missense;reference_codon=TCC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr6:g.117639398_117639399delGGinsAT;aliases=ENSP00000357494;source=Ensembl	inside_[cds_in_exon_37]	-	ENST00000368508	Lung adenocarcinoma
ROS1:S1986Y,S1986F	MUT		Responsive	ROS1 (S1986Y,S1986F)	RDientsmann	Lorlatinib	ALK&ROS1 inhibitor	Lorlatinib (ALK&ROS1 inhibitor)		Case report	ROS1		LUAD	PMID:27401242		chr6:g.117639399G>A	c.5957C>T	ROS1:S1986F	CSQN=Missense;reference_codon=TCC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr6:g.117639398_117639399delGGinsAA;aliases=ENSP00000357494;source=Ensembl	inside_[cds_in_exon_37]	-	ENST00000368508	Lung adenocarcinoma
SERPINB3:.	MUT		Responsive	SERPINB3 oncogenic mutation	RDientsmann	[]	[CTLA4 inhibitor]	CTLA4 inhibitors		Early trials	SERPINB3		CM	PMID:27668655									Cutaneous melanoma
SETD2:.	MUT		Responsive	SETD2 oncogenic mutation	RDientsmann	[]	[WEE1 inhibitor]	WEE1 inhibitors		Pre-clinical	SETD2		CANCER	ENA 2014 (abstr 211)									Any cancer type
SF3B1:K700E,K666N	MUT		Responsive	SF3B1 (K700E,K666N)	RDientsmann	[]	[Spliceosome inhibitor]	Spliceosome inhibitors		Pre-clinical	SF3B1		CANCER	ENA 2014 (abstr 456);ENA 2014 (abstr 575);PMID:25424858		chr2:g.198266834T>C	c.2098A>G	SF3B1:K700E	CSQN=Missense;reference_codon=AAA;candidate_codons=GAG,GAA;candidate_mnv_variants=chr2:g.198266832_198266834delTTTinsCTC;aliases=ENSP00000335321;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000335508	Any cancer type
SF3B1:K700E,K666N	MUT		Responsive	SF3B1 (K700E,K666N)	RDientsmann	[]	[Spliceosome inhibitor]	Spliceosome inhibitors		Pre-clinical	SF3B1		CANCER	ENA 2014 (abstr 456);ENA 2014 (abstr 575);PMID:25424858		chr2:g.198267359C>G	c.1998G>C	SF3B1:K666N	CSQN=Missense;reference_codon=AAG;candidate_codons=AAC,AAT;candidate_snv_variants=chr2:g.198267359C>A;aliases=ENSP00000335321;source=Ensembl	inside_[cds_in_exon_14]	-	ENST00000335508	Any cancer type
SH2B3:.	MUT		Responsive	SH2B3 oncogenic mutation	RDientsmann	[]	[JAK inhibitor]	JAK inhibitors		Pre-clinical	SH2B3		MDPS	PMID:20404132									Myelodisplasic proliferative syndrome
SLC29A1:.	MUT		Resistant	SLC29A1 oncogenic mutation	ARodriguez-Vida	Gemcitabine	Chemotherapy	Gemcitabine (Chemotherapy)		Pre-clinical	SLC29A1	BLCA	BLCA	PMID:21166756									Bladder
SMARCA1:.	MUT		Responsive	SMARCA1 oncogenic mutation	RDientsmann	[]	[EZH2 inhibitor]	EZH2 inhibitors		Pre-clinical	SMARCA1		CANCER	PMID:26552009									Any cancer type
SMARCA4:.	MUT		Responsive	SMARCA4 oncogenic mutation	RDientsmann	[]	[EZH2 inhibitor]	EZH2 inhibitors		Case report	SMARCA4		OV	ESMO 2015 (abstract 302)									Ovary
SMARCB1:.	MUT		Responsive	SMARCB1 oncogenic mutation	RDientsmann	[]	[EZH2 inhibitor]	EZH2 inhibitors		Case report	SMARCB1		MRT	ENA 2014 (abstr 6LBA);ESMO 2015 (abstract 302)									Malignant rhabdoid tumor
SMARCB1:.	MUT		Responsive	SMARCB1 oncogenic mutation	RDientsmann	[]	[HDAC inhibitor]	HDAC inhibitors		Pre-clinical	SMARCB1		MRT	PMID:26920892									Malignant rhabdoid tumor
SMO:D473H	MUT		Resistant	SMO (D473H)	RDientsmann	Vismodegib	SHH inhibitor	Vismodegib (SHH inhibitor)		Case report	SMO		MB	PMID:19726788;PMID:25759019		chr7:g.128849189G>C	c.1417G>C	SMO:D473H	CSQN=Missense;reference_codon=GAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr7:g.128849189_128849191delGACinsCAT;aliases=ENSP00000249373;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000249373	Medulloblastoma
SMO:D473H,D473G,W535L,L412F,W281C,Q477E,G497W	MUT		Resistant	SMO (D473H,D473G,W535L,L412F,W281C,Q477E,G497W)	DTamborero;RDientsmann	Vismodegib	SHH inhibitor	Vismodegib (SHH inhibitor)		Case report	SMO		BCC	PMID:25759020;PMID:25306392		chr7:g.128849189G>C	c.1417G>C	SMO:D473H	CSQN=Missense;reference_codon=GAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr7:g.128849189_128849191delGACinsCAT;aliases=ENSP00000249373;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000249373	Basal cell carcinoma
SMO:D473H,D473G,W535L,L412F,W281C,Q477E,G497W	MUT		Resistant	SMO (D473H,D473G,W535L,L412F,W281C,Q477E,G497W)	DTamborero;RDientsmann	Vismodegib	SHH inhibitor	Vismodegib (SHH inhibitor)		Case report	SMO		BCC	PMID:25759020;PMID:25306392		chr7:g.128849190A>G	c.1418A>G	SMO:D473G	CSQN=Missense;reference_codon=GAC;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr7:g.128849190_128849191delACinsGT,chr7:g.128849190_128849191delACinsGG,chr7:g.128849190_128849191delACinsGA;aliases=ENSP00000249373;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000249373	Basal cell carcinoma
SMO:D473H,D473G,W535L,L412F,W281C,Q477E,G497W	MUT		Resistant	SMO (D473H,D473G,W535L,L412F,W281C,Q477E,G497W)	DTamborero;RDientsmann	Vismodegib	SHH inhibitor	Vismodegib (SHH inhibitor)		Case report	SMO		BCC	PMID:25759020;PMID:25306392		chr7:g.128850341G>T	c.1604G>T	SMO:W535L	CSQN=Missense;reference_codon=TGG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_mnv_variants=chr7:g.128850340_128850341delTGinsCT,chr7:g.128850341_128850342delGGinsTA,chr7:g.128850340_128850342delTGGinsCTT,chr7:g.128850340_128850342delTGGinsCTA,chr7:g.128850340_128850342delTGGinsCTC;aliases=ENSP00000249373;source=Ensembl	inside_[cds_in_exon_9]	+	ENST00000249373	Basal cell carcinoma
SMO:D473H,D473G,W535L,L412F,W281C,Q477E,G497W	MUT		Resistant	SMO (D473H,D473G,W535L,L412F,W281C,Q477E,G497W)	DTamborero;RDientsmann	Vismodegib	SHH inhibitor	Vismodegib (SHH inhibitor)		Case report	SMO		BCC	PMID:25759020;PMID:25306392		chr7:g.128846398C>T	c.1234C>T	SMO:L412F	CSQN=Missense;reference_codon=CTC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr7:g.128846398_128846400delCTCinsTTT;aliases=ENSP00000249373;source=Ensembl	inside_[cds_in_exon_6]	+	ENST00000249373	Basal cell carcinoma
SMO:D473H,D473G,W535L,L412F,W281C,Q477E,G497W	MUT		Resistant	SMO (D473H,D473G,W535L,L412F,W281C,Q477E,G497W)	DTamborero;RDientsmann	Vismodegib	SHH inhibitor	Vismodegib (SHH inhibitor)		Case report	SMO		BCC	PMID:25759020;PMID:25306392		chr7:g.128845546G>T	c.843G>T	SMO:W281C	CSQN=Missense;reference_codon=TGG;candidate_codons=TGT,TGC;candidate_snv_variants=chr7:g.128845546G>C;aliases=ENSP00000249373;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000249373	Basal cell carcinoma
SMO:D473H,D473G,W535L,L412F,W281C,Q477E,G497W	MUT		Resistant	SMO (D473H,D473G,W535L,L412F,W281C,Q477E,G497W)	DTamborero;RDientsmann	Vismodegib	SHH inhibitor	Vismodegib (SHH inhibitor)		Case report	SMO		BCC	PMID:25759020;PMID:25306392		chr7:g.128849201C>G	c.1429C>G	SMO:Q477E	CSQN=Missense;reference_codon=CAG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.128849201_128849203delCAGinsGAA;aliases=ENSP00000249373;source=Ensembl	inside_[cds_in_exon_8]	+	ENST00000249373	Basal cell carcinoma
SMO:D473H,D473G,W535L,L412F,W281C,Q477E,G497W	MUT		Resistant	SMO (D473H,D473G,W535L,L412F,W281C,Q477E,G497W)	DTamborero;RDientsmann	Vismodegib	SHH inhibitor	Vismodegib (SHH inhibitor)		Case report	SMO		BCC	PMID:25759020;PMID:25306392		chr7:g.128850226G>T	c.1489G>T	SMO:G497W	CSQN=Missense;reference_codon=GGG;candidate_codons=TGG;aliases=ENSP00000249373;source=Ensembl	inside_[cds_in_exon_9]	+	ENST00000249373	Basal cell carcinoma
SMO:P641A	MUT		Responsive	SMO (P641A)	RDientsmann	Vismodegib	SHH inhibitor	Vismodegib (SHH inhibitor)		Case report	SMO		L	ASCO 2017 (abstr 9062)		chr7:g.128851596C>G	c.1921C>G	SMO:P641A	CSQN=Missense;reference_codon=CCT;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr7:g.128851596_128851598delCCTinsGCA,chr7:g.128851596_128851598delCCTinsGCC,chr7:g.128851596_128851598delCCTinsGCG;aliases=ENSP00000249373;source=Ensembl	inside_[cds_in_exon_11]	+	ENST00000249373	Lung
SRSF2:.	MUT		Responsive	SRSF2 oncogenic mutation	RDientsmann	[]	[Spliceosome inhibitor]	Spliceosome inhibitors		Pre-clinical	SRSF2		AML	PMID:27135740									Acute myeloid leukemia
STAG2:.	MUT		Responsive	STAG2 oncogenic mutation	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Pre-clinical	STAG2		G	PMID:24356817									Glioma
STK11:.	MUT		Resistant	STK11 oncogenic mutation	RDientsmann	[]	[BET inhibitor]	BET inhibitors		Pre-clinical	STK11		L	PMID:23129625;PMID:24045185									Lung
STK11:.	MUT		Responsive	STK11 oncogenic mutation	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	STK11		LUAD	PMID:19165201									Lung adenocarcinoma
STK11:.	MUT		Responsive	STK11 oncogenic mutation	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	STK11		CANCER	PMID:19541609									Any cancer type
STK11:.	MUT		Responsive	STK11 oncogenic mutation	RDientsmann	[]	[SRC inhibitor;PI3K/MEK inhibitor]	SRC inhibitor + PI3K/MEK inhibitors		Pre-clinical	STK11		LUAD	PMID:20541700									Lung adenocarcinoma
STK11:D194E	MUT		Responsive	STK11 (D194E)	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	STK11		PA	PMID:21189378		chr19:g.1220489C>G	c.582C>G	STK11:D194E	CSQN=Missense;reference_codon=GAC;candidate_codons=GAG,GAA;candidate_snv_variants=chr19:g.1220489C>A;aliases=ENSP00000324856;source=Ensembl	inside_[cds_in_exon_4]	+	ENST00000326873	Pancreas
STK11:.	MUT		Responsive	STK11 oncogenic mutation	RDientsmann	Phenformin	Anti-diabetic	Phenformin (Anti-diabetic)		Pre-clinical	STK11		LUAD	PMID:23352126									Lung adenocarcinoma
SUZ12:.	MUT		Responsive	SUZ12 oncogenic mutation	RDientsmann	[]	[BET inhibitor]	BET inhibitors		Pre-clinical	SUZ12		CANCER	PMID:25119042									Any cancer type
TERT::consequence::promoters_core:.	MUT		Responsive	TERT promoters core	CRubio-Perez	Eribulin	Macrocyclic analog	Eribulin (Macrocyclic analog)		Pre-clinical	TERT		GBM	PMID:25375122;https://academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc;18/suppl_4/iv50-b									Glioblastoma multiforme
TP53::wildtype:.	MUT		Responsive	TP53 wildtype	RDientsmann	[]	[HDM2 inhibitor]	HDM2 inhibitors		Early trials	TP53		AML	AACR 2017 (abstr CT152)									Acute myeloid leukemia
TP53:R248Q,R175H	MUT		Responsive	TP53 (R248Q,R175H)	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Pre-clinical	TP53		CANCER	PMID:26009011		chr17:g.7577538C>T	c.743G>A	TP53:R248Q	CSQN=Missense;reference_codon=CGG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr17:g.7577537_7577538delCCinsTT;aliases=ENSP00000269305;source=Ensembl	inside_[cds_in_exon_7]	-	ENST00000269305	Any cancer type
TP53:R248Q,R175H	MUT		Responsive	TP53 (R248Q,R175H)	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Pre-clinical	TP53		CANCER	PMID:26009011		chr17:g.7578406C>T	c.524G>A	TP53:R175H	CSQN=Missense;reference_codon=CGC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr17:g.7578405_7578406delGCinsAT;aliases=ENSP00000269305;source=Ensembl	inside_[cds_in_exon_5]	-	ENST00000269305	Any cancer type
TP53:R248Q,R175H	MUT		Responsive	TP53 (R248Q,R175H)	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Pre-clinical	TP53		CANCER	PMID:26009011		chr17:g.7577538C>T	c.743G>A	TP53:R248Q	CSQN=Missense;reference_codon=CGG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr17:g.7577537_7577538delCCinsTT;aliases=ENSP00000269305;source=Ensembl	inside_[cds_in_exon_7]	-	ENST00000269305	Any cancer type
TP53:R248Q,R175H	MUT		Responsive	TP53 (R248Q,R175H)	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Pre-clinical	TP53		CANCER	PMID:26009011		chr17:g.7578406C>T	c.524G>A	TP53:R175H	CSQN=Missense;reference_codon=CGC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr17:g.7578405_7578406delGCinsAT;aliases=ENSP00000269305;source=Ensembl	inside_[cds_in_exon_5]	-	ENST00000269305	Any cancer type
TP53:.	MUT		Resistant	TP53 oncogenic mutation	RDientsmann	[]	[MDM2 inhibitor]	MDM2 inhibitors		Early trials	TP53		LIP	PMID:23084521;ASCO 2015 (abstr 10564)									Liposarcoma
TP53:.	MUT		Responsive	TP53 oncogenic mutation	RDientsmann	[]	[WEE1 inhibitor]	WEE1 inhibitors		Pre-clinical	TP53		HNC	PMID:25125259									Head an neck
TP53:.	MUT		Resistant	TP53 oncogenic mutation	RDientsmann	Abemaciclib	CDK4/CDK6 inhibitor	Abemaciclib (CDK4/CDK6 inhibitor)		Early trials	TP53		BRCA	PMID:27217383									Breast adenocarcinoma
TP53:.	MUT		Responsive	TP53 oncogenic mutation	ECampo	AZD6738	ATR inhibitor	AZD6738 (ATR inhibitor)	Clinical Trials	Early trials	TP53		BCL	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	Indirect								B cell lymphoma
TP53:.	MUT		Resistant	TP53 oncogenic mutation	RDientsmann	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)		Early trials	TP53		FGCT;MGCT	PMID:27646943									Female germ cell tumor;Male germ cell tumor
TP53:.	MUT		Responsive	TP53 oncogenic mutation	RDientsmann	Decitabine	Chemotherapy	Decitabine (Chemotherapy)		Early trials	TP53		AML;MDPS	PMID:27959731									Acute myeloid leukemia;Myelodisplasic proliferative syndrome
TP53:.	MUT		Responsive	TP53 oncogenic mutation	RDientsmann	Doxorubicin	Anthracycline antitumor antibiotic	Doxorubicin (Anthracycline antitumor antibiotic)		Pre-clinical	TP53		BLCA	PMID:27397505									Bladder
TP53:.	MUT		Responsive	TP53 oncogenic mutation	RDientsmann	Gemcitabine	Chemotherapy	Gemcitabine (Chemotherapy)		Pre-clinical	TP53		BLCA	PMID:27397505									Bladder
TP53:.	MUT		Responsive	TP53 oncogenic mutation	RDientsmann	Mitomycin C	Chemotherapy	Mitomycin C (Chemotherapy)		Pre-clinical	TP53		BLCA	PMID:27397505									Bladder
TP53:.	MUT		Responsive	TP53 oncogenic mutation	KKarube;RDientsmann	MK-1775	WEE1 inhibitor	MK-1775 (WEE1 inhibitor)	Clinical Trials	Early trials	TP53		OV	NCT01357161;ASCO2015 (abstr 2507)	Indirect								Ovary
TP53:.	MUT		Responsive	TP53 oncogenic mutation	RDientsmann	Pramlintide	Amylin analogue	Pramlintide (Amylin analogue)		Pre-clinical	TP53		THYM	PMID:25409149									Thymic
TPMT::consequence::splice_acceptor_variant:.	MUT		Increased Toxicity (Ototoxicity)	TPMT splice acceptor variant	DTamborero;CRubio-Perez	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	FDA guidelines	TPMT		CANCER	FDA									Any cancer type
TPMT:A80P,Y240C,A154T,A167G	MUT		Increased Toxicity (Ototoxicity)	TPMT (A80P,Y240C,A154T,A167G)	DTamborero;CRubio-Perez	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	FDA guidelines	TPMT		CANCER	FDA		chr6:g.18143955C>G	c.238G>C	TPMT:A80P	CSQN=Missense;reference_codon=GCA;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr6:g.18143953_18143955delTGCinsAGG,chr6:g.18143953_18143955delTGCinsCGG,chr6:g.18143953_18143955delTGCinsGGG;aliases=ENSP00000312304;source=Ensembl	inside_[cds_in_exon_4]	-	ENST00000309983	Any cancer type
TPMT:A80P,Y240C,A154T,A167G	MUT		Increased Toxicity (Ototoxicity)	TPMT (A80P,Y240C,A154T,A167G)	DTamborero;CRubio-Perez	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	FDA guidelines	TPMT		CANCER	FDA		chr6:g.18130918T>C	c.719A>G	TPMT:Y240C	CSQN=Missense;reference_codon=TAT;candidate_codons=TGT,TGC;candidate_mnv_variants=chr6:g.18130917_18130918delATinsGC;aliases=ENSP00000312304;source=Ensembl	inside_[cds_in_exon_9]	-	ENST00000309983	Any cancer type
TPMT:A80P,Y240C,A154T,A167G	MUT		Increased Toxicity (Ototoxicity)	TPMT (A80P,Y240C,A154T,A167G)	DTamborero;CRubio-Perez	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	FDA guidelines	TPMT		CANCER	FDA		chr6:g.18139228C>T	c.460G>A	TPMT:A154T	CSQN=Missense;reference_codon=GCA;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr6:g.18139226_18139228delTGCinsCGT,chr6:g.18139226_18139228delTGCinsAGT,chr6:g.18139226_18139228delTGCinsGGT;aliases=ENSP00000312304;source=Ensembl	inside_[cds_in_exon_6]	-	ENST00000309983	Any cancer type
TPMT:A80P,Y240C,A154T,A167G	MUT		Increased Toxicity (Ototoxicity)	TPMT (A80P,Y240C,A154T,A167G)	DTamborero;CRubio-Perez	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	FDA guidelines	TPMT		CANCER	FDA		chr6:g.18134115G>C	c.500C>G	TPMT:A167G	CSQN=Missense;reference_codon=GCA;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr6:g.18134114_18134115delTGinsAC,chr6:g.18134114_18134115delTGinsCC,chr6:g.18134114_18134115delTGinsGC;aliases=ENSP00000312304;source=Ensembl	inside_[cds_in_exon_7]	-	ENST00000309983	Any cancer type
TPMT::consequence::splice_acceptor_variant:.	MUT		Increased Toxicity (Myelosupression)	TPMT splice acceptor variant	DTamborero;CRubio-Perez	Mercaptopurine	Purine analog	Mercaptopurine (Purine analog)	Approved	FDA guidelines	TPMT		CANCER	FDA									Any cancer type
TPMT:A80P,Y240C,A154T,A167G	MUT		Increased Toxicity (Myelosupression)	TPMT (A80P,Y240C,A154T,A167G)	DTamborero;CRubio-Perez	Mercaptopurine	Purine analog	Mercaptopurine (Purine analog)	Approved	FDA guidelines	TPMT		CANCER	FDA		chr6:g.18143955C>G	c.238G>C	TPMT:A80P	CSQN=Missense;reference_codon=GCA;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr6:g.18143953_18143955delTGCinsAGG,chr6:g.18143953_18143955delTGCinsCGG,chr6:g.18143953_18143955delTGCinsGGG;aliases=ENSP00000312304;source=Ensembl	inside_[cds_in_exon_4]	-	ENST00000309983	Any cancer type
TPMT:A80P,Y240C,A154T,A167G	MUT		Increased Toxicity (Myelosupression)	TPMT (A80P,Y240C,A154T,A167G)	DTamborero;CRubio-Perez	Mercaptopurine	Purine analog	Mercaptopurine (Purine analog)	Approved	FDA guidelines	TPMT		CANCER	FDA		chr6:g.18130918T>C	c.719A>G	TPMT:Y240C	CSQN=Missense;reference_codon=TAT;candidate_codons=TGT,TGC;candidate_mnv_variants=chr6:g.18130917_18130918delATinsGC;aliases=ENSP00000312304;source=Ensembl	inside_[cds_in_exon_9]	-	ENST00000309983	Any cancer type
TPMT:A80P,Y240C,A154T,A167G	MUT		Increased Toxicity (Myelosupression)	TPMT (A80P,Y240C,A154T,A167G)	DTamborero;CRubio-Perez	Mercaptopurine	Purine analog	Mercaptopurine (Purine analog)	Approved	FDA guidelines	TPMT		CANCER	FDA		chr6:g.18139228C>T	c.460G>A	TPMT:A154T	CSQN=Missense;reference_codon=GCA;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr6:g.18139226_18139228delTGCinsCGT,chr6:g.18139226_18139228delTGCinsAGT,chr6:g.18139226_18139228delTGCinsGGT;aliases=ENSP00000312304;source=Ensembl	inside_[cds_in_exon_6]	-	ENST00000309983	Any cancer type
TPMT:A80P,Y240C,A154T,A167G	MUT		Increased Toxicity (Myelosupression)	TPMT (A80P,Y240C,A154T,A167G)	DTamborero;CRubio-Perez	Mercaptopurine	Purine analog	Mercaptopurine (Purine analog)	Approved	FDA guidelines	TPMT		CANCER	FDA		chr6:g.18134115G>C	c.500C>G	TPMT:A167G	CSQN=Missense;reference_codon=GCA;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr6:g.18134114_18134115delTGinsAC,chr6:g.18134114_18134115delTGinsCC,chr6:g.18134114_18134115delTGinsGC;aliases=ENSP00000312304;source=Ensembl	inside_[cds_in_exon_7]	-	ENST00000309983	Any cancer type
TPMT::consequence::splice_acceptor_variant:.	MUT		Increased Toxicity (Myelosupression)	TPMT splice acceptor variant	DTamborero;CRubio-Perez	Thioguanine	Guanine analog	Thioguanine (Guanine analog)	Approved	FDA guidelines	TPMT		CANCER	FDA									Any cancer type
TPMT:A80P,Y240C,A154T,A167G	MUT		Increased Toxicity (Myelosupression)	TPMT (A80P,Y240C,A154T,A167G)	DTamborero;CRubio-Perez	Thioguanine	Guanine analog	Thioguanine (Guanine analog)	Approved	FDA guidelines	TPMT		CANCER	FDA		chr6:g.18143955C>G	c.238G>C	TPMT:A80P	CSQN=Missense;reference_codon=GCA;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr6:g.18143953_18143955delTGCinsAGG,chr6:g.18143953_18143955delTGCinsCGG,chr6:g.18143953_18143955delTGCinsGGG;aliases=ENSP00000312304;source=Ensembl	inside_[cds_in_exon_4]	-	ENST00000309983	Any cancer type
TPMT:A80P,Y240C,A154T,A167G	MUT		Increased Toxicity (Myelosupression)	TPMT (A80P,Y240C,A154T,A167G)	DTamborero;CRubio-Perez	Thioguanine	Guanine analog	Thioguanine (Guanine analog)	Approved	FDA guidelines	TPMT		CANCER	FDA		chr6:g.18130918T>C	c.719A>G	TPMT:Y240C	CSQN=Missense;reference_codon=TAT;candidate_codons=TGT,TGC;candidate_mnv_variants=chr6:g.18130917_18130918delATinsGC;aliases=ENSP00000312304;source=Ensembl	inside_[cds_in_exon_9]	-	ENST00000309983	Any cancer type
TPMT:A80P,Y240C,A154T,A167G	MUT		Increased Toxicity (Myelosupression)	TPMT (A80P,Y240C,A154T,A167G)	DTamborero;CRubio-Perez	Thioguanine	Guanine analog	Thioguanine (Guanine analog)	Approved	FDA guidelines	TPMT		CANCER	FDA		chr6:g.18139228C>T	c.460G>A	TPMT:A154T	CSQN=Missense;reference_codon=GCA;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr6:g.18139226_18139228delTGCinsCGT,chr6:g.18139226_18139228delTGCinsAGT,chr6:g.18139226_18139228delTGCinsGGT;aliases=ENSP00000312304;source=Ensembl	inside_[cds_in_exon_6]	-	ENST00000309983	Any cancer type
TPMT:A80P,Y240C,A154T,A167G	MUT		Increased Toxicity (Myelosupression)	TPMT (A80P,Y240C,A154T,A167G)	DTamborero;CRubio-Perez	Thioguanine	Guanine analog	Thioguanine (Guanine analog)	Approved	FDA guidelines	TPMT		CANCER	FDA		chr6:g.18134115G>C	c.500C>G	TPMT:A167G	CSQN=Missense;reference_codon=GCA;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr6:g.18134114_18134115delTGinsAC,chr6:g.18134114_18134115delTGinsCC,chr6:g.18134114_18134115delTGinsGC;aliases=ENSP00000312304;source=Ensembl	inside_[cds_in_exon_7]	-	ENST00000309983	Any cancer type
NTRK1:G595R	MUT		Resistant	NTRK1 (G595R)	RDientsmann	Larotrectinib	Topomyosine kinase inhibitor	Larotrectinib (Topomyosine kinase inhibitor)		Pre-clinical	NTRK1		CANCER	PMID:28578312		chr1:g.156846342G>A	c.1783G>A	NTRK1:G595R	CSQN=Missense;reference_codon=GGG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr1:g.156846342G>C;candidate_mnv_variants=chr1:g.156846342_156846344delGGGinsAGA,chr1:g.156846342_156846344delGGGinsCGA,chr1:g.156846342_156846344delGGGinsCGC,chr1:g.156846342_156846344delGGGinsCGT;aliases=ENSP00000431418;source=Ensembl	inside_[cds_in_exon_14]	+	ENST00000524377	Any cancer type
NTRK3:G623R	MUT		Responsive	NTRK3 (G623R)	RDientsmann	[]	[novel TRK inhibitor]	novel TRK inhibitors		Case report	NTRK3		CANCER	PMID:28578312		chr15:g.88476265C>T	c.1867G>A	NTRK3:G623R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr15:g.88476265C>G;candidate_mnv_variants=chr15:g.88476263_88476265delTCCinsCCT,chr15:g.88476263_88476265delTCCinsGCG,chr15:g.88476263_88476265delTCCinsCCG,chr15:g.88476263_88476265delTCCinsACG;aliases=ENSP00000354207;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000360948	Any cancer type
NTRK3:G623R	MUT		Resistant	NTRK3 (G623R)	RDientsmann	Larotrectinib	Topomyosine kinase inhibitor	Larotrectinib (Topomyosine kinase inhibitor)		Pre-clinical	NTRK3		CANCER	PMID:28578312		chr15:g.88476265C>T	c.1867G>A	NTRK3:G623R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr15:g.88476265C>G;candidate_mnv_variants=chr15:g.88476263_88476265delTCCinsCCT,chr15:g.88476263_88476265delTCCinsGCG,chr15:g.88476263_88476265delTCCinsCCG,chr15:g.88476263_88476265delTCCinsACG;aliases=ENSP00000354207;source=Ensembl	inside_[cds_in_exon_15]	-	ENST00000360948	Any cancer type
TSC1:.	MUT		Responsive	TSC1 oncogenic mutation	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Early trials	TSC1		RA	PMID:23312829;PMID:21525172;PMID:20048174									Renal angiomyolipoma
TSC1:.	MUT		Responsive	TSC1 oncogenic mutation	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)	Approved	Early trials	TSC1		BLCA	PMID:22923433	Indirect								Bladder
TSC1:.	MUT		Responsive	TSC1 oncogenic mutation	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	TSC1		R	PMID:24622468;PMID:26859683;ASCO 2015 (abstr 11010);ASCO 2015 (abstr 4519)									Renal
TSC1:.	MUT		Responsive	TSC1 oncogenic mutation	DTamborero	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)	Approved	FDA guidelines	TSC1		GCA	FDA									Giant cell astrocytoma
TSC1:.	MUT		Responsive	TSC1 oncogenic mutation	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)	Approved	Case report	TSC1		S;ST	PMID:26859683									Sarcoma;Stomach
TSC1:.	MUT		Responsive	TSC1 oncogenic mutation	ARodriguez-Vida	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)	Approved	FDA guidelines	TSC1	RA	RA	FDA									Renal angiomyolipoma
TSC2:.	MUT		Responsive	TSC2 oncogenic mutation	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Early trials	TSC2		RA	PMID:23312829;PMID:21525172;PMID:20048174									Renal angiomyolipoma
TSC2:.	MUT		Responsive	TSC2 oncogenic mutation	RDientsmann	[]	[SRC inhibitor]	SRC inhibitors		Pre-clinical	TSC2		LAM	PMID:24691995									Lymphangioleiomyomatosis
TSC2:.	MUT		Responsive	TSC2 oncogenic mutation	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)	Approved	Early trials	TSC2		BLCA	PMID:22923433	Indirect								Bladder
TSC2:.	MUT		Responsive	TSC2 oncogenic mutation	ARodriguez-Vida;DTamborero	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)	Approved	FDA guidelines	TSC2	RA	RA;GCA	FDA									Renal angiomyolipoma;Giant cell astrocytoma
TSC2:Q1178*	MUT		Responsive	TSC2 (Q1178*)	CRubio-Perez;RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)	Approved	Case report	TSC2		THCA	PMID:25295501	Indirect	chr16:g.2130300C>T	c.3532C>T	TSC2:Q1178*	CSQN=Nonsense;reference_codon=CAG;candidate_codons=TAA,TAG,TGA;candidate_mnv_variants=chr16:g.2130300_2130302delCAGinsTAA,chr16:g.2130300_2130302delCAGinsTGA;aliases=ENSP00000219476;source=Ensembl	inside_[cds_in_exon_30]	+	ENST00000219476	Thyroid carcinoma
TSC2:E66K	MUT		Responsive	TSC2 (E66K)	RDientsmann	Tensirolimus	MTOR inhibitor	Tensirolimus (MTOR inhibitor)		Case report	TSC2		ED	PMID:27016228		chr16:g.2100458G>A	c.196G>A	TSC2:E66K	CSQN=Missense;reference_codon=GAA;candidate_codons=AAG,AAA;candidate_mnv_variants=chr16:g.2100458_2100460delGAAinsAAG;aliases=ENSP00000219476;source=Ensembl	inside_[cds_in_exon_3]	+	ENST00000219476	Endometrium
U2AF1:.	MUT		Responsive	U2AF1 oncogenic mutation	RDientsmann	[]	[FLT3 inhibitor]	FLT3 inhibitors		Pre-clinical	U2AF1		CANCER	PMID:27397505									Any cancer type
UGT1A1:G71R,P229Q	MUT		Increased Toxicity	UGT1A1 (G71R,P229Q)	DTamborero;CRubio-Perez	Irinotecan	TOPO1 inhibitor	Irinotecan (TOPO1 inhibitor)	Approved	FDA guidelines	UGT1A1		CANCER	FDA		chr2:g.234669144G>A	c.211G>A	UGT1A1:G71R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr2:g.234669144G>C;candidate_mnv_variants=chr2:g.234669144_234669146delGGAinsAGG,chr2:g.234669144_234669146delGGAinsCGC,chr2:g.234669144_234669146delGGAinsCGG,chr2:g.234669144_234669146delGGAinsCGT;aliases=ENSP00000304845;source=Ensembl	inside_[cds_in_exon_1]	+	ENST00000305208	Any cancer type
UGT1A1:G71R,P229Q	MUT		Increased Toxicity	UGT1A1 (G71R,P229Q)	DTamborero;CRubio-Perez	Irinotecan	TOPO1 inhibitor	Irinotecan (TOPO1 inhibitor)	Approved	FDA guidelines	UGT1A1		CANCER	FDA		chr2:g.234669619C>A	c.686C>A	UGT1A1:P229Q	CSQN=Missense;reference_codon=CCG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr2:g.234669619_234669620delCGinsAA;aliases=ENSP00000304845;source=Ensembl	inside_[cds_in_exon_1]	+	ENST00000305208	Any cancer type
UGT1A1:G71R,P229Q	MUT		Increased Toxicity (Hyperbilirubinemia)	UGT1A1 (G71R,P229Q)	DTamborero;CRubio-Perez	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	FDA guidelines	UGT1A1		CANCER	FDA		chr2:g.234669144G>A	c.211G>A	UGT1A1:G71R	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr2:g.234669144G>C;candidate_mnv_variants=chr2:g.234669144_234669146delGGAinsAGG,chr2:g.234669144_234669146delGGAinsCGC,chr2:g.234669144_234669146delGGAinsCGG,chr2:g.234669144_234669146delGGAinsCGT;aliases=ENSP00000304845;source=Ensembl	inside_[cds_in_exon_1]	+	ENST00000305208	Any cancer type
UGT1A1:G71R,P229Q	MUT		Increased Toxicity (Hyperbilirubinemia)	UGT1A1 (G71R,P229Q)	DTamborero;CRubio-Perez	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	FDA guidelines	UGT1A1		CANCER	FDA		chr2:g.234669619C>A	c.686C>A	UGT1A1:P229Q	CSQN=Missense;reference_codon=CCG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr2:g.234669619_234669620delCGinsAA;aliases=ENSP00000304845;source=Ensembl	inside_[cds_in_exon_1]	+	ENST00000305208	Any cancer type
VHL:.	MUT	Retrospective analysis	Responsive	VHL oncogenic mutation	ARodriguez-Vida	[Sorafenib,Sunitinib,Bevacizumab,Axitinib]	[VEGFR inhibitor]	VEGFR inhibitors (Sorafenib,Sunitinib,Bevacizumab,Axitinib,etc)	Approved	Pre-clinical	VHL		R	PMID:18635227	Indirect								Renal
ZNRF3:.	MUT		Responsive	ZNRF3 oncogenic mutation	RDientsmann	[]	[Porcupine inhibitor]	Porcupine inhibitors		Pre-clinical	ZNRF3		COREAD	PMID:26023187									Colorectal adenocarcinoma
ABL1__BCR	FUS		Responsive	ABL1-BCR fusion	CRubio-Perez;DTamborero;RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	FDA guidelines	ABL1		CML	FDA									Chronic myeloid leukemia
ABL1__BCR	FUS		Responsive	ABL1-BCR fusion	CRubio-Perez;DTamborero;RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	FDA guidelines	ABL1		CML;ALL	FDA									Chronic myeloid leukemia;Acute lymphoblastic leukemia
ABL1__BCR	FUS		Responsive	ABL1-BCR fusion	RDientsmann	Dasatinib;Venetoclax	BCR-ABL inhibitor 2nd gen;BCL2 inhibitor	Dasatinib + Venetoclax (BCR-ABL inhibitor 2nd gen + BCL2 inhibitor)		Pre-clinical	ABL1		ALL	PMID:27582059									Acute lymphoblastic leukemia
ABL1__BCR	FUS		Responsive	ABL1-BCR fusion	CRubio-Perez;DTamborero;RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	FDA guidelines	ABL1		CML;ALL	EMA									Chronic myeloid leukemia;Acute lymphoblastic leukemia
ABL1__BCR	FUS		Responsive	ABL1-BCR fusion	CRubio-Perez;DTamborero;RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	FDA guidelines	ABL1		CML	FDA									Chronic myeloid leukemia
ABL1__BCR	FUS		Responsive	ABL1-BCR fusion	CRubio-Perez;DTamborero;RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Approved	FDA guidelines	ABL1		CML;ALL	FDA									Chronic myeloid leukemia;Acute lymphoblastic leukemia
AKT2:amp	CNA		Responsive	AKT2 amplification	RDientsmann	MK2206	Allosteric AKT inhibitor	MK2206 (Allosteric AKT inhibitor)	Clinical Trials	Pre-clinical	AKT2		CANCER	ENA 2014 (abstr 373)									Any cancer type
AKT3__.	FUS	Cell line	Responsive	AKT3 fusion	JAlbanell;ARovira;RDientsmann	[AZD5363,GSK2141795]	[ATP competitive AKT inhibitor]	ATP competitive AKT inhibitors (AZD5363,GSK2141795,etc)	Clinical Trials;Clinical Trials	Pre-clinical	AKT3		BRCA	PMID:22722202	Direct								Breast adenocarcinoma
ALK__.	FUS		Responsive	ALK fusion	RDientsmann	[]	[ALK inhibitor;IGF1R inhibitor]	ALK inhibitor + IGF1R inhibitors		Pre-clinical	ALK		LUAD	PMID:25173427									Lung adenocarcinoma
ALK__.	FUS		Responsive	ALK fusion	RDientsmann	[]	[ALK inhibitor;MEK inhibitor]	ALK inhibitor + MEK inhibitors		Pre-clinical	ALK		LUAD	PMID:26301689									Lung adenocarcinoma
ALK__.	FUS		Responsive	ALK fusion	RDientsmann	[]	[ALK inhibitor;SRC inhibitor]	ALK inhibitor + SRC inhibitors		Pre-clinical	ALK		LUAD	PMID:25394791									Lung adenocarcinoma
ALK__.	FUS		Responsive	ALK fusion	RDientsmann	[]	[ALK inhibitor]	ALK inhibitors		Case report	ALK		COREAD	PMID:26633560									Colorectal adenocarcinoma
ALK__.	FUS		Responsive	ALK fusion	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	ALK		LUAD	PMID:23553849									Lung adenocarcinoma
ALK__.	FUS		Responsive	ALK fusion	RDientsmann	[]	[novel ALK inhibitor]	novel ALK inhibitors		Early trials	ALK		LUAD	PMID:23639470									Lung adenocarcinoma
ALK__.	FUS		Responsive	ALK fusion	RDientsmann	Alectinib	ALK inhibitor	Alectinib (ALK inhibitor)		FDA guidelines	ALK		LUAD	FDA									Lung adenocarcinoma
ALK__.	FUS		Responsive	ALK fusion	EArriola;CRubio-Perez	Alectinib	ALK inhibitor	Alectinib (ALK inhibitor)	Clinical_Trials	FDA guidelines	ALK		NSCLC	FDA									Non-small cell lung
ALK:amp	CNA		Responsive	ALK amplification	RDientsmann	Brigatinib	Pan-TK inhibitor	Brigatinib (Pan-TK inhibitor)		Case report	ALK		LUAD	ASCO 2017 (abstr 9065)									Lung adenocarcinoma
ALK__.	FUS		Responsive	ALK fusion	CRubio-Perez;DTamborero;RDientsmann	Ceritinib	ALK inhibitor	Ceritinib (ALK inhibitor)	Approved	FDA guidelines	ALK		NSCLC;LUAD	FDA									Non-small cell lung;Lung adenocarcinoma
ALK__.	FUS		Responsive	ALK fusion	RDientsmann	Ceritinib	ALK inhibitor	Ceritinib (ALK inhibitor)		Case report	ALK		COREAD;IM	PMID:26633560;PMID:26933125;PMID:27742657									Colorectal adenocarcinoma;Inflammatory myofibroblastic
ALK__.	FUS		Responsive	ALK fusion	ECampo	Ceritinib	ALK inhibitor	Ceritinib (ALK inhibitor)	Clinical Trials	Early trials	ALK		HEMATO	NCT02186821	Direct								Hematologic malignancies
ALK__.	FUS		Responsive	ALK fusion	MMartínez;RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Early trials	ALK		LY;GB	PMID:24491302;NCT02270034									Lymphoma;Glioblastoma
ALK__.	FUS		Responsive	ALK fusion	CRubio-Perez;DTamborero;RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)	Approved	FDA guidelines	ALK		NSCLC;LUAD	FDA									Non-small cell lung;Lung adenocarcinoma
ALK__.	FUS		Responsive	ALK fusion	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ALK		IM;THCA	PMID:20979472;PMID:24687827									Inflammatory myofibroblastic;Thyroid carcinoma
ALK:amp	CNA		Resistant	ALK amplification	EArriola	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)	Approved	Clinical trials	ALK		NSCLC	PMID:22235099									Non-small cell lung
ALK:amp	CNA		Resistant	ALK amplification	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ALK		LUAD	PMID:22277784									Lung adenocarcinoma
ALK__.	FUS		Responsive	ALK fusion	RDientsmann	Entrictinib	Pan-TK inhibitor	Entrictinib (Pan-TK inhibitor)		Case report	ALK		COREAD	PMID:26633560;PMID:26933125									Colorectal adenocarcinoma
ALK__.	FUS		Responsive	ALK fusion	RDientsmann;CRubio-Perez	Lorlatinib	ALK&ROS1 inhibitor	Lorlatinib (ALK&ROS1 inhibitor)		Early trials	ALK		NSCLC	PMID:26951079 									Non-small cell lung
ALK__.	FUS		Responsive	ALK fusion	RDientsmann;CRubio-Perez	Brigatinib	Pan-TK inhibitor	Brigatinib (Pan-TK inhibitor)		FDA guidelines	ALK		NSCLC	FDA									Non-small cell lung
AR:amp	CNA		Responsive	AR amplification	RDientsmann	[]	[AR inhibitor next gen]	AR inhibitor next gens		Pre-clinical	AR		PRAD	PMID:23589709;PMID:21859989									Prostate adenocarcinoma
AR:over	EXPR		Responsive	AR overexpression	JAlbanell;ARovira	[Bicalutamide,Enzalutamide,Orterone,4OHtestosterone]	[AR inhibitor]	AR inhibitors (Bicalutamide,Enzalutamide,Orterone,4OHtestosterone,etc)	Clinical Trials	Early trials	AR		BRCA	ASCO 2015 (abstr 1003)	Direct								Breast adenocarcinoma
AR:amp	CNA		Resistant	AR amplification	RDientsmann	Abiraterone	AR inhibitor	Abiraterone (AR inhibitor)	Approved	Early trials	AR		PRAD	PMID:26537258									Prostate adenocarcinoma
AR:over	EXPR		Responsive	AR overexpression	ARodriguez-Vida	Enzalutamide	AR inhibitor	Enzalutamide (AR inhibitor)	Approved	Early trials	AR	PRAD	PRAD	PMID:24882673	Direct								Prostate adenocarcinoma
AR:F877L;AR:T878A	MUT;MUT		Responsive	AR (F877L) + AR (T878A)	RDientsmann	Enzalutamide	AR inhibitor	Enzalutamide (AR inhibitor)		Pre-clinical	AR;AR		PRAD	PMID:27196756									Prostate adenocarcinoma
AREG:amp	CNA		Responsive	AREG amplification	RDientsmann	[]	[EGFR mAb inhibitor]	EGFR mAb inhibitors		Early trials	AREG		COREAD	PMID:19738126;PMID:26341080									Colorectal adenocarcinoma
ARID1A:.;ANXA1:over	MUT;EXPR		Resistant	ARID1A oncogenic mutation + ANXA1 overexpression	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)	FDA approved	Early trials	ARID1A;ANXA1		BRCA	PMID:27172896									Breast adenocarcinoma
ARID1A:amp;ANXA1:over	CNA;EXPR		Resistant	ARID1A amplification + ANXA1 overexpression	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)	FDA approved	Early trials	ARID1A;ANXA1		BRCA	PMID:27172896									Breast adenocarcinoma
ATM:del	CNA		Responsive	ATM deletion	RDientsmann	[]	[ATR inhibitor]	ATR inhibitors		Case report	ATM		COREAD	ENA 2015 (abstr A48)									Colorectal adenocarcinoma
ATM:del	CNA		Responsive	ATM deletion	RDientsmann	[]	[DNA-PKc inhibitor]	DNA-PKc inhibitors		Pre-clinical	ATM		LY	PMID:23761041									Lymphoma
ATM:del	CNA		Responsive	ATM deletion	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Early trials	ATM		ST	ENA 2014 (abstr 8LBA)									Stomach
ATM:.	BIA		Responsive	ATM biallelic inactivation	ECampo	AZD6738	ATR inhibitor	AZD6738 (ATR inhibitor)	Clinical Trials	Early trials	ATM		BCL	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	Indirect								B cell lymphoma
ATM:del	CNA		Responsive	ATM deletion	ARodriguez-Vida	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	Early trials	ATM	BLCA	BLCA	PMID:26238431	Indirect								Bladder
ATR:del	CNA	Cell line	Responsive	ATR deletion	CRubio-Perez;ECampo;RDientsmann	Olaparib	PARP inhibitor	Olaparib (PARP inhibitor)	Approved	Pre-clinical	ATR		OV;CANCER	PMID:23548269	Indirect								Ovary;Any cancer type
AURKA:amp	CNA		Responsive	AURKA amplification	RDientsmann	[]	[AURK inhibitor]	AURK inhibitors		Pre-clinical	AURKA		PRAD;CANCER	PMID:22302096;PMID:22389870									Prostate adenocarcinoma;Any cancer type
BAP1:del	CNA		Responsive	BAP1 deletion	RDientsmann	[]	[EZH2 inhibitor]	EZH2 inhibitors		Pre-clinical	BAP1		MESO	PMID:26437366									Mesothelioma
BAP1:del	CNA		Responsive	BAP1 deletion	RDientsmann	[]	[HDAC inhibitor]	HDAC inhibitors		Pre-clinical	BAP1		CM	PMID:22038994									Cutaneous melanoma
BAP1:del	CNA		Responsive	BAP1 deletion	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Pre-clinical	BAP1		R;CANCER	PMID:22683710									Renal;Any cancer type
BCL2:over	EXPR		Responsive	BCL2 overexpression	CRubio-Perez	Venetoclax;Bortezomib	BCL2 inhibitor;Proteasome inhibitor	Venetoclax + Bortezomib (BCL2 inhibitor + Proteasome inhibitor)		Early trials	BCL2		MM	ASH 2015 (Blood 2015 126:2975)									Multiple myeloma
BCL2:amp	CNA		Responsive	BCL2 amplification	RDientsmann	[]	[BCL2 inhibitor]	BCL2 inhibitors		Pre-clinical	BCL2		LY	PMID:22649144									Lymphoma
BCL6:over	EXPR		Responsive	BCL6 overexpression	CRubio-Perez	Onalespib	HSP90 inhibitor	Onalespib (HSP90 inhibitor)		Early trials	BCL6		LY	NCT02572453									Lymphoma
BRAF__.	FUS		Responsive	BRAF fusion	RDientsmann	[]	[BRAF inhibitor;MEK inhibitor]	BRAF inhibitor + MEK inhibitors		Case report	BRAF		LUAD	ASCO 2017 (abstr 9072)									Lung adenocarcinoma
BRAF__.	FUS		Responsive	BRAF fusion	RDientsmann	[Trametinib]	[MEK inhibitor]	MEK inhibitors (Trametinib,etc)		Pre-clinical	BRAF		LUAD;CM;PRAD	PMID:24727320;PMID:24345920;PMID:20526349									Lung adenocarcinoma;Cutaneous melanoma;Prostate adenocarcinoma
BRAF__.	FUS		Responsive	BRAF fusion	RDientsmann	Selumetinib	MEK inhibitor	Selumetinib (MEK inhibitor)		Case report	BRAF		OV	PMID:26324360									Ovary
BRAF__.	FUS		Responsive	BRAF fusion	RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Pre-clinical	BRAF		CM;LUAD;PRAD	PMID:238900088;PMID:20526349;PMID:24727320									Cutaneous melanoma;Lung adenocarcinoma;Prostate adenocarcinoma
BRAF:G469A;EGFR:.	MUT;MUT		Responsive	BRAF (G469A) + EGFR oncogenic mutation	RDientsmann	[]	[EGFR TK inhibitor;MEK inhibitor]	EGFR TK inhibitor + MEK inhibitors		Pre-clinical	BRAF;EGFR		LUAD	PMID:22773810									Lung adenocarcinoma
BRCA1:del	CNA		Responsive	BRCA1 deletion	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Pre-clinical	BRCA1		OV	PMID:22392482									Ovary
BRCA2:del	CNA		Responsive	BRCA2 deletion	RDientsmann	[Olaparib]	[PARP inhibitor]	PARP inhibitors (Olaparib,etc)		Pre-clinical	BRCA2		OV	PMID:22392482									Ovary
BRD4__C15orf55	FUS		Responsive	BRD4-C15orf55 fusion	RDientsmann	[]	[BET inhibitor]	BET inhibitors		Case report	C15orf55		NMC	ENA 2015 (abstr A49)									NUT midline carcinoma
CA9:over	EXPR	Cell line	Responsive	CA9 overexpression	ARodriguez-Vida	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)	Approved	Pre-clinical	CA9		R	PMID:24086736	Indirect								Renal
CCND1:amp	CNA		Responsive	CCND1 amplification	RDientsmann	[]	[CDK4/6 inhibitor]	CDK4/6 inhibitors		Case report	CCND1		CM	ASCO 2014 (abstr 2528)									Cutaneous melanoma
CCND1:amp	CNA		Responsive	CCND1 amplification	RDientsmann	[]	[CDK4/6 inhibitor]	CDK4/6 inhibitors		Pre-clinical	CCND1		CANCER	PMID:22471707									Any cancer type
CCND1:amp	CNA		Resistant	CCND1 amplification	DTamborero;RDientsmann	[]	[SMO inhibitor]	SMO inhibitors		Pre-clinical	CCND1		MB	PMID:24951114									Medulloblastoma
CCND1:amp	CNA		No Responsive	CCND1 amplification	RDientsmann	Palbociclib	CDK4/6 inhibitor	Palbociclib (CDK4/6 inhibitor)		Early trials	CCND1		L	ASCO 2017 (abstr 9056)									Lung
CCND2:amp	CNA		Responsive	CCND2 amplification	RDientsmann	[]	[CDK4/6 inhibitor]	CDK4/6 inhibitors		Pre-clinical	CCND2		CANCER	PMID:22471707									Any cancer type
CCND2:amp	CNA		Responsive	CCND2 amplification	CRubio-Perez;DTamborero	Palbociclib	CDK4/6 inhibitor	Palbociclib (CDK4/6 inhibitor)	Approved	Early trials	CCND2		L	NCT02154490	Indirect								Lung
CCND3:amp	CNA		Responsive	CCND3 amplification	RDientsmann	[]	[CDK4/6 inhibitor]	CDK4/6 inhibitors		Pre-clinical	CCND3		CANCER	PMID:22471707									Any cancer type
CCNE1:amp	CNA		Responsive	CCNE1 amplification	RDientsmann	[]	[CDK2 inhibitor]	CDK2 inhibitors		Pre-clinical	CCNE1		CANCER	PMID:22471707									Any cancer type
CD274:amp	CNA		Responsive	CD274 amplification	RDientsmann	[]	[PD1 Ab inhibitor]	PD1 Ab inhibitors		Case report	CD274		BCC	PMID:27942391									Basal cell carcinoma
CD274:amp	CNA		Responsive	CD274 amplification	RDientsmann	[]	[PDL1 inhibitor]	PDL1 inhibitors		Pre-clinical	CD274		CANCER	PMID:25079317									Any cancer type
CD274:over	EXPR		Responsive	CD274 overexpression	ARodriguez-Vida	Atezolizumab	PDL1 inhibitor	Atezolizumab (PDL1 inhibitor)	Clinical Trials	Early trials	CD274	BLCA	CM;R;CANCER	NCT01375842;doi: 10.1093/annonc/mdu337.2	Direct								Cutaneous melanoma;Renal;Any cancer type
CD274:over	EXPR		Responsive	CD274 overexpression	ARodriguez-Vida	Nivolumab	PD1 Ab inhibitor	Nivolumab (PD1 Ab inhibitor)	Clinical Trials	Early trials	CD274	R	R	PMID:25452452	Indirect								Renal
CD274:over	EXPR		Responsive	CD274 overexpression	ARodriguez-Vida	Pembrolizumab	PD1 Ab	Pembrolizumab (PD1 Ab)	Clinical Trials	Early trials	CD274	BLCA	BLCA	NCT01848834	Indirect								Bladder
CD69:under	EXPR	Cell line	Responsive	CD69 undexpression	CRubio-Perez	Bendamustine	Alkylating agent	Bendamustine (Alkylating agent)	Approved	Pre-clinical	CD69		CLL	PMID:26701728									Chronic lymphocytic leukemia
CDK12:amp	CNA		Responsive	CDK12 amplification	RDientsmann	[]	[PARP inhibitors]	PARP inhibitors		Pre-clinical	CDK12		OV	PMID:24240700;PMID:24554720									Ovary
CDK4:amp	CNA		Responsive	CDK4 amplification	CRubio-Perez;DTamborero	LEE011	CDK4/6 inhibitor	LEE011 (CDK4/6 inhibitor)	Clinical Trials	Early trials	CDK4		LIP;LY;CANCER	NCT02187783;NCT01237236; http://meetinglibrary.asco.org/content/83791-102	Direct								Liposarcoma;Lymphoma;Any cancer type
CDK4:amp	CNA		No Responsive	CDK4 amplification	RDientsmann	Palbociclib	CDK4/6 inhibitor	Palbociclib (CDK4/6 inhibitor)		Early trials	CDK4		L	ASCO 2017 (abstr 9056)									Lung
CDK4:amp;RB1:norm	CNA;EXPR		Responsive	CDK4 amplification + RB1 expression	RDientsmann	[]	[CDK4 inhibitor]	CDK4 inhibitors		Early trials	CDK4;RB1		LIP	PMID:23569312									Liposarcoma
CDK6:amp	CNA		Responsive	CDK6 amplification	RDientsmann	[]	[CDK6 inhibitor]	CDK6 inhibitors		Pre-clinical	CDK6		CANCER	PMID:22471707									Any cancer type
CDK6:amp	CNA		Responsive	CDK6 amplification	CRubio-Perez;DTamborero	LEE011	CDK4/6 inhibitor	LEE011 (CDK4/6 inhibitor)	Clinical Trials	Early trials	CDK6		LIP;LY;CANCER	NCT02187783;NCT01237236;http://meetinglibrary.asco.org/content/83791-102	Direct								Liposarcoma;Lymphoma;Any cancer type
CDKN1A:del	CNA		Responsive	CDKN1A deletion	RDientsmann	[]	[CDK2/4 inhibitor]	CDK2/4 inhibitors		Pre-clinical	CDKN1A		CANCER	PMID:22471707;PMID:22997239									Any cancer type
CDKN1B:del	CNA		Responsive	CDKN1B deletion	RDientsmann	[]	[CDK2/4 inhibitor]	CDK2/4 inhibitors		Pre-clinical	CDKN1B		CANCER	PMID:22471707									Any cancer type
CDKN2A:del	CNA		Responsive	CDKN2A deletion	RDientsmann	[]	[CDK4/6 inhibitor]	CDK4/6 inhibitors		Case report	CDKN2A		CM	ASCO 2013 (abstr 2500)									Cutaneous melanoma
CDKN2A:del	CNA		Responsive	CDKN2A deletion	RDientsmann	[]	[CDK4/6 inhibitor]	CDK4/6 inhibitors		Pre-clinical	CDKN2A		G;CANCER	PMID:22471707;PMID:22586120;PMID:22711607									Glioma;Any cancer type
CDKN2A:del	CNA		Responsive	CDKN2A deletion	CRubio-Perez;DTamborero	Ilorasertib	AURKA-VEGF inhibitor	Ilorasertib (AURKA-VEGF inhibitor)	Clinical Trials	Early trials	CDKN2A		CANCER	NCT02478320	Indirect								Any cancer type
CDKN2B:del	CNA		Responsive	CDKN2B deletion	RDientsmann	[]	[CDK4/6 inhibitor]	CDK4/6 inhibitors		Pre-clinical	CDKN2B		G;CANCER	PMID:22471707;PMID:22711607									Glioma;Any cancer type
CDKN2C:del	CNA		Responsive	CDKN2C deletion	RDientsmann	[]	[CDK2 inhibitor]	CDK2 inhibitors		Pre-clinical	CDKN2C		G;CANCER	PMID:22471707;PMID:22997239;PMID:22711607									Glioma;Any cancer type
CHEK2:del	CNA		Responsive	CHEK2 deletion	RDientsmann	Olaparib	PARP inhibitor	Olaparib (PARP inhibitor)		Early trials	CHEK2		PRAD	AACR 2015 (abstr CT322)									Prostate adenocarcinoma
CRBN:under	EXPR		Resistant	CRBN undexpression	DTamborero	Lenalidomide	Immunomodulator	Lenalidomide (Immunomodulator)		Case report	CRBN		MYMA	PMID:21860026									Myeloma
CRBN:under	EXPR		Resistant	CRBN undexpression	DTamborero	Pomalidomide	Immunomodulator	Pomalidomide (Immunomodulator)		Case report	CRBN		MYMA	PMID:21860026									Myeloma
CRLF2__.	FUS		Responsive	CRLF2 fusion	RDientsmann	[]	[BET inhibitor]	BET inhibitors		Pre-clinical	CRLF2		ALL	PMID:22904298									Acute lymphoblastic leukemia
CRLF2__.	FUS		Responsive	CRLF2 fusion	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	CRLF2		ALL	PMID:22955920									Acute lymphoblastic leukemia
CYP17A1:norm	EXPR		Responsive	CYP17A1 expression	ARodriguez-Vida	Abiraterone	AR inhibitor	Abiraterone (AR inhibitor)	Approved	Early trials	CYP17A1	PRAD	PRAD	PMID:22184395	Direct								Prostate adenocarcinoma
CYP17A1:norm	EXPR		Responsive	CYP17A1 expression	ARodriguez-Vida	Enzalutamide	AR inhibitor	Enzalutamide (AR inhibitor)	Approved	Early trials	CYP17A1	PRAD	PRAD	PMID:24882673	Indirect								Prostate adenocarcinoma
DPYD:.	BIA		Increased Toxicity	DPYD biallelic inactivation	DTamborero;CRubio-Perez	Capecitabine	Fluoropyrimidine	Capecitabine (Fluoropyrimidine)	Approved	FDA guidelines	DPYD		CANCER	FDA									Any cancer type
DPYD:.	BIA		Increased Toxicity	DPYD biallelic inactivation	DTamborero;CRubio-Perez	Flourouracil	Fluoropyrimidine	Flourouracil (Fluoropyrimidine)	Approved	FDA guidelines	DPYD		CANCER	FDA									Any cancer type
DPYD:.	BIA		Increased Toxicity	DPYD biallelic inactivation	DTamborero;CRubio-Perez	Tegafur	Fluoropyrimidine	Tegafur (Fluoropyrimidine)	Approved	CPIC guidelines	DPYD		CANCER	PMID:23988873									Any cancer type
EGFR:amp	CNA		No Responsive	EGFR amplification	RDientsmann	[]	[EGFR inhibitor 1st gen]	EGFR inhibitor 1st gens		Early trials	EGFR		G	PMID:16282176;PMID:16278407									Glioma
EGFR:amp	CNA		No Responsive	EGFR amplification	RDientsmann	[]	[EGFR inhibitor 2nd gen]	EGFR inhibitor 2nd gens		Early trials	EGFR		G	PMID:16282176;PMID:16278407									Glioma
EGFR:amp	CNA		No Responsive	EGFR amplification	RDientsmann	[]	[EGFR inhibitor 3rd gen]	EGFR inhibitor 3rd gens		Early trials	EGFR		G	PMID:16282176;PMID:16278407									Glioma
EGFR:amp	CNA		Responsive	EGFR amplification	RDientsmann	[]	[EGFR inhibitor]	EGFR inhibitors		Case report	EGFR		HNSC	PMID:26763254									Head an neck squamous
EGFR:amp	CNA		Responsive	EGFR amplification	RDientsmann	[]	[EGFR mAb inhibitor]	EGFR mAb inhibitors		Late trials	EGFR		COREAD	PMID:18794099;PMID:17664472									Colorectal adenocarcinoma
EGFR:over	EXPR		Responsive	EGFR overexpression	CRubio-Perez	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)	Approved	FDA guidelines	EGFR		COREAD	FDA									Colorectal adenocarcinoma
EGFR__RAD51	FUS		Responsive	EGFR-RAD51 fusion	EArriola	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)	Approved	Case report	EGFR		NSCLC	PMID:27102076									Non-small cell lung
EGFR__RAD51	FUS		Responsive	EGFR-RAD51 fusion	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)		Case report	EGFR		L	PMID:27102076									Lung
EGFR:amp	CNA		No Responsive	EGFR amplification	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)	Approved	Early trials	EGFR		L	ASCO2015(abstre19028)									Lung
EGFR:amp	CNA		No Responsive	EGFR amplification	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	Early trials	EGFR		HNC	PMID:21274259;PMID:22261807									Head an neck
EGFR:amp	CNA		Responsive	EGFR amplification	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	Late trials	EGFR		ED	PMID:24950987									Endometrium
EGFR:over	EXPR		Resistant	EGFR overexpression	CRubio-Perez;RDientsmann	Panitumumab	EGFR mAb inhibitor	Panitumumab (EGFR mAb inhibitor)	Approved	FDA guidelines	EGFR		COREAD	FDA guidelines									Colorectal adenocarcinoma
EPHA2:amp	CNA		Responsive	EPHA2 amplification	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	EPHA2		CANCER	PMID:18047674;PMID:19010823;PMID:19861960									Any cancer type
EPHA2:amp	CNA		Responsive	EPHA2 amplification	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	EPHA2		CANCER	PMID:18047674;PMID:19010823;PMID:19861960									Any cancer type
EPHA3:amp	CNA		Responsive	EPHA3 amplification	RDientsmann	[]	[EPHA3 inhibitor]	EPHA3 inhibitors		Pre-clinical	EPHA3		CANCER	PMID:25125683									Any cancer type
EPHA3:amp	CNA		Responsive	EPHA3 amplification	RDientsmann	[]	[EPHA3 inhibitor]	EPHA3 inhibitors		Pre-clinical	EPHA3		CANCER	PMID:25125683									Any cancer type
ERBB2:amp	CNA		Resistant	ERBB2 amplification	EArriola	[]	[EGFR inhibitor]	EGFR inhibitors		Pre-clinical	ERBB2		LUAD	PMID:22956644									Lung adenocarcinoma
ERBB2:amp	CNA		Resistant	ERBB2 amplification	RDientsmann	[]	[EGFR mAb inhibitor]	EGFR mAb inhibitors		Early trials	ERBB2		COREAD	PMID:22586653;PMID:23348520									Colorectal adenocarcinoma
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann	[]	[ERBB2 inhibitor;CDK4/6 inhibitor]	ERBB2 inhibitor + CDK4/6 inhibitors		Pre-clinical	ERBB2		BRCA	PMID:26977878									Breast adenocarcinoma
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann	Ado-Trastuzumab Emtansine	EGFR mAb inhibitor	Ado-Trastuzumab Emtansine (EGFR mAb inhibitor)		FDA guidelines	ERBB2		BRCA	FDA									Breast adenocarcinoma
ERBB2:over	EXPR		Responsive	ERBB2 overexpression	CRubio-Perez	Ado-Trastuzumab Emtansine	ERBB2 mAb inhibitor	Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)	Approved	FDA guidelines	ERBB2		BRCA	FDA									Breast adenocarcinoma
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann	Afatinib	ERBB2&EGFR inhibitor 2nd gen	Afatinib (ERBB2&EGFR inhibitor 2nd gen)		Case report	ERBB2		ST	AACR 2014 (abstr CT228)									Stomach
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann	Afatinib	ERBB2&EGFR inhibitor 2nd gen	Afatinib (ERBB2&EGFR inhibitor 2nd gen)		Late trials	ERBB2		BRCA	PMID:20142587;PMID:22418700;PMID:23632474									Breast adenocarcinoma
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann	Afatinib	ERBB2&EGFR inhibitor 2nd gen	Afatinib (ERBB2&EGFR inhibitor 2nd gen)		Case report	ERBB2		BLCA	PMID:27044931									Bladder
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann;CRubio-Perez	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		FDA guidelines	ERBB2		BRCA	FDA									Breast adenocarcinoma
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Early trials	ERBB2		BT	PMID:26022204									Billiary tract
ERBB2:over	EXPR		Responsive	ERBB2 overexpression	CRubio-Perez	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)	Approved	FDA guidelines	ERBB2		BRCA	FDA									Breast adenocarcinoma
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann	Lapatinib;Chemotherapy	ERBB2 inhibitor;Chemotherapy	Lapatinib + Chemotherapy (ERBB2 inhibitor + Chemotherapy)		Early trials	ERBB2		ST	PMID:25694417;NCT02015169									Stomach
ERBB2:over	EXPR		Responsive	ERBB2 overexpression	DCasadevall	MK2206;Trastuzumab	Allosteric AKT inhibitor;ERBB2 mAb inhibitor	MK2206 + Trastuzumab (Allosteric AKT inhibitor + ERBB2 mAb inhibitor)		Early trials	ERBB2		SOLID	ASCO 2013 (abstr 2605);PMID:26104654									Solid tumors
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Late trials	ERBB2		BRCA	PMID:20142587;PMID:22418700;PMID:23632474									Breast adenocarcinoma
ERBB2:amp	CNA		Resistant	ERBB2 amplification	EArriola	Osimertinib	3rd generation EGFR inhibitor	Osimertinib (3rd generation EGFR inhibitor)	Approved	Case report	ERBB2		LUAD	PMID:27252416									Lung adenocarcinoma
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann	Pertuzumab	ERBB2 mAb inhibitor	Pertuzumab (ERBB2 mAb inhibitor)		Early trials	ERBB2		ST	PMID:24960402									Stomach
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann;CRubio-Perez	Pertuzumab	ERBB2 mAb inhibitor	Pertuzumab (ERBB2 mAb inhibitor)		FDA guidelines	ERBB2		BRCA	FDA									Breast adenocarcinoma
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann	Pertuzumab	ERBB2 mAb inhibitor	Pertuzumab (ERBB2 mAb inhibitor)		Early trials	ERBB2		BT	PMID:26022204									Billiary tract
ERBB2:over	EXPR		Responsive	ERBB2 overexpression	CRubio-Perez	Pertuzumab	ERBB2 mAb inhibitor	Pertuzumab (ERBB2 mAb inhibitor)	Approved	FDA guidelines	ERBB2		BRCA	FDA									Breast adenocarcinoma
ERBB2:amp	CNA		Resistant	ERBB2 amplification	EArriola	Rociletinib	3rd generation EGFR inhibitor	Rociletinib (3rd generation EGFR inhibitor)		Case report	ERBB2		LUAD	PMID:27252416									Lung adenocarcinoma
ERBB2:amp	CNA		Responsive	ERBB2 amplification	CRubio-Perez	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		FDA guidelines	ERBB2		ST;GEJA	FDA									Stomach;Gastroesophageal junction adenocarcinoma
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann;CRubio-Perez	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		FDA guidelines	ERBB2		BRCA	FDA									Breast adenocarcinoma
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Early trials	ERBB2		BT	PMID:26022204									Billiary tract
ERBB2:amp	CNA		No Responsive	ERBB2 amplification	DTamborero;RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Early trials	ERBB2		ED	PMID:26099744;PMID:19840887									Endometrium
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Case report	ERBB2		HNC	PMID:21380780									Head an neck
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Early trials	ERBB2		OV	PMID:20003286;PMID:12525520									Ovary
ERBB2:over	EXPR		Responsive	ERBB2 overexpression	CRubio-Perez	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)	Approved	FDA guidelines	ERBB2		BRCA	FDA									Breast adenocarcinoma
ERBB2:over	EXPR		Responsive	ERBB2 overexpression	CRubio-Perez	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)	Approved	FDA guidelines	ERBB2		ST;GEJA	FDA									Stomach;Gastroesophageal junction adenocarcinoma
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann	Ado-Trastuzumab Emtansine	ERBB2 mAb inhibitor	Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)		Case report	ERBB2		COREAD	http://ascopubs.org/doi/full/10.1200/PO.16.00055									Colorectal adenocarcinoma
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann	Trastuzumab;Everolimus;Chemotherapy	ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy	Trastuzumab + Everolimus + Chemotherapy (ERBB2 mAb inhibitor + MTOR inhibitor + Chemotherapy)		Early trials	ERBB2		BRCA	PMID:21107682;PMID:20975068									Breast adenocarcinoma
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann	Trastuzumab;HSP90 inhibitor	ERBB2 mAb inhibitor;HSP90 inhibitor	Trastuzumab + HSP90 inhibitor (ERBB2 mAb inhibitor + HSP90 inhibitor)		Early trials	ERBB2		BRCA	PMID:21558407									Breast adenocarcinoma
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann	Trastuzumab;Lapatinib	ERBB2 mAb inhibitor;ERBB2 inhibitor	Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)		Late trials	ERBB2		COREAD	ASCO 2015 (abstr 3508);NCT01104571;EBCC10									Colorectal adenocarcinoma
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann	Trastuzumab;Lapatinib	ERBB2 mAb inhibitor;ERBB2 inhibitor	Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)		Pre-clinical	ERBB2		ED	PMID:25294905									Endometrium
ERBB2:norm;ESR1:over	EXPR;EXPR		Responsive	ERBB2 expression + ESR1 overexpression	JAlbanell;ARovira	[Tamoxifen,Letrozole,Anastrozole,Exemestane,Fulvestrant,LHRH analogues or antagonist]	[Hormonal therapy]	Hormonal therapys (Tamoxifen,Letrozole,Anastrozole,Exemestane,Fulvestrant,LHRH analogues or antagonist,etc)	Approved	FDA guidelines	ERBB2;ESR1		BRCA	FDA									Breast adenocarcinoma
ERBB2:norm;ESR1:over	EXPR;EXPR		Responsive	ERBB2 expression + ESR1 overexpression	DTamborero;CRubio-Perez	Abemaciclib	CDK4/6 inhibitor	Abemaciclib (CDK4/6 inhibitor)		Early trials	ERBB2;ESR1		BRCA	PMID:26658964									Breast adenocarcinoma
ERBB2:norm;ESR1:over	EXPR;EXPR		Responsive	ERBB2 expression + ESR1 overexpression	JAlbanell;ARovira	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)	Approved	FDA guidelines	ERBB2;ESR1		BRCA	FDA									Breast adenocarcinoma
ERBB2:norm;ESR1:over	EXPR;EXPR		Responsive	ERBB2 expression + ESR1 overexpression	CRubio-Perez	Palbociclib	CDK4/6 inhibitor	Palbociclib (CDK4/6 inhibitor)	Approved	FDA guidelines	ERBB2;ESR1		BRCA	FDA									Breast adenocarcinoma
ERBB3:amp	CNA		Resistant	ERBB3 amplification	RDientsmann	[]	[EGFR mAb inhibitor]	EGFR mAb inhibitors		Early trials	ERBB3		COREAD	PMID:25520391									Colorectal adenocarcinoma
ERBB4__.	FUS		Responsive	ERBB4 fusion	RDientsmann	Lapatinib;Afatinib	ERBB2 inhibitor;ERBB2 inhibitor&EGFR inhibitor 2nd gen	Lapatinib + Afatinib (ERBB2 inhibitor + ERBB2 inhibitor&EGFR inhibitor 2nd gen)		Pre-clinical	ERBB4		LUAD	PMID:24727320									Lung adenocarcinoma
ERCC1:del	CNA		Responsive	ERCC1 deletion	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Pre-clinical	ERCC1		L	PMID:23934192									Lung
ERCC1:del	CNA		Responsive	ERCC1 deletion	RDientsmann	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)		Pre-clinical	ERCC1		L	PMID:23275151;PMID:23934192									Lung
ERCC1:over	EXPR		Resistant	ERCC1 overexpression	ARodriguez-Vida	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	Pre-clinical	ERCC1	BLCA	BLCA	PMID:20846399;PMID:21177407									Bladder
EREG:amp	CNA		Responsive	EREG amplification	RDientsmann	[]	[EGFR mAb inhibitor]	EGFR mAb inhibitors		Early trials	EREG		COREAD	PMID:19738126;PMID:26341080									Colorectal adenocarcinoma
ESR1__YAP1	FUS		Resistant	ESR1-YAP1 fusion	RDientsmann	[]	[ESR1 inhibitor]	ESR1 inhibitors		Pre-clinical	ESR1		BRCA	PMID:24055055									Breast adenocarcinoma
FANCA:del	CNA		Responsive	FANCA deletion	RDientsmann	Olaparib	PARP inhibitor	Olaparib (PARP inhibitor)		Case report	FANCA		PRAD	PMID:26510020									Prostate adenocarcinoma
FANCC:del	CNA		Responsive	FANCC deletion	ARodriguez-Vida	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	Early trials	FANCC	BLCA	BLCA	PMID:26238431	Indirect								Bladder
FBXW7:del	CNA		Resistant	FBXW7 deletion	RDientsmann	[]	[Tubulin inhibitor]	Tubulin inhibitors		Pre-clinical	FBXW7		CANCER	PMID:21368834									Any cancer type
FBXW7:del	CNA	Cell line	Responsive	FBXW7 deletion	CRubio-Perez	Sirolimus	MTOR inhibitor	Sirolimus (MTOR inhibitor)	Approved	Pre-clinical	FBXW7		COREAD	PMID:23558291	Indirect								Colorectal adenocarcinoma
FGF3:amp	CNA		Responsive	FGF3 amplification	RDientsmann	Dovitinib	FGFR inhibitor	Dovitinib (FGFR inhibitor)		Early trials	FGF3		BRCA	PMID:23658459									Breast adenocarcinoma
FGF3:amp	CNA		Responsive	FGF3 amplification	JAlbanell;ARovira	Lucitanib	FGFR inhibitor	Lucitanib (FGFR inhibitor)	Clinical Trials	Early trials	FGF3		BRCA	PMID:25193991	Indirect								Breast adenocarcinoma
FGF4:amp	CNA		Responsive	FGF4 amplification	RDientsmann	Dovitinib	FGFR inhibitor	Dovitinib (FGFR inhibitor)		Early trials	FGF4		BRCA	PMID:23658459									Breast adenocarcinoma
FGF4:amp	CNA		Responsive	FGF4 amplification	JAlbanell;ARovira	Lucitanib	FGFR inhibitor	Lucitanib (FGFR inhibitor)	Clinical Trials	Early trials	FGF4		BRCA	PMID:25193991	Indirect								Breast adenocarcinoma
FGFR1:amp	CNA		Responsive	FGFR1 amplification	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Case report	FGFR1		LUSC	PMID:27870574									Lung squamous cell
FGFR1:amp	CNA		Responsive	FGFR1 amplification	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Case report	FGFR1		ED	ASCO 2017 (abstr 2500)									Endometrium
FGFR1:amp	CNA		Responsive	FGFR1 amplification	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Early trials	FGFR1		LUSC	AACR 2012 (abstr LB-122);AACR 2013 (abstr LB-145)									Lung squamous cell
FGFR1:amp	CNA		Responsive	FGFR1 amplification	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR1		HNC	PMID:23418312									Head an neck
FGFR1:amp	CNA		Responsive	FGFR1 amplification	RDientsmann;JAlbanell	[Lucitanib]	[FGFR inhibitor]	FGFR inhibitors (Lucitanib,etc)		Early trials	FGFR1		BRCA	PMID:25193991									Breast adenocarcinoma
FGFR2__.	FUS		Responsive	FGFR2 fusion	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Early trials	FGFR2		BT	ASCO 2016 (abstr 109)									Billiary tract
FGFR2:amp	CNA		Responsive	FGFR2 amplification	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Early trials	FGFR2		ST	ASCO 2015 (abstr 2508)									Stomach
FGFR2:amp	CNA		Responsive	FGFR2 amplification	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Case report	FGFR2		BRCA	PMID:25193991									Breast adenocarcinoma
FGFR2:N549H,V564F,K659M,L617V,K641R,R565A;FGFR2__.	MUT;FUS		Resistant	FGFR2 (N549H,V564F,K659M,L617V,K641R,R565A) + FGFR2 fusion	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Early trials	FGFR2;FGFR2		CH	PMID:28034880;ASCO 2017 (abstr 2500)									Cholangiocarcinoma
FGFR2__.	FUS		Responsive	FGFR2 fusion	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Early trials	FGFR2		COREAD	ASCO 2017 (abstr 2500)									Colorectal adenocarcinoma
FGFR3__.	FUS		Responsive	FGFR3 fusion	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Early trials	FGFR3		G	PMID:26324363									Glioma
FGFR3__.	FUS		Responsive	FGFR3 fusion	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Case report	FGFR3		BLCA	PMID:26324363;ASCO 2017 (abstr 2500)									Bladder
FGFR3__TACC3	FUS		Responsive	FGFR3-TACC3 fusion	EArriola		[FGFR inhibitor]	FGFR inhibitors (,etc)		Pre-clinical	FGFR3		NSCLC	PMID:25294908									Non-small cell lung
FLCN:del	CNA		Responsive	FLCN deletion	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	FLCN		TH	PMID:25295501									Thyroid
VEGFR1:over	EXPR	Cell line	Responsive	FLT1 overexpression	ARodriguez-Vida	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)	Approved	Pre-clinical	FLT1		R	PMID:24086736;PMID:21478036	Direct								Renal
VEGFR2:over	EXPR	Cell line	Responsive	FLT1 overexpression	ARodriguez-Vida	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)	Approved	Pre-clinical	FLT1		R	PMID:24086736;PMID:21478036	Direct								Renal
FOXA1:amp	CNA		Responsive	FOXA1 amplification	RDientsmann	[]	[BCL2 inhibitor]	BCL2 inhibitors		Pre-clinical	FOXA1		COREAD	PMID:27397505									Colorectal adenocarcinoma
FRS2:amp	CNA		Responsive	FRS2 amplification	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FRS2		LIP	PMID:23393200									Liposarcoma
G6PD:.	BIA		Increased Toxicity (Haemolytic Anemia)	G6PD biallelic inactivation	DTamborero;CRubio-Perez	Dabrafenib	BRAF inhibitor	Dabrafenib (BRAF inhibitor)	Approved	FDA guidelines	G6PD		CANCER	FDA									Any cancer type
G6PD:V98M;G6PD:N156D	MUT;MUT		Increased Toxicity (Haemolytic Anemia)	G6PD (V98M) + G6PD (N156D)	DTamborero;CRubio-Perez	Dabrafenib	BRAF inhibitor	Dabrafenib (BRAF inhibitor)	Approved	FDA guidelines	G6PD;G6PD		CANCER	FDA									Any cancer type
GLI2:amp	CNA		Resistant	GLI2 amplification	DTamborero;RDientsmann	[]	[SMO inhibitor]	SMO inhibitors		Pre-clinical	GLI2		MB	PMID:24951114									Medulloblastoma
HDAC2:.	BIA		Responsive	HDAC2 biallelic inactivation	RDientsmann;CRubio-Perez	Olaparib	PARP inhibitor	Olaparib (PARP inhibitor)		Case report	HDAC2		PRAD	PMID:26510020									Prostate adenocarcinoma
HGF:over	EXPR	Xenograft	Responsive	HGF overexpression	CRubio-Perez;ARodriguez-Vida	Cabozantinib	Pan-kinase inhibitor	Cabozantinib (Pan-kinase inhibitor)	Approved	Pre-clinical	HGF		UTC	PMID:25534569	Indirect								Urinary tract carcinoma
HGF:amp;ERBB2:amp	CNA;CNA		Resistant	HGF amplification + ERBB2 amplification	RDientsmann;CRubio-Perez	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Early trials	HGF;ERBB2		BRCA	PMID:22850551									Breast adenocarcinoma
HIF1A:over	EXPR	Cell line	Responsive	HIF1A overexpression	ARodriguez-Vida	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)	Approved	Pre-clinical	HIF1A		R	PMID:24086736	Indirect								Renal
IGF1R:amp	CNA		Resistant	IGF1R amplification	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)		Pre-clinical	IGF1R		LUAD	PMID:24458568									Lung adenocarcinoma
IGF2:amp	CNA		Resistant	IGF2 amplification	RDientsmann	[]	[EGFR mAb inhibitor]	EGFR mAb inhibitors		Early trials	IGF2		COREAD	PMID:25632036									Colorectal adenocarcinoma
IL7R::consequence::inframe_insertion:237-255,::inframe_deletion:237-255;SH2B3:del	MUT;CNA		Responsive	IL7R inframe insertion (237-255),inframe deletion (237-255) + SH2B3 deletion	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	IL7R;SH2B3		ALL	PMID:22955920									Acute lymphoblastic leukemia
IL7R:S185C;SH2B3:del	MUT;CNA		Responsive	IL7R (S185C) + SH2B3 deletion	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	IL7R;SH2B3		ALL	PMID:22955920									Acute lymphoblastic leukemia
IL7R::consequence::inframe_insertion:237-255,::inframe_deletion:237-255;SH2B3:del	MUT;CNA		Responsive	IL7R inframe insertion (237-255),inframe deletion (237-255) + SH2B3 deletion	RDientsmann	Ruxolitinib	JAK inhibitor	Ruxolitinib (JAK inhibitor)		Pre-clinical	IL7R;SH2B3		ALL	PMID:22897847;PMID:22955920									Acute lymphoblastic leukemia
IL7R:S185C;SH2B3:del	MUT;CNA		Responsive	IL7R (S185C) + SH2B3 deletion	RDientsmann	Ruxolitinib	JAK inhibitor	Ruxolitinib (JAK inhibitor)		Pre-clinical	IL7R;SH2B3		ALL	PMID:22897847;PMID:22955920									Acute lymphoblastic leukemia
INPP4B:del	CNA		Responsive	INPP4B deletion	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Pre-clinical	INPP4B		BRCA	PMID:23551093									Breast adenocarcinoma
JAK2:amp	CNA		Responsive	JAK2 amplification	RDientsmann	[]	[JAK inhibitor]	JAK inhibitors		Pre-clinical	JAK2		BRCA	PMID:27075627									Breast adenocarcinoma
JAK2__BRAF	FUS		Responsive	JAK2-BRAF fusion	RDientsmann	Ruxolitinib	JAK inhibitor	Ruxolitinib (JAK inhibitor)		Pre-clinical	JAK2		ALL	PMID:22875628;PMID:22899477									Acute lymphoblastic leukemia
KIT:amp	CNA		No Responsive	KIT amplification	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Early trials	KIT		CM	PMID:23775962									Cutaneous melanoma
KIT:amp	CNA		No Responsive	KIT amplification	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Early trials	KIT		CM	PMID:22261812									Cutaneous melanoma
KRAS:amp	CNA		Resistant	KRAS amplification	RDientsmann	[]	[BRAF inhibitor;EGFR mAb inhibitor]	BRAF inhibitor + EGFR mAb inhibitors		Case report	KRAS		COREAD	ENA 2014 (abstr 428)									Colorectal adenocarcinoma
KRAS:amp	CNA		Resistant	KRAS amplification	RDientsmann	[]	[BRAF inhibitor;MEK inhibitor]	BRAF inhibitor + MEK inhibitors		Case report	KRAS		COREAD	ENA 2014 (abstr 428)									Colorectal adenocarcinoma
LRP1B:del	CNA		Resistant	LRP1B deletion	RDientsmann	Liposomal Doxorubicin	Chemotherapy	Liposomal Doxorubicin (Chemotherapy)		Early trials	LRP1B		OV	PMID:22896685									Ovary
MAP2K1:P124S,I111S;BRAF:.	MUT;MUT		Responsive	MAP2K1 (P124S,I111S) + BRAF oncogenic mutation	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	MAP2K1;BRAF		CM	PMID:22588879									Cutaneous melanoma
MCL1:amp	CNA		Resistant	MCL1 amplification	RDientsmann	[]	[Tubulin inhibitor]	Tubulin inhibitors		Pre-clinical	MCL1		CANCER	PMID:21368834									Any cancer type
MDM2:amp	CNA		Responsive	MDM2 amplification	RDientsmann	[]	[MDM2 inhibitor]	MDM2 inhibitors		Early trials	MDM2		LIP	PMID:23084521;ASCO 2015 (abstr 10564)									Liposarcoma
MDM2:amp	CNA		Resistant	MDM2 amplification	RDientsmann	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)		Early trials	MDM2		MGCT	PMID:27646943									Male germ cell tumor
MDM4:amp	CNA		Responsive	MDM4 amplification	RDientsmann	[]	[MDM2/MDMX inhibitor]	MDM2/MDMX inhibitors		Pre-clinical	MDM4		S	PMID:24336067									Sarcoma
MET:amp	CNA		Responsive	MET amplification	RDientsmann	[]	[BCL2 inhibitor]	BCL2 inhibitors		Pre-clinical	MET		COREAD	PMID:27397505									Colorectal adenocarcinoma
MET:amp	CNA		Resistant	MET amplification	DTamborero	[]	[EGFR inhibitor 1st gen]	EGFR inhibitor 1st gens		Early trials	MET		NSCLC;COREAD	PMID:22189054;PMID:23729478									Non-small cell lung;Colorectal adenocarcinoma
MET:amp	CNA		Resistant	MET amplification	RDientsmann	[]	[EGFR mAb inhibitor]	EGFR mAb inhibitors		Early trials	MET		COREAD	PMID:23729478									Colorectal adenocarcinoma
MET:amp	CNA		Responsive	MET amplification	RDientsmann	[]	[MET inhibitor]	MET inhibitors		Case report	MET		HC	ENA 2015 (abstract A55)									Hepatic carcinoma
MET:amp	CNA		Responsive	MET amplification	RDientsmann	[]	[MET inhibitor]	MET inhibitors		Pre-clinical	MET		ST	PMID:22729845;PMID:23327903									Stomach
MET:amp	CNA		Responsive	MET amplification	RDientsmann	[]	[MET inhibitor]	MET inhibitors		Early trials	MET		R	PMID:23213094;AACR 2016 (abstr CT2006)									Renal
MET:amp	CNA		Responsive	MET amplification	RDientsmann	Cabozantinib;Panitumumab	Pan-kinase inhibitor;EGFR mAb inhibitor	Cabozantinib + Panitumumab (Pan-kinase inhibitor + EGFR mAb inhibitor)	Clinical Trials	Case report	MET		COREAD	ENA 2015 (abstr A52)									Colorectal adenocarcinoma
MET__.	FUS		Responsive	MET fusion	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	MET		G	PMID:27748748									Glioma
MET:amp	CNA		Responsive	MET amplification	EArriola;CRubio-Perez	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)	Clinical Trials	Early trials	MET		NSCLC	NCT02499614;ASCO 2015 (abstr 2595)									Non-small cell lung
MET:amp	CNA		Responsive	MET amplification	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Early trials	MET		LUAD;ST	ASCO 2014 (abstr 8001);ASCO 2015 (abstr 2595);ASCO GI 2015 (abstr 1)									Lung adenocarcinoma;Stomach
MET:amp	CNA		Responsive	MET amplification	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	MET		G	PMID:22162573									Glioma
MET:amp	CNA		Resistant	MET amplification	EArriola	Osimertinib	[EGFR inhibitor 3rd gen]	EGFR inhibitor 3rd gens (Osimertinib,etc)	Approved	Case report	MET		LUAD	PMID:27252416									Lung adenocarcinoma
MET:amp	CNA		Resistant	MET amplification	EArriola	Rociletinib	[EGFR inhibitor 3rd gen]	EGFR inhibitor 3rd gens (Rociletinib,etc)		Case report	MET		LUAD	PMID:27252416									Lung adenocarcinoma
MET:amp;BRAF:V600E	CNA;MUT		Responsive	MET amplification + BRAF (V600E)	RDientsmann	Crizotinib;Vemurafenib	ALK inhibitor;BRAF inhibitor	Crizotinib + Vemurafenib (ALK inhibitor + BRAF inhibitor)		Case report	MET;BRAF		COREAD	PMID:27325282									Colorectal adenocarcinoma
MET:amp;BRAF:V600E	CNA;MUT		Resistant	MET amplification + BRAF (V600E)	RDientsmann	Vemurafenib;Panitumumab	BRAF inhibitor;EGFR mAb inhibitor	Vemurafenib + Panitumumab (BRAF inhibitor + EGFR mAb inhibitor)		Case report	MET;BRAF		COREAD	PMID:27325282									Colorectal adenocarcinoma
MET:amp;EGFR:.	CNA;MUT		Resistant	MET amplification + EGFR oncogenic mutation	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Early trials	MET;EGFR		LUAD	ASCO 2015 (abstr 8089)									Lung adenocarcinoma
MET:amp;ERBB2:amp	CNA;CNA		Responsive	MET amplification + ERBB2 amplification	RDientsmann	Crizotinib;Trastuzumab	ALK inhibitor;ERBB2 mAb inhibitor	Crizotinib + Trastuzumab (ALK inhibitor + ERBB2 mAb inhibitor)		Case report	MET;ERBB2		ST	PMID:26432108									Stomach
MET:amp;ERBB2:amp	CNA;CNA		Responsive	MET amplification + ERBB2 amplification	RDientsmann	Crizotinib;Trastuzumab	ALK inhibitor;ERBB2 mAb inhibitor	Crizotinib + Trastuzumab (ALK inhibitor + ERBB2 mAb inhibitor)		Case report	MET;ERBB2		ST	PMID:26432108									Stomach
MET:amp;ERBB2:amp	CNA;CNA		Resistant	MET amplification + ERBB2 amplification	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	MET;ERBB2		ST	PMID:22238368									Stomach
MET:amp;ERBB2:amp	CNA;CNA		Resistant	MET amplification + ERBB2 amplification	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Early trials	MET;ERBB2		BRCA	PMID:22850551									Breast adenocarcinoma
MET:amp;ERBB2:amp	CNA;CNA		Resistant	MET amplification + ERBB2 amplification	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Early trials	MET;ERBB2		BRCA;ST	PMID:22850551; PMID:26432108									Breast adenocarcinoma;Stomach
MITF:amp	CNA		Resistant	MITF amplification	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	MITF		CM	PMID:24265153									Cutaneous melanoma
MITF:amp	CNA		Resistant	MITF amplification	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	MITF		CM	PMID:24265153									Cutaneous melanoma
MKI67:over	EXPR	Cell line	Responsive	MKI67 overexpression	ARodriguez-Vida	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)	Approved	Pre-clinical	MKI67		R	PMID:24086736	Indirect								Renal
MLL__.	FUS		Responsive	MLL fusion	RDientsmann	[]	[BET inhibitor]	BET inhibitors		Pre-clinical	MLL		AML	PMID:21964340									Acute myeloid leukemia
MLL__.	FUS		Responsive	MLL fusion	ECampo;RDientsmann	Belinostat	HDAC inhibitor	Belinostat (HDAC inhibitor)	Approved	Early trials	MLL		AML	NCT00351975;NCT00357032;PMID:22015773	Indirect								Acute myeloid leukemia
MLL__.	FUS		Responsive	MLL fusion	RDientsmann	Daunorubicin	Chemotherapy	Daunorubicin (Chemotherapy)	Approved	FDA guidelines	MLL		AML	PMID:22417203									Acute myeloid leukemia
MLL__.	FUS		Responsive	MLL fusion	ECampo;RDientsmann	EPZ-5676	DOTL1 inhibitor	EPZ-5676 (DOTL1 inhibitor)	Clinical Trials	Early trials	MLL		AML;ALL;MDS	NCT02141828;NCT01684150;PMID:21741596	Indirect								Acute myeloid leukemia;Acute lymphoblastic leukemia;Myelodisplasic syndrome
MYC:amp	CNA		Responsive	MYC amplification	RDientsmann	[]	[BET inhibitor]	BET inhibitors		Pre-clinical	MYC		MYMA;NB	PMID:21889194;PMID:23430699									Myeloma;Neuroblastoma
MYC:amp	CNA		Responsive	MYC amplification	RDientsmann	[]	[CDK7 inhibitor]	CDK7 inhibitors		Pre-clinical	MYC		NB	PMID:25416950									Neuroblastoma
MYC:amp	CNA		Responsive	MYC amplification	RDientsmann	[]	[FACT inhibitor]	FACT inhibitors		Pre-clinical	MYC		NB	PMID:26537256									Neuroblastoma
MYC:amp	CNA		Responsive	MYC amplification	RDientsmann	[]	[PIM inhibitor]	PIM inhibitors		Pre-clinical	MYC		PRAD	PMID:25505253									Prostate adenocarcinoma
MYC:amp	CNA		Responsive	MYC amplification	RDientsmann	Temozolomide	Chemotherapy	Temozolomide (Chemotherapy)		Pre-clinical	MYC		COREAD	PMID:27397505									Colorectal adenocarcinoma
MYCN:amp	CNA		Resistant	MYCN amplification	DTamborero;RDientsmann	[]	[SMO inhibitor]	SMO inhibitors		Pre-clinical	MYCN		MB	PMID:24951114									Medulloblastoma
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	[]	[AURK inhibitor]	AURK inhibitors		Pre-clinical	NF1		MPN	PMID:24373973									Malignant peripheral nerve sheat tumor
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	[]	[BRD4 inhibitor]	BRD4 inhibitors		Pre-clinical	NF1		MPN	PMID:24373973									Malignant peripheral nerve sheat tumor
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	[]	[KIT inhibitor;MTOR inhibitor]	KIT inhibitor + MTOR inhibitors		Pre-clinical	NF1		MPN	PMID:24718867									Malignant peripheral nerve sheat tumor
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	NF1		MPN	PMID:23221341									Malignant peripheral nerve sheat tumor
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	NF1		G;LK	PMID:22573716;PMID:19727076									Glioma;Leukemia
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	[]	[MTOR inhibitor;HSP90 inhibitor]	MTOR inhibitor + HSP90 inhibitors		Pre-clinical	NF1		MPN	PMID:21907929									Malignant peripheral nerve sheat tumor
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	NF1		G;MPN;LK	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877									Glioma;Malignant peripheral nerve sheat tumor;Leukemia
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	[]	[Pan-RAF inhibitor;MEK inhibitor]	Pan-RAF inhibitor + MEK inhibitors		Pre-clinical	NF1		CM	PMID:26351322									Cutaneous melanoma
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	[]	[PD1 Ab inhibitor]	PD1 Ab inhibitors		Early trials	NF1		CM	ASCO 2016 (abstr 105)									Cutaneous melanoma
NF1:del	CNA		Resistant	NF1 deletion	RDientsmann	[]	[Retinoic Acid]	Retinoic Acids		Pre-clinical	NF1		NB	PMID:20655465									Neuroblastoma
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	Bevacizumab	VEGFR mAb inhibitor	Bevacizumab (VEGFR mAb inhibitor)		Case report	NF1		G	PMID:24232489;PMID:2485933									Glioma
NF1:del	CNA		No Responsive	NF1 deletion	RDientsmann	Cediranib	ALK inhibitor	Cediranib (ALK inhibitor)		Early trials	NF1		PLEN	NCT00326872									Plexiform neurofibroma
NF1:del	CNA		Resistant	NF1 deletion	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	NF1		L	PMID:24296828									Lung
NF1:del	CNA		Resistant	NF1 deletion	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)		Pre-clinical	NF1		L	PMID:24535670									Lung
NF1:del	CNA		No Responsive	NF1 deletion	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Early trials	NF1		MPN	NCT01365468									Malignant peripheral nerve sheat tumor
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	NF1		HNC;SG	PMID:26859683;ASCO 2016 (abstr e17557)									Head an neck;Salivary glands
NF1:del	CNA		No Responsive	NF1 deletion	RDientsmann	Everolimus;Bevacizumab	MTOR inhibitor;VEGFR mAb inhibitor	Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)		Early trials	NF1		MPN	ASCO 2016 (abstr 11053)									Malignant peripheral nerve sheat tumor
NF1:del	CNA		No Responsive	NF1 deletion	RDientsmann	Everolimus;Erlotinib	MTOR inhibitor;EGFR inhibitor 1st gen	Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)		Case report	NF1		G	PMID:24634382									Glioma
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Early trials	NF1		PLEN	PMID:23099009									Plexiform neurofibroma
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	NF1		PLEN;MPN	PMID:24173684									Plexiform neurofibroma;Malignant peripheral nerve sheat tumor
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	PLX3397	Pan-TK inhibitor	PLX3397 (Pan-TK inhibitor)		Pre-clinical	NF1		PLEN	PMID:23099891									Plexiform neurofibroma
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	Selumetinib	MEK inhibitor	Selumetinib (MEK inhibitor)		Early trials	NF1		PLEN	ASCO 2014 (abstr 10018)									Plexiform neurofibroma
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	Sirolimus	MTOR inhibitor	Sirolimus (MTOR inhibitor)		Early trials	NF1		PLEN	PMID:25314964									Plexiform neurofibroma
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	Sirolimus;Erlotinib	MTOR inhibitor;EGFR inhibitor 1st gen	Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)		Case report	NF1		G	PMID:22434731									Glioma
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	Sorafenib;Sirolimus	Pan-TK inhibitor;MTOR inhibitor	Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)		Pre-clinical	NF1		MPN	PMID:25810463									Malignant peripheral nerve sheat tumor
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	Tamoxifen	Hormonal therapy	Tamoxifen (Hormonal therapy)		Pre-clinical	NF1		MPN	PMID:21075781									Malignant peripheral nerve sheat tumor
NF1:del	CNA		No Responsive	NF1 deletion	RDientsmann	Tipifarnib	Farnesyltransferase inhibitor	Tipifarnib (Farnesyltransferase inhibitor)		Early trials	NF1		PLEN	PMID:24500418									Plexiform neurofibroma
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	Trametinib	MEK inhibitor	Trametinib (MEK inhibitor)		Case report	NF1		G	PMID:26936308									Glioma
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	Trametinib	MEK inhibitor	Trametinib (MEK inhibitor)		Pre-clinical	NF1		CM	PMID:24576830;PMID:2524381									Cutaneous melanoma
NF1:del	CNA		No Responsive	NF1 deletion	RDientsmann	Trametinib	MEK inhibitor	Trametinib (MEK inhibitor)		Case report	NF1		OS	PMID:26325560									Osteosarcoma
NF1:.	BIA		Resistant	NF1 biallelic inactivation	DTamborero	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)		Pre-clinical	NF1		CM	PMID:23171796									Cutaneous melanoma
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	Vinblastine	Chemotherapy	Vinblastine (Chemotherapy)		Early trials	NF1		G	ASCO 2016 (abstr 2019)									Glioma
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	Vinblastine;Nilotinib	Chemotherapy;BCR-ABL inhibitor 2nd gen	Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)		Case report	NF1		G	ASCO 2016 (abstr 10555)									Glioma
NF1:.;BRAF:.	MUT;MUT		Resistant	NF1 oncogenic mutation + BRAF oncogenic mutation	RDientsmann	Selumetinib	MEK inhibitor	Selumetinib (MEK inhibitor)		Case report	NF1;BRAF		CM	PMID:23444215									Cutaneous melanoma
NF1:del;BRAF:.	CNA;MUT		Resistant	NF1 deletion + BRAF oncogenic mutation	RDientsmann	Selumetinib	MEK inhibitor	Selumetinib (MEK inhibitor)		Case report	NF1;BRAF		CM	PMID:23444215									Cutaneous melanoma
NF1:.;BRAF:.	MUT;MUT		Resistant	NF1 oncogenic mutation + BRAF oncogenic mutation	RDientsmann	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)		Case report	NF1;BRAF		CM	PMID:23288408;PMID:231718									Cutaneous melanoma
NF1:del;BRAF:.	CNA;MUT		Resistant	NF1 deletion + BRAF oncogenic mutation	RDientsmann	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)		Case report	NF1;BRAF		CM	PMID:23288408;PMID:231718									Cutaneous melanoma
NF2:del	CNA		Responsive	NF2 deletion	RDientsmann	[]	[FAK inhibitor]	FAK inhibitors		Early trials	NF2		MESO	ENA 2012 (abstr 610)									Mesothelioma
NF2:del	CNA		Responsive	NF2 deletion	RDientsmann	[]	[FAK inhibitor]	FAK inhibitors		Pre-clinical	NF2		MESO;OV	PMID:24848258;PMID:24786638									Mesothelioma;Ovary
NF2:del	CNA		Responsive	NF2 deletion	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Pre-clinical	NF2		MEN	PMID:23714726									Meningioma
NF2:del	CNA		Responsive	NF2 deletion	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	NF2		TH	PMID:26359368									Thyroid
NF2:del	CNA		Responsive	NF2 deletion	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	NF2		MEN	PMID:19451225;PMID:2242646									Meningioma
NF2:del	CNA		Responsive	NF2 deletion	RDientsmann	[]	[PAK inhibitor]	PAK inhibitors		Pre-clinical	NF2		SCHW;MEN	PMID:23960073;PMID:25596744									Schwannoma;Meningioma
NF2:del	CNA		Responsive	NF2 deletion	RDientsmann	[]	[PDK1 inhibitor]	PDK1 inhibitors		Pre-clinical	NF2		SCHW	PMID:19359162									Schwannoma
NF2:del	CNA		Responsive	NF2 deletion	RDientsmann	AR42	HDAC inhibitor	AR42 (HDAC inhibitor)		Pre-clinical	NF2		SCHW	PMID:21778190									Schwannoma
NF2:del	CNA		Responsive	NF2 deletion	RDientsmann	AR42	HDAC inhibitor	AR42 (HDAC inhibitor)		Early trials	NF2		MEN	ASCO 2016 (abstr 2558)									Meningioma
NF2:del	CNA		Responsive	NF2 deletion	RDientsmann	Bevacizumab	VEGFR mAb inhibitor	Bevacizumab (VEGFR mAb inhibitor)		Early trials	NF2		SCHW	PMID:19587327;PMID:22805104;PMID:26022982									Schwannoma
NF2:del	CNA		No Responsive	NF2 deletion	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)		Early trials	NF2		SCHW	PMID:20736812									Schwannoma
NF2:del	CNA		Responsive	NF2 deletion	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Early trials	NF2		SCHW	PMID:24311643;2556735									Schwannoma
NF2:del	CNA		Responsive	NF2 deletion	RDientsmann	Everolimus;Octreotide	MTOR inhibitor;Somatostatin analog	Everolimus + Octreotide (MTOR inhibitor + Somatostatin analog)		Pre-clinical	NF2		MEN	PMID:26015296									Meningioma
NF2:del	CNA		Responsive	NF2 deletion	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	NF2		SCHW	PMID:19509233;PMID:2290085									Schwannoma
NF2:del	CNA		Responsive	NF2 deletion	RDientsmann;MMartínez	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Early trials	NF2		SCHW;NF	PMID:22844108;NCT00973739									Schwannoma;Neurofibroma
NF2:del	CNA		Responsive	NF2 deletion	RDientsmann	Tensirolimus;Chemotherapy	MTOR inhibitor;Chemotherapy	Tensirolimus + Chemotherapy (MTOR inhibitor + Chemotherapy)		Case report	NF2		BRCA	PMID:25878190									Breast adenocarcinoma
NF2:.;EGFR:.	MUT;MUT		Resistant	NF2 oncogenic mutation + EGFR oncogenic mutation	RDientsmann	Erlotinib;Cetuximab	EGFR inhibitor 1st gen;EGFR mAb inhibitor	Erlotinib + Cetuximab (EGFR inhibitor 1st gen + EGFR mAb inhibitor)		Case report	NF2;EGFR		L	PMID:24813888									Lung
NF2:del;EGFR:.	CNA;MUT		Resistant	NF2 deletion + EGFR oncogenic mutation	RDientsmann	Erlotinib;Cetuximab	EGFR inhibitor 1st gen;EGFR mAb inhibitor	Erlotinib + Cetuximab (EGFR inhibitor 1st gen + EGFR mAb inhibitor)		Case report	NF2;EGFR		L	PMID:24813888									Lung
NOTCH1__.	FUS		Responsive	NOTCH1 fusion	RDientsmann	[]	[Gamma secretase inhibitor]	Gamma secretase inhibitors		Pre-clinical	NOTCH1		ALL	PMID:16688224;PMID:23033986									Acute lymphoblastic leukemia
NOTCH1__.	FUS		Responsive	NOTCH1 fusion	RDientsmann	[]	[Gamma secretase inhibitor]	Gamma secretase inhibitors		Pre-clinical	NOTCH1		BRCA	PMID:22101766									Breast adenocarcinoma
NOTCH2__.	FUS		Responsive	NOTCH2 fusion	RDientsmann	[]	[Gamma secretase inhibitor]	Gamma secretase inhibitors		Pre-clinical	NOTCH2		BRCA	PMID:22101766									Breast adenocarcinoma
NRG1__.	FUS		Responsive	NRG1 fusion	RDientsmann	Afatinib	ERBB2&EGFR inhibitor 2nd gen	Afatinib (ERBB2&EGFR inhibitor 2nd gen)		Case report	NRG1		LUAD	AACR 2016 (abstr 2631)									Lung adenocarcinoma
NRG1__.	FUS		Responsive	NRG1 fusion	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	NRG1		LUAD	PMID:24727320									Lung adenocarcinoma
NTRK1__.	FUS		Responsive	NTRK1 fusion	RDientsmann	[]	[Pan-TK inhibitor]	Pan-TK inhibitors		Pre-clinical	NTRK1		LUAD	PMID:24162815									Lung adenocarcinoma
NTRK1__.	FUS		Responsive	NTRK1 fusion	RDientsmann	[]	[Pan-TKR inhibitor]	Pan-TKR inhibitors		Early trials	NTRK1		CANCER	PMID:28183697;ASCO 2017 (LBA2501)									Any cancer type
NTRK1__.	FUS		Responsive	NTRK1 fusion	RDientsmann	[Entrectinib]	[Pan-TK inhibitor]	Pan-TK inhibitors (Entrectinib,etc)		Case report	NTRK1		COREAD	PMID:26546295									Colorectal adenocarcinoma
NTRK1__.	FUS		Responsive	NTRK1 fusion	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	NTRK1		LUAD	ASCO 2013 (abstr 8023)									Lung adenocarcinoma
NTRK3__.	FUS		Responsive	NTRK3 fusion	RDientsmann	[]	[IGF1R inhibitor]	IGF1R inhibitors		Pre-clinical	NTRK3		BRCA	PMID:21148487;PMID:23131561									Breast adenocarcinoma
NTRK3__.	FUS		Responsive	NTRK3 fusion	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Pre-clinical	NTRK3		BRCA	PMID:21148487;PMID:23131561									Breast adenocarcinoma
NTRK3__.	FUS		Responsive	NTRK3 fusion	RDientsmann	Midostaurin	Pan-TK inhibitor	Midostaurin (Pan-TK inhibitor)		Pre-clinical	NTRK3		BRCA	PMID:21148487;PMID:23131561									Breast adenocarcinoma
PAK1:amp	CNA		Responsive	PAK1 amplification	RDientsmann	[]	[PAK inhibitor]	PAK inhibitors		Pre-clinical	PAK1		CM	PMID:23535073									Cutaneous melanoma
PALB2:del	CNA		Responsive	PALB2 deletion	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Early trials	PALB2		PRAD	AACR 2015 (abstr CT322);PMID:26510020									Prostate adenocarcinoma
PALB2:del	CNA		Responsive	PALB2 deletion	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Pre-clinical	PALB2		PA	PMID:25263539;NCT01585805									Pancreas
PALB2:del	CNA		Responsive	PALB2 deletion	RDientsmann	Mytomycin C	Chemotherapy	Mytomycin C (Chemotherapy)		Case report	PALB2		PA	PMID:21135251									Pancreas
PALB2:del	CNA		Responsive	PALB2 deletion	RDientsmann	Platinum Agent	Chemotherapy	Platinum Agent (Chemotherapy)		Case report	PALB2		PA	PMID:25719666									Pancreas
PBRM1:del	CNA		Responsive	PBRM1 deletion	RDientsmann	[]	[EZH2 inhibitor]	EZH2 inhibitors		Pre-clinical	PBRM1		CANCER	PMID:26552009									Any cancer type
PBRM1:under	EXPR	Cell line	Responsive	PBRM1 undexpression	ARodriguez-Vida	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)	Approved	Pre-clinical	PBRM1		R	PMID:25997916									Renal
PDGFRA:amp	CNA		No Responsive	PDGFRA amplification	RDientsmann	[]	[PDGFR inhibitor]	PDGFR inhibitors		Pre-clinical	PDGFRA		G	PMID:23544171									Glioma
PDGFRA__.	FUS		Responsive	PDGFRA fusion	CRubio-Perez;DTamborero;RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	FDA guidelines	PDGFRA		MDS;MDPS	EMA									Myelodisplasic syndrome;Myelodisplasic proliferative syndrome
PDGFRA__FIP1L1	FUS		Responsive	PDGFRA-FIP1L1 fusion	CRubio-Perez;DTamborero;RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	FDA guidelines	PDGFRA		HES;ECL	EMA									Hyper eosinophilic advanced snydrome;Eosinophilic chronic leukemia
PDGFRA:over	EXPR	Cell line	Responsive	PDGFRA overexpression	ARodriguez-Vida	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)	Approved	Pre-clinical	PDGFRA		R	PMID:24086736	Direct								Renal
PDGFB__COL1A1	FUS		Responsive	PDGFB-COL1A1 fusion	CRubio-Perez;DTamborero;RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	FDA guidelines	PDGFB		DFS	FDA									Dermatofibrosarcoma
PDPK1:amp	CNA		Responsive	PDPK1 amplification	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Pre-clinical	PDPK1		BRCA	PMID:19602588									Breast adenocarcinoma
PIK3CA:amp	CNA		Resistant	PIK3CA amplification	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Pre-clinical	PIK3CA		BRCA	PMID:24366379									Breast adenocarcinoma
PIK3CA:.;ERBB2:amp	MUT;CNA		Responsive	PIK3CA oncogenic mutation + ERBB2 amplification	RDientsmann	Everolimus;Trastuzumab;Chemotherapy	MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy	Everolimus + Trastuzumab + Chemotherapy (MTOR inhibitor + ERBB2 mAb inhibitor + Chemotherapy)		Late trials	PIK3CA;ERBB2		BRCA	PMID:27091708									Breast adenocarcinoma
PML__RARA	FUS		Responsive	PML-RARA fusion	DTamborero;CRubio-Perez	Tretinoin	Retinoid	Tretinoin (Retinoid)	Approved	FDA guidelines	PML		APML	FDA									Acute promyelocytic leukemia
PML__RARA	FUS		Responsive	PML-RARA fusion	RDientsmann	Tretinoin;Arsenic Trioxide	Retinoid;Chemotherapy	Tretinoin + Arsenic Trioxide (Retinoid + Chemotherapy)	Approved	FDA guidelines	PML		AML	FDA									Acute myeloid leukemia
PML__RARA	FUS		Responsive	PML-RARA fusion	ECampo	Volasertib	PLK1 inhibitor	Volasertib (PLK1 inhibitor)	Clinical Trials	Early trials	PML		AML	NCT02198482;NCT01662505	Indirect								Acute myeloid leukemia
PRKCH:amp;ABL1__BCR	CNA;FUS		Responsive	PRKCH amplification + ABL1-BCR fusion	RDientsmann	Trametinib;Imatinib	MEK inhibitor;BCR-ABL inhibitor 1st gen&KIT inhibitor	Trametinib + Imatinib (MEK inhibitor + BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	PRKCH;ABL1		CML	PMID:25186176									Chronic myeloid leukemia
PTEN:del	CNA		Responsive	PTEN deletion	RDientsmann	[]	[AKT inhibitor]	AKT inhibitors		Case report	PTEN		PA	PMID:22025163									Pancreas
PTEN:del	CNA		Resistant	PTEN deletion	RDientsmann	[]	[EGFR mAb inhibitor]	EGFR mAb inhibitors		Late trials	PTEN		COREAD	PMID:21163703;PMID:19398573									Colorectal adenocarcinoma
PTEN:del	CNA		No Responsive	PTEN deletion	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Early trials	PTEN		ED	PMID:21788564;PMID:23238879									Endometrium
PTEN:del	CNA		Responsive	PTEN deletion	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Case report	PTEN		ED	PMID:21468130;PMID:20944090									Endometrium
PTEN:del	CNA		Responsive	PTEN deletion	RDientsmann	[]	[PD1 Ab inhibitor]	PD1 Ab inhibitors		Early trials	PTEN		CM	PMID:26645196									Cutaneous melanoma
PTEN:del	CNA		Responsive	PTEN deletion	RDientsmann	[]	[PI3K pathway inhibitor;AR antagonist]	PI3K pathway inhibitor + AR antagonists		Pre-clinical	PTEN		PRAD	PMID:21575859									Prostate adenocarcinoma
PTEN:del	CNA		Responsive	PTEN deletion	RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Pre-clinical	PTEN		OV	PMID:21632463									Ovary
PTEN:del	CNA		Responsive	PTEN deletion	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Pre-clinical	PTEN		TH;G;L;OV;BRCA;CANCER;ED	PMID:21289267;PMID:21325073;PMID:21191045;PMID:17804702;PMID:23136191;PMID:21632463;PMID:21673091;PMID:23287563;PMID:21998291;PMID:22662154;PMID:23085766;PMID:22932669									Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium
PTEN:del	CNA		Responsive	PTEN deletion	RDientsmann	[]	[PIK3CB inhibitor]	PIK3CB inhibitors		Case report	PTEN		PRAD	ASCO 2014 (abstr 2514)									Prostate adenocarcinoma
PTEN:.	BIA		Resistant	PTEN biallelic inactivation	DTamborero	BYL719	PIK3CA inhibitor	BYL719 (PIK3CA inhibitor)	Clinical Trials	Case report	PTEN		BRCA	PMID:25409150									Breast adenocarcinoma
PTEN:.	BIA		Resistant	PTEN biallelic inactivation	DTamborero	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)	Approved	Case report	PTEN		COREAD	Caris molecular intelligence									Colorectal adenocarcinoma
PTEN:del	CNA		Responsive	PTEN deletion	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Early trials	PTEN		PRAD	PMID:23582881									Prostate adenocarcinoma
PTEN:.	BIA		Resistant	PTEN biallelic inactivation	DTamborero	Panitumumab	EGFR mAb inhibitor	Panitumumab (EGFR mAb inhibitor)		Case report	PTEN		COREAD	Caris molecular intelligence									Colorectal adenocarcinoma
PTEN:del	CNA		Responsive	PTEN deletion	RDientsmann	Sirolimus	MTOR inhibitor	Sirolimus (MTOR inhibitor)		Early trials	PTEN		CANCER	ASCO 2013 (abstr 2532)									Any cancer type
PTEN:.;BRAF:.	MUT;MUT		Resistant	PTEN oncogenic mutation + BRAF oncogenic mutation	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Early trials	PTEN;BRAF		CM	http://ascopubs.org/doi/abs/10.1200/PO.16.00054									Cutaneous melanoma
PTEN:del;BRAF:.	CNA;MUT		Resistant	PTEN deletion + BRAF oncogenic mutation	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Early trials	PTEN;BRAF		CM	http://ascopubs.org/doi/abs/10.1200/PO.16.00054									Cutaneous melanoma
PTEN:.;BRAF:.	MUT;MUT		Resistant	PTEN oncogenic mutation + BRAF oncogenic mutation	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	PTEN;BRAF		CM	PMID:23039341									Cutaneous melanoma
PTEN:del;BRAF:.	CNA;MUT		Resistant	PTEN deletion + BRAF oncogenic mutation	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	PTEN;BRAF		CM	PMID:23039341									Cutaneous melanoma
PTEN:.;ERBB2:amp	MUT;CNA		Responsive	PTEN oncogenic mutation + ERBB2 amplification	RDientsmann	Everolimus;Trastuzumab;Chemotherapy	MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy	Everolimus + Trastuzumab + Chemotherapy (MTOR inhibitor + ERBB2 mAb inhibitor + Chemotherapy)		Late trials	PTEN;ERBB2		BRCA	PMID:27091708									Breast adenocarcinoma
RAC1:P29S;BRAF:.	MUT;MUT		Resistant	RAC1 (P29S) + BRAF oncogenic mutation	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	RAC1;BRAF		CM	PMID:25056119									Cutaneous melanoma
RAC1:P29S;BRAF:.	MUT;MUT		Resistant	RAC1 (P29S) + BRAF oncogenic mutation	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	RAC1;BRAF		CM	PMID:25056119									Cutaneous melanoma
RAD50:L1237F;ATM:del	MUT;CNA		Responsive	RAD50 (L1237F) + ATM deletion	RDientsmann	Irinotecan;CHK1/2 inhibitor	TOPO1 inhibitor;CHK1/2 inhibitor	Irinotecan + CHK1/2 inhibitor (TOPO1 inhibitor + CHK1/2 inhibitor)		Case report	RAD50;ATM		CANCER	PMID:24934408									Any cancer type
RAF1__.	FUS	Cell line	Responsive	RAF1 fusion	ARodriguez-Vida	[]	[Pan-RAF inhibitor]	Pan-RAF inhibitors	Pre-clinical	Pre-clinical	RAF1		PRAD	PMID:20526349	Direct								Prostate adenocarcinoma
RAF1__.	FUS		Responsive	RAF1 fusion	RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Pre-clinical	RAF1		PRAD	PMID:20526349									Prostate adenocarcinoma
RAF1:over	EXPR	Cell line	Responsive	RAF1 overexpression	CdeTorres	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Pre-clinical	RAF1		OS	PMID:24375110									Osteosarcoma
RAF1__.	FUS	Cell line	Responsive	RAF1 fusion	ARodriguez-Vida	U0126	MEK inhibitor	U0126 (MEK inhibitor)	Approved	Pre-clinical	RAF1		PRAD	PMID:20526349	Indirect								Prostate adenocarcinoma
RAF1:S257P,G361A,P261P;BRAF:.	MUT;MUT		Resistant	RAF1 (S257P,G361A,P261P) + BRAF oncogenic mutation	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Pre-clinical	RAF1;BRAF		CM	PMID:23737487									Cutaneous melanoma
RB1:del	CNA		Responsive	RB1 deletion	RDientsmann	[]	[HDAC inhibitor]	HDAC inhibitors		Pre-clinical	RB1		RB	PMID:18483379									Retinoblastoma
RB1:del	CNA		Responsive	RB1 deletion	RDientsmann	[]	[MDM2/MDMX inhibitor]	MDM2/MDMX inhibitors		Pre-clinical	RB1		RB	PMID:17080083;PMID:21515735									Retinoblastoma
RB1:del	CNA		Responsive	RB1 deletion	ARodriguez-Vida;RDientsmann	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	Early trials	RB1	BLCA	BLCA	PMID:26238431	Indirect								Bladder
RB1:over	EXPR	Xenograft	Responsive	RB1 overexpression	ARodriguez-Vida	Palbociclib	CDK4/6 inhibitor	Palbociclib (CDK4/6 inhibitor)	Pre-clinical	Pre-clinical	RB1		PRAD	PMID:23708653	Indirect								Prostate adenocarcinoma
RET__.	FUS		Responsive	RET fusion	RDientsmann	[]	[RET inhibitor]	RET inhibitors		Pre-clinical	RET		LUAD	PMID:22327624;PMID:22327622									Lung adenocarcinoma
RET__TPCN1	FUS		Responsive	RET-TPCN1 fusion	RDientsmann	[]	[RET inhibitor]	RET inhibitors		Pre-clinical	RET		TH	PMID:23056499									Thyroid
RET__.	FUS		Responsive	RET fusion	RDientsmann	Cabozantinib	Pan-kinase inhibitor	Cabozantinib (Pan-kinase inhibitor)		Early trials	RET		LUAD	PMID:28447912									Lung adenocarcinoma
RET__TPCN1	FUS		Responsive	RET-TPCN1 fusion	RDientsmann	Cabozantinib	Pan-kinase inhibitor	Cabozantinib (Pan-kinase inhibitor)		Pre-clinical	RET		THCA	PMID:21470995									Thyroid carcinoma
RET__.	FUS		Responsive	RET fusion	RDientsmann	Nintedanib	Pan-TK inhibitor	Nintedanib (Pan-TK inhibitor)		Case report	RET		LUAD	PMID:26787234									Lung adenocarcinoma
RET__.	FUS		Responsive	RET fusion	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Early trials	RET		LUAD	PMID:28447912									Lung adenocarcinoma
RET__TPCN1	FUS		Responsive	RET-TPCN1 fusion	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Pre-clinical	RET		THCA	PMID:21470995									Thyroid carcinoma
RET__.	FUS		Responsive	RET fusion	RDientsmann	Vandetanib	Pan-TK inhibitor	Vandetanib (Pan-TK inhibitor)		Early trials	RET		LUAD	PMID:28447912									Lung adenocarcinoma
RET__TPCN1	FUS		Responsive	RET-TPCN1 fusion	RDientsmann	Vandetanib	Pan-TK inhibitor	Vandetanib (Pan-TK inhibitor)		Pre-clinical	RET		THCA	PMID:21470995									Thyroid carcinoma
RICTOR:amp	CNA		Responsive	RICTOR amplification	RDientsmann	[]	[MTORC1/2 inhibitor]	MTORC1/2 inhibitors		Case report	RICTOR		L	PMID:26370156									Lung
ROS1__.	FUS		Responsive	ROS1 fusion	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Pre-clinical	ROS1		LUAD	PMID:23533265									Lung adenocarcinoma
ROS1__.	FUS		Responsive	ROS1 fusion	RDientsmann	Cabozantinib	Pan-kinase inhibitor	Cabozantinib (Pan-kinase inhibitor)		Case report	ROS1		LUAD	PMID:27370605									Lung adenocarcinoma
ROS1__.	FUS		Responsive	ROS1 fusion	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ROS1		IM	PMID:24875859									Inflammatory myofibroblastic
ROS1__.	FUS		Responsive	ROS1 fusion	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Early trials	ROS1		LUAD	PMID:25264305									Lung adenocarcinoma
ROS1__.	FUS		Responsive	ROS1 fusion	CRubio-Perez;EArriola	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)	Clinical trials	FDA guidelines	ROS1		NSCLC	FDA									Non-small cell lung
SETD2:del	CNA		Responsive	SETD2 deletion	RDientsmann	[]	[WEE1 inhibitor]	WEE1 inhibitors		Pre-clinical	SETD2		CANCER	ENA 2014 (abstr 211)									Any cancer type
SH2B3:del	CNA		Responsive	SH2B3 deletion	RDientsmann	[]	[JAK inhibitor]	JAK inhibitors		Pre-clinical	SH2B3		MDPS	PMID:20404132									Myelodisplasic proliferative syndrome
SLC44A4:over	EXPR		Responsive	SLC44A4 overexpression	CRubio-Perez	[]	[SLC44A4 inhibitor]	SLC44A4 inhibitors		Pre-clinical	SLC44A4		PRAD;PAAD	PMID:27550944 									Prostate adenocarcinoma;Pancreas adenocarcinoma
SMARCA4:del	CNA		Responsive	SMARCA4 deletion	RDientsmann	[]	[EZH2 inhibitor]	EZH2 inhibitors		Case report	SMARCA4		OV	ESMO 2015 (abstract 302)									Ovary
SMARCB1:del	CNA		Responsive	SMARCB1 deletion	RDientsmann	[]	[EZH2 inhibitor]	EZH2 inhibitors		Case report	SMARCB1		MRT	ENA 2014 (abstr 6LBA);ESMO 2015 (abstract 302)									Malignant rhabdoid tumor
SMARCB1:del	CNA		Responsive	SMARCB1 deletion	RDientsmann	[]	[EZH2 inhibitor]	EZH2 inhibitors	Clinical Trials	Early trials	SMARCB1		MRT	ESMO 2015 (abstract 302)									Malignant rhabdoid tumor
STK11:del	CNA		Responsive	STK11 deletion	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	STK11		LUAD	PMID:19165201									Lung adenocarcinoma
STK11:del	CNA		Responsive	STK11 deletion	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	STK11		CANCER	PMID:19541609									Any cancer type
STK11:del	CNA		Responsive	STK11 deletion	RDientsmann	[]	[SRC inhibitor;PI3K/MEK inhibitor]	SRC inhibitor + PI3K/MEK inhibitors		Pre-clinical	STK11		LUAD	PMID:20541700									Lung adenocarcinoma
STK11:del	CNA		Responsive	STK11 deletion	RDientsmann	Phenformin	Anti-diabetic	Phenformin (Anti-diabetic)		Pre-clinical	STK11		LUAD	PMID:23352126									Lung adenocarcinoma
STK11:.;KRAS:.	MUT;MUT		Resistant	STK11 oncogenic mutation + KRAS oncogenic mutation	RDientsmann	[]	[PD1 Ab inhibitor]	PD1 Ab inhibitors		Early trials	STK11;KRAS		LUAD	ASCO 2017 (abstr 9016)									Lung adenocarcinoma
STK11:del;KRAS:.	CNA;MUT		Resistant	STK11 deletion + KRAS oncogenic mutation	RDientsmann	[]	[PD1 Ab inhibitor]	PD1 Ab inhibitors		Early trials	STK11;KRAS		LUAD	ASCO 2017 (abstr 9016)									Lung adenocarcinoma
STK11:.;KRAS:.	MUT;MUT		Resistant	STK11 oncogenic mutation + KRAS oncogenic mutation	RDientsmann	MEK inhibitor;Docetaxel	MEK inhibitor;Chemotherapy	MEK inhibitor + Docetaxel (MEK inhibitor + Chemotherapy)		Pre-clinical	STK11;KRAS		LUAD	PMID:22425996									Lung adenocarcinoma
STK11:del;KRAS:.	CNA;MUT		Resistant	STK11 deletion + KRAS oncogenic mutation	RDientsmann	MEK inhibitor;Docetaxel	MEK inhibitor;Chemotherapy	MEK inhibitor + Docetaxel (MEK inhibitor + Chemotherapy)		Pre-clinical	STK11;KRAS		LUAD	PMID:22425996									Lung adenocarcinoma
SUZ12:del	CNA		Responsive	SUZ12 deletion	RDientsmann	[]	[BET inhibitor]	BET inhibitors		Pre-clinical	SUZ12		CANCER	PMID:25119042									Any cancer type
SYK:amp	CNA		Responsive	SYK amplification	RDientsmann	[]	[SYK inhibitor]	SYK inhibitors		Pre-clinical	SYK		MCL;CLL	PMID:16409295;PMID:19549911									Mantle cell lymphoma;Chronic lymphocytic leukemia
TMPRSS2__.	FUS		Responsive	TMPRSS2 fusion	RDientsmann	[]	[DNA-PKc inhibitor]	DNA-PKc inhibitors		Pre-clinical	TMPRSS2		PRAD	PMID:21575865									Prostate adenocarcinoma
TMPRSS2__.	FUS		Responsive	TMPRSS2 fusion	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Pre-clinical	TMPRSS2		PRAD	PMID:21575865									Prostate adenocarcinoma
TOP2A:amp	CNA		Responsive	TOP2A amplification	RDientsmann	Anthracyclines	Chemotherapy	Anthracyclines (Chemotherapy)		Late trials	TOP2A		BRCA	PMID:22864769									Breast adenocarcinoma
TP53:del	CNA		Responsive	TP53 deletion	ECampo	AZD6738	ATR inhibitor	AZD6738 (ATR inhibitor)	Clinical Trials	Early trials	TP53		BCL	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	Indirect								B cell lymphoma
TP53:del	CNA		Responsive	TP53 deletion	RDientsmann	Pramlintide	Amylin analogue	Pramlintide (Amylin analogue)		Pre-clinical	TP53		THYM	PMID:25409149									Thymic
TPMT:.	BIA		Increased Toxicity (Ototoxicity)	TPMT biallelic inactivation	DTamborero;CRubio-Perez	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	FDA guidelines	TPMT		CANCER	FDA									Any cancer type
TPMT:.	BIA		Increased Toxicity (Myelosupression)	TPMT biallelic inactivation	DTamborero;CRubio-Perez	Mercaptopurine	Purine analog	Mercaptopurine (Purine analog)	Approved	FDA guidelines	TPMT		CANCER	FDA									Any cancer type
TPMT:.	BIA		Increased Toxicity (Myelosupression)	TPMT biallelic inactivation	DTamborero;CRubio-Perez	Thioguanine	Guanine analog	Thioguanine (Guanine analog)	Approved	FDA guidelines	TPMT		CANCER	FDA									Any cancer type
TSC1:del	CNA		Responsive	TSC1 deletion	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	TSC1		R	PMID:24622468;ASCO 2015 (abstr 11010);ASCO 2015 (abstr 4519)									Renal
TSC2:del	CNA		Responsive	TSC2 deletion	RDientsmann	[]	[SRC inhibitor]	SRC inhibitors		Pre-clinical	TSC2		LAM	PMID:24691995									Lymphangioleiomyomatosis
TUBB3:over	EXPR		Resistant	TUBB3 overexpression	ARodriguez-Vida	Paclitaxel	Taxane	Paclitaxel (Taxane)		Pre-clinical	TUBB3	BLCA	BLCA	PMID:23184177									Bladder
UGT1A1:.	BIA		Increased Toxicity	UGT1A1 biallelic inactivation	DTamborero;CRubio-Perez	Irinotecan	TOPO1 inhibitor	Irinotecan (TOPO1 inhibitor)	Approved	FDA guidelines	UGT1A1		CANCER	FDA									Any cancer type
UGT1A1:.	BIA		Increased Toxicity (Hyperbilirubinemia)	UGT1A1 biallelic inactivation	DTamborero;CRubio-Perez	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	FDA guidelines	UGT1A1		CANCER	FDA									Any cancer type
UGT1A1:.	BIA		Increased Toxicity (Hyperbilirubinemia)	UGT1A1 biallelic inactivation	DTamborero;CRubio-Perez	Pazopanib	VEGFR inhibitor	Pazopanib (VEGFR inhibitor)	Approved	FDA guidelines	UGT1A1		CANCER	FDA									Any cancer type
VEGFA:amp	CNA		Responsive	VEGFA amplification	RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Early trials	VEGFA		HC	PMID:24687604									Hepatic carcinoma
ZBTB16:under	EXPR		Resistant	ZBTB16 undexpression	ARodriguez-Vida	[]	[LHRH analogues or antagonist]	LHRH analogues or antagonists		Pre-clinical	ZBTB16	PR	PRAD	PMID:16637071									Prostate adenocarcinoma
